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Phosphatidylinositol-3-kinase (PI3K) are a group of the lipid kinases 
superfamily, that play a crucial role in signalling pathways involved in the 
regulation of numerous cellular processes such as survival, growth, 
proliferation and differentiation. PI3K δ belongs to the class-IA subset of 
PI3Ks and is mainly present in leukocytes, where it regulates the 
development and function of adaptive immune cells (the B and T 
lymphocytes). However, PI3K δ dysregulation is implicated in human 
diseases, including blood cancers such as leukaemia and autoimmune 
diseases such as rheumatoid arthritis. The selective inhibition of PI3K δ may 
therefore provide an exciting therapeutic opportunity to treat different types of 
haematological malignancies and autoimmune disorders. 
Idelalisib (8) is the only selective PI3K δ inhibitor approved by the Food and 
Drug Administration (FDA) for the treatment of chronic lymphocytic 
leukaemia, small lymphocytic lymphoma and follicular lymphoma. However 
when dosed, idelalisib (8) has been shown to have several side effects such 
as chronic diarrhoea, colitis and hepatotoxicity, which often lead to the 
discontinuation of treatment. Therefore, this medicinal chemistry research 
was undertaken with the aim to discover alternative PI3K δ inhibitors that can 
display comparable or greater potency and selectivity than idelalisib (8), but 
without adverse effects. 
The first chapter describes how the non-selective PI3K inhibitor pictilisib (4) 
was used as the starting point for the design and synthesis of novel, flat-




Herein, structural modifications were performed on pictilisib (4) based on its 
key reported interactions seen in the ligand co-crystal structure with PI3K δ. 
The aim of the research presented in this chapter was to optimize the 
interactions in the conserved affinity pocket and to occupy the unexploited 
tryptophan shelf, the space between Trp760 and Thr750, that is exclusively 
found in the PI3K δ isoform and not in the other three isoforms (α, β and Ɣ). 
This optimization strategy led to the synthesis of 38 thienopyrimidine 
derivatives as new PI3K δ inhibitors. Among them, indole analogue 48, 
bearing a fluoropiperidine group was identified as the best compound, due to 
its combination of low nanomolar potency for PI3K δ inhibition and excellent 
selectivity for PI3K δ over the other isoforms. In addition, it possesses 
favourable predicted physicochemical properties for oral administration. 
Based on the docking studies from ligand crystal structure studies from other 
research groups, it was hypothesized that aliphatic heterocycles such as 
fluoropiperidine may form a favourable C-H/pi interaction with the tryptophan 
shelf, which may explain the improved PI3K δ potency and selectivity of 
compound 48. On the other hand, occupancy of the affinity pocket by the 
indole ring of compound 48 may aid in increasing the PI3K δ selectivity 
through the formation of a distal hydrogen bond network that can be 





Chapter 3, 4 and 5 focused on propeller-shaped PI3K δ inhibitors. The crystal 
structure of the FDA-approved idelalisib (8) bound to PI3K δ showed that the 
affinity pocket is not occupied in this class of inhibitor. Therefore, the goal of 
the work in chapters 2 and 3 was to extend the structure 8 (IC50 = 11 nM) into 
the unoccupied affinity pocket so as to further improve the PI3K δ potency. 
However, this structure-based approach proved unsuccessful with all 18 
extended idelalisib analogues exhibiting weak or no activity against PI3K δ, 
suggesting that chemical modification of the core structure of 8 was needed. 
Consequently, chapter 5 reports, bioisosteric replacement of the purine group 
of idelalisib (8) with a 4-aminopyrimidine ring, followed by addition of a new 
affinity pocket-binding substituent at the C-5 position of this ring. The resulting 
11 aminopyrimidine analogues displayed excellent inhibitory activity against 
PI3K δ at a single concentration of 500 nM. For example, the cyclohexyl 
analogue 218, showed 87.7% of PI3K δ inhibitory activity. Unfortunately, full 
determination of the IC50 values of the 4-aminopyrimidine derivatives against 
PI3K δ has been delayed due to the COVID-19 pandemic. However, these 
results will be obtained from our collaborator in Monash, and if successful will 
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ADME Absorption, distribution, metabolism and excrexretion 
ADP Adenosin diphosphate 
ALT Alanine transaminase 
APC Allophycocyanin 
APDS Activated PI3K kinase delta syndrome 
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HBD Hydrogen bond donor 
HER2 Human epidermal growth factor receptor 2 
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HR-positive Hormone receptor-positive breast cancer 
HTRF Homogeneous time-resolved fluorescence 
IBCF Isobutyl chloroformate 
IFN Interferon 
ILs Interleukins 
IRS Insulin receptor substrate 
LUMO Lowest unoccupied molecular orbital 
mTOR Mammalian target of rapamcycin 





PDB Protein data bank 
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SS Sjörgen syndrome 
ssRNA Single-stranded RNA 
T1D Type 1 diabetes 
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TLC Thin-layer chromatography 
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TNF Tissue necrosis factor 
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Chapter 1  Introduction 
1.1 Phosphoinositide 3-kinase (PI3K) 
Kinases are enzymes that catalyse the transfer of the terminal phosphate 
group from adenosine triphosphate (ATP) to free hydroxyl groups on a 
specific substrate1. The introduction of the bulky negatively charged 
phosphate group leads to a significant effect on the properties of the 
substrates, such as activity, subcellular localization and the ability to bind to 
other molecules2. Kinases are classified into three types based on the nature 
of their substrates: protein kinases, lipid kinases and sugar kinases 3,4. PI3Ks 
are a family of lipid kinase enzymes that can selectively introduce a 
phosphate group to the 3-hydroxyl group of the inositol ring in 
phosphoinositide such as phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) 
to form phospholipids such as phosphatidylinositol-3,4,5-trisphosphate 
(PI(3,4,5)P3), which acts as a second messenger (Figure 1)5,6, activating 
specific protein kinases, which in turn, phosphorylate transcription factors, to 
produce a particular cellular response7–11. Thus, PI3Ks play a major part in 






Figure 1. PI3K catalyses the transfer of phosphate group from ATP to the 3 position hydroxyl 
group of the inositol ring of PI(4,5)P2 to generate the second messenger PI(3,4,5)P3, which, 
activates intracellular enzymes. 
1.2 PI3K/Akt/mTOR pathway 
PI3K/Akt/mTOR represents a major pathway downstream of growth factor 
tyrosine kinase receptors (RTKs) that is involved in cell growth and 
metabolism13,14. The activation of protein tyrosine kinases by growth factors15, 
induces the recruitment of PI3K to the plasma membrane16. The phospho-
tyrosine residues on RTKs bind to PI3K through a Src homology domain-2 
(SH2), leading to activation of PI3K. Once activated, PI3K converts PI(4,5)P2 
to the second messenger PI(3,4,5)P3 (Figure 2)15–18. Akt is then activated by 
the binding of its PH domain to PI(3,4,5)P3 enriched sites at the plasma 
membrane. Activated Akt, in turn, phosphorylates mTOR at Ser2448 in the 
kinase activation loop, causing partial activation of mTOR19,20. Once 
activated, mTOR phosphorylates and activates two ribosomal proteins P70S6 
kinase (S6K1) and eIf4E Binding Protein (4EBP) (Figure 2)10,21,22, which then 
translocate to the nucleus where they promote various biological processes, 
including transcription, translation, protein and lipid synthesis, cell growth/size 





Figure 2. Graphical representation illustrating the role of PI3K/Akt/mTOR pathway in 
promoting cellular growth, survival, proliferation, metabolism and differentiation. Binding of 
ligands to receptor tyrosine kinase RTK (or GPCRs) activates PI3K (in grey) at the plasma 
membrane. Then, PI3K phosphorylates PI(4,5)P2 (in blue) into PI(3,4,5)P3 (in magenta), 
which in turn, activates the serine/threonine kinases AKT (in violet) that phosphorylates 
mTOR (in yellow). The activation of mTOR leads to the stimulation of ribosomal protein S6K1 
(in cyan) and inactivation of 4E-BP1 (a repressor of translation initiation) (in cyan), which in 
turn, stimulate gene expression and protein synthesis in the nucleus. The lipid phosphatase 
PTEN (in green) reverses the effect of PI3K by dephosphorylating PI(3,4,5)P3 (in magenta) 
into PI(4,5)P2 (blue)25–27. 
Over activation of the PI3K/Akt/mTOR pathway has the potential to cause 
significant dysregulation of a variety of cellular process such as protein 
synthesis, cell proliferation, cell survival and apoptosis (Figure 2). For 
instance, somatic mutations in the PI3K signalling pathway are among the 
most common genetic abnormalities detected in cancer28,29. Moreover, 
hyperactivation of the PI3K/Akt/mTOR signalling pathway is also associated 
with autoimmune disorders, cardiovascular diseases and diabetes30,31. 
Therefore, these findings suggest that PI3K/Akt/mTOR axis is an attractive 




1.3 Classes of PI3K 
The PI3K family is divided into three classes based on the lipid substrate structure, 
sequence homology and function33. There are eight isoforms of PI3K in humans, 
four isoforms of class I, three isoforms of class II and one isoform of class III34–36. 
The four isoforms of class I have long been considered promising therapeutic 
targets for the many drug discovery programs, whereas the isoforms of class 
II and class III have been largely neglected as potential therapeutic targets35. 
1.3.1 Class I PI3K 
Class I PI3Ks are 110-130 kDa heterodimeric enzymes, composed of 
catalytic and regulatory subunits37–39. The catalytic subunit p110 is linked to 
the upstream signalling proteins (RTKs or G-protein-coupled receptors 
(GPCRs)) by regulatory subunits (Figure 3) 38,40. Class I PI3Ks are normally 
kept in an inactive state by association of the catalytic subunit (p110) with its 
regulatory subunits41,42. However, binding of regulatory subunits to the cell 
surface receptor (RTKs or GPCRs) results in the activation of the PI3K 
pathway41. 
Class I PI3Ks are subdivided into two classes, which differ in upstream 
signalling and regulatory subunits42: Class IA includes α, β and δ isoforms 
which are activated by RTK, the p110 catalytic subunits of class IA PI3Ks 
interact with the same regulatory subunit p85 (Figure 3)33,43. The α and β 
isoforms are ubiquitously expressed while δ isoform is mainly expressed in 
leukocytes 37. Class IB contains only a single isoform (PI3K Ɣ) which is 
activated by GPCRs (Figure 3), the p110 catalytic subunit of PI3K Ɣ is 




hematopoietic cells and in negligible number in smooth muscles, endothelia 
and cardiomyocyte44. 
 
Figure 3. Class IA PI3Ks (PI3K α, β and δ) are heterodimers composed of the catalytic 
subunit p110 (in yellow) and regulatory subunit p85 (in green). Class IA isoforms are 
activated by extracellular signals through tyrosine kinase receptor (RTKs), whereas in Class 
IB PI3K (PI3K Ɣ), the catalytic subunit p110 (in cyan) associates with the regulatory subunit 
p101 or p87 (in red). PI3K Ɣ is activated by extracellular signals through GPCRs. 
Class I PI3Ks catalyse the conversion of phosphatidylinositol (PI) into 
phosphatidylinositol-3-phosphate (PI(3)P), phosphatidylinositol 4-phosphate 
(PI(4)P) into phosphatidylinositol (3,4)-bisphosphate (PI(4)P) and 
phosphatidylinositol (4,5)-bisphosphate into phosphatidylinositol (3,4,5)-
trisphosphate (PI(3,4,5)P3)45, where the class I PI3Ks have the unique ability 
to produce (PI(3,4,5)P3)44,45, which is necessary for PI3K-mediated tumour 
development, explaining the fact that class II and class III PI3Ks have not 
associated with cancer45. 
1.3.2 Class II PI3K 
Class II PI3Ks are monomeric enzymes with a high molecular weight46, there 
are three isoforms of class II PI3K : PI3K-C2α, PI3K-C2β and PI3K-C2Ɣ. 




Class II PI3Ks differ from class I PI3Ks for being unable to generate 
PI(3,4,5)P336,48. PI3K-C2α is ubiquitously expressed in all cells and tissues, 
with particularly high levels in the pancreatic β-cells 49. Leibiger et al50 showed 
that knockdown of PI3K-C2α impaired glucose-stimulated insulin secretion 
from the β-cells of the pancreas. This finding revealed that PI3K-C2α pathway 
may constitute a potential druggable target for treatment of type 2 diabetes50. 
PI3K-C2β is ubiquitously expressed, with particularly high levels in T-cells, 
where PI3K-C2β-mediated PtdIns (3)P production leads to the activation of 
the voltage-gated K+ channel involved in T-cell proliferation51,52, thus PI3K-
C2β may represent a novel therapeutic target for treatment of blood cancers 
(lymphoma and leukaemia)34. Finally, PI3K-C2Ɣ is only expressed in 
hepatocytes, whereas its physiological role is presently unknown53. 
1.3.3 Class III PI3K 
Class III is the only class of PI3K which is conserved in yeasts, plants and 
mammals54. There is a single isoform in this class, which is known as vacuolar 
protein sorting 34 (Vps34)55. Vps34 is only able to phosphorylate 
phosphatidylinositol to produce PI(3)P56. Vps34 plays an important role in the 
stimulation of autophagy in different cell types57. Autophagy is the process 
that delivers long-lived proteins and damaged cellular organelles to 
lysosomes for degradation58. Disruption of Vps34 function is associated with 
abnormalities in autophagy, which leads to accumulation of aggregated 





1.4 Isoforms of class I 
As previously mentioned, class I PI3K is further subdivided into two classes: 
class IA which includes three isoforms (PI3K α, PI3K β and PI3K δ). Class IB 
is composed of only one isoform - PI3K Ɣ. In this chapter, the four isoforms 
of class I PI3K will be reviewed, with a particular focus on the PI3K δ isoform, 
as the main aim of this project is to design and develop novel selective 
inhibitors for PI3K δ. 
1.4.1 PI3K α 
1.4.1.1 Physiological role of PI3K α 
PI3K α is ubiquitously expressed in all cells in the body60, where receptor 
tyrosine kinase (RTKs) functions upstream of PI3K α signalling 61. PI3K α 
plays a key role in mediating the metabolic effects of insulin, where it involves 
in insulin-mediating glucose uptake in adipose tissue via glucose transporter 
protein type-4 (GLUT4) (Figure 4) 62,63. In the hepatic cells, PI3K α transmits 
the insulin signal downstream from insulin receptor substrate-1 (IRS-1) to Akt 
and other downstream signalling molecules64. Insulin signalling in the liver 
maintains normal glucose and lipid homeostasis63,65, by inhibiting 
gluconeogenesis and promoting the conversion of excess glucose into 
glycogen for storage and later use64,66.  
1.4.1.2 Pathological role of PI3K α 
Dysregulation of the PI3K α signalling pathway in the liver results in the 
development of insulin resistance and type 2 diabetes mellitus that cannot be 
recovered by metformin63,67. Additionally, it was found that PI3K α is the 





Figure 4. PI3K α pathway mediates glucose uptake by peripheral tissues. Binding of insulin 
to the insulin receptor inducing its activation via autophosphorylation. When activated, insulin 
receptor triggers activation of PI3K that converts PI(4,5)P2 into PI(3,4,5)P3, resulted in 3-
phosphoinositoid-depentent kinase 1 (PDK1) activation, which in turn, stimulates Akt 
phosphorylation. Activated Akt catalyses the phosphorylation of AS160 (Akt substrate of 
160kDa) which is necessary for translocation of glucose transporter (Glut4) from the 
cytoplasm to the plasma membrane, leading to increased glucose uptake into the cell69. 
tumorigenesis associated with over activation of the PI3K α pathway results 
from mutation in PI3KCA, the gene that encodes PI3K α, or from 
hyperactivation of upstream RTK signalling61. Mutations in PI3KCA lead to 
the development of different types of cancers such as breast, prostate and 
colon cancers 40. Therefore, PI3K α inhibition provides an attractive target for 
therapeutic intervention in different types of solid tumours and metastasis70. 
For instance, the selective PI3K α inhibitor alpelisib (1) (Figure 5) has recently 
been approved by the US FDA for the treatment of hormone receptor HR-
positive, human epidermal growth factor 2 negative (HER2-) advanced or 






Figure 5. The selective PI3K α inhibitor alpelisib (1), which was approved by the FDA in 2019 
for treatment of metastatic HR-positive, HER2-negativ metastatic breast cancer73. 
1.4.2 PI3K β 
1.4.2.1 Physiological role of PI3K β 
PI3K β is similar to PI3K α, being ubiquitously expressed61. However, the lipid 
phosphorylation activity of PI3K β is notably less compared to PI3K α74. In 
addition, PI3K β is unique among the PI3Ks in its ability to be activated by 
both RTK and GPCRs (Figure 6)75,76, whereas the PI3K α pathway can only 
be activated by RTKs77. Among the four isoforms of class I PI3K, PI3K β 
serves the most important role in platelet activation and platelet procoagulant 
activity78. The mechanism by which PI3K β regulates platelet function remains 
undefined, but it is thought to integrate signalling proteins regulated 
downstream of PI(3,4,5)P3 (Figure 6), where the platelets, unlike many other 
body cells, have Ras GTPase-activating protein 3 (RASA3) as a major 
PI(3,4,5)P3-binding protein instead of Akt.  
1.4.2.2 Pathological role of PI3K β 
PI3K β is the predominant isoform expressed in phosphatase and tensin 
homolog PTEN-deficient tumours, which indicates that PTEN-null tumours 
appear to be highly dependent on PI3K β signaling79. Thus, PI3K β inhibitors 
may be useful for treating PTEN-null tumors61,68,79. On the other hand, PI3Kβ 
plays a major role in thrombus formation by promoting vascular collagen-





Figure 6. Physiological role of PI3K β in regulating platelet migration, proliferation and 
differentiation. Fibrinogen binds to its platelet receptor, integrinαIIbβ3, resulted in outside-in 
signalling, which triggers the activation of PI3K β leads to the generation of the second 
messenger PI(3,4,5)P3. This, in turn, binds and inhibits RASA3. Inactivation of RASA3 
permits CALDAG-GEFI-mediated activation of RAP-GTP to process unreversed. Activated 
GTP-bound Rap1 induces the stimulation of integrinαIIbβ and inside-out signalling process 
resulting eventually in platelet spreading and granule secretion80. 
secretion and mobilization81. This finding was confirmed by the study showing 
that blocking of PI3K β delays initial thrombus formation and prevents 
platelets aggregation without increasing the bleeding82. Therefore, the PI3K 
β isoform could be a new therapeutic target for antithrombotic drugs83. For 
instance, the selective PI3K β inhibitor AZD 6482 (2) (Figure 7), developed 
by AstraZeneca, has passed phase I clinical trials as an antithrombic drug. 
AZD 6482 (2) prevents platelet aggregation by blocking PI3K β signalling 
pathway84 and is associated with a lower risk of major bleeding compared 
with warfarin and other anticoagulants. 
Figure 7. The selective PI3K β inhibitor AZD6482 (2), which is currently undergoing phase I 




1.4.3 PI3K Ɣ 
1.4.3.1 Physiological role of PI3K Ɣ 
PI3K Ɣ is the only PI3K isoform within the class IB subfamily85. In different 
types of immune cells, Binding of an extracellular ligand to GPCRs leads to 
the activation of PI3K Ɣ and rapid synthesis of the second messenger 
PI(3,4,5)P386. The most common extracellular ligands activating PI3K Ɣ 
signalling via GPCRs include chemokines and cytokines, which are involved 
in inflammatory and immune responses to infection and tissue injury 87. PI3K 
Ɣ is primarily expressed in haematopoietic cells and it plays a critical 
physiological role in promoting the innate immune response88,89, by 
controlling many neutrophil activities, including chemotactic migration to the 
site of infection, endothelial adhesion, and subsequent pathogen killing 90–93.  
1.4.3.2 Pathological role of PI3K Ɣ 
PI3K Ɣ takes part in the pathogenic mechanism of several acute and chronic 
inflammatory conditions and autoimmune diseases such as rheumatoid 
arthritis, systemic lupus erythematosus and asthma94. It is widely believed 
that over activation of PI3K Ɣ signalling in neutrophils and T-cells (both 
involved in the physiological immune response), causes these cells to release 
excessive amounts of pro-inflammatory cytokines such as tissue necrosis 
factor α (TNF-α) and interleukin-1β, -6 and -8 (IL-1β, IL-6 and IL-8), therefore, 
disrupting immune homeostasis, eventually leading to the development of a 
plethora of chronic inflammatory and autoimmune diseases92. Camps et al95 
and Banham-Hall et al92 showed that the pharmacological inhibition of PI3K 





Furthermore, PI3K Ɣ can increase tumour growth and metastasis by 
promoting the trafficking and infiltration of inflammatory cells into tumours96. 
Schmid et al96 reported that blocking the PI3K Ɣ signalling pathway stops 
tumour growth by inhibiting tumour inflammation and angiogenesis without 
directly affecting cancer cells96. Hence, the inhibition of PI3K Ɣ with a 
pharmacological inhibitor represents an attractive strategy for treatment of 
different types of solid tumours and haematological malignancies97. For 
example, selective PI3K Ɣ inhibitor eganelisib (3) (Figure 8) has passed 
phase I clinical trials for the treatment of advanced solid tumours98. 
 
Figure 8. The selective PI3K Ɣ inhibitor eganelisib (3), which is in phase II clinical studies for 
treatment of different types of advanced solid tumours such as breast cancer99. 
1.4.4 PI3K δ 
1.4.4.1 Physiological role of PI3K δ 
PI3K δ is mainly expressed in haematopoietic cells100, where it plays an 
important physiological role in the activation, proliferation and survival of 
adaptive immune cells (B- and T-cells) (Figure 10a). B-cells have a central 
role in the body’s immune response, by secreting antibodies and by serving 
as antigen-presenting cells (APCs) for T-cells. PI3K δ has a major role in 
transducing antigen-dependent signals from B-cell receptors (BCR) to the 








Figure 10. Blood B-cells in normal and cancerous state. a) In normal B-cells, PI3K δ is 
normally physiologically active (in yellow), thus it leads to the controlled proliferation of B-
cells. b) In cancerous B-cells, the PI3K δ isoform is overactive (in green), resulting in over-
phosphorylation of PIP2 and overproduction of the second messenger PI(3,4,5)P3, which 
finally leads to the development of 2 types of diseases: haematological cancers and 
autoimmune diseases. 
regulate the survival, proliferation and activation of B-cells101. Therefore, PI3K 
δ signalling is required for B cell development and antibody secretion102,103. 
In T-cells, PI3K δ acts as a key component in the CD20-evoked signalling 




Th1 cells secrete the cytokines interferon-Ɣ (IFN-Ɣ) and tumour necrosis 
factor-β (TNF-β)104, which have the ability to defend the body against 
infectious diseases caused by viruses and intracellular bacteria that grow in 
the macrophages as well as killing cancerous cells 105. Whereas Th2 cells 
secrete IL-4, -5, -10 and 13 which induce antibody production from B-cells to 
fight against parasitic organisms104,106,107.  
Furthermore, PI3K δ regulates the development and function of Treg cells 
that are responsible for establishing tolerance to self-antigens and innocuous 
antigens such as intestinal flora108. Additionally, Tregs cells have the capacity 
to prevent autoimmune diseases and inflammations by suppressing other 
cells in the immune system such as helper T-cells and B-cells109,110. 
1.4.4.2 Pathological role of PI3K δ 
The dysregulation of PI3K δ signaling in B-cells leads to two types of 
diseases: (i) blood cancers such as lymphoma and leukemia; (ii) autoimmune 
diseases such as rheumatoid arthritis and systemic lupus erythematosus 
(Figure 10b)100,111–113. 
1.4.4.2.1 PI3K δ and blood cancers 
PI3K δ plays a role in the development of several types of haematological 
malignancies such as chronic lymphocytic leukaemia (CLL), follicular 
lymphoma (FL) and small lymphocytic lymphoma (SLL)100,111. CLL is the most 
common type of leukaemia in adults, it is characterized by progressive 
accumulation of mature-appearing neoplastic B lymphocytes in the blood, 
bone marrow, lymph nodes and spleen114. As the number of cancerous 




in a decreased number of normal lymphocytes in blood, which causes a 
decrease in the amount of antibodies produced and weakens the immune 
system115. It was found that PI3K δ is over activated and/or overexpressed in 
CLL cells compared to normal B-cells (Figure 10b), suggesting that 
hyperactive PI3K δ signalling contributes to the pathogenesis of CLL116,117. 
This is supported by the fact that disruption of PI3K δ signalling promotes CLL 
cells death through one of two pathways (intrinsic and extrinsic)116,118. In the 
intrinsic mitochondrial pathway, inhibition of PI3K δ results in the upregulation 
of pro-apoptotic proteins (Bim, Bad, Bax and Bak), which increases the 
mitochondrial membrane permeability119, followed by subsequent release of 
cytochrome c from mitochondria to the cytosol, resulting in B-cell 
death116,118,120. In the extrinsic pathway, PI3K δ inhibition blocks the external 
pro-survival signal provided by microenvironmental cytokines, leading to B 
cell death121. 
SLL is also a type of non-Hodgkin lymphoma, which shares many similarities 
with CLL, both diseases affect B lymphocytes and tend to grow slowly over 
time 122. The only difference between SLL and CLL is the part of the body 
where the cancer primarily occurs. In SLL most of the cancer cells are located 
in the lymph nodes, whereas in CLL, they are mainly in the bloodstream and 
bone marrow123. As in CLL, PI3K δ has been found to be overexpressed in 
SLL cells, where it enhances tumour cell survival and proliferation124,125. 
Thus, PI3K δ offers a new treatment target for SLL126.  
FL is a blood cancer that arises from B lymphocytes, and is characterized by 
uncontrolled proliferation of abnormal B-cells in the lymph nodes, the cancer 




growth and proliferation of follicular B-cells are dependent on the crosstalk 
between these cells and the follicular helper T-cells, in which the latter cells 
secret tumour necrosis factor-α (TNF-α), lymphotoxin α and IL-4, which bind 
to BCRs resulting in activation of follicular cells128. In FL tumour cells, PI3K δ 
acts as an exclusive transducer of BCR downstream signalling in follicular B-
cells128, therefore, PI3K δ plays a fundamental role in the pathogenesis of 
FL129. 
1.4.4.2.2 PI3K δ in autoimmune diseases and inflammation 
Autoimmune disease is a condition in which the immune system, designed to 
only attack cancer cells or foreign cells such as viruses and bacteria, 
mistakenly attacks and destroys healthy body cells and tissues92. There are 
over 80 different types of autoimmune diseases, the most common include: 
rheumatoid arthritis, colitis, systemic lupus erythematosus and type I diabetes 
(T1D)112,113. B-cells contribute to the pathogenesis of a plethora of 
autoimmune diseases through their secretion of autoantibodies and 
presentation of antigen to T-cells130. Autoantibodies can bind to different 
receptors or receptor ligands leading to activation or inhibition of receptor 
functions131. For example, autoantibodies secreted by auto-reactive B-cells 
are necessary for the initiation of rheumatoid arthritis by binding to cartilage 
proteoglycan, subsequently triggering chemokine and cytokine secretion from 
activated macrophages in synovial fluid132, which results in cartilage 
degradation and bone erosion133. A large number of studies have found that 
autoreactive B cell activation and proliferation are highly regulated by PI3K δ 




autoantibodies directed against cartilage proteoglycan which in turn prevents 
irreversible joint damage134. 
On the other hand, T helper cells are also known to play a role in the 
pathophysiology of multiple autoimmune diseases. For example, in T1D, β-
cell destruction is mediated through pro-inflammatory cytokine secretion by 
helper T-cells within pancreatic islets135. PI3K δ takes part in the releasing of 
pro-inflammatory cytokines from pancreatic T lymphocytes in T1D136,137, 
where it was found that T-cells in T1D patients expressed higher levels of 
PI3K δ compared to healthy T-cells, suggesting that PI3K δ over activation 
plays an essential role in the development of T1D92. Taken together, these 
results demonstrate that PI3K δ inhibitors could prove to be effective in the 
treatment of different types of autoimmune diseases138.  
1.5 ATP substrate-binding sites of class I PI3Ks 
ATP substrate-PI3K Ɣ (PDB code 1E8X) (Figure 11) was the first reported 
crystal structure of the class I PI3Ks139. ATP binds in the cleft between the 
smaller N-terminal lobe and larger C-terminal lobe of the catalytic domain of 
PI3K139,140. The ATP binding site is similar in all 4 isoforms of class I PI3K141, 
where the active site of PI3K α, β, Ɣ and δ contain twenty fully conserved 
residues139. The crystal structure of the ATP-PI3K Ɣ complex (Figure 11b) 
reveals that ATP binds to PI3K Ɣ in three regions: the adenine-binding region 
(hinge region), the ribose region (hydrophobic region II), and the phosphate 
region142142,143.  
In the hinge region, the nitrogen-1 (N-1) atom of the adenine ring engages in 




a)                                                               b) 
  
Figure 11. Molecular structure of ATP, highlighting the three binding motifs (exocylic amine, 
nitrogen-1 and triphosphate group)140. b) Crystal structure of porcine PI3K Ɣ (PDB code 
1E8X) with ATP bound, highlights the three regions of the PI3K Ɣ binding site. Blue dashed 
lines represent the proposed hydrogen interactions140. 
interaction is preserved in all PI3K-inhibitor complexes where all of the 
inhibitors possess a hydrogen bond acceptor occupying the identical position 
to nitrogen-1 of ATP140,141. Moreover, the backbone carbonyl of hinge Glu880 
makes a hydrogen bond with the exocyclic amino group of adenine140. In the 
phosphate region, ATP makes three additional hydrogen bonds to PI3K 
(Figure 11b). These hydrogen bonds involve the three phosphate groups 
attached to the ribose ring: the α-phosphate group interacts with Lys833, β-
phosphate interacts with Ser806 and Ɣ-phosphate interacts with Asn951 140,144. 
None of the PI3K inhibitors binds in the position occupied by the β and Ɣ 
phosphates of ATP. The ribose group extends toward hydrophobic region II 
(ribose region), where it does not participate in hydrogen bond interaction with 
PI3K (Figure 11b)144. 
1.6 Regions of the PI3K δ binding site 
All four isoforms of class I PI3K possess three common binding regions, two 
of them occupied by ATP which are hinge region and hydrophobic region II 
(Table 1)144–146, whereas the third region, called the affinity pocket, is not 




regions which are not present in the other three isoforms: the specificity 
pocket and tryptophan shelf (hydrophobic dimple) (Table 1). 
Table 1. Different Regions of the PI3K binding site. The region that presents in PI3K isoforms 
is highlighted in blue, whereas the isoform-lacking region is highlighted in red. It also 
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1.6.1 Hinge region 
As mentioned, all four class I PI3K isoforms are composed of a smaller N-
terminal lobe and larger C-terminal lobe (Figure 12)139,147. The short linker of 
four residues (826- 829 in PI3K δ) that connects between the two lobes is 
known as hinge region (Figure 12)147–149. All four of these residues (δGlu826, 
δVal827, δVal828 and δLeu829) are conserved across all isoforms of class I PI3K 
(Figure 13b), so interaction at the hinge region cannot modulate isoform 
selectivity144. All PI3K inhibitors make a key hydrogen bond with the backbone 
amide of hinge δVal828 (Figure 13b), which is essential for activity144, thus, all 
PI3K δ inhibitors possess a hydrogen acceptor (primarily nitrogen) which 
points towards the hinge region150. In addition, the backbone carbonyl of 
Glu826 at the hinge region is usually involved in inhibitor-enzyme interaction 




the formation of double hydrogen bonds with PI3K δ inhibitors150. As a result, 
many PI3K δ inhibitors have a hydrogen bond donor and acceptor separated 
by one atom in syn-like arrangement150. 
 
Figure 12. Crystal structure of murine PI3K δ (PDB code 4XE0). Highlights the Hinge region 
in the black square. This region connects the larger C-lobe to the smaller N-lobe and is thus 
known as the hinge region. 
1.6.2 Hydrophobic region II 
Hydrophobic region II (also known as the ribose-binding region) is located at 
the entrance of the ATP-binding site (Figure 13a)145,146, where it is occupied 
by the ribose moiety of ATP. Hydrophobic region II does not appear to play 
an important role in inhibitor binding. However, it can be exploited to increase 
the aqueous solubility of PI3K δ inhibitors, by introducing a polar substituent 
to this region145,146. There are 8 residues (δLeu829, δHis830, δSer831, δAsp832, 
δThr833, δIle834, δAla835 and δAsn836) in the hydrophobic region II, four of them 
are variable across the four isoforms (Figure 13c)144. Among the 8 residues, 
only Asn836 has been reported to have the ability to modulate inhibitor 





a)                                                                            b) 
   
c)                                                                          d) 
                      
e)                                                                          f) 
          
Figure 13. a) The binding site of PI3K δ (PDB code 4XE0), highlighting the binding regions 
with colored squares. It should be noted that the affinity pocket cannot be shown in this two-
dimensional structure, as it is located behind the bulge. b) The hinge region consists of 4 
residues, two of them Glu826 and Val828 ( highlighted in magneta)) are typically engaged in 
key hydrogen bond interactions with PI3K δ inhibitors. c) The hydrophobic region II is 
composed of 8 residues, among them, only Asn836 (highlighted in magenta) was identified as 
a key residue for selectivity151. d) The affinity pocket is comprised of 6 residues, four of them 




PI3K δ inhibitors. e) The specificity pocket is formed upon inhibitor binding by reorientation 
Met752 and Trp760 residues (highlighted in magenta). f) The tryptophan shelf is the space 
located between conserved δTrp760 (green) and non-conserved Thr750 (magenta), this 
region is not accessible in the other three isoforms. 
1.6.3 Affinity pocket (hydrophobic region I) 
The affinity pocket lies outside of the ATP binding site (Figure 13a)140,152. The 
six residues that line the affinity pocket are strictly conserved across the class 
I isoforms151,158. These 6 residues include δLys779, δLeu784, δAsp787, δLeu791, 
δTyr815 and δAsp911 (Figure 13d)160,162. The affinity pocket is not directly 
involved in ATP binding, whereas many PI3K inhibitors make hydrogen bond 
interactions with this pocket, resulting in increased binding affinity (discussed 
in more details in Section 0)149.  
1.6.4 Specificity pocket 
The specificity pocket is not present in the PI3K δ apoenzyme146. The 
specificity pocket is created between Trp760 and Met752, that are normally 
packed against each other in the apoenzyme, on binding a PI3K δ inhibitor 
the residues are displaced by ~ 6.5 Å (Figure 13e)153, forming a pocket in 
which the inhibitor is sandwiched between the indole ring of Trp760 and the 
side chain of Met752, suggesting that this pocket is created by an induced-fit 
mechanism146,154. The induced Met752/Trp760 specificity pocket exists in PI3K 
δ and is believed to be the main factor of the PI3K δ isoform selectivity of 
propeller-shaped PI3K δ inhibitors (discussed in more details in Section 0)154–
156, while the formation of this pocket in the other isoforms (α and β) is less 




1.6.5 Tryptophan shelf  
The tryptophan shelf (hydrophobic dimple) is the region of space located 
between Trp760 and the non-conserved residue Thr750 (Figure 13f)157,158. The 
tryptophan shelf is exclusively found in the PI3K δ isoform, as the equivalent 
residues to δThr750 are Arg770 in PI3K α, Lys802 in PI3K β and Lys771 in PI3K 
Ɣ (Figure 14)159,160. These amino acid side chains make cation-pi interactions 
with the corresponding tryptophan residue and occlude access to the 




































































































Figure 14. Sequence of the residues at the periphery of the tryptophan shelf in the four 
isoforms of class I PI3K. The key tryptophan (orange) is conserved between the four 
isoforms. However, in PI3K δ, the residue opposed to the key tryptophan is threonine (red), 
while in the other three isoforms is Arg (yellow) or Lys (blue), which forms a cation/pi 
interaction with Trp, blocking access to the tryptophan shelf. 
1.7 PI3K δ isoform selectivity 
1.7.1 Isoform selective PI3K δ inhibitors compared to pan-PI3K 
inhibitors 
Pharmacological inhibition of the four isoforms of class I PI3K (pan-class I 
PI3K inhibition) for the treatment of blood cancers and autoimmune diseases 
Non-conserved 
residues opposed to 
the key tryptophan 
The key conserved 





is not tolerated due to the generation of off-target side effects162–167, including: 
(i) hyperglycaemia (likely resulting from inhibition of the α isoform, because 
intracellular PI3K α signalling mediates insulin action downstream of insulin 
receptor substrate-1 (IRS-1)168,169); (ii) colitis (likely secondary to inhibition of 
PI3K Ɣ162–167); (iii) neutropenia a blood disorder characterized by a decrease 
in the number of neutrophils in the blood stream and associated with 
increased susceptibility to infection170 (the inhibition of PI3K Ɣ signaling 
pathway in neutrophils by pan PI3K inhibitors may be associated with the 
incidence of neutropenia166,171). Based on these findings, it was suggested 
that the severe side effects associated with pan PI3K inhibitors are the major 
challenge to obtain the drug exposure needed to achieve the optimal 
treatment effectiveness32. Hence, selective inhibition of a single PI3K isoform 
over the other isoforms will be necessary.  
1.7.2 Approaches achieve PI3K δ isoform selectivity 
The four class I isoforms PI3K bind to the same substrates which are ATP 
and PI(4,5)P2. Thus, the active sites of the four isoforms have a high degree 
of amino acid conservation combined with high structural similarity139,161, 
which explains the difficulty in achieving PI3K δ isoform selectivity85. 
However, there are 3 unique regions of the PI3K δ binding site that can be 
exploited to achieve PI3K δ selectivity over the other three isoforms144,149. The 
3 binding regions include: 1) the tryptophan shelf, 2) the specificity pocket and 
3) the affinity pocket. Although the residues occupying the above-mentioned 
regions are conserved, there are subtle variations in the non-binding amino 
acid residues that are positioned around the periphery of these regions, which 




1.7.2.1 Tryptophan shelf 
The tryptophan shelf defines the region of space located between δTrp760 and 
δThr750. δTrp760 is located within PI3K δ binding site and it is conserved 
across all isoforms (Trp780 in α, Trp812 in β and Trp781 in Ɣ) (Figure 15), 








Figure 15. Comparison of the tryptophan region of PI3K δ, PI3K α, PI3K β and PI3K Ɣ. a) 
Crystal structure of murine PI3K δ (PDB4XE0) demonstrates a big gap between the key 
Trp760 (magenta) and the opposed Thr750 (green), which is called the tryptophan shelf. b) 
Crystal structure of human PI3K α (PDB code 3HHM) demonstrates a cation-pi interaction 
between the key Trp780 (magenta) and the opposed Arg770 (green). c) Crystal structure of 
human PI3K β (PDB code 3Y3A) demonstrates a cation-pi interaction between the key Trp781 
(magenta) and the opposed Lys771 (green). d) Crystal structure of human PI3K Ɣ (PDB code 
3ENE) demonstrates a cation-pi interaction between the key Trp812 (magenta) and the 
opposed Lys802 (green). 
b) PI3K α C) PI3K β d) PI3K Ɣ 













other three isoforms, the position equivalent to δThr750 is occupied by a basic 
amino acid (arginine or lysine) (Figure 15)159,160, which forms a cation-pi 
interaction with Trp760, resulting in the blocking of the tryptophan shelf. Thus, 
this subtle difference in δThr750 residue peripheral to the ATP binding site can 
be exploited to improve PI3K δ selectivity, where PI3K δ inhibitors can make 
pi-pi or C-H/pi interactions with Trp760 (more details in chapter 2)159,172. 
1.7.2.2 Specificity pocket 
As mentioned in Section 1.6.4, the specificity pocket is an induced 
hydrophobic pocket, which is not found in the PI3K δ apoenzyme and only 
created upon contact of an inhibitor with PI3K δ, it is worth noting that this 
hypothesis is based on observation of the crystal structure of PI3K δ and it is 
not necessary a reflection of what actually happens. The specificity pocket 
comprises of the side chains of Trp760 and Ile777 on one side and Met752 and 
Pro758, on the other side173. These four residues are conserved in the four 
isoforms of class I PI3K. However, there are slight differences in the amino 
acid residues surrounding the specificity pocket (Figure 16)149. In PI3K δ, the 
specificity pocket is created due the movement of Trp760 side chain away from 
Met752, forming a wide deep pocket which can be filled by an inhibitor scaffold 
such as the quinazolinone ring (Figure 17a). The ability of the Trp760 residue 
to move is due to the high degree of flexibility of its side chain, which is not 
involved in any hydrogen bond with the neighbouring Met762 residue (Figure 
17a)149. Whereas in the other three isoforms (α, β and Ɣ) the movement of 
Trp residues (equivalent to Trp760 of PI3K δ) is partially or completely 











Figure 16. Amino acid sequence alignment of the specificity pocket of PI3K δ with other three 
isoforms of class I PI3K. PI3K α, β and Ɣ contains polar residue glutamate (highlighted in 
blue) located adjacent to the specificity pocket, which makes a hydrogen bond with the key 
tryptophan, thereby restricting its movement and disfavouring the opening of the specificity 
pocket. Whereas in PI3K δ, the equivalent residue to glutamate is the non-polar methionine 
(highlighted in red) which cannot form a hydrogen bond with the key tryptophan, the flexibility 
of tryptophan allows the opening of the specificity pocket in PI3K δ. 
a) PI3K δ 
 
b) PI3K Ɣ                                                                c) PI3K α 
 
Figure 17. The specificity pocket. (a) The specificity pocket in PI3K δ (PDB code 4XE0) is 
opened by the synchronized movement between Trp760 (magenta) and Met752 (magenta), 
Trp760 is flexible because it does not make an interaction with the surrounding residue Met762 
. (b) The specificity pocket in PI3K Ɣ (PDB 3ENE) is difficult to access because the movement 
of Trp812 (magenta) is partially restricted by the hydrogen bond network (blue dashed line) 
with the surrounding residues Glu814 (grey) and Thr827 (grey). (C) The specificity pocket in 
PI3K α (PDB 4JPS) cannot be accessed because the movement of Trp812 (magenta) is tightly 
restricted by the hydrogen bond network (blue dashed line) with the surrounding residues 
Glu798 (grey), Asn782 (grey) and Arg852 (grey). The distances between Trp (magenta) and Met 
(magenta) in the specificity pocket are marked with red dashed lines. 
PI3K α Trp780 Met772 Glu798 
PI3K β Trp781 Met773 Glu858 
PI3K Ɣ Trp812 Met804 Glu814 
PI3K δ Trp760 Met752 Met762 
The two conserved 
residues that form the 
specificity pocket 
The non-conserved 
residue at the periphery 




energetically favoured compared to PI3K δ144,173,174. In PI3K Ɣ, the movement 
of Trp812 (corresponding to Trp760 in PI3K δ) is partially restricted by the 
hydrogen bond network with the neighbouring residue Glu814 (equivalent to 
Met762 in PI3K δ) (Figure 17b). In contrast to the relatively hydrophobic 
residue δMet762, ƔGlu814 has a polar, charged side chain, which is able to 
form a hydrogen bond with ƔTrp812, causing restriction of its movement 
(Figure 17b) 175, thus, the specificity pocket in PI3K Ɣ needs more energy to 
open144,173,174. Whereas in the PI3K α isoform, the movement of Trp780 
(corresponding to Trp760 in PI3K δ) is tightly restricted (Figure 17c), as it 
makes a hydrogen bond with the surrounding residue Glu798 (corresponding 
to Met762 in PI3K δ). Glu798 in turn forms two hydrogen bond interactions with 
Asn782 and Arg852, leads to the formation of an extended hydrogen bond 
network (Figure 17c), consequently, the opening of the specificity pocket in 
PI3K α requires overcoming a high energy barrier for the breaking of the 
hydrogen network144,173,174. 
1.7.2.3 The affinity pocket 
This pocket is lined with polar and hydrophobic residues (two aspartates, 
lysine, tyrosine and two leucines). All of these 6 residues are conserved 
across the four isoforms of class I PI3K144,145. Interestingly, Sutherlin et al160, 
Schwehm et al159 and Berndt et al145 reported that the affinity pocket can be 
exploited to achieve selectivity for PI3K δ, which can be attributed to 
differences in the hydrogen bond network, caused by non-conserved 
residues beyond the affinity pocket140,149,172. In PI3K α, β and Ɣ, the tyrosine 
residue (αTyr836, βTyr833 and ƔTyr867), which lines the affinity pocket and 




a)                                                                         b) 
 
c)                                                                         d) 
 
Figure 18. The Affinity pocket (a) Affinity pocket in PI3K α (PDB code 4JPS), highlights the 
key αTyr836, which is conformationally restrained by a hydrogen bond to αArg818 (magenta), 
located outside the affinity pocket. (b) Affinity pocket in PI3K β (PDB code 2Y3A), highlights 
the key tyrosine residue (βTyr833), which is conformationally restrained by a hydrogen bond 
to βArg815 (magenta), located outside the affinity pocket. (c) Affinity pocket in PI3K Ɣ (PDB 
code 3ENE), highlights the key tyrosine residue (ƔTyr867), which is conformationally 
restrained by a hydrogen bond to ƔArg849 (magenta), located outside the affinity pocket. (d) 
Affinity pocket in PI3K δ (PDB code 4XE0), highlights the key tyrosine residue (δTyr813), which 
is NOT conformationally restrained by a hydrogen bond, as the equivalent residue to arginine 
is Glutamine (δGln795) that has a shorter side chain. The lack of hydrogen bond interaction is 
explained by 5.96 Å separation distance between the carbonyl backbone of δTyr813 and the 
side chain of δGln795. 
because it is involved in a hydrogen bond network with the nearby arginine 
(αArg818, βArg815 and ƔArg849) (Figure 18a, 18b and 18c). However, the 
corresponding residue to arginine is a glutamine (Gln795) in PI3K δ. Glutamine 




a hydrogen bond with δTyr813 (Figure 18d). Accordingly, δTyr813 has greater 
rotational freedom when compared to its equivalents in other three isoforms 
(discussed in chapter 2 in more detail)144. 
1.8 Types of PI3K inhibitors based on their isoform selectivity 
Class-I PI3K inhibitors are subdivided into three categories based on their 
isoform selectivity profile: non-selective (pan) inhibitors (inhibit the four 
isoforms), dual inhibitors (inhibit two isoforms) and isoform-selective PI3K 
inhibitors (inhibit a single isoform)176,177. The following section reviews 
selected examples of each class (Table 2).  
Table 2. List of PI3K inhibitors that are approved for use or undergoing clinical development. 
This list also includes the therapeutic use of these inhibitors and their biochemical activities 
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SLL and FL 




1.8.1 Pan-PI3K inhibitor: pictilisib (4) 
Pictilisib (4) (Figure 19) is a potent, orally available, highly selective class-I 
PI3K inhibitor with a good margin of selectivity against other members of the 
PI3K-related kinases (PIKK) family such as mTOR and DNA-dependent 
protein kinase (DNA-PK)181,182. Pictilisib (4) possesses equal activities 
against PI3K α and δ with IC50 = 3 nM, but shows comparatively less activity 
against PI3K β and Ɣ with IC50 values of 33 nM and 75 nM, respectively (Table 
2)181,182. In vitro and preclinical studies have displayed that 4 was effective 
against tumours driven by PI3KCA or PTEN mutations181,183,184. Pictilisib (4) 
is currently undergoing phase II clinical trials in combination with other 
anticancer drugs such as paclitaxel and anastrozole, for treatment of locally 
advanced and metastatic solid tumours that harbour PI3KCA mutations such 
as breast cancer185–187.  
However, the efficacy of 4 was likely limited by the development of serious, 
often intolerable adverse effects especially neutropenia, haemolytic anaemia, 
decreased appetite and diarrhoea, which appear to be attributable to the non-
isoform selective inhibition of PI3K. Diarrhoea was found to be the major 
cause for discontinuation of pictilisib (4) treatment in the clinical studies187. 
Based on these findings, Genentech stopped the clinical development of 4 in 
2018186. 
1.8.1.1 Binding Interactions of pictilisib (4) with PI3K δ 
Pictilisib (4) has a thienopyrimidine core that bears three binding arms (Figure 
19). The morpholine ring forms a critical hydrogen bond to the amide 
backbone of Val828 (conserved) in the hinge region of the kinase (Figure 19b). 




a)                                                     b) 
 
Figure 19. a) The non-selective PI3K inhibitor pictilisib (4) and its binding points at PI3K δ182. 
b) Crystal structure of murine PI3K δ (PDB code 2WXP) with pictilisib (4) bound. Dashed pink 
lines represent the proposed hydrogen bonds149. 
the indazole N-1 forms a hydrogen bond with the side chain of Asp787 and N-
2 makes a hydrogen bond with the phenolic side chain of Tyr813 (Figure 19b). 
The 4-methanesulfonyl-piperazine-ylmethyl group fits into a channel pointing 
towards solvent, leading to the improvement the solubility (Figure 19b)182. All 
the residues (Val828, Tyr813 and Asp787) that 4 binds to are conserved among 
the four isoforms of class I PI3K, thus 4 is considered a non-selective class I 
PI3K inhibitor182,188.  
1.8.2 Dual-selective PI3K inhibitor 
The term ‘dual-selective PI3K inhibitors’ refers to the compounds with a 
predominant activity against only two PI3K isoforms and little or no activity 
against the other two isoforms189. The main idea behind developing dual 
inhibitors is that they can offer an improvement in safety versus pan PI3K 
inhibitors190. Moreover, dual PI3K inhibitors show superior efficacy when 
compared with isoform-specific inhibitors for treating different types of blood 




1.8.2.1 PI3K δ and γ dual inhibitor: duvelisib (5)  
Duvelisib (5) (Figure 20) was developed by Verastem Oncology as an orally 
bioavailable dual PI3K δ/ Ɣ inhibitors (Table 2)192. δ and Ɣ isoforms are both 
preferentially expressed in immune cells, where they exert complementary 
non-overlapping roles in the pathogenesis of blood cancers and 
inflammation193. In CLL disease, PI3K δ is expressed in malignant B-
cells96,194, where it regulates CLL cell survival, migration and 
proliferation96,194,195, whereas PI3K Ɣ is mainly expressed in macrophages 
within tumour microenvironment, where it mediates the release of cytokines 
that induce immune suppression and promotes CLL proliferation (cross-talk 
mechanism)196–198. Thus, dual blockade of isoforms PI3K δ and Ɣ provides 
an effective therapeutic strategy for patients with CLL and other blood 
cancers199. Accordingly, duvelisib (5) (Copiktra, developed by Verastem) has 
been approved by the FDA in 2018 for treatment of CLL, SLL and follicular 
non-Hodgkin’s lymphoma (FL) (Table 2)189,200. 
However, 5 treatment was associated with severe adverse events including 
colitis, pneumonitis, hepatotoxicity and diarrhoea201,202. Duvelisib-induced 
colitis and pneumonitis are thought to be immune-related, caused by the 
suppression of the PI3K δ signalling in the Treg cells, which play a key role in 
the prevention of autoimmune response by maintaining self-tolerance202–204. 
The mechanism responsible for duvelisib-induced liver injury is not known, 
but it can be a consequence of inhibition of PI3K δ and/or PI3K Ɣ in 
hepatocytes (direct toxicity) or due to immune-mediated liver injury (indirect 
toxicity)202,205. Hepatoxicity of 5 explains why it has not been commonly used 




1.8.2.2 Binding Interactions of duvelisib (5) with PI3K δ 
The PI3K δ and Ɣ isoforms have unique structural differences from the α and 
β isoforms, that could be exploited for their selective targeting145. It was widely 
suggested that 5 achieved a high degree of selectivity for PI3K δ and Ɣ 
isoforms versus α and β by exploiting the induced specificity pocket that can 
be easily accessed in PI3K δ and PI3K Ɣ189, while the opening of this pocket 
in α and β isoforms was less easy (see Section 0 and Figure 17c for more 
details).  
To date, a crystal structure of PI3K δ in complex with 5 is not available189. 
However, owing to the structural similarity between 5 and idelalisib (8) (will 
be covered in Section 1.8.3.2.2), it was hypothesized that the binding 
mechanisms of the two compounds to the active site of PI3K δ are similar189. 
(Figure 23 in Section 1.8.3.2.2 shows the crystal structure of PI3K δ with 
idelalisib (8) bound. To support this hypothesis, molecular docking of 5 to the 
PI3K δ binding site was carried out (Figure 20b). The docking results were 
consistent with the above hypothesis, revealing that the 8-
chloroisoquinolinone ring of 5 was sandwiched between the side chains of 
Met750 and Trp760 in the newly created specificity pocket. The occupation of 
this pocket forces 5 to adopt a propeller-shaped conformation in the PI3K δ 
binding site, where the 8-chloroisoquinolone scaffold lies perpendicular to the 
purine and phenyl rings (Figure 20b). The purine ring makes two hydrogen 
bonds with the hinge region, one formed between the hydrogen bond 
acceptor purine N-3 and the amide backbone of Val828. The second between 
the hydrogen bond donor NH-9 of the purine and the carbonyl backbone of 




hydrophobic region II where it makes hydrophobic interactions with the side 
chains of Asp832, Thr833 and Asn836 (Figure 20b). 
a)                                                                            b) 
 
Figure 20. The dual PI3K δ/ Ɣ inhibitor duvelisib (5) and its binding points at PI3K δ178. b) 
Duvelisib (5) docked into the PI3K δ model (generated from PDB code 4XE0), It can be 
noticed that duvelisib (5) adopts a perpendicular conformation in the binding site of PI3K δ. 
Dashed blue lines represent the proposed hydrogen bonds. 
1.8.2.3 PI3K δ and α dual inhibitor: copanilisib (6) 
Copanilisib (6) (Figure 21) is an intravenous dual PI3K inhibitor, mainly 
targeting PI3K α and δ isoforms206,207. Copanilisib (6) displayed sub-
nanomolar potency against PI3K δ and α isoforms (IC50 values of 0.7 and 0.3 
nM, respectively) with more than 10-fold selectivity over PI3K β and PI3K Ɣ 
(Table 2)179,208,209. Copanilisib (6) is the only approved PI3K inhibitor, that is 
given intravenously209, this might be because 6 has a highly reactive amide 
group (Figure 21), which is prone to hydrolysis by intestinal digestive 
enzymes210.  
Copanilisib (6) can be used for the treatment of solid tumours as well as 
haematological cancers (Table 2)179,211. In solid tumours, 6 is capable of 




α (encoded by the PIK3CA gene)208, which is considered to be among the 
most frequently mutated oncogenes in solid tumours such as breast 
cancer208,212. Whereas in haematological cancers, 6 exerts antitumor activity 
by inducing apoptosis of cancerous B-cells through the inhibition of the PI3K 
δ pathway208,209. For instance, 6 was found to be around 10-fold more active 
than 5 in inhibiting survival of CLL cells192, suggesting that dual inhibition of 
PI3K δ and α is more effective treatment for CLL than dual PI3K δ and Ɣ 
inhibition192. Accordingly, on September, 2017, the FDA granted accelerated 
approval for 6 (Aliqopa, developed by Bayern) to treat patients with relapsed 
FL who have received at least two prior systemic therapies, based on the 
results of phase II clinical trials (Table 2)207. 
The most common adverse effects of 6 include hyperglycaemia, neutropenia, 
infections, hypertension and diarrhoea209,213. Hyperglycaemia is attributable 
to the on-target effect of PI3K α inhibition that results in disruption of insulin-
receptor signalling and decreased glucose uptake in peripheral 
tissue207,209,214. Copanilisib-induced hyperglycaemia could be managed with 
short-acting insulin and/or oral anti-diabetic drugs following intravenous 
treatment with copanilisib (6)215. Hypertension is an uncommon adverse 
effect of PI3K inhibitors, and is only noticed with 6, it is likely attributable to 
the infusion-related inhibition of the PI3K α isoform209,213,216. However, 
copanilisib-related hypertension is reversible and temporary in nature and 
can be relieved by stopping the taking of the drug215. In comparison to other 
class I PI3K inhibitors, 6 is associated with less gastrointestinal toxic 
effects209,213, which is not surprising, given the fact that 6 is only administered 




1.8.2.4 Binding Interactions of copanilisib (6) with PI3K δ 
There is no available crystal structure of PI3K δ bound to 6. However, Bayern 
published the only crystal structure of 6 bound to human PI3K Ɣ (PDB code 
5G2N) (Figure 21b)179,209. The structure reveals that nitrogen N-1 on the 
imidazoline ring makes a hydrogen bond with Val882 (equivalent to δVal828) in 
the hinge region (Figure 21b)179,209. The aminopyrimidine ring extends to the 
affinity pocket, where the exocyclic amino group N-2 is involved in two 
hydrogen bonds with Asp836 and Asp841 (equivalent to δAsp911 and δAsp787, 
respectively), whereas the pyrimidine nitrogen N-3 acts as a hydrogen bond 
acceptor for Lys833 (equivalent to δLys779) (Figure 21b)179,209. The methoxy 
group projects toward the ribose-binding pocket, the introduction of the 
methoxy group or other substituents to this pocket did not lead to an increase 
in potency, which could explain the fact that the ribose pocket is not frequently 
exploited in the discovery of PI3K inhibitors217. Finally, the morpholine group 
a)                                 b) 
     
Figure 21. a) The dual PI3K α/δ inhibitor copanilisib (6),and its binding points at PI3K Ɣ, 
highlights the atoms and groups (in red) involved in interactions with PI3K Ɣ b) Crystal 
structure of human PI3K Ɣ (PDB code 5G2N) with copanilisib (6) bound, pink dashed lines 
indicate the proposed hydrogen bond with Lys833 (Lys779 in PI3K δ), Asp841 (Asp911 in PI3K δ) 





was added to position 4 of the central scaffold via a propoxy linker, where it 
extends towards the solvent channel at the entrance of the binding pocket 
(Figure 21b). The main role of the morpholine group is to increase the water 
solubility and oral bioavailability of 6179,209. 
1.8.3 PI3K δ isoform-specific inhibitors 
Single isoform inhibitors represent the newest generation of PI3K inhibitors 
that maximize on-target and minimize off-target binding events. Yang et al206 
and Wang et al177 have reported that isoform-selective PI3K δ inhibitors have 
superior safety than dual and pan PI3K inhibitors. Moreover, the functional 
non-redundancy between the four isoforms of PI3K expressed in solid and 
haematological malignancies has encouraged the development of isoform-
specific inhibitors177. Selective PI3K δ inhibitors are sub classified into two 
categories, based on their binding modes within the active site of PI3K δ: 
relatively flat-shaped inhibitors and propeller-shaped inhibitors144,145. 
1.8.3.1 Relatively flat-shaped PI3K δ inhibitors: leniolisib (7) 
The flat-shaped inhibitors adopt a flat (extended) conformation in the ATP 
binding site when bound to PI3K δ 146,159. Flat-shaped inhibitors bind to PI3K 
δ by interacting with three binding regions: 1) The affinity pocket is typically 
filled by either an aryl or heteroaryl group, where it forms two hydrogen bonds, 
one with the carboxylate side chain of δAsp787 and the other with the phenolic 
side chain of δTyr813157. 2) The hinge region is usually occupied by either a 
saturated or unsaturated heterocycle, where it engages in a single hydrogen 




occupied by a linear or saturated heterocyclic group, where it makes C-H/pi 
interactions with the δTrp760 218–220, (more details in chapter 2). 
There are currently no FDA-approved flat-shaped PI3K δ inhibitors, however 
leniolisib (7) has been developed by Novartis and is currently is being tested 
in phase III clinical trials for the treatment of activated PI3K δ syndrome 
(APDS) (Table 2)221, which is a genetic disorder caused by mutations in 
PI3K3D gene encoding the PI3K δ enzyme, resulting in hyperactivation of 
PI3K δ signalling in B and T lymphocytes222. APDS leads to 
immunodeficiency associated with increased susceptibility to bacterial and 
viral infections223. Moreover, 7 is currently in phase II clinical trials for 
treatment of Sjögren syndrome (SS) (Table 2)219,221, an autoimmune disease 
characterized by two hallmark symptoms dry eyes and dry mouth224, it results 
from lymphocytes attacking salivary and lacrimal glands, leading to their 
dysfunction and destruction225. Novartis reported that in Phase II/III, 7 did not 
cause hyperglycaemia, neutropenia and diarrhoea, which are known class 
effects of PI3K inhibitors226–228. Leniolisib (7) displayed excellent potency 
against PI3K δ (IC50 value of 9 nM) with 29, 183 and 514-fold selectivity over 
PI3K α, β and Ɣ respectively (Table 2)229. 
1.8.3.1.1 Binding Interactions of leniolisib (7) with PI3K δ 
Crystal structure of PI3K δ in complex with Leniolisib (7) (PDB code 5O83) 
was determined. The structure revealed that 7 adopts a relatively extended 
conformation (Figure 22b)229, where the propionamide group is directed 
towards the tryptophan shelf, stacking with the indole ring of δTrp760, resulting 
in a C-H/pi interaction. The methoxypyridine moiety inserts deeply into the 




hydrogen bond with δLys779 (Figure 22b). Lastly, the nitrogen atom N-1 of the 
central piperido-pyrimidine scaffold forms a single hydrogen bond interaction 
with δVal828 of the hinge region (Figure 22b)219,229. 
a)                                                                 b) 
 
Figure 22. a) The flat-shaped selective PI3K δ inhibitor leniolisib (7), and its binding points at 
PI3K δ. b) Crystal structure of leniolisib (7) complexed with murine PI3K δ (PDB code 5O83) 
showed that 7 adopts a relatively flat conformation at the PI3K δ binding site. The 
propionamide group folds to fit the tryptophan shelf and make C-H/pi interactions with Trp760. 
Dashed pink lines represent the proposed C-H/pi interactions. 
1.8.3.2 Propeller-shaped PI3K δ inhibitor: idelalisib (8) 
In contrast to flat-shaped PI3K δ inhibitors, all propeller-shaped PI3K 
inhibitors adopt orthogonal conformations when they bind to PI3K δ146,149, 
where the three substituents (blades) are twisted almost perpendicularly 
146,149. It is also important to note that propeller-shaped inhibitor interaction 
regions on PI3K δ are different from flat-shaped inhibitor binding regions, the 
former inhibitors bind to PI3K δ at the hinge region, specificity pocket and 
hydrophobic region II (Table 3), while the latter interact with PI3K δ in the 
hinge region, affinity pocket and tryptophan shelf145,146,152. The specificity 
pocket is generally occupied by a hetero-bicyclic ring system, which is usually 
quinazolinone ring145. Hydrophobic region II is usually filled by an aryl ring 




interactions with the residues lining this region. Lastly, in the hinge region, 
propeller-shaped inhibitors engage in dual hydrogen bond interactions with 
the backbones of Glu826 and Val828. Therefore, the hinge binder of propeller-
shaped inhibitors is typically a heterocyclic ring, which contains both a 
hydrogen bond acceptor and donor such as a purine and aminopyrimidine 
ring180. A classic example of a propeller-shaped PI3K δ inhibitor is idelalisib 
(8) (Figure 23a) 154,230,231, which is the only FDA-approved single isoform 
selective PI3K δ inhibitor. Thus, in this thesis, 8 will be used as a starting point 
to develop more potent and selective PI3K δ inhibitors. 
Table 3. The difference between the binding regions of flat-shaped inhibitors and propeller-
shaped inhibitors in the PI3K δ binding site145,146,152. 




Specificity pocket Not bound Bound 
Hydrophobic region II Not bound Bound 
Hinge region 
Bound 
(1 H.B interaction) 
Bound 
(2 H.B interactions) 
Affinity pocket Bound Not bound 
Tryptophan shelf Bound Not bound 
1.8.3.2.1 Uses and biological activity of idelalisib (8) 
Idelalisib (8) (Zydelig, developed by Gilead) was approved in 2014 for the 
treatment of three types of B-malignancies126,180. Idelalisib (8) is used in 
combination with rituximab (monoclonal antibody) to treat patients with 
relapsed or refractory CLL (Table 2)232,233. Moreover, it can be used alone in 
the treatment of patients with relapsed FL and relapsed SLL, who have 
received two lines of treatment, including rituximab and alkylating agents as 




potency against PI3K δ (IC50 = 11 nM) while having 1273, 255 and 5-fold 
selectively over PI3K α, β and Ɣ, respectively (Table 2)180. To understand the 
mechanism underlying PI3K δ selectivity of 8, the crystal structure of the 
idelalisib-PI3K δ complex was studied. 
1.8.3.2.2 Binding interactions of idelalisib (8) to PI3K δ 
Somoza et al153 disclosed the crystal structure of 8 in complex with PI3K δ. 
The structure showed that 8 adopts a propeller-shaped (T-shaped) 
conformation in the binding site of PI3K δ (Figure 23b)234. Idelalisib (8) 
occupies the induced specificity pocket with the quinazolinone ring, where 
Trp760 and Met752 that are normally packed against each other in the 
apoenzyme, when they come in contact with 8 they move away from each 
other by  ~ 6.5 A°, to create the pocket for the fluoro quinazolinone core to fit 
(Figure 23)153. The phenyl group is oriented perpendicular to the 
quinazolinone scaffold and points toward the hydrophobic region II, where it 
a)                                                                 b) 
             
Figure 23. a) The propeller-shaped selective PI3K δ inhibitor idelalisib (8). b) Crystal structure 
of murine PI3K δ (PDB code 4XE0) with 8 bound. It can be noticed that 8 adopts a 
perpendicular conformation in the binding site of PI3K δ. Dashed blue lines represent the 




forms Van der Waals interactions with the side chains of Asp832, Thr833 and 
Asn836 (Figure 23b)140,145,153. Idelalisib (8) occupies the hinge region with the 
purine ring, which comprises the third arm of the inhibitor and adopts a 
binding conformation perpendicular to the quinazolinone ring235. The N-3 of 
the purine ring serves as a hydrogen bond acceptor to the amide backbone 
of Val828, whereas the NH-9 acts as a hydrogen bond donor to the carbonyl 
backbone of Glu826 (Figure 23b)234.The number of hydrogen bond interactions 
at the hinge region is one of the most striking differences between the 
propeller-shaped inhibitors such as 8 and flat-shaped inhibitors such as 7, the 
former make two hydrogen bonds (Figure 23b), while the latter only form one 
hydrogen bond (Figure 22b)159,218,229. 
1.8.3.2.3 Side effects of idelalisib (8) 
Unfortunately, 8 has a black box warning on its product label for causing 
serious and fatal side effects which can include diarrhoea, serious 
hepatotoxicity, colitis, serious pneumonitis and neutropenia154,230,231. One or 
more of these adverse events were observed in 68% of patients treated with 
8236,237, where they are the main cause of dose reduction and treatment 
discontinuation of 8 238.  
1.8.3.3 A new hypothesis about the nature of idelalisib-induced 
side effects 
As outlined in Section 1.8.3.1, Rao et al226 reported that the selective oral 
PI3K δ inhibitor, 7, does not cause serious adverse effects such as diarrhoea, 
colitis, neutropenia and liver toxicity, that are observed with 8 (Table 4). 
Moreover, a recent study by Shin et al239 reported that idelalisib-related 




structure. These findings contradict the traditional hypothesis that idelalisib-
associated adverse effects produced as a result of inhibition of PI3K δ (on-
target effect). Thus, based on the literature information mentioned above, a 
new hypothesis could be proposed, which states that serious toxicities 
observed with 8 are chemical-based and not mechanism-related, providing a 
great opportunity for the development of safer and more effective PI3K δ 
inhibitors, by using classic medicinal chemistry structure-activity relationship 
(SAR) approach. 
Table 4. Comparison of side effects of 8 (number of patients= 110)237 and 7 (number of 
patients= 6)226. 
Adverse effects Idelalisib (8) Leniolisib (7) 
Diarrhoea and colitis 35 / 110 patients 0 / 6 patients 
Neutropenia 71 / 110 patients 2 / 6 patients 
Liver 
toxicity 
ALT increased 43 / 110 patients 0 / 6 patients 
AST increased 31 / 110 patients 0 / 6 patients 
Skin rash 31 / 110 patients 0 / 6 patients 
1.9 Aim and objectives 
Currently, 8 is the only selective PI3K δ inhibitor approved in the market155. 
However, the efficacy of 8 is limited for its frequent therapy-related adverse 
events (described above), which might cause patients to permanently stop 8 
treatment240, thus 8 has a black box warning in its package insert given by 
FDA154. Accordingly, the main aim of this work was to discover and develop 
potent and highly selective PI3K δ inhibitors as potential anticancer and anti-
inflammatory drugs, which may represent better alternatives to 8. The novel 




with an improved tolerability and safety profile. In turn, these research efforts 
were centred in the development of novel compounds belong to two classes 
of PI3K δ inhibitors (flat-shaped and propeller-shaped inhibitors). The 
distinctions between the flat-shaped and propeller-shaped PI3K δ inhibitors 
are shown in Figure 24. 
a)                                                                       b) 
  
Figure 24. Differences between the flat-shaped inhibitor 7 and propeller-shaped inhibitor 8. 
a) Crystal structure of murine PI3K δ (PDB code 5O83) with 7 bound, displays that 7 adopts 
a relatively flat conformation in the binding site of PI3K δ, where it interacts with three binding 
regions: affinity pocket (in green), tryptophan shelf (in yellow) and hinge region (in violet). b) 
Crystal structure of murine PI3K δ (PDB code 4XE0) with 8 bound displays that 8 adopts a 
perpendicular conformation in the binding site of PI3K δ, where it interacts with three binding 
regions: specificity pocket (in blue), hydrophobic region II (in red) and hinge region (in violet). 
1.9.1 Flat-shaped inhibitors (chapter 2)  
The non-selective PI3K inhibitor pictilisib (4) serves as a lead compound for 
extensive structural modification with an aim to explore novel and selective 
PI3K δ inhibitors. In this research, a novel series of thienopyrimidine 
derivatives were designed, synthesised and evaluated for their PI3K δ activity 
and selectivity. 
Based on the crystal structure of murine PI3K δ with 4 (PDB code 2WXP), 
two directions were explored to improve the PI3K δ activity and selectivity of 
4. First, PI3K δ, in contrast to the other three isoforms, exclusively contains a 
tryptophan shelf, which could be exploited to achieve selective inhibition of 




display selective activity against PI3K δ. This could be attributed to the 
conformational rigidity of the cyclic side chain (4-methanesulfonyl-piperazine-
ylmethyl group), which makes 4 unable to fold and interact with Trp760 at the 
tryptophan shelf (Figure 25). Driven by this hypothesis, a bioisosteric 
replacement of the cyclic piperazine with an open side chain (Figure 25), 
which can fold to fit the tryptophan shelf due to its increased conformational 
flexibility, was conducted. Meanwhile, a terminal binding group (R) was 
introduced onto the flexible side chain to interact with Trp760 at the tryptophan 
shelf.  
 
Figure 25. The replacement of the piperazine ring of 4 with acyclic analogues could improve 
the flexibility of the side chain and potentially allow it to fit in the tryptophan shelf region. Thus, 
the binding group R (in yellow) would be able to make an interaction withTrp760 at the 
tryptophan shelf. 
The second direction was to utilize the affinity pocket to confer PI3K δ 
selectivity. It is widely believed that selective PI3K δ inhibition at the affinity 
pocket is the most difficult to achieve because the residues lining this pocket 
are conserved across all isoforms. However, Sutherlin et al160, Schwehm et 
al159 and Berndt et al145 reported that substitutions at the affinity pocket could 
modulate PI3K δ potency and selectivity, which is most likely due to the 
presence of non-conserved residues outside this pocket (in the surrounding) 




PI3K δ (PDB code 2WXP) shows that the indazole moiety resides within the 
affinity pocket where it engages in two hydrogen bonds with Asp787 and Tyr813. 
Thus, similar motifs to indazole which would be able to form similar 
interactions with the affinity pocket were sought out. Bioisosteric groups such 
as indole and phenol groups were explored (Figure 26), in order to mimic the 
spatial arrangement of indazole such that interactions with the affinity pocket 
were retained or enhanced. To test this hypothesis, in this research, two 
series of compounds would be designed and synthesized by replacing the 
indazole ring with an indole and phenol groups to test their potential as 
selective PI3K δ inhibitors. 
Figure 26. The proposed two series of compounds resulting from bioisosteric replacement of 
indazole moiety in 4. One series will have an indole group as an affinity pocket binder while 
the second series will have a phenol group as an affinity pocket binder. 
1.9.2 Propeller-shaped inhibitors (Chapters 3, 4 and 5): 
The majority of propeller-shaped inhibitors including 8 have been designed to 
interact with PI3K δ at the three binding points (specificity pocket, hinge 
region and hydrophobic region II), while leaving the fourth region (affinity 
pocket) unoccupied (Figure 27). Figure 24a has shown that the affinity pocket 
is normally occupied by the flat-shaped PI3K δ inhibitors which accounts for 
their high PI3K δ activity. This finding suggests that the affinity pocket is 




a)                                                             b) 
  
Figure 27. a) The typical propeller-shaped PI3K δ inhibitor idelalisib (8) and its binding points 
at PI3K δ, highlights the unoccupied affinity pocket153. b) Crystal structure of murine PI3K δ 
(PDB code 4XE0) with 8 bound, shows that 8 adopts a propeller-shaped conformation. The 
hinge region is shown in violet, the open specificity pocket in yellow, the hydrophobic region 
II in orange, and the unoccupied affinity pocket in grey180.  
increase the number of binding interactions from 3 to 4, leading to a positive 
impact on the potency of the inhibitors. In support of this hypothesis, Berndt 
et al173 and Williams et al193 reported that additional gains of activity for 
propeller-shaped inhibitors 9 can be obtained when substituents bearing 
hydrogen bond donor and/or acceptor added to the lead compound that 
extended to the affinity pocket and involved in hydrogen bonding with polar 
residues that lined the affinity pocket241. For instance, 3-flourophenol in SW13 
(10) and butynol in SW30 (11) (Table 5) projects from the central 
pyrazolopyrimidinineamine core to the affinity pocket where they engage in 
hydrogen bonding with Asp787 (in 10 and 11) and Lys779 (in 10). These 
interactions result in improved affinity at the δ isoform in comparison to the 
parent compound 9 (Table 5)242. However, this extension strategy has never 
been tried on FDA-approved 8, thus, pioneering research would be carried 
out, in which the structure of 8 (IC50 = 11 nM) is modified by extending the 




hydrogen bond interactions with the residues lining this pocket. This approach 
is known as drug extension and it may increase the potency of 8 by 10 to 100-
fold. 
 
Table 5. Biological evaluation and isoform selectivity for PI3K δ for compounds 9-11 reported 
by Berndt et al173, Compound 10 and 11 have a substituent (R) that extends towards the 
affinity pocket, resulting in a significant improvement of PI3K δ potency, compared to the 
parent compound 9. 
compd R PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
9173 -H 130 1538 123 469 
10173 
 
0.7 1857 314 47 
11173 
 





Chapter 2  Design, Synthesis and 
Pharmacological Characterization of Novel 
Thienopyrimidine-based PI3K δ selective Inhibitors 
(Flat-Shaped Inhibitors) 
2.1 Aim 
As mentioned in the introduction, selective PI3K δ inhibitors are segregated 
into two classes: flat-shaped inhibitors and propeller-shaped inhibitors, this 
chapter will cover the former class. They are called flat-shaped inhibitors 
because they adopt a flat conformation in the ATP binding site when they 
bound to class I PI3Ks (see Figure 24a in Chapter 1), in contrast to propeller-
shape inhibitors that adopt orthogonal conformation (see Figure 24b in 
Chapter 1). In this medicinal chemistry research, pictilisib (4) (Figure 28) 
(Table 6), a non-selective PI3K inhibitor (IC50 values of 44, 220, 220 and 11 
nM for isoforms PI3K α, β and Ɣ and δ, respectively), was chosen as the 
starting point for chemical modification in order to improve PI3K δ potency 
and selectivity. Therefore, the co-crystal structure of PI3K δ and pictilisib (4) 
is crucial for structure-based design of isoform selective PI3K δ inhibitors 
(Figure 28b).  
Table 6. Biological evaluation and isoform selectivity for PI3K δ for non-selective PI3K 
inhibitor (pictilisib, 4). 
aPotency against the different PI3K isoforms is given as IC50 values (n = 7). bThe potency 
threshold for the PI3K δ assay is ~ IC50 1 nM due to substrate concentration. The standard 
errors were not provided by GlaxoSmithKline (GSK).  
Isoform potencya,b IC50 (nM) Isoform selectivity 
PI3Kδ δ/α δ/β δ/Ɣ 




a)                                             b) 
  
Figure 28. a) The non-selective PI3K inhibitor pictilisib (4) and its binding points at PI3K δ182. 
b) Crystal structure of murine PI3K δ (PDB code 2WXP) with pictilisib (4) bound. Dashed pink 
lines represent the proposed hydrogen bonds. 
PI3K δ selectivity can be achieved by taking advantage of the difference in 
the peripheral residues contained within the ATP binding sites of the PI3K 
class 1 isoforms. One of these sites is called the “tryptophan shelf” that is 
exclusively found in the PI3K δ isoform and not in other three isoforms (α, β 
and Ɣ)160. The tryptophan shelf in PI3K δ is the region in space located 
between Trp760 and Thr750 (see Figure 15 in Chapter 1), where -stacking 
groups can bind. PI3K α, β and Ɣ lack this tryptophan shelf, as the equivalent 
residues to Thr (PI3K δ) are Arg in PI3K α and Lys in PI3K β and Ɣ. These 
amino acid side chains make cation-pi interactions with the corresponding Trp 
residue and occlude access to the tryptophan shelf (see Figure 15 in Chapter 
1).  
There is currently no clinically-approved drug from this class of PI3K δ 
inhibitors. The most advanced compound (leniolisib, 7) (see Section 1.8.3.1 
and Figure 22 in Chapter 1) is in phase II clinical studies for treatment of 
Sjogren syndrome229. The aim of this medicinal chemistry program is the 
discovery of a novel series of highly potent and selective thienopyrimidine-




maintain the desirable PI3K δ activity in pictilisib (4) (Table 6), while improving 
the selectivity against the other three isoforms (PI3K α, β and Ɣ).  
2.2 Binding Interactions of the lead compound (pictilisib, 4) 
Pictilisib (4) has a thienopyrimidine core that bears three binding arms (Figure 
28). The morpholine ring forms a critical hydrogen bond to the amide 
backbone of Val828 (conserved) in the hinge region of the kinase. On the other 
hand, the indazole ring fits deeply into the affinity pocket where the indazole 
N-1 forms a hydrogen bond with the side chain of Asp787 and N-2 makes a 
hydrogen bond with the phenolic side chain of Tyr813. The 4-
(methanesulfonyl)piperazine-ylmethyl group fits into a channel pointing 
towards solvent, leading to the improvement of solubility (Figure 28b)182. All 
the residues (Val828, Tyr813 and Asp787) that pictilisib (4) binds to are 
conserved among the four isoforms of class I PI3K, thus pictilisib (4) is 
considered to be a non-selective class I PI3K inhibitor (PI3K δ= 11 nM, PI3K 
α= 44 nM , PI3K β= 220 nM and PI3K Ɣ= 220 nM)182,188.  
2.3 Structural Modifications on pictilisib (4) 
2.3.1 Thienopyrimidine scaffold  
The thienopyrimidine nucleus serves as the scaffold for many PI3K δ 
inhibitors159,243, Schwem et al159, Sutherlin et al160 and Safina et al161 reported 
series of thienopyrimidine-based selective PI3K δ inhibitors (Table 7)159,243, 
where it was found that the thienopyrimidine scaffold can retain the original 
binding groups of the molecule in a good binding orientation182,243, proposing 
that subtype selectivity for PI3K δ could be achieved within the 
thienopyrimidine class of PI3K inhibitors. Thus, thienopyrimidine is 




suggested compounds in this chapter would be thienopyrimidine-based 
derivatives. 
 
Table 7. Biological evaluation and isoform selectivity for PI3K δ for thienopyrimidine-based 
selective PI3K δ inhibitors.  
compd PI3K δ potencyIC50 (nM) 
Isoform fold-selectivity 
δ/α δ/β δ/ Ɣ 
12144 0.7 4000 400 2000 
13160 3.8 340 200 410 
14161 1.8 129 104 1444 
2.3.2 Morpholine (hinge binder) 
The morpholine ring has been reported in many selective PI3K δ 
inhibitors159,182,243. The crucial characteristic of these inhibitors is the critical 
interaction between the morpholino oxygen and the backbone amide of Val828 
in the hinge region (Figure 28b). Replacement of oxygen of the morpholine 
moiety by sulfur, nitrogen, hydroxymethyl or methylene led to a major loss in 
the PI3K δ activity (Table 8)244,245. This showed that the desirable PI3K δ 




region244. Moreover, morpholine proved to have better physiochemical 
properties than its analogues where the weak basicity (pKa= 8.4) of 
morpholine allows an increase in solubility without affecting permeability246. 
According to this, the morpholine is the best group combining potency and 
physiochemical properties.  
Table 8. Biological evaluation and isoform selectivity for PI3K δ for compounds 15 and 16 
reported by Andrs et al245.  
2.3.3 N-sulfonylpiperazine side chain (tryptophan shelf binder) 
Pictilisib (4) will undergo structural modifications to increase its PI3K δ 
selectivity. This can be achieved by increasing the flexibility of the side chain 
(4-(methanesulfonyl)piperazine-ylmethyl group) that points towards the 
solvent channel, where it does not play a significant role in the binding182. The 
increase in the side chain flexibility might allow it to access the face of Trp760 
(tryptophan shelf), that can be only accessed in PI3K δ (see Figure 15 in 
Chapter 1), affording improved PI3K δ potency and selectivity. A ring opening 
strategy would be applied to the piperazine ring to generate a flexible and 
linear acyclic side chain (Figure 29), with a higher degree of conformational 
freedom. This side chain will act as a flexible linker to bridge between a 
thienopyrimidine scaffold and the functional group R that could target the 
tryptophan shelf.  
Compd R1 
Isoform Potency IC50 (nM) 
PI3Kδ PI3Kα PI3Kβ PI3KƔ 
15245 
 
100 500 5 > 10000 
16245 
 





Figure 29. The replacement of the piperazine ring of pictilisib (4) with acyclic analogues could 
improve the flexibility of the side chain and potentially allow it to fit in the tryptophan shelf 
region. 
2.3.4 Indazole ring (Affinity pocket binder) 
Additionally, the second functional group in the pictilisib (4) chemical structure 
which will undergo structural modification is the indazole moiety that fits deep 
into the affinity pocket (Figure 30), where indoles and phenols will be used as 
bioisosteres for the indazole ring. Although the affinity pocket contains 
conserved residues across the class 1 isoforms, it was found that 
replacement of the indazole with an indole group offers higher PI3K δ 
selectivity, while PI3K δ potency was improved by replacement of indazole 
with a phenol group159,182,243. The variation in the PI3K δ activity and 
selectivity between the bioisosteric analogues is due to differences in the 
hydrogen bond network, caused by non-conserved residues that surrounding 
the affinity pocket (see Section 2.5.1, Figure 34 and Figure 35 for more 
details)140,149,172.  
In conclusion, the thienopyrimidine scaffold and the morpholine hinge binder 
would be retained in the proposed compounds. The indazole ring that fits into 
the affinity pocket would be replaced by the bioisosteric indole and phenol 




flexibility of the sulfonylpiperazine side chain to allow access to the tryptophan 
shelf.  
 
Figure 30. The non-selective PI3K inhibitor pictilisib (4), highlighting the indazole group in the 
affinity pocket that will undergo bioisosteric replacement.  
2.4 Discussion  
2.4.1 Chemistry Section 
Compound 17 (supplied by GSK) was reacted with sarcosine ethyl ester 
hydrochloride under reductive amination conditions to give intermediate 18 
(Scheme 1), the relatively low yield of the compound 18 was due to some of 
the aldehyde being reduced to the corresponding alcohol before reacting with 
amine. Compound 18 underwent a Pd-catalysed Suzuki coupling with 
arylboronic acids (4-indazole, 4-indole and 3-phenol), yielding the biaryl 
compounds (19-21) using microwave irradiation. Generally, aryl chlorides are 
less reactive towards Suzuki cross coupling reactions as compared to aryl 
bromides and iodides247,248. However, in compound 18, the electron 
withdrawing pyrimidine ring facilitated the reaction by weakening the C-Cl 
bond and accelerated SN2 oxidative addition to the palladium centre247. In 
addition to aryl-aryl coupling, ester hydrolysis took place to yield the free 
carboxylic acids (19-21). with various aliphatic amines in the presence of 





Scheme 1. Synthesis of compounds (17-39) 
 
aReagents and conditions: (a) triethylamine, picoline borane, 10% AcOH in ethanol, rt, 20 h, 
yield 42%; (b) Na2CO3, ethanol (EtOH), boronic acid, bis(triphenylphosphine) palladium (II) 
chloride, microwave 125 °C, 3 h, yield 68-71%; (c) (1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo{4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), N,N-
Diisopropylethylamine (DIPEA), rt, 24 h, yields 26-87%.  
In the first reaction to synthesise the second set of the compounds (Scheme 
2), Suzuki couplings were used to introduce 3-phenol and 4-indole rings, 
derived from commercially available 3-phenolboronic acid and 4-indole 
pinacol ester respectively, into a compound 18. Somewhat surprisingly, the 
use of THF as a solvent in this Suzuki coupling reaction did not result in the 
formation zwitterionic compounds 19 and 21 as it was observed with ethanol 
(step b in Scheme 1), this may be due to the fact that the resulting biaryl 
products (31 and 32) were insoluble in THF, and thus they did not undergo in 
situ hydrolysis of ester. In the second step, KOH was used to hydrolyse the 
ester. The resulting carboxylic acids 19 and 21 were then coupled with 




the desired analogues (42-55). Finally, deprotection of the N-tert-
butoxycarbonyl (N-Boc) protected amines (52, 53, 54, 55) led to the amine 
hydrochloride salts (56, 57, 58 and 59, respectively). 
Scheme 2. Synthesis of compounds (42- 59) 
  
aReagents and conditions: (a) Na2CO3, bis(triphenylphosphine) palladium (II) chloride, 
tetrahydrofuran (THF), microwave 125 °C, 3 h, yield 81-82%; (b) KOH, methanol, 35 °C, 20 






2.5 Biology Section 
 
 
Table 9. Biological evaluation and isoform selectivity for PI3K δ for compounds 19-39. 
Compd R1 R2 












δ/α δ/β δ/Ɣ 
19 A OH 175 1400 710 555 8 4 3 
20 B OH 1000 441 1400 1400 0.4 1.4 1.4 
21 C OH 110 100 710 140 1 6 1.3 
22 A 
 
28 2800 2800 1400 100 100 50 
23 B 
 
44 280 2800 710 6 63 14 
24 C 
 
14 70 1000 175 4 63 14 
25 A 
 
35 2225 2800 1750 64 80 50 
26 B 
 
44 280 3500 555 6 80 13 
27 C 
 
14 56 555 175 4 40 13 
28 A 
 




Compd R1 R2 












δ/α δ/β δ/Ɣ 
29 B 
 
22 140 1750 220 6 80 10 
30 C 
 
7 28 280 140 4 40 20 
31 A 
 
35 2800 3500 1100 79 100 32 
32 B 
 
44 280 4400 1750 6 100 40 
33 C 
 
10 44 555 140 5 63 16 
34 A 
 
70 220 5500 1000 3 79 14 
35 B 
 
28 1400 1400 1400 50 50 50 
36 C 
 
* * * * * * * 
37 A 
 
11 1100 2800 280 100 255 25 
38 B 
 
10 140 2800 110 14 280 11 
39 C 
 
2 35 44 35 18 220 18 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 
threshold for the PI3K δ assay is ~ IC50 1 nM due to substrate concentration. Compounds 20, 
22, 23, 25, 26, 28, 31, 32, 34, 35, 36, 37 and 38 were prepared by Jia Ong. * Compound 33 




2.5.1 Matched molecular pair analysis of the functional groups 
that occupy the affinity pocket. 
The compounds (19, 20 and 21), (22, 23 and 24), (25, 26 and 27), (28, 29 
and 30), (31, 32 and 33), (34, 35 and 36) and (37, 38 and 39) were all matched 
molecular pairs, they differ only by the aryl group in the right hand of the 
molecule which occupies the affinity pocket. Matched molecular pair analysis 
was used to identify any change in PI3K δ activity and selectivity following 
bioisosteric replacement of indazole with indole and phenol. Table 9 showed 
that the 4-indole analogues (22, 25, 28, 31, 34 and 37) exhibited high PI3K δ 
selectivity compared to their 4-indazole (23, 26, 29, 32, 35 and 38) and 3-
phenol counterparts (24, 27, 30, 33, 36 and 39). This is very apparent when 
looking at a matched pair analysis between compounds containing the 4-
indole ring and the 4-indazole containing compounds, where the PI3K δ 
activity of these compounds were plotted against their δ/α selectivity (Figure 
32), based on the assumption suggested by Safina et al161, which states that 
the selectivity against PI3K α could be an acceptable predictor for overall 
isoform selectivity159,161. This analysis showed that the matched-pairs 
commonly had comparable potency against PI3K δ, however 4-indole 
analogues demonstrated less potent activity against PI3K α and thus have 
high δ/α selectivity. For example, 4-indole analogue 22 inhibited PI3K δ with 
IC50 of 28 nM with 100-fold PI3K δ/α selectivity in contrast to the non-selective 
4-indazole 23 and 3-phenol 24 analogues (only 6 and 4-fold, PI3K δ/α 
selectivity respectively) (Table 9). In comparison, 4-indole analogue 37 was 
10-times more PI3K δ selective than its 4-indazole 38 and 3-phenol 39 




was due to the loss of activity against the latter rather than increased potency 
against the former. For instance, 4-indazole 23 and 3-phenol 24 analogues 
displayed sub-micromolar potency against PI3K α with IC50 of 280 and 70 nM, 
respectively, while the 4-indole counterpart 22 inhibited PI3K α in the 
micromolar range with IC50 of 2500 nM.  
 
Figure 32. Plot of PI3K δ activity (pIC50) as a function of PI3K δ isoform selectivity (vs PI3K 
α), Matched-pair analysis for the 4-indole-containing compounds (green), and 4-indazole-
containing compounds (red) showing a general trend that indole compounds are more PI3K 
δ selective than their corresponding matched pair 4-indazole. 
Generally, replacement of 4-indole with 4-indazole and 3-phenol can cause 
2- to 4-fold drop in δ over Ɣ selectivity (compare matched-pairs 22, 23 and 24 
and matched-pairs 37, 38 and 39 for PI3K δ/Ɣ), whereas PI3K β/δ selectivity 
of the three series was greater than selectivity for PI3K δ over α or δ over Ɣ 
isoforms, it is noteworthy that 4-indole and 4-indazole compounds had similar 
level of selectivity for PI3K δ over PI3K β (compare matched-pairs 25 and 28 
and matched-pairs 31 and 32 for PI3K β/δ selectivity). These high levels of 
PI3K δ isoform selectivity achieved at the affinity pocket by the indole 
analogues was somewhat surprising, given the fact that the affinity pockets 
are conserved between the four isoforms of class I PI3K and consists of only 







All residues that line the affinity pocket are conserved 
PI3K δ Lys779 Leu784 Asp787 Ile825 Tyr813 Asp911 
PI3K α Lys802 Leu807 Asp810 Ile848 Tyr836 Asp933 
PI3K β Lys799 Leu804 Asp807 Ile845 Tyr833 Asp931 
PI3K Ɣ Lys833 Leu838 Asp841 Ile879 Tyr867 Asp964 
Figure 33. a) Crystal structure of murine PI3K δ (PDB code 2WXP) and human PI3K Ɣ (PDB 
code 3DBS). Superposition of residues lining the affinity pocket of the PI3K δ and Ɣ isoforms 
shows that this pocket is highly conserved in both isoforms. PI3K δ residues are colored pink, 
whereas PI3K Ɣ residues are colored green. b) Sequences of the residues lining the affinity 
pocket in the four isoforms of class I PI3K. In total, 6 residues that line the affinity pocket are 
conserved in the four isoforms of class I PI3K.  
This variation in PI3K δ selectivity between the three series can be attributed 
to the distal hydrogen bond network to residues beyond the affinity pocket 
which is able to influence isoform selectivity. The hydrogen bond networks 
made by the indole group in the affinity pocket cannot be formed by the less 




the high δ selectivity of their 4-indole-containing compounds over their 4-
indazole counterparts (Table 10) by hypothesizing that the hydrogen bond 
networks formed with Tyr813 and the indole ring C-H in the affinity pocket is 
different from that formed by the isosteric indazole ring243. This can be seen 
in the crystal structure of human K802T-mutant PI3K Ɣ bound to the indole-
based compound 60 (PDB code 4EZJ) (Figure 34) and indazole-based 
compound 61 (PDB code 4EZK) (Figure 35) which have great structural 
similarity to the final compounds presented in this chapter. The change of an 
indole 60 for an indazole moiety 61 significantly decreases the δ/α selectivity 
by 10-fold (Table 10).  
 
Table 10. Biological evaluation and isoform selectivity for PI3K δ for compounds 60 and 61 
reported by Sutherlin et al243. 
compd X PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
60243 -CH- 3.8 1292 760 1558 
61243 -N- 6.3 139 491 1638 
In compound 60, C-H (C-2) of the indole ring makes a hydrogen bonding 
interaction with the phenolic oxygen of Tyr867 (Tyr813 in PI3K δ) (Figure 34), 
while the phenolic hydrogen makes a new interaction with the carbonyl 
backbone of His962 (His909 in PI3K δ), establishing a new hydrogen bonding 
network that can be accommodated only in PI3K δ (Figure 34), while the other 
three isoforms cannot adapt this new network of hydrogen bonds. This leads 








Figure 34. a) The selective PI3K δ inhibitor compound 60. b) Crystal structure of human 
K802T-mutant PI3K Ɣ (PDB code 4EZJ) with compound 60 bound, pink dashed lines indicate 
the proposed hydrogen bond network that is suggested to be responsible for PI3K δ 
selectivity of compound 60. c) Simplified diagram depicts the hydrogen bond network 
(dashed blue line) between compound 60, Tyr867 (Tyr813 in PI3K δ) and His962 (His909 in PI3K 
δ) in the affinity pocket. 
In contrast, in 4-indazole-containing compound 61 (Table 10), the N-2 of the 
indazole acts as a hydrogen bond acceptor and makes a hydrogen bond to 
the phenolic hydrogen of Tyr867 (Tyr813 in PI3K δ) (Figure 35), while the 
phenolic oxygen with its lone pair becomes free and results in electrostatic 
repulsion (lone pair-lone pair repulsion) with the carbonyl backbone of His962 
(His909 in PI3K δ). This can be seen by the increase in the distance between 
the two residues to 3.79 A° (Figure 35), thus indazole compounds cannot 
form the hydrogen bond network, which translates into reduced isoform 
selectivity. However, there is uncertainty about the Sutherlin’s hypothesis160, 
which will be discussed in more detail in Chapter 6 (see compound 62 versus 








Figure 35. a) The selective PI3K δ inhibitor compound 61. b) Crystal structure of human 
K802T-mutant PI3K Ɣ (PDB code 4EZK) with compound 61 bound, pink dashed lines indicate 
the proposed hydrogen bond between compound 61 and Tyr867 (Tyr813 in PI3K δ), it also 
displays the electrostatic repulsion between the Tyr867 (Tyr813 in PI3K δ) and His962 (His909 in 
PI3K δ), as the distance between them increases up to 3.79 A°. c) Simplified diagram shows 
the electrostatic repulsion between Tyr867 (Tyr813 in PI3K δ) and His962 (His909 in PI3K δ) with 
distance between them increased up to 3.79 A°, which excludes the possibility of forming the 
hydrogen bond network. 
In terms of PI3K δ activity, the 3-phenol analogues (24, 27, 30, 33, 39) 
exhibited the best inhibitory activity against PI3K δ amongst the three series. 
This can be seen clearly in Figure 36, which describes the matched pair 
analysis between the phenol-containing compounds and indazole containing 
compounds, where the PI3K δ activity of these compounds was plotted 
against their δ/α selectivity, it showed that 3-phenol containing compounds 
were more potent than the corresponding 4-indazoles. For example, the 
phenol derivative 39 was 5-fold more potent against PI3K δ with IC50 value of 
2 nM than the corresponding indole 37 and indazole 38 analogues (IC50 




10 nM was 3-fold more active than indole 31 and indazole 32 derivatives (IC50 
values of 35 and 44 nM, respectively) (Table 9). However, the 3-phenol-
containing analogues had less selectivity for PI3K δ over PI3K α, compared 
to the indoles and indazoles, whereas all phenol derivatives (24, 27, 30, 33 
and 39) were more selective for PI3K δ over PI3K α by factors of only 1-18-
fold. For example, compound 24 was only 4-fold more selective against PI3K 
δ over PI3K α, in contrast to its indole analogue 22 which was 100-fold 
selective. The selectivity of phenol-containing compound 33 was only 5-fold 
higher for PI3K δ than PI3K α, while its indole counterpart 31 was 79-fold 
selective (Table 9). On the other hand, replacing the 4-indole group with 3-
phenol displayed a smaller decrease in the selectivity against PI3K β and Ɣ. 
In general, 3-phenol analogues generally showed a range of 2- to 3-fold 
reduction in the selectivity against PI3K β and Ɣ comparing to their 4-indole 
counterparts.  
 
Figure 36. Plot of PI3K δ activity (pIC50) as a function of PI3K δ isoform selectivity (vs PI3K 
α), Matched-pair analysis for the phenol-containing compounds (yellow), and indazole-
containing compounds (red) showing a general trend that phenol compounds are more PI3K 
δ potent than their corresponding matched pair indazoles. However, they show similar 
selectivity profile.  
The binding modes of the phenol-containing compound 39 with PI3K δ were 




activity and low selectivity of the phenol series, where compound 39 was 
docked into the crystal structure of human K802T-mutant PI3K Ɣ (generated 
from PDB code 4EZJ) (Figure 37). The proposed binding mode of compound 
39 revealed that the 3-phenol ring bound to the affinity pocket in a different 
orientation to that of the indole and indazole groups contained in compounds 
37 and 38, respectively, (Figure 37b). The 3-phenol group was oriented in 
such a manner that this group was in close proximity to the Lys833 (Lys779 in 
PI3K δ) and Asp964 (Asp911 in PI3K δ) residues (Figure 38) instead of Tyr867 
(Tyr813 in PI3K δ) and Asp841 (Asp787 in PI3K δ) which indole and indazole 
bound to (Figure 34b and 35b), thus the 3-phenol makes two charge-
enhanced hydrogen bonding interactions with Lys833 (Lys779 in PI3K δ) and 
Asp964 (Asp911 in PI3K δ) (Figure 38), while the indole and indazole isosteres 
only make one conventional hydrogen bonding interaction with Tyr867 (Tyr813 
in PI3K δ) and one charge-enhanced hydrogen bond with Asp841 (Asp787 in 
PI3K δ) (Figure 34b) (Figure 35b). This substantial change in the residue 
interactions could suggest the high potency observed with phenol-containing 
series.  
The second possible reason for the high PI3K δ activity of phenol analogues 
may be explained by the strength of the hydrogen bond that they formed with 
the polar residues in the affinity pocket, in contrast to their indole and indazole 
analogues. The strength of hydrogen bonds relies on the proton donor ability, 
the stronger the proton donor the stronger the hydrogen bond249, Abraham et 
al250 and Bauer et al251 mentioned that the hydroxy group (-OH) is generally 
greater hydrogen bond donor than amine (-NH), thus it could make a stronger 




hydrogen bond than their indole counterparts, resulting in higher PI3K δ 
activity. A future study will be performed to enhance the hydrogen bond donor 
character of phenol by increasing the acidity of the phenolic proton in the 
presence of an electron withdrawing group at the para position (this will be 





Figure 37. a) Compounds 37 and 39, highlight the indole and phenol groups that bind to the 
affinity pocket b) Compounds 37 and 39 docked into K802T-mutant PI3K Ɣ receptor model 
(generated from PDB code 4EZJ). Illustrates that indole group in compound 37 (blue) and 
phenol group in compound 39 (green) bind in two different orientations into the affinity pocket.  
 
Figure 38. Compound 39 docked into K802T-mutant PI3K Ɣ receptor model (generated from 





Meanwhile, modelling studies did not explain the poor selectivity of the 
phenolic series in contrast to the indole-containing compounds particularly 
against PI3K α, where phenolic analogues were 5- to 25-fold less selective 
versus PI3K α than their indole counterparts. A docking study of compound 
39 (Figure 38) did not reveal any hydrogen bonding networks between 
compound 39 and the protein such as that found in the indole-containing 
series, which Sutherlin et al160 believed was responsible for the observed high 
PI3K δ selectivity of indole analogues. Since there is no crystal structure 
available for phenol-containing compounds bound to PI3K δ, the mechanism 
underlying their poor PI3K δ selectivity cannot be revealed. It was 
hypothesized that the predicted interaction with Lys779, could be behind the 
drop in PI3K δ selectivity of the phenol series. Hoegenauer et al218 in his paper 
described the quinazoline-based analogue 64 with 2-methoxypyridine 
inserted into the affinity pocket possessed a PI3K δ/α selectivity of 13-fold 
(Table 11), while the introduction of trifluoromethyl group into the 3-position 
of the pyridine resulted in compound 65 with reduced PI3K δ selectivity, 
especially for PI3K α isoforms (δ/α= 9-fold) (Table 11) 218. The authors 
theorised that the decrease in the PI3K δ selectivity in compound 65 was 
 
Table 11. Biological evaluation and isoform selectivity for PI3K δ for compounds 64 and 65 
reported by Hoegenauer et al218, highlights the drop in the selectivity against PI3K α, after 
the addition of trifluoromethyl group that potentially binds to Lys779. 
compd R PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
64218 H 20 14 208 395 




due to the charge-enhanced hydrogen bond between Lys799 and one of 
fluorine atoms of the newly added trifluoromethyl group218, which is consistent 
with the hypothesis stated above. 
Additionally, it was noticed that this lack of PI3K δ selectivity was also 
observed in the FDA-approved drug (copanilisib 6) which exhibited potency 
against isoforms PI3K δ and α with IC50 values of 0.7 and 0.5 nM, 
respectively, and almost 10-fold selectivity over the other class I isoforms179. 
The crystal structure of the copanilisib-PI3K Ɣ complex (see Figure 21b in 
Chapter 1) showed that the nitrogen of pyrimidine forms a key hydrogen bond 
with Lys833 (Lys779 in PI3K δ) in the affinity pocket. This interaction significantly 
improves activity against PI3K δ and α 179. According to this, one could 
hypothesize that the hydrogen bonding with Lys779 could be the reason for 
the diminished PI3K δ selectivity of the 3-phenol containing series. 
In the light of the findings, in the three different series of compounds, the 
indole-containing compounds showed the highest selectivity for PI3K δ 
against the remaining three class I PI3K isoforms (Figure 39), while the 
phenol analogues turned out to possess the best inhibitory activity against 
PI3K δ isoform (Figure 39). Finally, the indazole analogues exhibited 
moderate PI3K δ selectivity in contrast to their indole counterparts and 3- to 
5-fold decrease in potency compared to their phenol counterparts (Figure 39). 
Thus, the indazole series was considered unsuitable for a focused 
optimisation effort. Based on this potency and selectivity profile, two series of 
indole compounds (most PI3K δ selective) and phenol compounds (most 





Figure 39. Plot of PI3K δ isoform activity (pIC50) as a function of PI3K δ isoform selectivity 
(vs PI3K α). Matched-pair analysis for the indole-containing compounds (blue), phenol-
containing compounds (green) and indazole-containing compounds (yellow). The indole 
series is the most PI3K δ selective and phenol series is the most PI3K δ active. 
2.5.2 Matched molecular pair analysis of the functional groups 
that occupy the tryptophan shelf 
In the tryptophan shelf region (R2), all carboxylic acids (19, 20 and 21) 
exhibited poor PI3K δ inhibitory activity with IC50 values in low-micromolar to  
mid-nanomolar range (IC50 values of 175, 1000 and 110 nM, respectively) 
with complete loss of PI3K δ selectivity over the other three isoforms of class 
I PI3K. Introduction of propylamine by amide coupling resulted in compounds 
22, 23 and 24 which exhibited superior improvement in PI3K δ potency and 
selectivity with IC50 values of 28, 44 and 14 nM against PI3K δ, respectively. 
This modification was also accompanied by improving in δ isoform selectivity, 
for example, compound 22 exhibited 100-fold selectivity over PI3K α and β 
and 50-fold against PI3K Ɣ. 
It was hypothesized that the reason behind the high PI3K δ activity and 
selectivity of the propyl-containing compounds was possibly due to the ability 
of the propyl group to make a favourable C-H/pi interaction with the 




between aliphatic C-H donors (soft acid, propyl group) and aromatic -
acceptors (soft base, Trp760)252,253. These findings are consistent to that 
published by Hoegenaur. K et al218,229 who confirmed that the propionamide 
group of leniolisib (7) (Figure 40) and acetyl-piperazine group of compound 
66 (Figure 41) (Table 12) were directed towards the tryptophan shelf, stacked 
to the indole ring of Trp760, resulting in attractive dispersion forces. This 
interaction could only take place in PI3K δ, as the residue that opposed to 
Trp760 was Thr750 (Figure 40b), whereas in PI3K α, β and Ɣ was the larger 
side chain of Arg or Lys, which also forms a strong cation/pi interaction with 
Trp, blocking access to the tryptophan shelf, as this would need to be 
disrupted for any interaction to take place with the ligand. This could be seen 
clearly in the crystal structure of compound 66 in human PI3K α (PDB code 
5ITD) (Figure 41c), where the compound 66 adopted an extended 
conformation in PI3K α because the acetyl piperazine cannot access the 
tryptophan shelf, that was occluded by the large and cationic residue (Arg770), 
whereas in PI3K δ, compound 66 adopted a folded conformation because the 
acetyl piperazine group was able to fold and make a C-H/pi interaction with 
the tryptophan shelf (Figure 41b). This contributes to the enhanced PI3K δ 
potency leading to increased PI3K δ selectivity of leniolisib (7) and compound 
66 versus the other three isoforms of class I PI3K (Table 12)218,229. 
Table 1. Biological evaluation and isoform selectivity for PI3K δ for leniolisib (7) and 
compound 66 reported by Hoegenaur. K et al218,229. 
 
compd PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/γ 
Leniolisib (7)239 28 25 63 357 




a)                                                              b) 
  
Figure 40. a) The selective PI3K δ inhibitor leniolisib (7), highlighted the propionamide side 
chain that forms key C-H/pi interactions with tryptophan shelf. b) Crystal structure of leniolisib 
(7) complexed with murine PI3K δ (PDB code 5O83) indicated that the propionamide group 
folds to fit the tryptophan shelf and make C-H/pi interactions with Trp760. Dashed pink lines 
represent the proposed C-H/pi interactions. 




Figure 41. a) The selective PI3K δ inhibitor compound 66, highlighted the N-acetylpiperazine 
that forms a key C-H/pi interaction with tryptophan shelf218. b) Crystal structure of murine 
PI3K δ (PDB code 5IS5) with compound 66 bound, pink dashed lines indicate the proposed 
C-H/pi interaction that takes place between the piperazine ring and Trp760 at the tryptophan 
shelf218. c) Crystal structure of human PI3K α (PDB code 5ITD) bound to the compound 66. 
The tryptophan shelf is blocked by a cation/pi interaction (represented by a red dashed line) 
between Arg770 and Trp780 makes the compound 66 to adopt an extended conformation, 




The importance of the propylamide was probed by replacing it with ethoxy 
ethylamide resulted in compounds 19,20 and 21 which displayed equipotent 
activity against PI3K δ compared with their propyl analogues with similar 
selectivity profile. Amidation of the parent carboxylic acids with glycine ethyl 
ester resulted in compounds (28-30) which demonstrated comparable PI3K δ 
inhibitory activity as their propyl counterparts but lower selectivity over PI3K 
α and β by almost 2-fold. Compounds (31-33) with a racemic alanine methyl 
ester showed a pronounced increase in the selectivity against PI3K β 
(approximately 2-fold) compared to the propyl analogues (22-24), while 
maintaining similar potency against PI3K δ. 
Replacing the N-alkyl amide with the corresponding N-benzylamide group 
was explored, to direct the phenyl-substituent towards the tryptophan shelf to 
probe a potential pi-pi stacking interaction. The resulting N-benzyl 
compounds (34 and 35) showed equipotent inhibition compared with their 
propyl analogues (22 and 23), while demonstrating less selectivity for PI3K δ 
over PI3K α, β and Ɣ with only 50-fold selectivity over the other class I PI3K 
isoforms. This was somewhat a surprising finding, given the ability of benzyl 
moiety to make a pi-pi interaction with Trp760 in the tryptophan shelf and thus 
benzyl analogues were expected to exhibit greater PI3K δ potency and 
selectivity compared to their alkyl analogues which were only able to make 
hydrophobic interactions. These results were compatible with Terstiege et 
al220 findings, which showed that the replacement of the phenyl group of 
compound 67 with morpholine (compound 68) and tetrahydropyran 
(compound 69) did not lead to a decrease in the PI3K δ activity and selectivity 




confirmed that the non-covalent interaction that took place between the R2 
substituent and Trp760 in the tryptophan shelf was a C-H/pi interaction and not 
a pi-pi stacking.  
 
Table 13. Biological evaluation and isoform selectivity for PI3K δ for compounds (67-69 
reported byTerstiege et al220). 
Finally, amidation of the carboxylic acids 19, 20 and 21 with piperidine 
resulted in compounds 37, 38 and 39, which showed improved PI3K δ activity 
(IC50 values of 11, 10 and 2 nM, respectively) compared to their acyclic 
analogues (22 to 33). As examples, the piperidine derivatives 37, 38 and 39 
showed 3-, 4- and 7-fold increase of potency comparing to their propyl 
counterparts 22, 23 and 24, respectively. Additionally, the piperidine ring 
imparts improved selectivity (220- to 280-fold) for PI3K δ relative to PI3K β. 
This led us to the exciting possibility that saturated heterocycles, such as 
piperidine, might be able to make stronger attractive dispersion force (C-H/pi) 
interaction with the tryptophan shelf than linear alkyl derivatives254. Kozmon, 
et al255 and Ran J, et al254 in their studies proved that stronger CH/pi 
interactions exist for cyclic against linear alkanes. This can be attributed to 
two possible factors. First, Aliphatic heterocycles have more polar character 
compd R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/γ 
67220 
 
22 6 25 13 
68220 
 
22 6 32 13 
69220 
 




than their linear counterparts, as the strength of the dispersion energy 
depends on polarizability254,256, thus, the CH donor ability of aliphatic 
heterocycles is stronger than their acyclic counterparts. A second reason is 
that the piperidine ring is able to make multiple C-H/pi interactions with Trp760, 
Chen Zhao et al and Ciunik Z, et al 257,258 reported that the strength of C-H/pi 
interaction was correlated with the number of C-H/pi contacts, as they could 
work in a cooperative manner (Figure 42). It was proved that the saturated 
hydrocarbon-aromatic system complex gave the most stable conformation 
when they contact each other by multiple (2-4) CH/pi interactions (Figure 
42)253,254. The piperidine group could position a greater number of carbon 
atoms (5 carbons) over the aromatic ring of tryptophan, this allowed it to 
establish 3 CH/pi contacts using the 3 axial hydrogens that were located on 
the same face of the piperidine ring (Figure 43), made an attractive 
complementary surface for the planar indole ring of Trp760259. 
  
Figure 42. Graph taken from Zhao et al257: correlation between the number of carbons 
forming CH/pi contacts and the interaction energy. The C-H/pi interaction exhibits additivity 
for linear alkyl groups (methyl and ethyl), as the ethyl/pi interaction energy is nearly twice that 
for the methyl/pi complex, whereas the C-H groups of the branched chain (isopropyl group) 
interact with the π system in a cooperative manner, which results in a C-H/pi interaction 
energy larger than expected. According to Kozmon et al255, the positive cooperativity of C-




a)                                                                               b 
                 
c)  
 
Figure 43. a) The suggested C-H/pi interactions between three electropositive hydrogens in 
the piperidine ring and indole ring of Trp760, which could contribute to high PI3K δ activity and 
selectivity of piperidine derivatives (37-39). b) Compound 39, highlights the piperidine ring 
that might form a key C-H/pi interaction with tryptophan shelf. c) Compound 39 docked into 
the PI3K δ model (generated from PDB code 5IS5). Dashed pink lines represent the 
proposed C-H/pi interaction.  
2.5.3 Conclusion derived from the first SAR study (Table 9) 
First SAR study (Table 9) revealed that high PI3K δ activity and selectivity 
could be obtained through three structural modifications on the lead 
compound (pictilisib, 4). 
First, the ring opening strategy by substituting the piperazine group with a 
flexible linker resulted in better PI3K δ inhibitory activity and isoform selectivity 
than the lead compound (pictilisib, 4). This could be because the flexible linker 
has the capability to insert the R2 group into the tryptophan shelf. This can be 




pictilisib (4) into PI3K δ (PDB code 2WXP) where compound 39 adopted a 
folded conformation due to the flexibility of the linear linker connecting the 
thienopyrimidine scaffold to the tryptophan shelf binder (piperidine) which 
inserted deep into the tryptophan shelf (Figure 44c). In contrast, the rigid 
piperazine linker retained the extended conformation of pictilisib (4), 
preventing it from folding and accessing the tryptophan shelf. 




Figure 44. a) The non-selective PI3K inhibitor pictilisib (4), highlighted the restricted linker 
(piperazine ring). b) Compound 39, highlighted the flexible open-chain linker. c) Compound 
39 (pink) docked into the PI3K δ model (generated from PDB code 2WXP), overlaid on 
pictilisib (4) (green), showing pictilisib (4) adopts an extended conformation, while compound 
39 adopts a folded conformation.  
Second, the isosteric replacement of the 4-indazole moiety in the affinity 
pocket with a 4-indole group could achieve the highest level of PI3K δ 
selectivity, whereas substitution of the 4-indazole group with a 3-phenol ring 
achieved the highest degree of PI3K δ inhibitory activity. Thus, two series 




group as an affinity pocket binder while the second series will have a phenol 
group as an affinity pocket binder. 
Third, high PI3K δ potency and selectivity could be obtained by targeting the 
tryptophan shelf with saturated nitrogen containing heterocycles. It was 
thought that C-H/pi interaction with the tryptophan shelf could be improved by 
enhancing the proton donor ability of the piperidine ring. Several studies have 
reported that an increase in the acidity of the donor protons results in an 
increase in the strength of the C-H/pi interaction252,253,259. This can be 
achieved by implementing two strategies, firstly, replacement of piperidine 
with more electron deficient saturated rings, such as morpholine or 
piperazine, in which the carbon atom in the 4-position of the piperidine ring 
was replaced by a more electronegative heteroatom (oxygen in morpholine 
and nitrogen in piperazine). These replacements induce an electron 
withdrawing inductive effect (Figure 45c and 45d), resulted in increasing the 
acidity (proton-donor ability) of C-Hs leading to the stronger C-H/pi interaction 
with tryptophan shelf. Secondly, incorporation of one or two strongly 
electronegative fluorine atoms at the 4-position of a piperidine ring could 
increase the acidity of hydrogens of the piperidine ring (Figure 45e and 45f), 
resulting in a strengthening of the C-H/pi interaction and thus in an 
enhancement of biological activity260. These two approaches could optimize 
the C-H/pi interaction at the tryptophan shelf and hence might improve PI3K 





a)                                                b) 
             
c)                                                d) 
             
e)                                                f) 
           
Figure 45. Two approaches suggested to increase the proton donor ability of the piperidine 
ring and enhance the CH/pi interaction with tryptophan shelf: a) Chemical structure of the 
piperidine ring. b) Electrostatic potential map of piperidine ring c) One carbon atom of 
piperidine is replaced by one of the heteroatoms oxygen or nitrogen, which makes the ring 
more electron deficient and thus better C-H donor than piperidine. d) Electrostatic potential 
map of morphline. e) Introduction of the strong electronegative fluorine atom at the 4-position 
of piperidine ring makes the ring more electropositive than piperidine and thus increases the 





Table 14. Biological evaluation and isoform selectivity for PI3K δ for compounds (37, 39 and 
42- 59).  













δ/α δ/β δ/γ 
37  A 11 1100 2800 280 100 255 25 
39  B 2 35 44 35 18 220 18 
42  A 11 2800 2800 1400 255 255 127 
43  B 2.2 110 1750 220 50 795 100 
56  A 11 1100 555 1750 100 50 159 
57  B 5.5 28 140 220 5 25 40 
44  A 17.5 1750 1750 4400 100 100 251 
45  B 5.5 70 555 110 6 101 20 
52  A 5.5 7000 5500 17.5 1273 1000 3 

















δ/α δ/β δ/γ 
46  A 100 28000 22000 350 280 220 3.5 
47  B 22 11000 7000 7000 500 318 318 
58 
 
A 11 5500 1400 7000 500 127 636 
59 
 
B 2.2 17.5 175 350 8 79 159 
54 
 
A 11 2800 2800 710 255 255 65 
55 
 
B 4.4 100 2800 110 23 506 25 
48  A 4.4 2225 2800 710 506 636 161 
49  B 1.1 17.5 555 35 16 505 32 
50 
 
A 4.4 1400 1400 710 318 318 161 
51 
 
B 2.2 35 555 56 16 500 25 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 
threshold for the PI3K δ assay is ~ IC50 1 nM due to substrate concentration.  
The two piperidine compounds (37 and 39) would be used as parent 
compounds in this SAR study (Table 14) to evaluate any enhancement in 
PI3K δ activity or selectivity. The morpholine analogues (42 and 43) 
demonstrated comparable PI3K δ inhibitory potency (IC50 value of 11 and 2.2 
nM, respectively) to their piperidine counterparts (37 and 39). However, they 
displayed higher selectivity over PI3K α and Ɣ. Morpholine-containing 




Ɣ, respectively than their corresponding piperidine analogues 37 and 39. This 
increase in the selectivity is due to loss of activity against PI3K α and Ɣ. These 
consistent results are interesting, because they showed PI3K α/δ and PI3K 
Ɣ/δ selectivity advantage of morpholine analogues over their piperidine 
analogues.  
Piperazine derivatives 56 and 57 exhibited similar potency to the parent 
piperidines 37 and 39 with slightly higher isoform selectivity versus PI3K Ɣ 
(159 and 40-fold, respectively) compared to their piperidine analogues. 
However, they were far less selective against PI3K β where β/δ selectivity 
ratio reduced by 5- and 9-fold for compounds 56 and 57, respectively (Table 
14). N-methylation of piperazine ring in compounds 44 and 45 had little impact 
on PI3K δ potency and isoform selectivity against PI3K α and Ɣ. However, it 
enhanced the selectivity against β isoform by 2 and 4-fold, respectively, in 
comparison with their non-methylated analogues 56 and 57. 
N-Boc-protected piperazine analogues 52 and 53 exhibited high PI3K δ 
potency profile (IC50 values of 5.5 and 1.4 nM, respectively) with 2- and 4-fold 
improvement than their unprotected analogues 56 and 57 (Table 14). 
Strikingly, bulky group (Boc group) at N-4 of piperazine could be tolerated in 
the tryptophan shelf without loss of activity, which suggested that tryptophan 
shelf of the PI3K δ was not spatially constrained and a wide range of groups 
could be tolerated in this position. Thus, replacement of acid-labile group Boc 
with similar size bioisosteres such as urea and sulfonamide will lead to the 
development of the physiologically stable analogues which can be useful tool 
for medicinal chemistry and drug discovery (Figure 46). Furthermore, 




(10-fold) against PI3K α, while their δ/β selectivity increased by 12- to 80-fold 
comparing to their unprotected analogues 56 and 57. However, compound 
52 showed an unexpected diminish in the selectivity against PI3K Ɣ (Ɣ/δ= 3) 
which was due to its high activity against PI3K Ɣ (IC50= 17.5 nM).  
 
Figure 46. Bioisosteric replacement of metabolically labile Boc group of compounds 52 and 
53 with stable urea and sulphonamide groups. 
N-acetylation of piperazine 56 resulted in compound 46 which was the least 
active compound in this series with an IC50 of 100 nM. This finding was 
unexpected, because it was known that the acetyl group was an electron 
withdrawing group by inductive effect, which made the piperazine ring more 
electron deficient and possibly enhanced C-H/pi interaction261. Thus, it was 
expected to be more active than the deacetylated analogue 56. Moreover, it 
showed almost no inhibitory activity on PI3K α and β, while displaying poor 
selectivity against Ɣ isoform (Ɣ /δ= 3.5) (Table 14). The matched pair phenol 
47 was about 5-fold more potent as PI3K δ inhibitor compared to its indole 
counterpart 46. Additionally, it was found to be 100-fold more selective for 
PI3K δ against PI3K Ɣ. 
Introduction of aminomethyl group at the 2-position of piperidine in 
compounds 37 and 39 resulted in analogues 58 and 59 which exhibited 
similar potency (IC50 values of 11 and 2 nM, respectively) to their 
unsubstituted counterparts (Table 14). The compound 58 possessed 




fold against PI3K α, β and Ɣ, respectively). Interestingly, Boc-protected 2-
(aminomethyl) piperidine derivatives 54 and 55 showed equipotent inhibition 
of PI3K δ compared with non-protected counterparts. These findings proved 
that substitution at the 2-position of piperidine group even with a bulky group 
did not have a detrimental impact on PI3K δ inhibitory activity and selectivity. 
However, PI3K Ɣ/δ selectivity had reduced by 10- and 6-fold in compounds 
54 and 55, respectively.  
Introduction of fluorine atom at the 4-position of piperidine in compounds 37 
and 39 affording monofluorinated analogues 48 and 49 resulted in a 2-fold 
increase of potency against PI3K δ (IC50 of 4.4 and 1.1 nM, respectively) as 
well as accompanied enhancement in the selectivity versus the other three 
class I isoforms (5, 2.5 and 6.5-fold against PI3K α, β and Ɣ, respectively) 
(Table 14). It was hypothesized that the favorable PI3K δ activity and 
selectivity profile of monofluoropiperidine derivatives 48 and 49 might be due 
to the strong electronegative fluorine atom pulling electron density away from 
the piperidine ring by the inductive effect (Figure 45e and 45f) which would 
make the hydrogens of the ring more acidic than the des-fluoro analogues 37 
and 39 and thus increased the strength of C-H/pi interaction with Trp760 in the 
tryptophan shelf252,262. The increase in the acidity of piperidine protons can 
be observed using nuclear magnetic resonance (NMR) technique by 
assessing the deshielding of protons on piperidine caused purely by the 
inductive effect of the fluorine atoms. This can be done through comparing 
the 1H NMR spectra of monofluorinated analogue 48 with its desfluorinated 
counterpart 37 (Table 15). The fluorine atom caused a strong deshielding of 




decreased with the distance to fluorine atom increased, whereas H-3 and H-
2 experienced downfield shifts of 0.26 and 0.04, respectively (Table 15). It 
was hypothesized that despite the substitution of a fluorine atom for a 
hydrogen, monofluorinated analogues 48 and 49 were still able to form 3 C-
H/pi interactions with Trp760, which was equal to the number of C-H/pi 
interactions that non-fluorinated analogues made (Figure 47), because the 
newly introduced fluorine atom preferred to be in the equatorial position 
because it avoided the steric interaction with the axial hydrogen atoms (Figure 
47), thus there would be 3 axial hydrogens on the α-face of piperidine that 
could make 3 C-H/pi interactions with Trp760 in the tryptophan shelf (Figure 
47).  
 
Figure 47. Depicts the possible number of potential C-H/pi interactions that could be made 
by desfluorinated (37 and 39) and monofluorinated analogues (48 and 49) with the tryptophan 
shelf. 
Table 15. Assessing the deshielding of the piperidine protons caused purely by the inductive 







H-4 1.45 ppm 3.61 ppm + 2.16 
H-3 1.57 ppm 1.83 ppm + 0.26 




An additional fluorine atom was introduced at the C-4 position of piperidine 
ring in compounds 48 and 49 resulted in the generation of gem-difluoro 
analogues 50 and 51, respectively. The newly added fluorine atom could 
make the piperidine hydrogens more acidic and thus formed a stronger C-
H/pi interaction with Trp760 than that of monofluorinated analogues 48 and 49. 
Comparison of 1H NMR spectra of compound 49 with 51 (Table 16) showed 
that the two fluorine atoms resulted in a further deshielding of H-3 by 0.16 
and H-2 by 0.15 comparing to the monofluoro analogues. Surprisingly, 
Compounds 50 and 51 showed no improvement in PI3K δ activity (IC50 values 
of 4.4 and 2.2 nM, respectively) over their monofluorinated counterparts 48 
and 49, respectively. Additionally, no change in PI3K δ selectivity was 
observed. It was hypothesized that in spite of the slight increase in the acidity 
of the H-3 and H-2, the C-H/pi interaction was not reinforced due to the loss 
of the geminal and the most acidic proton (H-4) by the ipso substitution of the 
second fluorine atom (Figure 48), thus, no further gain in PI3K δ activity and 
selectivity was achieved.  
 
Figure 48. Depicts the possible number of potential C-H/pi interactions that could be made 





Table 16. Assessing the deshielding of piperidine protons in compound 51, caused purely by 
the inductive effect of the second fluorine atom. 
Based on these findings, 4-fluoropiperidyl analogue 48 showed the best 
balance between PI3K δ potency (IC50 value of 4.4 nM) and selectivity over 
other class I isoforms (Figure 49) with more than 500-fold over PI3K α and β 
and 160-fold against PI3K Ɣ. In addition to high PI3K δ activity and selectivity, 
compound 48 was more likely to have more optimal physiochemical and 
absorption, distribution, metabolism and excretion (ADME) properties for oral 
drugs, than the other analogues and the lead compound pictilisib (4), where 
it has calculated log P (clog P) value of 2.79 (calculated by DataWarrior, using 
principal component analysis), which lies in the optimum range of lipophilicity 
(log P= 2- 3) (Figure 50) that gives a good balance between solubility and 
permeability263,264, whereas the lead compound pictilisib (4) has a clog P 
value of 1.33 (calculated by DataWarrior) (Figure 50). Moreover, compound 
48 possesses a topological polar surface area (tPSA) of 105.83 Å that is lower 
than that of pictilisib (4) (Figure 51), which has a tPSA of 144.17 Å (exceeding 
140 Å) and is thus more likely to show poor membrane permeability 265–267. 
The matched pair phenol 49 displayed the highest degree of PI3K δ inhibitory 
activity in this series with IC50 value of 1.1 nM, however, it had moderate 







H-4 3.61 ppm Not exist - 
H-3 1.83 ppm 1.99 ppm + 0.16 





Figure 49. Plot of PI3K δ activity as a function of PI3K δ isoform selectivity (vs PI3K α). 
Highlighted is the compound 48 that shows the most favourable PI3K δ isoform selectivity. 
 
Figure 50. Plot of PI3K δ activity (pIC50) as a function of calculated log P, highlighted is the 
compound 48 that lies in the optimum region of lipophilicity for oral drugs (clog P= 2- 3, 
highlighted in the red box). 
 
Figure 51. Plot of PI3K δ activity (pIC50) as a function of tPSA, highlighted is the compound 





respectively. Thus, only compound 48 had fulfilled the optimal expectations 
for ideal selective PI3K δ inhibitors (excellent PI3K δ potency, selectivity and 
predicted physicochemical properties).  
2.6 Conclusion 
This chapter has shown how the thienopyrimidine based inhibitors, originating 
from non-selective PI3K inhibitor (pictilisib, 4), could be converted into a 
series of highly potent and selective PI3K δ inhibitors. Compound 48 had 
emerged to be the best compound in the whole series, having excellent PI3K 
δ inhibitory activity with great selectivity (161- 636-fold) over other PI3K 
isoforms, it was noteworthy that the compound 48 had more favorable PI3K 
δ selectivity profile than the developmental candidate (Leniolisib, 7) (Table 
17). Furthermore, this research led to the discovery of compound 49, which 
was 10-fold more potent than pictilisib (4) and idelalisib (8) at inhibiting PI3K 
δ (Table 17), but did have moderate selectivity against PI3K α and Ɣ. High 
PI3K δ activity and selectivity have been achieved by using a flexible linker 
which could increase the accessibility of R2 group to the tryptophan shelf that 
was exposed only in δ isoform, where it was found that targeting the 
tryptophan shelf with saturated heterocycles was an efficient strategy for the 
future design of highly selective PI3K δ inhibitors. Furthermore, modulation in 
the affinity pocket could enhance the PI3K δ inhibitory activity as well as the 
selectivity against the other three isoforms. The use of indole was required to 
provide PI3K δ selectivity, whereas phenols moiety exhibited the highest PI3K 





Table 17. Biological evaluation and isoform selectivity for PI3K δ for compounds pictilisib (4), 
idelalisib (8), leniolisib (7), 48 and 49. 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 





Compd R1 PI3Kδ δ/α δ/β δ/Ɣ 
Pictilisib (4) - 11 4 20 20 
Idelalisib (8) - 11 14000 56 56 
Leniolisib (7)239 - 28 25 63 357 
48 
 
4.4 506 636 161 
49 
 




Chapter 3  Design, Synthesis and 
Pharmacological Characterization of Novel 
Quinazolinone-based PI3K δ selective Inhibitors 
(Propeller-shaped inhibitors) 
3.1 Aim 
This chapter covered the second class of PI3K δ inhibitors which were called 
“the propeller-shaped” PI3K δ inhibitors which adopted a orthogonal 
conformation when bound to PI3K δ, where the three substituents (blades) 
are twisted almost perpendicularly (Figure 52)146,149, this is distinct from the 
flat-shaped inhibitors, which adopt a flat conformation (discussed in the 
previous chapter). It is important to note that propeller-shaped inhibitors 
interact with several pockets in PI3K δ different from the flat-shaped inhibitors 
binding regions (see Table 3 in Chapter 1), the former inhibitors bound to 
PI3K δ at the hinge region, specificity pocket and hydrophobic region II, while 
the latter interacted with PI3K δ in the hinge region, affinity pocket and the 
tryptophan shelf 145,146,152. One example of the propeller-shaped inhibitors is 
idelalisib (8) (Figure 52), which was the first FDA-approved selective PI3K δ 
inhibitor to treat three types of hematological malignancies including CLL, 
relapsed follicular B-cell non-Hodgkin lymphoma and relapsed SLL. However, 
8 was associated with a significant number of side effects include long-term 
diarrhoea, hepatoxicity, colitis and pneumonitis154,230,231. 
In this research, Idelalisib (8) was synthesized and tested against the four 
isoforms of class I PI3K. As reported in the literature, it displays good potency 
for PI3K δ with an IC50 of 11 nM and very good selectivity over the other 








Figure 52. a) The typical propeller-shaped selective PI3K δ inhibitor idelalisib (8) 153. b) 
Diagram shows the three-bladed propeller-like structure of 8 and its interactions in the three 
regions of PI3K δ binding site. c) Crystal structure of murine PI3K δ (PDB code 4XE0) with 
idelalisib (8) bound, showing that 8 adopts a propeller-shaped conformation. The hinge 
region is shown in violet, the open specificity pocket in yellow, the hydrophobic region II in 
orange180. 
potency of 8 could be further improved, given the fact that there was a 
plethora of published PI3K δ inhibitors that were 10- to 100-fold more potent 
than 8, some of these compounds were developed in the previous chapter 
(compounds 48, 49, 50, 51 and 59). It was hypothesized that gains in 
idelalisib (8) potency could be obtained by exploiting the unoccupied affinity 
pocket, which is lined with polar residues. First, the co-crystal structure of 




3.2 Binding interaction of the lead compound: idelalisib (8)  
3.2.1 Quinazolinone scaffold (Specificity pocket) 
The propeller shape of 8 induces structural changes in the conformation of 
the binding site of the PI3K δ enzyme174. It was seen that Trp760 and Met752 
that are normally packed against each other in the apoenzyme distance away 
from each other by ~ 6.5 A° when 8 binds (see Figure 17a in Chapter 1). This 
creates a new pocket (termed specificity pocket) in which the fluoro 
quinazolinone ring fits153, sandwiched between Trp760 and Ile777 on one side 
and Met752 and Pro758 on the other side (see Figure 17a in Chapter 1)153. The 
induced specificity pocket is believed to be the main factor of the PI3K δ 
isoform selectivity of idelalisib (8) and other propeller-shaped PI3K δ 
inhibitors154–156, as discussed earlier in Section 0. 
3.2.2 Purine group (Hinge binder) 
The purine ring interacts with the hinge region of PI3K δ, the N3 of purine 
makes a critical hydrogen bond with the amide backbone of Val828, whereas 
the NH-9 of purine also bound to the Glu826’s carbonyl oxygen (Figure 53b). 
Thus, 8 and all propeller-shaped inhibitors engage in dual hydrogen bond 
interactions with the hinge region. In contrast, all flat-shaped inhibitors make 
only one hinge interaction via hydrogen bonding between the oxygen of 
morpholine and the amide backbone of Val828 (see Figure 28b in Chapter 2), 
as it was already mentioned in the previous chapter. This is another difference 





a)                                                                    b) 
          
Figure 53. a) The propeller-shaped selective PI3K δ inhibitor idelalisib (8), highlighted the 
nitrogen atoms N3 and NH-9 of the purine that make two critical hydrogen bonds to the hinge 
region. b) Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) bound, blue 
dashed lines indicate the proposed dual hydrogen bonds to the hinge region180. 
3.2.3 Phenyl group (hydrophobic region II) 
The phenyl group occupies the hydrophobic region II (ribose binding pocket), 
where the crystal structure of murine PI3K δ in complex with 8 (PDB code 
4XE0) revealed that the phenyl group interacts through hydrophobic 
interactions with the side chains of Asp832, Thr833 and Asn836 (Figure 54). 
Hydrophobic region II is composed of 8 residues, four of them are variable 
across the four isoforms.  
The hydrophobic region II has been exploited to provide PI3K δ selectivity. 
Perry et al151 has reported the design of thiazolidinopyridone-based 
compound 70, which showed poor PI3K δ selectivity, particularly against PI3K 
Ɣ. The introduction of basic centres at the meta-position of the phenyl group 
resulting in the discovery of a new generation of PI3K δ inhibitors. For 
example, compound 71 with a dimethylamino methyl group was selected as 
a representative of this series (Table 18)151. Compound 71 showed 3- and 
28-fold improvement in PI3K δ selectivity over PI3K α and Ɣ, respectively, 




a)                                                               b) 
                             
Figure 54. a) The selective PI3K δ inhibitor idelalisib (8), highlights the phenyl ring that fills the 
hydrophobic region II. b) Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) bound, 
highlights the eight amino acid residues that line the hydrophobic region II that make hydrophobic 
interactions with the phenyl moiety of idelalisib (8). 
 
Table 18. Biological evaluation and isoform selectivity for PI3K δ for compounds 70 and.71 
reported by Perry et al151. 
compd R PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
70151 H 0.4 1388 110 28 
71151 CH2NMe2 0.7 4000 80 793 
The crystal structure of murine PI3K δ in complex with 71 (PDB code 5NCY) 
revealed that the dimethylamino methyl group pointed toward δAsn836 (Figure 
55), where the side chain of δAsn836 shifted slightly in order to accommodate 
the inhibitor. However, in PI3K Ɣ, the corresponding residues of δAsn836 was 
the cationic residue ƔLys890, which made an unfavourable electrostatic 
interaction with the dimethylamino group, resulted in a large decrease in PI3K 
Ɣ potency (Table 18). Whereas in the PI3K α isoform, the equivalent residue 




clash with the dimethylamino methyl group. As a consequence, compound 71 
displayed a 5-fold drop in PI3K α potency compared with its unsubstituted 
analogue 70 (Table 18). On the contrary, the introduction of the 
dimethylamino methyl group was associated with a slight decrease in δ/β 
selectivity (Table 18). This could be because, in PI3K β, δAsn832 was 
substituted by the negatively charged residue βAsp856, which formed a salt 
bridge with the dimethylamino methyl group of 71. Taken together, these 
findings suggested that the hydrophobic region II contributed to the isoform 
selectivity of PI3K δ inhibitors over other class-I PI3K members. However, in 
this research, the hydrophobic region II would not be explored, thus the 
phenyl group of 8 was kept unchanged.  
 
Figure 55. Overlay of crystal structures of 70 (PDB code 5NCZ) (green) and 71 (PDB code 
5NCY) (magenta) bound to PI3K δ. It reveals that Asn836 (magenta) in the case of compound 
71 changes its side chain position to allow the dimethylamino methyl group to fit. In contrast, 
the corresponding Gln856 in PI3K α and Lys890 in PI3K Ɣ does not undergo a conformational 
change to accommodate compound 71, which might explain the superior selectivity of 
compound 71 for PI3K δ versus α and Ɣ isoforms. 
3.2.4 Affinity pocket (unoccupied) 
This pocket is lined with polar and hydrophobic residues (two aspartates, 
lysine, tyrosine and two leucines). All these residues are conserved among 




affinity pocket leaving it unoccupied (Figure 56). Whereas, flat-shaped 
inhibitors bind within this pocket making two hydrogen bond interactions with 
Tyr813 and Asp787, as stated previously in Chapter 2. 
3.3 Aims 
As it was already mentioned, 8 binds to PI3K δ at the three interaction points 
(specificity pocket, hinge region and hydrophobic region II) leaving the fourth 
region (affinity pocket) unused. Therefore, targeting of this pocket would 
increase the number of binding pockets engaged from 3 to 4 (Figure 56). It 
was believed that the current inhibitor potency (IC50 = 11 nM) of 8 could be 
further increased by exploring interactions with the polar residues lining the 
unoccupied affinity pocket (Figure 56b). The design strategy was to increase 
the size of idelalisib (8) by adding a new substituent to access the affinity 
pocket. The additional substituent should bear polar binding groups in order 
to make hydrogen bonding with the polar residues (Asp787, Asp911, Tyr813 and 
Lys779) surrounding the affinity pocket (Figure 56b). This appeared to be an  
a)                                                           b) 
   
Figure 56. a) The selective PI3K δ inhibitor idelalisib (8) and its binding points at PI3K δ. b) 
Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) bound, highlights the 
addition of extra functional group to idelalisib (8) in order to probe the binding interactions 




attractive strategy to develop a new series of propeller-shaped PI3K δ 
inhibitors which could be 10-100 times more potent than 8. This approach is 
known as drug extension or tree growing branches. 
The strategy of extension was not novel and has been used to increase the 
activity of many published propeller-shaped PI3K δ inhibitors, but to the best 
of this author’s knowledge, has never been tried on FDA-approved idelalisib 
(8). Berndt et al173 and Williams et al193 concluded that additional gains of 
activity for propeller-shaped inhibitors 9 can be obtained when substituents 
bearing hydrogen bond donor and/or acceptor motifs added to the lead 
compound that extended to the affinity pocket and involved in hydrogen 
bonding with polar residues that lined the affinity pocket241. For instance, 3-
flourophenol in SW13 (10) (Table 19) (Figure 57a) projected from the central 
pyrazolopyrimidinineamine core to the affinity pocket where it engaged in 
hydrogen bonding with Asp787 and Lys779 (Figure 57b). These interactions 
resulted in improving the affinity at δ isoform in comparison to the parent 
compound 9 (Table 19)242. 
 
Table 19. Biological evaluation and isoform selectivity for PI3K δ for compounds 9 and 10 
reported by Berndt et al173, highlighted the improvement in PI3K δ potency in compound 10 
173. 
compd R PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
9173 H 130 1538 123 469 
10173 
 





a)                                                                                  b) 
                          
Figure 57. a) The selective PI3K δ inhibitor compound 10, highlights the meta-fluorophenol 
group that forms hydrogen bond interactions with the affinity pocket. b) Crystal structure of 
murine PI3K δ (PDB code 2WXG) with compound 10 bound. Blue dashed lines represent the 
proposed hydrogen bonds that take place between the phenol group in compound 10 with 
Asp787 and Tyr813 in the affinity pocket.  
3.4 Medicinal chemistry strategy 
3.4.1 Variation of Linker length 
The first task in this medicinal chemistry project was to identify the optimal 
length of the linker that could connect between 8 and the newly added 
functional group (hydrogen bond donor and/or acceptor) that would be 
targeting the affinity pocket. The strategy used in the current study was to link 
the new binding group (hydroxy, amido and cyano) with 8 through a linker of 
variable length (2-4 carbon atoms) (Figure 58), this would help to identify the 
most appropriate linker length for PI3K δ inhibition. It was believed that 
increases in the linker length past 4 carbons may reduce PI3K δ activity. 
3.4.2 Types of binding groups 
The second task was to determine the terminal polar functional groups that 
would interact with the unoccupied affinity pocket. There are four polar 





Figure 58. Idelalisib (8) connected by variable length linkers to the terminal functional group 
(hydroxyl, amide or cyano) in order to explore the affinity pocket. 
a key point to be considered when selecting the binding group, is the ability 
to participate in hydrogen bonding interactions with these polar residues. 
Based on this, the hydroxyl group, amido group and cyano group were 
chosen (Figure 58). The hydroxyl and amido groups could serve as hydrogen 
bond acceptors and donors, whereas the cyano group can only act as an 
acceptor.268 The absence of a hydrogen bond donating ability in cyano group 
could be useful in the identification of the specific binding residues in the 
affinity pocket. If nitrile-containing compounds exhibited PI3K δ potency 
comparable with that of alcohol and amide analogues, then it is likely that 
Lys779 or Tyr813 are involved in ligand binding. On the other hand, if nitrile 
analogues are much less active than the corresponding alcohols and amides, 
then Asp787 or Asp911 residues may directly interact with the ligands. 
3.4.3 Site of extension 
The last task was to identify the best site on 8 from which to build the 
additional substituent that could extend directly into the affinity pocket. Based 
on the crystal structure of murine PI3K δ in complex with 8 (PDB code 4XE0) 
(Figure 59b), there are three potential points of attachment on 8 to introduce 




It was believed that the exocyclic amine was the best site to place the new 
functional group in order to access the affinity pocket. Moreover, the 
introduction of a new functional group to the exocyclic amine is synthetically 
accessible and convenient than functionalisation of N-7 and C-8 of purine 
positions.  
a)                                               b) 
             
Figure 59. a) The selective PI3K δ inhibitor idelalisib (8). b) Crystal structure of murine PI3K 
δ (PDB code 4XE0) with 8 bound, highlights the three possible sites (exocyclic amine, N-7 
and C-8 of purine) in idelalisib structure to add the extra substituents which may extend to 
the unoccupied affinity pocket. 
3.5 Discussion 
3.5.1 Chemistry Section 
A general synthetic strategy was developed, through which 8 would be 
synthesised first (Scheme 3), followed by the addition of the new substituent 
(affinity pocket binder) onto the exocyclic amine by an alkylation reaction. 
3.5.1.1 Synthesis of idelalisib 8 (step a-e) 
The route (Scheme 3) began by following the procedure mentioned by Liu, J 
et al269. The benzamide derivative 74 was prepared in high yield by reacting 
2-fluoro-6-nitrobenzoic acid (73) with aniline using HATU as a coupling 
reagent and DIPEA as a base. Then, 74 was subjected to catalytic 




Scheme 3. Synthesis of idelalisib (8) 
 
aReagents and conditions: (a) HATU (2.5 equiv), DIPEA (3 equiv), dimethylformamide (DMF), 
rt, 24 h, yield 98%; (b) H2, 10%Pd/C (0.05 equiv), methanol, rt, 12 h, yield 100%; (c) isobutyl 
chloroformate (IBCF) (3.5 equiv), N-methylmorpholine (3.5 equiv), THF, 60 ºC, 24 hr, yield 
61%; (d) hexamethyldisilazane (HMDS) (9 equiv), I2 (3 equiv), dichloromethane (DCM), rt, 24 
h, 56%; e) DIPEA (10 equiv), tert-butanol, microwave 130 °C, 10 h, yield 75%. 
amine 75. In a first attempt to synthesize the diamide derivative 76, compound 
75 underwent amidation with N-Boc-L-alpha-aminobutyric acid following the 
same conditions outlined in step a, however this reaction went extremely 
slowly with very low yield (5%), this could be attributed to the steric effect 
exerted by the bulky group (N-acetylaniline) at the ortho-position of amine in 
compound 75. Steric hindrance is a common issue that negatively impacts 
the reactivity of amide coupling270,271, resulting in increases in the duration of 
reaction and reduction in yield. As a result, an alternative coupling reagent 
IBCF was investigated. Thus, N-Boc-L-alpha-aminobutyric acid was treated 
with 3.5 equiv. of N-methylmorpholine (NMM) followed by the addition of 3.5 
equiv of IBCF in THF at -10 °C for 2h. Then aniline derivative 75 was added 
gradually to the reaction mixture, and the reaction was heated at 60 °C for 12 
h, to provide the diamide 76 in 60% yield, which was relatively high comparing 
to HATU-coupling method. 
The most challenging step in this synthesis is the cyclisation and formation of 




the literature to synthesise the compound 77272,273. However, the drawback 
of these methods was that they were carried out in two steps. Fortunately, a 
novel and convenient one-step synthesis of quinolizinone-based compound 
77 with simultaneous deprotection of boc group was described by Xialong. 
W. et al274. In which HMDS-iodine induced the intramolecular dehydrative 
cyclisation of diamide 76 affording the quinazolinone derivative 77 (Scheme 
3). However, the mechanism of simultaneous deprotection of the Boc group 
in this reaction is still not understood. 
In the next step, the primary amine 77 was reacted with 6-chloropurine 78 in 
tert-butanol with DIPEA. The reaction was carried out either by reflux for 
conventional synthesis or by microwave irradiation (130°C). The microwave 
assisted reaction was completed within 8-10 h and gave idelalisib (8) in good 
yield (75%). In contrast, conventional heating needed longer reaction time (48 
h) to achieve its maximum yield (53%). These findings are in agreement with 
the previous studies275,276, which reported that the optimum conditions for 
nucleophilic displacement of 6-chloropurine 78 were to be carried out in 
microwave (130ºC) in alcohol solvent (isopropanol, n-butanol and tert-
butanol) with DIPEA used as a base. 
3.5.1.2 Introduction of the new functional group (step f) 
The final step involved the addition of the new functionalities which were 
simple chain haloalcohol derivatives (β-chloroethanol, Ɣ-chloropropanol and 
δ-chlorobutanol) into the exocyclic amine of idelalisib (8). The reaction was 
carried out under two conditions; the conventional reflux and the microwave 
irradiation with a screening of the temperature (25, 60 and 120°C), solvents 




(DIPEA, triethylamine TEA and K2CO3) (Table 20). Unfortunately, N-
alkylation did not take place with any of the reaction conditions tried. 
Table 20. Screening of the reaction conditions in the synthesis of compound 72. 
 
Solvent Tempa(°C) Baseb Convc(%) 
DMF RT DIPEA 0 
DMF 60°C DIPEA 0 
DMF 60°C TEA 0 
DMF 60°C K2CO3 0 
DMF 120°C DIPEA 0 
DMF 120°C K2CO3 0 
DMSO 60°C DIPEA 0 
DMSO 60°C TEA 0 
DMSO 60°C K2CO3 0 
DMSO 120°C DIPEA 0 
DMSO 120°C K2CO3 0 
NMP 120°C DIPEA 0 
NMP 120°C K2CO3 0 
aHeating at 120°C was carried out under microwave irradiation. bThe reactions were carried 
out in the presence of 3 equiv of base. cConversion was based on liquid chromatography-
mass spectrometry (LC-MS) analysis. 
It was suggested that the combined steric and electronic effects were 
responsible for the failure of the final N-alkylation step. The steric effect could 
be exerted by the three surrounding substituents (purine ring, quinazolinone 
ring and/or ethyl side chain) (Figure 60a). The steric hindrance has been 
known for being a main factor in the failure of SN2 reactions277,278. The 




nucleophilicity of the exocyclic amine by resonance delocalisation (Figure 
60b). Thus, reversing the steps was proposed, where one of the three bulky 
groups would be introduced at the final step of the synthesis after the 
introduction of the required substituent at the exocyclic amine. 
a)                                                                        b) 
    
Figure 60. a) The selective PI3K δ inhibitor idelalisib (8), displays the three substituents 
(highlighted in orange) that could exert steric hindrance on the exocyclic amine (highlighted 
in green). b) The lone pair of electrons on exocyclic amine delocalises into the purine ring, 
resulting in reduced nucleophilicity. 
3.5.1.2.1 Purine group  
The purine ring could reduce the nucleophilicity of the exocyclic amine by 
steric hindrance and electronic effect by conjugation. Thus, it was 
hypothesised that the N-alkylation could take place when the exocyclic amine 
is not attached to the purine ring. Hence, reversing the steps (e and f) was 
considered (Scheme 4), it was speculated that alkylation of exocyclic amine 
(step f) with the new functionality prior to the introduction of the purine ring 
(step e) (reordering of steps) might overcome the problem of the low 
nucleophilicity of exocyclic amine. 
Thus, monoalkylation of primary amine 77 using iodoalkyl alcohols of different 
chain length (C2 to C4) in acetonitrile in the presence of alkali carbonate 
(K2CO3) has been carried out resulted in the generation of secondary amines 





Scheme 4. Failed attempt to synthesize the final products 72 and 79- 93, by reversing steps 
e and f  
 
aReagents and conditions: f) K2CO3 (3 equiv), CH3CN, 80 ºC, 12 h, yield 30- 51%. e) DIPEA 
(10 equiv), tert-Bu OH, microwave 130 °C, 16 h, (unsuccessful). 
 was (30-51%), the reaction did not go to the completion with 50% of starting 
amine recovered. However, no overalkylation products were detected, 
suggesting the reaction had good chemoselectivity. Whereas, N-alkylation of 
primary amine 77 by the corresponding alkyl iodides resulted in a mixture of 
the desired secondary amines (82, 84, 86) and the undesired tertiary amines 
(83, 85, 87). Unfortunately, the reaction of the resulting secondary amines 
(79- 81, 82, 84 and 86) with 6-chloropurine 78 failed to give the desired 
products (72 and 88- 93), although the reaction was conducted under the 
optimum conditions for nucleophilic displacement of 6-chloropurine 78 (Hünig 
base, n-butanol, 130°C) that was reported by Kolarski, D et al275 and Chang, 
Y et al276. 
After the displacement of 6-chloropurine 78 proved to be difficult, a new 
strategy to replace the 6-chloro purine 78 with more reactive 6-substituted 
purine was conducted. Liu. J et al279 and Legraverend. M et al280 reported that 
the order of the reactivity of 6-halopurine for aromatic nucleophilic 




were displaced more rapidly in nucleophilic aromatic substitution reactions. 
Thus, 6-bromopurine 94 was employed as an alkylating reagent in the 
alkylation of the secondary amines (79- 81, 82, 84 and 86), the reaction 
followed the appropriate conditions that was reported by Bernal Anchuela F 
J et al281 for displacement of 6-bromopurine 94 (scheme 5a), where the 
reaction of secondary amine 79 with 6-bromopurine 94 was carried out in tert-
butanol at 80 °C 281. However, the reaction was unsuccessful and both the 
starting materials were recovered (Scheme 5b). 
Scheme 5. a) Reaction reported by Anchuela et al281 representing an example of nucleophilic 
displacement of 6-bromopurine 94 with a secondary amine 95. b) Failed attempt to displace 
the 6-bromopurine with a secondary amine 79 using Anchuela conditions 
 
aReagents and conditions: a) DIPEA (1.1 equiv), tert-Bu OH, 80 ºC, 16 h, yields 80%281. b) 
Employing the same reaction conditions reported for step a, (unsuccessful). 
Alternatively, Liu, J et al279 and Xiaoyu lin et al282 mentioned that 6-
(alkylsulfonyl) purine was found to be more reactive than all 6-halopurine 
derivatives. Thus, 6-(propylsulfonyl) purine 98 (Scheme 6) was prepared from 
6-chloropurine 78 starting material, which was coupled with 1-propanethiol at 
ambient temperature, to afford 6-(propylthio) purine 97. The reaction of 
compound 97 with oxone in DCM provided the corresponding sulfone 98 in 




79 in n-butanol at 100°C to afford the final products 72, only resulted in 
unreacted starting materials. 
Scheme 6. Failed attempt to Synthesize the final product 72 via 6-(propylsulfonyl) purine 
intermediate 98 
 
aReagents and conditions: a) DBU (3 equiv), DMF, rt, 16 h, yield 13%; b) oxone (9.5 equiv), 
DCM, rt, 15 h, yield 36%. c) n-butanol, 100 °C, 15 h, (unsuccessful). 
Despite reordering of the last two steps, by adding the purine group after the 
introduction of the new functional group, the synthesis of final idelalisib 
analogues (72 and 88- 93) still remained a highly challenging task. Thus, a 
number of alternative approaches would be considered. 
3.5.1.2.2 Quinazolinone ring  
It was assumed that the steric hindrance could be exerted by the bicyclic 
quinazolinone ring on the exocyclic amine. Additionally, intramolecular 
hydrogen bonding could take place between the N1 of quinazolinone and the 
proton on the exocyclic amino group forming a five-membered ring (Figure 
61), which could hamper the reactivity of the exocyclic amine against the 
nucleophilic substitution reaction. 
 
Figure 61. The suggested five-membered hydrogen-bonded ring, which might reduce the 




Thus, a new synthetic pathway of the final compounds (72 and 88- 93) was 
developed (Scheme 7). In this case, the steps would be reordered such that 
the exocyclic amine alkylation preceded quinazolinone formation. The 
introduction of the affinity pocket functional group would take place in the 
beginning of the reaction sequence, to form intermediate 102 which would 
later undergo cyclisation to quinazolinone 103 followed by O-debenzylation 
to generate the final product 72. The alkylation of the amino group of 2-
aminobutyric methyl ester 99 took place in refluxing acetonitrile overnight, 
resulted in secondary amine intermediate 100. However, displacement of 
chlorine from 6-chloropurine did not take place and no traces of product 101 
could be detected, although the reaction took place under the optimum 
conditions needed for the displacement of 6-chloropurine (n-butanol, DIPEA 
and 120 ºC)276. 
Scheme 7. Failed attempt to synthesize the compound 72 by a new synthetic pathway 
 
aReagents and conditions: (a) K2CO3 (6 equiv), CH3CN, reflux, yield 28%; (b) DIPEA (3 
equiv), n-butanol, reflux, 15 h, (unsuccessful). 
These findings revealed that the synthesis of tertiary amine 101 bearing a 




were relatively small and proved that bicyclic quinazolinone ring was not 
responsible for the very low nucleophilicity of the exocyclic amine.  
3.5.1.2.3 Ethyl side chain 
Another approach to diminish the steric effect was the removal of the ethyl 
side chain alpha to the exocyclic amino moiety (Figure 60). Cushing, T. et 
al156 pointed out in his series of propeller-shaped inhibitors that were 
structurally related to idelalisib (8) (Figure 62), that the presence of a methyl 
group located α to the exocyclic amine made it more sterically hindered.  
 
Figure 62. Structure of PI3K δ selective inhibitors 104 and 105 described by Cushing et al156, 
which have very close structural similarity to idelalisib (8). Cushing proposed that the addition 
of the methyl group at α-position of the exocyclic amine leads to more sterically congested 
exocyclic amine. 
Thus, idelalisib (8) would undergo structural simplification then structural 
extension to afford synthetically more tractable exocyclic N-substituted 
analogues (Figure 63). As might be expected, the removal of the ethyl group 
could lead to a reduction in the PI3K δ activity (the role of the ethyl group in 
ligand-protein interaction will be discussed later in Section 3.6.7). However, 
because the main purpose of this research was to examine the increase in 
inhibitor potency that could be obtained by exploring interactions within the 
affinity pocket. Thus, comparison of the biological activity between des-






Figure 63. Structural simplification of idelalisib (8) by removal of the ethyl side chain followed 
by structural extension with a new binding group added to the exocyclic amine. 
Des-ethyl idelalisib analogue 106 was obtained by the same synthetic 
procedure as idelalisib (8), but in this synthetic methodology (Scheme 8), 
aniline intermediate 75 was acylated with N-boc-glycine instead of N-boc-2-
aminobutyric acid to afford the amide intermediate 108 in yield 30%, followed 
by cyclisation to give quinazolinone derivative 109 in low yield (20%), which 
then further reacted with 9-paramethoxybenzyl-6-chloropurine 110 to form 
des-ethyl idelalisib 111 in 39% yield. 
Scheme 8. Synthesis of the des-ethylated idelalisib analogue 107 
 
aReagents and conditions. (a) IBCF (3.5 equiv), NMM (3.5 equiv), dry THF, 60 ºC, 24 h, 25%; 
(b) HMDS (9 equiv), I2 (3 equiv), DCM, rt, 24 h, 20%; (c) DIPEA (9 equiv), tert-butanol, reflux, 
15 h, 39%; (d) K2CO3 (3.5 equiv), KI (0.5 equiv), DMF, 55 °C, 22 h (unsuccessful, 
fragmentation of 111 to the two side products). 
With 111 in hand, the final alkylation step was attempted to generate the 
tertiary amine product 112. Unfortunately, it was found that treatment of 111 




potassium carbonate in DMF at 55 °C (Scheme 8), gave rise to the formation 
of two side products with no traces of product 112 detected. By combination 
of LC-MS and 1H NMR, one of the side products was identified as being 9-
para-methoxybenzyl-6-aminopurine 113 (Figure 64). Which indicated that 
considerable amount of the starting amine 111 was decomposed, such 
decomposition could occur through the aliphatic C-N bond cleavage156, which 
suggested that des-ethyl idelalisib 111 was chemically unstable, owing to the 
absence of the steric hindrance exerted by the ethyl group, that would 
enhance the susceptibility to N-dealkylation. This was supported by the fact 
that such decomposition was not seen in the parent compound (idelalisib 8). 
   
Figure 64. The 9-PMB-6-aminopurine 113 fragment produced by decomposition of the 
compound 111 with its 1H NMR spectrum. 
3.5.1.2.4 Test the feasibility of the exocyclic amine alkylation  
It is well known that SN2 reactions are accelerated by adjacent multiple bonds 
at Cα position of the leaving group, for example, the rate of the SN2 reaction 
of benzyl halides is 800 times faster than that of the alkyl bromide283, while 
the allyl halide undergoes SN2 reaction 40 times faster than n-propyl halide284–
286, this effect is named benzylic and allylic effect284, which is attributed to the 




electron-pulling sp2 hybridized carbon atom, this makes it more electrophilic 
and more susceptible to nucleophilic attack287. The second is that the 
hyperconjugation between the pi-system of the adjacent double bond and the 
orbital of nucleophile would stabilize the bimolecular transition state (Figure 
65)288,289. It has been reported that allylic and benzylic substrates are the 
optimum model system to study the effect of steric hindrance on the reactivity 
trend290. To test this hypothesis, allyl and benzyl halides would be used as 
alkylating reagents to investigate the possibility of alkylation on the sterically 
crowded amine overcoming the observed steric resistance. 
 
Figure 65. a) The p-orbital on the allylic carbon aligns with the pi-system of the alkene, 
resulting in the extra stabilization of the transition state, which improves the rate of SN2 
reaction. b) In propylbromide, there is no extra stabilisation of the transition state of SN2 
reaction. 
When benzyl halide derivative (3-nitrobenzylbromide) was used as an 
alkylating agent in isopropanol with DIPEA, exocyclic N-alkylation took place 
for the first time, however N-9 of purine was benzylated as well, resulted in 
the formation of 3 compounds (Scheme 9): two regioisomers 116 and 117 
and the dialkylated side product 118. The desired regioisomer 116 was the 




in a yield of 7% (Scheme 9). Heteronuclear multiple bond correlation (2D 1H-
13C HMBC NMR) technique was used to distinguish between the two 
regioisomeric structures 116 and 117 (Figure 66 and 67, respectively). 
Scheme 9. Synthesis of N-benzylated idelalisib derivatives 116, 117 and 118 
 
aReagents and conditions. (a) DIPEA (3 equiv), isopropanol, microwave 130°C, 4 h, yield of 
116 is 40%, yield of 117 is 7%. 
Under the same reaction conditions, allylation of the exocyclic amine of 
idelalisib (8) with allyl bromide was achieved, to give a mixture of two 
regioisomers 119 and 120 in isolated yields of 53 and 12%, respectively, in 
addition to the diallylated side product 121 (Figure 68), which was the same 
regioselectivity observed in the alkylation with benzylbromide derivative. 2D 
1H-13C HMBC NMR technique was used again to distinguish between the two 
synthetic regioisomers 119 and 120. 
 









Figure 66. HMBC spectra of regioisomers 116. The peaks outlined in blue showed the three-
bond correlation between C-1 and H-2, which indicates that the correlation between C-1 and 
H-2 are three bonds apart. 
C-1 
Chemical 











Figure 67. HMBC spectra of regioisomer 117 demonstrates that there is no correlation 
between H-2 and C-1 or any other aliphatic carbons, while it displays a lot of correlations 
(peaks) with many aromatic carbons, which indicates that benzylation took place at N-9 of 
the purine. 
It was suggested that the success of the alkylation of the exocyclic amine with 
benzyl and allyl halides in contrast to the alkyl halides was due to the 
improved rate of bimolecular nucleophilic substitution at a saturated carbon 
adjacent to a double bond283. Two classes of electrophile that have adjacent 
unsaturated functionality similar to allylic and benzylic halide are the α-
halocarbonyl compounds (esters and amides) and α-halonitriles. Thus, they 
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could be used for introducing substituents containing the desired functional 
groups (hydroxyl, amido and cyano) at the sterically hindered exocyclic 
amine. But before going further in the synthesis, it was essential to protect 
the N-9 of the purine. 
3.5.1.2.5 Protection of N-9 of purine  
The formation of regioisomeric side products in the previous two reactions 
suggested the need for the protection of N-9 of purine with a suitable 
protecting group (Figure 70). Tetrahydropyran (THP) was effectively used as 
a protecting group of N-9 of purine during the synthesis of idelalisib (8) by Liu 
et al269 and Vinayak et al291. THP can be installed easily and it is stable under 
the basic conditions used for the alkylation of the exocyclic amine292. 
Moreover, it can be removed by mildly acidic aqueous conditions. For 
instance, Liu, J et al269 reported the deprotection of THP from N-9 purine of 
idelalisib (8) with 99% yield using aqueous hydrochloric acid (1 M) in ethanol, 
at room temperature (RT). The formation of 9-(tetrahydropyran-2-yl)-6-
chloropurine 122 was conducted by reacting 6-chloropurine 78 with 3, 4-
dihydro-2H-pyran in the presence of p-toluenesulfonic acid in ethyl acetate, 
providing N-9-THP-protected 6-chloropurine 123 in 99% yield. 
 
Figure 70. Installation and removal of the protecting group on the N-9 of purine ring, to 




3.5.1.2.6 Reaction with -halo carbonyl and nitrile 
The success of introducing of benzyl and allyl to the exocyclic amine and 
formation of tertiary amines 116 and 119 showed the necessity of using very 
reactive electrophiles to overcome the steric effect. However, in contrast to 
allylic and benzylic halides, which could follow both unimolecular (SN1) or 
bimolecular (SN2) nucleophilic substitution mechanism293, α-halo carbonyl 
compounds have been known to react only via SN2 mechanism284. Clayden 
et al294 mentioned that α-halocarbonyl compounds are 500 and 1260 times 
more reactive towards SN2 reaction than benzyl and allyl halides, 
respectively294. Where the adjacent carbonyl group accelerates the SN2 
reaction by making C-Br more reactive, because (C=O) has low-energy 
empty orbital (π*) and also (C-Br) has low-energy empty orbital (σ*), where 
these two orbitals combine to form a new lowest unoccupied molecular orbital 
(LUMO) (π* + σ*) (Figure 71), this makes the two neighbouring carbons very 
strong electrophile293. Hence, a practical method for β-functionalisation of the 
exocyclic amine via substitution reaction with α-halo carbonyl (α-
haloacetamide and ester) and α-halonitrile was suggested. 
According to this, protected idelalisib analogue 123 was treated with α-
bromoacetamide in DMF in the presence of K2CO3 as a base (Scheme 10). 
This reaction afforded a complex mixture of three compounds: the protected 
124 and deprotected 125 products and the starting material 123. This 
composition of protected 124 and deprotected 125 products was surprising, 
as the THP protecting group was expected to be relatively stable under the 
strong basic conditions295. Fortunately, however, the final product 125 was 





Figure 71. The low-energy empty orbital of C=O (π*) and the low-energy empty orbital C-Br 
(σ*) align together, to generate LUMO (π*+σ*), making the two adjacent carbons highly 
electrophilic, which explains the high reactivity of -halocarbonyl compound for SN2 reaction. 
Scheme 10. Synthesis of the final amide 125 and nitrile 127 products 
aReagents and conditions: (a) K2CO3 (3 equiv), DMF, 50 °C, 16 h, yield of 125 is 12%, yield 
of 127 is 15%. 
strong basic conditions295. Fortunately, however, the final product 125 was 
isolated in 12% yield and confirmed by 2D 1H-13C HMBC NMR. Under the 
same condition (Scheme 10), the exocyclic amine of N-9-THP protected 




protected 126 as well as deprotected 127 nitrile product. The latter was 
isolated in 15% yield. 
Our final task was to synthesize the final alcohol analogue 72. This would be 
conducted in a two-step procedure where tert-butyl ester would be introduced 
at exocyclic amine (Scheme 11) and reduced to the corresponding primary 
alcohol. It was believed that THP might be unsuitable for this two-step 
reaction, because it proved to be unstable in the desired reaction condition 
and this led to the side products and accordingly low yields in the previous 
two reactions (Scheme 10), Thus, the THP group was removed and replaced 
by a sufficiently stable protecting group. Lebraud et al296 mentioned that para-
methoxybenzyl (PMB) group was more stable than THP as a protecting group 
for N-9 of a purine. To make the final alcohol product 72. N-9-PMB protected 
idelalisib analogue 128 underwent reaction with tert-butyl bromoacetate in dry 
DMF at 60°C with K2CO3 used as a base (Scheme 11), LC-MS and thin-layer 
chromatography (TLC) clearly showed the formation of tertiary amine product 
129 with no side products observed. However, ester hydrolysis took place 
during the aqueous work-up, which reduced the yield of the pure product to 
15%, while the yield of the resulting carboxylic acid 130 was 26%. 
Scheme 11. Synthesis of the ester product 129 and the side product 130 
 
aReagents and conditions: (a) K2CO3 (3 equiv), DMF, 50 °C, 16 h, after work-up yield of 129 




3.5.1.2.7 Deprotection of PMB group and formation of the 
deprotected ester 
There were a plethora of reagents that were reported in the literature for 
deprotection of PMB from N-9 of purine including refluxing trifluoroacetic acid 
(TFA)297, TFA in DCM-anisole298, TFA/triisopropylsilane299, ceric ammonium 
nitrate (CAN)300,301 and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). In 
order to investigate the optimum conditions for deprotection of PMB, the 
simple protected purine (9-PMB-6-chloropurine 110) was chosen as a model 
substrate (Table 21). It was found that TFA/triisopropylsilane and CAN were 
the only methods which achieved complete consumption of the starting 
material 110, TFA/triisopropylsilane gave the cleanest reaction, while the 
CAN reaction resulted in the formation of side products, while other reagents 
(DDQ, neat TFA and TFA/anisole) resulted in undesirable partial deprotection 
of the starting material with appearance of side products (Table 21).  
 
Table 21. PMB-deprotection conditions screening. 
Reagent Solvent Temp (°C) Convb(%) Purityc(%) 
TFA  triisopropylsilane 60° 100 100 
CAN CH3CN: H2O RT 100 70 
TFA with anisole DCM 40 
(Reflux) 
70 60 
DDQ DCM RT 40 40 
b,c Conversion and purity were based on LC/MS analysis.  
Based on this, TFA/triisopropylsilane and CAN were selected as PMB-
deprotecting reagents in the current synthesis. However, upon exposure of 




changing the reagent to CAN resulted in the N-deprotected product 131 with 
16% yield (Scheme 12). 
Scheme 12. PMB-deprotection of the ester compound 131 
 
aReagents and conditions: (a) CAN (3 equiv), CH3CN: H2O (1: 1), rt, yield 16%. 
3.5.1.2.8 Reduction of ester  
The last step of synthesis was to reduce the tert-butyl ester 131 to the final 
alcohol 72. In this reaction, lithium aluminium hydride could not be used, 
because of the presence of the tertiary aromatic amide, thus weaker reducing 
agent was required. Studies have found that lithium borohydride could 
selectively reduce the ester in the presence of amide under mild condition 
(0°C)302–304. It was reported that, for the reduction of ester, 2 equivalents of 
lithium borohydride was required302. Although the reaction led to complete 
consumption of the starting ester, it gave a mixture of product 72 and side 
product in a 1:1 ratio. The purification step proved impossible, even in HPLC, 
since the product and the side product have similar polarity. Surprisingly, the 
side product was identified by crude1H NMR and LC-MS analysis as a 
cyclised compound 133 (Figure 72). A plausible mechanism for the formation 
of 133 involves intramolecular reductive amination of N-7 of purine with the 
aldehyde 132 produced as an intermediate during the reduction of ester 129 
to alcohol 72 (Scheme 13). In addition to that, the ease of the formation of 6-
membered ring could promote the formation of the cyclised side product 133 








Figure 72. a) The desired product 72. b) The suggested cyclised side product 133. c) 1H NMR 
spectrum of the crude product (a mixture of compound 72 and 133). Peaks at 3.02 and 3.24 
ppm are assigned to H-1 of the side product 133. Peaks at 4.06 and 4.57 ppm are assigned 
to H-2 of the product 72. Peaks at 7.93 and 7.96 ppm are assigned to the H-3 of the product 
72 and side product 133. Peaks at 8.23 and 8.29 ppm are assigned to the H-4 of the product 
72 and the side product 133. 






To avoid the generation of the cyclised side product 133, it was suggested 
that alkylation at N-7 through NH-tautomerization of the imidazole ring might 
be avoided by blocking N-9 with a protecting group (Figure 73). 
 
Figure 73. Strategy to prevent the formation of the cyclised side product 133 by blocking N-
9 of purine. 
Hence, the reduction of the ester was carried out first, followed by the 
deprotection step, where the N-9-PMB-protected ester 129 was treated with 
LiBH4 in dry THF at 0°C (Scheme 14). Unfortunately, over-reduced side 
product was obtained in 100% yield, with partial hydrogenation of one of the 
aromatic rings which can be observed from 1H NMR studies. The partial 
reduction was believed to occur on the pyrimidine ring of purine to afford the 
2,3-dihydropurine derivative 134 (Scheme 14), where a new CH2 proton 
signal appeared at 5.11 ppm assigned to the 2-methylene hydrogen of 2,3-
dihydropurine. This finding is in agreement with a study published by Shadbolt 
et al308, which reported that the reduction of heterocyclic ring systems, usually 
occurs at an unsubstituted carbon. For example, Shadbolt et al308 reported 
that when 2,4,5-trisubstituted pyrimidines (135- 137) were treated with LiBH4, 







Scheme 14. Failed attempt to synthesize the final alcohol 112 via ester 129 reduction using 
LiBH4 
 
aReagents and conditions: (a) LiBH4 (2 equiv), THF, 0 °C, 1 h, (unsuccessful, possible 
formation of the over-reduced side product 134, yield 100%). 
Scheme 15. Examples of the partial reduction of pyrimidine ester derivatives by LiBH4 to 
give1,6-dihydropyrimidines have been reported by Shadbolt et al308 
 
aReagents and conditions: (a) LiBH4 (1 equiv), THF, 0 °C, 2 h, yield 23- 92%. 
3.5.1.2.9 N-alkylation of exocyclic amine in the presence of Grignard 
reagent 
After an attempt to reduce the ester 129 to alcohol product 112 was 
unsuccessful. It was suggested to use an efficient alternative method for the 
direct N-alkylation of exocyclic amine with a hydroxyethyl halide, where the 
exocyclic amino group of compound 54 was subjected to deprotonation with 
a Grignard reagent in THF, followed by addition of alkylating agent (2-
iodoethanol) to the deprotonated substrate to complete the reaction (Scheme 
16). The pKa of the Grignard reagent is approximately 30.1309. Hence it 
should be able to deprotonate the aryl exocyclic amine exhibiting the pKa 
value of 10.29310. The reaction resulted in the formation of the tertiary amine 
product 141 which on subsequent deprotection of THP gave the final N-





Scheme 16. Synthesis of the final alcohol product 72 with the Grignard reagent used as the 
base 
 
aReagents and conditions: (a) i-PrMgCl (1.1 equiv), THF, 70 °C, 16 h, yield 18%. (b) HCl, 
ethanol, rt, 4 h, yield 90%. 
3.5.1.3 Conclusion of Chemistry 
The synthesis of the exocyclic N-substituted idelalisib was challenging 
because of the difficulty in the alkylation of the exocyclic amine, it was 
proposed that the purine ring effectively retards the alkylation of the exocyclic 
amine due to the two potential factors. Firstly, the purine ring is a bulky group 
which could exert steric hindrance on the nearby nucleophile. A second 
reason is that purine is a heteroaromatic system which could reduce the 
nucleophilicity of the attached amine by a combination of resonance 
delocalization and inductive effects. Additionally, the two nitrogen atoms of 
imidazole ring of purine (N-7 and N-9) are reactive and they create unwanted 
reactions that compete with the desired reaction, for instance N-9 formed the 
regioisomeric side products (as seen in scheme 9). As a result, two additional 
protection and deprotection steps were necessary, which increased the 
number of steps in the synthesis. It must be pointed out that they were two 
findings which could have implementations in the future synthesis of this 
series of compounds. 
Alkylation and formation of 3ry amine. In general, formation of tertiary 
amine containing one purine ring on the nitrogen atom. proved difficult, only 




haloester can achieve this task. Additionally, N-alkylation could be effectively 
carried out by deprotonation of the exocyclic amine with the use of strong 
base such as a Grignard reagent followed by addition of electrophiles. 
Protection and deprotection strategies of N-9-purine. In this research, 
THP has been found to be the best protecting group for N-9 of purine, 
because it could be installed and removed easily relative to other N-9 
protecting groups such as PMB. However, surprisingly, it was found that THP-
protecting group was unstable under the basic conditions required for the N-
alkylation of the exocyclic amine, resulted in the occurrence of the 
regioisomeric side product. 
3.6 Biological section  
The ten low molecular weight compounds (fragments, 77- 87) were tested 
(Table 22), which were defined as the final products without the purine hinge 
binder for their activity against the four isoforms of PI3K. These fragments 
possessed linear side chains ranging from n-ethyl to n-butyl at the exocyclic 
amine (Figure 74). The side chains of compounds (79, 80 and 81) contained 
a terminal hydroxyl group which capable of exploring new binding interaction 
with the affinity pocket, whereas fragments (82- 84) had non-polar side chain, 
provided reference compounds in which hydrogen bonding was not possible. 
The aim of this SAR study was to identify the fragment-sized affinity pocket 
binder with optimum linker length which could work as an advantageous 
chemical starting point for the future project, aiming at growing the fragment 
into idelalisib analogue after attaching it to the purine hinge binder (Figure 








Table 22. Biological evaluation and isoform selectivity for PI3K δ for compounds (77, 79-87 
and 76). 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 
threshold for the PI3K δ assay is ~ IC50 0.001 μM due to substrate concentration. Compounds 
with IC50 > 28 μM exhibited no inhibitory activity. 
The starting point for the modification was the primary amine intermediate 77, 
with no hinge binder (purine ring), which exhibited no activity at all isoforms 
Compd R1 R2 
Isoform potencya,bIC50 (μM) 
PI3K δ PI3K α PI3K β PI3K Ɣ 
77 H H >28 >28 >28 >28 
82  H >28 >28 >28 >28 
79  H 1.4 2.8 >28 5.5 
142 
 
H >28 >28 >28 >28 
84  H >28 >28 >28 17.5 
85   3.5 >28 >28 11 
81  H >28 >28 >28 >28 
86  H >28 >28 >28 >28 
87   14 >28 14 1.75 




of class-I PI3K (IC50> 28 μM), this result was consistent with the findings of 
the previous studies which proved that the purine ring (hinge binder) is the 
most crucial part of the structure of the propeller-shaped PI3K δ 
inhibitors144,153,244,311, identifying the key role of the interaction with hinge 
region in the PI3K δ inhibition. 
Monoalkylation of primary amine 77 with ethyl, propyl and butyl produced the 
secondary amines 82, 84 and 86, respectively, which showed no noticeable 
change in PI3K δ activity compared to the primary amine 77, such findings 
were not unexpected, given the fact that the side chains of these compounds 
did not possess hydrogen bond donor or acceptor, no hydrogen bond was 
formed with the polar residues in the affinity pocket. The introduction of the 
second propyl group at the exocyclic amine of compound 84 resulting in N,N-
dipropyl derivative 85 which demonstrated low micromolar range inhibitory 
activity against PI3K δ (IC50= 3.5 μM) and mid-micromolar range against Ɣ 
isoform (IC50= 11 μM). This significant enhancement of the activity of dipropyl 
analogue 85 over monopropyl analogue 84 could be attributed to that the 
additional second propyl group could form a C-H/pi interaction with Trp760 in 
tryptophan shelf. This was supported by docking studies which revealed that 
one of the propyl group sat at the tryptophan shelf where the distance 
between this group and the indole ring of the Trp760 is located within the 
optimum distance range of C-H/pi interaction (3.8- 4.4 ºA) (Figure 75b)312. If 
this finding was confirmed by crystal structure, it would be for the first time, 
as far as known, for any propeller-shaped inhibitor to involve in interaction 
with tryptophan shelf174,313,314. Dibutyl derivative 87 demonstrated a slight 




monobutyl analogue 86, surprisingly, it displayed a great increase in the 
potency against PI3K Ɣ with IC50 equals to 1.7μM. 
a)                                                                 b) 
                
Figure 75. a) Compound 85, highlights the propyl group that forms a potential C-H/pi 
interaction with the tryptophan shelf. b) Compound 85 docked into PI3K δ model (generated 
from PDB code 4XE0). The propyl group makes a C-H/pi interaction with Trp760 at the 
tryptophan shelf. Blue dashed lines represent the proposed C-H/pi interactions. 
Introduction of hydroxyethyl group into the primary amine of compound 77 
resulted in β-amino alcohol analogue 79, with considerable activity against 
PI3K δ (IC50= 1.4 μM). The higher activity of the compound 78 compared to 
the non-hydroxylated analogue 82, may be explained by either formation of 
hydrogen bond interaction between compound 79 and PI3K δ, where the 
hydroxy group acted as a hinge binder or directed toward the affinity pocket. 
The binding mode of compound 79 with PI3K δ was suggested by molecular 
docking analysis (Figure 76), it was found that the hydroxyethyl group 
extended into the affinity pocket, where it involved in an enhanced hydrogen 
bond with the side chain carboxylate of Asp911 (Figure 76b), thereby indicating 
why this compound had gained activity against PI3K δ. Thus, two-carbon 
atom was the optimum length of linker to promote the interaction with the 




it with a benzyl group in compound 142 resulting in a significant deterioration 
of activity, which proved that the presence of a free hydroxyl group was an 
important factor behind PI3K δ activity. 
a)                                                      b) 
            
Figure 76. Compound 79, highlights the hydroxyethyl group. b) Compound 79 docked into 
the PI3K δ model (generated from PDB code 4XE0) reveals that the hydroxyethyl group 
extending into the affinity pocket rather than interacting with residues on the hinge region. 
Monoalkylation of primary amine with 3-hydroxypropyl, resulted in Ɣ-amino 
alcohol analogue 80, which surprisingly showed no activity against all four 
isoforms of class I PI3K. This indicated that propyl chain was too long which 
positioned the hydroxyl group at too great a distance to interact with the 
affinity pocket efficiently. Whereas δ-amino alcohol 81 exhibited modest 
potency at PI3K δ with IC50 value in the mid-micromolar range (IC50= 10 μM), 
while it did not exhibit any activity against the other three isoforms.  
3.6.1 Conclusion derived from the initial SAR study (Table 22) 
In this study, a screening strategy was used to identify affinity pocket binding 
fragments. Table 22 showed that the PI3K δ inhibitory activity afforded by 
compounds (79- 87) were clearly dependent on linker length, because only 
compound 79 with an ethylene bridge was active in low micromolar range 
(IC50= 1.4 μM) compared to the propyl 80 and butyl 81 analogues. The 




79, which revealed that promising activity displayed by a hydroxyethyl 
compound 79 could be due to the interaction with Asp911 residue in the affinity 
pocket, which indicated that ethyl linker exhibited the optimal chain length 
needed to fit the H.B.D and/or H.B.A into the affinity pocket. Compound 79 
with its low molecular weight (MW= 341 Da) could act as an excellent starting 
point for further optimisation into larger and more potent compounds for 
example N-hydroxyethyl idelalisib 72, by attaching it with the purine hinge 
binder (Figure 77). It would be interesting to see whether the final compound 
72 will show higher PI3K δ activity and selectivity than the lead compound 
(idelalisib 8) and by how much. 
                       
Figure 77. Strategy for fragment optimisation by joining the compound 79 with a purine hinge 
binder to produce the final compound 72. 
3.6.2 The linking strategy to make the final compounds 
Three final products were prepared by using fragment-based extension 
approaches, by joining the fragment 79 with the purine hinge binder to create 
the final compound 72 (Figure 77). Whereas the final compound 125 and 127 
contain amide and nitrile group, respectively, at the other end of the linker for 
binding to the affinity pocket. Thus, Linker 72 terminated in a hydroxy group, 





3.6.3 Screening of the final compounds (Single concentration 
compound screening) (Table 23) 
 
Table 23. % inhibition of PI3K δ activity at 1 μM and 500 nM of compounds (idelalisib 8, 72, 
125 and 127). 
aPI3K δ % inhibition was determined at 1μM and 500 nM compound concentration. 
*Compound 125 was not tested at 500 nM final concentration.  
Unfortunately, the final compounds (72, 125 and 127) could not be 
synthesized before the screening deadline, this had been attributed to 
challenges associated with the formation of these compounds that were 
mentioned in the Chemistry Section. Consequently, these compounds could 
not be sent to GSK to have full IC50 measurements. Thus, an internal 
screening was performed by our group at the University of Nottingham, which 
would be a single-concentration screen against PI3K δ at 1 μM and 500 nM 
final concentration. The details will be discussed in Chapter 7, Section 
7.4.1.3. 
Compounds 72, 125, 127 and idelalisib (8) were tested at single concentration 
(1 μM) for their inhibitory activity against PI3K δ (Table 23), which would give 
 Inhibition of PI3K δa 
Compd R1 
% Inhibition at  
1 μM 
% Inhibition at  
500 nM 
8 H 76 80 








preliminary activity data to choose compounds for further more detailed 
screening (500 nM), the FDA-approved idelalisib (8) was included for direct 
comparison. First a preliminary screening with an inhibitor concentration of 1 
μM showed that PI3K δ was inhibited by 76% at 1 μM idelalisib (8). The 
alcohol 72 and nitrile 127 analogues were active against PI3K δ, with > 40% 
inhibition at 1 μM. By contrast, amide derivative 125 showed a little activity (< 
20%). The active compounds from primary screening, alcohol 72 and nitrile 
127 were selected to test at 500 nM final compound concentrations against 
PI3K δ, however, these compounds exhibiting < 10% inhibitory activity at 500 
nM concentration (72: 2%, 127: 5%), while the control compound (idelalisib 
8) showed 80% inhibition.  
The poor activity of the alcohol 72, amide 125 and nitrile 127 compounds 
compared with idelalisib (8) was somewhat surprising, because it was thought 
that these compounds would be higher or at least equipotent to idelalisib (8), 
as they are able to make the same interactions as that of parent compound 
(idelalisib, 8). This indicated that the addition of the new functional group to 
the exocyclic amine can significantly deteriorate the PI3K δ potency. This 
drastic decrease in the potency could be reasoned by the steric clash that 
might occur between the additional functional group and the PI3K δ enzyme, 
where the new substituents could cause undesirable interactions with the so-
called gatekeeper residues (Ile825) at the entrance of the affinity pocket in the 
PI3K δ binding site (Figure 78). This steric clash would orient the hinge binder 
purine out of the preferred binding conformation, resulted in the loss of a 
crucial hydrogen bonds with Val828 and Glu826 in the hinge region and 




evidence to support this hypothesis, it revealed that the purine ring of 
compound 8 did not form any hydrogen bond interactions with Val828 and 
Glu826 in the hinge region (Figure 79b) as idelalisib (8) did. It was 
hypothesized that this lack of interactions would orient the compound 72 away 
from the ATP binding site, translated experimentally by a major drop in activity 
a)                                                                                    b) 
 
Figure 78. a) Idelalisib-PI3Kδ is depicted by a chemical structure, the gatekeeper residue 
(Ile825) (highlighted in green) controls the accessibility to the affinity pocket. The chemical 
structure depicts the purine ring that engages in crucial hydrogen bonds to the hinge region. 
Dashed red lines represent the proposed hydrogen bonds with the hinge region. b) 
Compound 72-PI3Kδ is depicted by a chemical structure, the steric clash between the 
hydroxyethyl group and the isoleucine gatekeeper, impedes drug binding through loss of a 
crucial hydrogen bonding interaction to the hinge region. 
a)                                                                        b) 
                
Figure 79. a) Compound 72, highlights the purine hinge binder b) Compound 72 docked into 
the PI3K δ model (generated from PDB code 4XE0) reveals that the purine ring does not 
involve in a critical hinge region hydrogen bond interaction, probably due to the steric clash 
between the newly introduced substituent (hydroxyethyl) with the isoleucine gatekeeper, 




against PI3K δ. Generally, loss of hydrogen bond interaction with the hinge 
region was the major reason for the deterioration of activity of a plethora of 
kinase inhibitors including PI3K δ inhibitors315–318. Before going any further, 
important details about the gatekeeper need to be covered. 
3.6.4 Gatekeeper  
Is a single residue that is located at the kinase hinge region and governed 
access of the inhibitors deep in the affinity pocket29,45,317,319–321, which 
appeared to take part in affecting the sensitivity of inhibitors in a plethora of 
PI3Ks. The size of the gatekeeper’s side chain determines the size of the 
kinase inhibitors that can be accommodated320. Most of kinases possess 
small threonine residue as a gatekeeper29,321,322. However, the four isoforms 
of class I PI3K including PI3K δ have a bulky isoleucine at this position, which 
makes the entrance of the affinity pocket narrow and restricted resulting in a 
steric clash which prevented compounds 72, 125 and 127 from binding 
properly45,323. It was hypothesized that the poor activity of the compounds 72, 
125 and 127 was probably due to loss of the crucial hydrogen bond interaction 
with the hinge region of PI3K δ, that was caused by the steric clash between 
the newly introduced functional group with the isoleucine gatekeeper. Ina 
Terstiege et al220 reported that the compound 143 with a pyrazole ring 
oriented towards the affinity pocket showed excellent potency against PI3K δ 
with IC50 of 4 nM (Table 24), however, dimethylation of the pyrazole ring at 
C-3 and C-5 resulted in compound 144 with a 700-fold drop in potency. The 
authors explained the lack of potency for dimethylpyrazole analogue 144 by 




(Ile825), rendering it incapable of adopting a favourable conformation for 
establishing two hydrogen bonds with the kinase hinge region. 
 
Table 24. Biological evaluation for PI3K δ for compounds 143 and 144 reported by Ina 
Terstiege et al220.  







3.6.5 Determination of IC50 (Table 25) 
As a part of a collaboration with GSK, idelalisib (8) was sent along with other 
nine compounds to GSK for screening for activity (defined by IC50) against 
PI3K (Table 25). Among these, compounds 117, 120 and 146 were N-9-
regioisomeric side products, although these compounds have emerged as 
side products during synthesis of the desired product, they would be screened 
to determine the impact of the lack of the one of the conserved pair of 
hydrogen bonds to the hinge on PI3K δ activity. 
Carboxylic acid 145 produced as a side product during the synthesis of ester 
129 and tested against the four isoforms of class I PI3K. The carboxylate 
group of compound 145 could bind to the affinity pocket as a hydrogen bond 
acceptor, where it could make an enhanced hydrogen bond with Tyr813 
residue or a salt bridge with Lys779 (Figure 56b). However, unexpectedly, 





Table 25. Biological evaluation and isoform selectivity for PI3K δ for compounds (8, 116, 117, 
119, 120, 145, 146 and 147). 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 
threshold for the PI3K δ assay is ~ IC50 1 nM due to substrate concentration. 
molecule (idelalisib 8) (Table 25), which indicated that the carboxymethyl 
group of compounds 145 group did not occupy the affinity pocket. This finding 
was consistent with the hypothesis that the bulky isoleucine (gatekeeper) 
hindered access to the affinity pocket and thus would clash sterically with the 
additional substituent (carboxymethyl group) of compound 145, this would 
influence the positioning of the hinge binder (purine) and its potential for 
hydrogen bonding with the hinge region.  
Insertion of ally group to the exocyclic amine of idelalisib (8) led to a 150-fold 
drop in the activity of compound 119, while its N-9-regioisomeric derivative 
 Isoform potencya,b IC50 (nM) 
Compd R1 R2 PI3Kδ PI3Kα PI3Kβ PI3KƔ 
8 H H 11 14000 2800 56 
145 
 
H 4400 14000 17500 14000 
119  H 1750 28000 28000 14000 
120 H  3500 28000 28000 28000 
146 
 
H 11000 14000 28000 28000 
147 H 
 
10000 28000 28000 22000 
116 
 
H 14000 28000 28000 14000 
117 H 
 




121 was 318-fold less active (IC50 value of 3.5 μM) (Table 25), supporting the 
role of the NH-9 of purine at the hinge region for PI3K δ inhibition, where it 
acts as a hydrogen bond donor to the backbone oxygen of Glu826 153. This 
finding is in agreement with WO 2014/128612 A1 study324, which mentioned 
that the loss of a hydrogen bond donor (NH-9 of purine) could have a 
significant impact on PI3K δ activity, for instance, removal of a hydrogen bond 
donor of compound 148 via methylation of N-9 of purine resulting in derivative 
149 with 17-fold drop in PI3K δ potency (Table 26). 
 
Table 26. Biological evaluation for PI3K δ for compounds 148 and 149 described in the WO 
2014/128612 A1 study324. 
compd R2 PI3K δ IC50 (nM) 
148324 -H 85 
149324 -CH3 1430 
N-arylation of idelalisib (8) with p-nitrophenyl led to the two regioisomeric 
substitution products 146 and 147 which exhibited similar activity against 
PI3K δ with mid-micromolar range (IC50= 10 μM) (Table 25). The p-nitrobenzyl 
derivatives 116 and its regioisomer 117 were the least active compounds in 
this series, where the former was shown to exhibit activity in mid-micromolar 
range (IC50 value of 14 μM), while the latter showed no inhibitory activity 
(Table 25). A general finding obtained from this series of exocyclic N-
substituted idelalisib derivatives (8, 116, 119, 145 and 146) was that as the 




(p-nitrobenzyl< p-nitrophenyl< carboxymethyl< allyl< hydrogen) (Table 27), 
which proved that the steric clash between the exocyclic amine substituent 
and the gatekeeper (Ile825) was the main reason behind the poor activity of 
these compounds towards PI3K δ. 
 
Table 27. The influence of the bulkiness of the exocyclic amine substituent on the PI3K δ 
activity in compounds (idelalisib 8, 116, 119, 145 and 146). 
Compd 8 119 145 146 116 
R1 H     
PI3K δ IC50 (nM) 11 1750 4400 11000 14000 
Bulkiness of substituent increases 
PI3K δ activity decreases 
3.6.6 Conclusion derived from the second structure activity 
relationship (Table 23 and Table 25) 
The conclusion derived from studies of the SAR of compounds (8, 116, 117, 
119, 120, 145, 146 and 147) was that the exocyclic N-alkylation was 
associated with loss of potency, which was rationalised to steric hindrance 
between the new substituent with the gatekeeper (Ile825), which controls the 
access to the affinity pocket, disrupted the binding of inhibitors to the active 
site of PI3K δ. Similarly, activity was lost when a new functionality was 
introduced at N-9 of the purine hinge binder of idelalisib (8). This large 
decrease in the activity was attributed to the loss of the strong hydrogen bond 




support to the key role of the double hydrogen bond interactions at the hinge 
region in determining PI3K δ inhibitory activity144,153,155,244.  
3.6.7 Effect of the ethyl side chain (R3) on PI3Kδ activity  
To probe the importance of the α-ethyl side chain (R3) for the PI3K δ activity 
of idelalisib (8), the biological activity of idelalisib (8) was compared to that of 
its des-ethylated analogue 106 (Table 28). 
 
Table 28. Biological evaluation and isoform selectivity for PI3K δ for compounds 1 and 106. 
aPotency against the different PI3K isoforms is given as IC50 values (n = 1). bThe potency 
threshold for the PI3K δ assay is ~ IC50 1 nM due to substrate concentration. 
Des-ethylated analogue 106 showed weak PI3K δ inhibitory activity in 
micromolar range (IC50= 4.4 μM), with 400-fold less activity than idelalisib (8) 
(Table 28). Somoza et al180 who first published the crystal structure of 
idelalisib (8) with PI3K δ reported that the role of the ethyl group in idelalisib 
(8) is to make hydrophobic interactions with Ile825, Met900 and Met752. 
However, this could not explain the dramatic loss of potency observed for 
des-ethylated analogue 106. It was believed that ethyl group might have 
additional role beyond making hydrophobic interactions with PI3K δ active 
site. Cushing et al156 pointed out in his series of propeller-shaped inhibitors, 
that shared chemical similarity to idelalisib (8) (Table 29), that the presence 
 Isoform potencya,b IC50 (nM) 
Compd R1 R3 PI3Kδ PI3Kα PI3Kβ PI3KƔ 
8 H  11 14000 2800 56 




of the alkyl group at position α to the exocyclic amine, could restrict the free 
rotation around the bond at the 2-position of quinazolinone core, which 
resulted in increasing the molecular rigidity in low energy state closer to the 
binding conformation, where the ethyl group acted as a conformational 
blocker to fix the purine ring into a desired orientation for effective binding 
with the hinge region. Cushing et al156 synthesized and compared des-methyl 
analogue 104, S-methyl isomer 105 and R-methyl isomer 150 on the basis of 
their PI3K δ activity. The S-methyl isomer 105 was found to be 5 times more 
active than des-methyl analogue 104 and about 370 times than the R-methyl 
isomer 150 (Table 29). The author hypothesized that the steric clash between 
the R-methyl group and the protein might account for the loss of activity of the 
R-methyl isomer.  
 
Table 29. Comparison of the PI3K δ activity of S-methyl analogue 105 with des-methyl 104 
and R-methyl analogues 150. 
Compd R3 PI3K δ IC50 (nM) 
104 H 39 
105 S-methyl 8 
150 R-methyl 2960 
3.7 Conclusion 
In summary, the FDA-approved PI3K δ inhibitor idelalisib (8) was used as a 
starting point for the current study. The aim herein was to increase the 
inhibitor potency of idelalisib (8) by exploring interactions with residues within 




compounds (without the purine hinge binder) to select the best starting point. 
Fragment 79 with an ethyl linker between the quinazolinone scaffold and a 
terminal hydrogen bond donating moiety showed promising activity with low 
micromolar range (IC50= 1.4 μM). The molecular docking study revealed a 
key hydrogen bonding interaction between the hydroxyethyl group of 
fragment 79 and the unoccupied affinity pocket, which may explain its higher 
PI3Kδ potency. Encouraged by this finding, compound 79 was selected for 
fragment growing approach, after encountering many challenges 
experienced during the synthesis of the target compounds 72, 125 and 127, 
unfortunately. They were inactive with dramatic loss of activity in comparison 
with idelalisib (8). It was theorized that the newly introduced substituent would 
clash with the gatekeeper residue (Ile825), resulted in the loss of hydrogen 
bonds with the hinge region and reorientation of the ligands which led to a 
negative impact on PI3K δ activity. Moreover, it was noted that alkylation of 
NH-9 of purine binding to the hinge region with different substituents resulted 
in compounds with very weak PI3K δ potency, proved that the double-
hydrogen bond interactions with the hinge region to be essential for the 
inhibitory activity toward PI3K δ. Lastly, it was also found that the PI3K δ 
activity of idelalisib (8) is 440-fold higher than the activity reported for the 
analogue with deleted ethyl side chain 106, suggesting that the ethyl side 
chain plays a key role in reducing the conformational flexibility and locked the 





Chapter 4  Design, Synthesis and 
Pharmacological Characterization of Novel N-7-
substituted purine derivatives as PI3K δ selective 
Inhibitors (Propeller-shaped inhibitors). 
4.1 Aim 
A complex of idelalisib (8) bound to PI3K δ (see Figure 56 in Chapter 3) 
indicates that there is unoccupied pocket called the affinity pocket. In this 
medicinal chemistry project, this unused affinity pocket was explored with a 
functional group to gain additional binding to improve the binding affinity 
between the inhibitor class (idelalisib, 8) and PI3K δ.  
A previous study in Chapter 3 has shown that the addition of the extra 
functional group into the exocyclic amine in order to gain access to the 
unoccupied affinity pocket resulted in sever loss of PI3K δ potency (Figure 
80), this is likely due to steric clash that might occur between the exocylic N-
substituent and the bulky side chain of the isoleucine (Ile825) gatekeeper 
which prevents the compounds from binding. The results suggest that the 
exocyclic amine may not be the ideal position for the extension of the binding 
group into the affinity pocket (Figure 80). Therefore, correctly positioning a 
binding group on the idelalisib structure relative to the affinity pocket may 






Figure 80. The selective PI3K δ inhibitor idelalisib (8), highlights the effect of new substituents 
in different positions of idelalisib (8) towards the PI3K δ inhibitory activity. SAR studies 
discussed in Chapter 3, reveals that substitution of idelalisib (8) on the exocyclic amine 
results in loss of PI3K δ activity. In Chapter 4, SAR will focus on the substitution of the purine 
hinge binder of idelalisib (8). 
Subsequently, the aim of this chapter was to orient the binding group into the 
affinity pocket by joining it to idelalisib (8) using a new point of attachment. 
After reviewing data from several studies focusing on PI3K δ 
inhibitors144,154,155,173, it was concluded that the binding group can be directed 
into the affinity pocket when it is attached to the hinge region binding group 
(Figure 80). This strategy has led to the identification of highly potent PI3K δ 
inhibitors. For instance, Brendt et al173 projected a m-fluorophenol group from 
the hinge binding scaffold (pyrazolopyrimidineamine moiety) of compound 10 
into the affinity pocket (see Figure 57b in Chapter 3), where the phenolic 
hydroxyl group serves as a hydrogen bond acceptor to Tyr813 and as a 
hydrogen bond donor for the side chain of Asp787 within the affinity pocket. 
These novel interactions lead to a 186-fold increase of potency against PI3K 
δ, compared to the parent compound 9 (see Table 19 in Chapter 3). 
In another interesting study, Patel et al155 reported the design of the PI3K δ 
inhibitor 152 with sub-nanomolar activity (Table 30) via substitution of a new 
binding group (pyrazole) on the hinge-binding core (4-aminopyrimidine) 




establishes double hydrogen bond interactions with Lys779 and Asp787 (Figure 
81b) leading to a dramatic 330-fold increase in potency against PI3K δ 
compared with the unsubstituted derivative 151 (Table 30). 
 
Table 30. Biological evaluation and isoform selectivity for PI3K δ for compounds 151 and 152 
reported by Patel et al155, Compound 152 shows improvement in PI3K δ potency compared 
with the parent compound 151.  
compd R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
151155 -H 99 1600 120 320 
152155  0.3 1500 260 230 
a)                                                              b) 
     
Figure 81. a) Compound 152, highlights the pyrazole ring (in red) that projects from the 
aminopyrimidine hinge binding motif (highlighted in blue) into the affinity pocket. b) Crystal 
structure of murine PI3K δ (PDB code 5I6U) with compound 152 bound. Blue dashed lines 
represent the proposed hydrogen bonds between the pyrazole ring with Asp787 and Lys779 in 
the affinity pocket and between the aminopyrimidine group with Glu826 and Val828 in the hinge 
region.  
Based on the previous findings, the design strategy is to introduce the new 
functional group to the purine hinge binder of idelalisib (8) that could then 




pocket. Substitution at the N-7 site of purine provides the best conventional 
extension strategy to position the binding group into the affinity pocket (Figure 
82), this can be attributed to three factors. First, based on the crystal structure 
of idelalisib (8) in murine PI3K δ (PDB code 4XE0), the N-7 position of purine 
is the closest idelalisib atom to the unoccupied affinity pocket, as shown in 
(Figure 82b). The second factor is that idelalisib (8) in complex with PI3K δ 
adopts a bound conformation that orients the N-7 atom of the purine towards 
the opening of the affinity pocket (Figure 82b), it is thus apparent that 
substitution at the N-7 position may extend deep into the affinity pocket. The 
third factor is that introduction of a binding group onto the N-7 of purine 
generates a structure which is more synthetically feasible, whereas 
introduction of the functional group on the carbon skeleton of purine such as 
the C-8 position demands a more complicated synthesis (Figure 82a). 
a)                                                     b) 
     
Figure 82. a) The selective PI3K δ inhibitor idelalisib (8). b) Crystal structure of murine PI3K 
δ (PDB code 4XE0) with idelalisib (8) bound. It shows that idelalisib (8) adopts a conformation 
allowing the N-7 atom of the purine ring to orient towards the opening of the affinity pocket.  
4.2 Drawback associated with the extension of binding group 
from N-7 of purine 
Targeting the affinity pocket with a functional group substituted at N-7 purine 
of idelalisib (8) might be a promising strategy, however, there is a major 




substitution leads to the loss of the tautomeric proton on the N-9 atom of the 
purine ring (Figure 83). The NH-9 proton acts as a hydrogen bond donor to 
the backbone oxygen atom of Glu826 in the hinge region (Figure 83a), where 
the absence of this critical hydrogen bond could lead to a major loss in the 
PI3K δ activity. Accordingly, idelalisib analogues with N-7-substituted purine 
can only form a single hydrogen bond with the hinge region through the N-3 
of purine as a hydrogen bond acceptor (Figure 83b), whereas the lead 
compound (idelalisib 8) makes two hydrogen bonds to the hinge region using 
the N-3 and NH-9 of the purine ring (Figure 83a)180. 
a)                                                                                              b) 
 
Figure 83. Schematic representation of ligand binding interactions in the hinge region of PI3K 
δ. a) the purine group of idelalisib (8) forms two hydrogen bonds to the hinge backbone. b) 
Installation of a new substituent at the N-7 of the purine, leads to the loss of the hydrogen 
bond between NH-9 of purine and the backbone carbonyl of Glu826. 
Interestingly, Patel et al155 published a study which focused on the importance 
of the hydrogen bond donor at the hinge region to the PI3K δ activity. It was 
found the removal of the amino group (-NH2) from a pyrimidine hinge binder 
in compound 153 resulted in a des-amino analogue 154 with a dramatic drop 
(17-fold) in PI3K δ potency (Table 31), which was caused by loss of important 
hydrogen bond interaction. However, the addition of the affinity pocket binding 




exhibited 210-fold improvement in potency against PI3K δ (IC50= 8 nM) (Table 
31). These interesting findings suggest that the loss of the strong hydrogen 
bond between the -NH2 of 153 and the hinge region can be compensated by 
the gain of new binding interactions within the affinity pocket. For comparison, 
compound 155 which has affinity pocket binding motif (nitrile) but lacking the 
hydrogen bond donor (-NH2) is 12 times more potent than compound 153 
which has the hydrogen bond donor (-NH2) but lacking the affinity pocket 
binder (nitrile) (Table 31). 
 
Table 31. Biological evaluation for PI3K δ for compounds (153-155 reported by Patel et al155), 












H.B at the 
hinge region 
153155 NH2- H- 99 dual 
154155 H- H- 1700 single 
155155 H- CN- 8 single 
Based on the results obtained from Patel et al study155, one might expect that 
the proposed N-7-substituted purine derivatives which have affinity pocket 
binding groups could be more potent than the parent compound (idelalisib 8) 




4.3 Medicinal chemistry strategy 
The success of the extension strategy to the affinity pocket depends on the 
careful selection of the linker length and the terminal binding group (Figure 
84). 
 
Figure 84. General structure of the series of N-7-substituted purine derivatives, bearing an 
affinity pocket-binding group (highlighted in blue) connected through an ethyl linker 
(highlighted in red) to the purine hinge binder. 
4.3.1 Length of the linker  
The first step is to determine the length of the linker that could effectively 
connect the N-7 of purine to the affinity pocket binder (polar functional group). 
The length of the linker is important in order to arrange the binding group at 
a distance compatible with the formation of a hydrogen bond with the polar 
residues lining the affinity pocket. It was proposed to use a flexible alkyl linker 
to allow better placement of the binding group within the affinity pocket. The 
ethyl linker was selected based on the observation of the distance between 
the entrance of the affinity pocket and the N-7 atom of the purine hinge binder 
(3.70 Å) (Figure 85a), the length of a spacer of two carbon chain will have a 
distance of 2.52 Å325 , in addition to the bond that links the ethyl chain to the 
heteroatom functional group (O or N), the projected distance of C-O and C-N 
are1.17 and 1.47Å, respectively325. Thus, the full linker length is 




to the estimated distance between the N-7 atom of purine and the entrance 
of the affinity pocket (3.70 Å) (Figure 85a), which indicates that the ethyl linker 
has the optimum length to place the binding group at the distance permitting 
the establishment of a hydrogen bond with Asp911 and Tyr813. 
a)                                                                                     b) 
  
Figure 85. a) Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) bound, 
highlights the distance between the N-7 atom of the purine and the entrance of the affinity 
pocket (represented by a magenta sphere), which is within hydrogen bonding distance to 
Asp911 and Tyr813. b) Maximum bond distance between the purine core and the functional 
group (hydroxyl) is 3.70Å, when a two-carbon atom linker is employed325,326. This is in good 
agreement to the estimated distance between the N-7 atom of purine and the centre of the 
affinity pocket (3.70Å). 
4.3.2 Affinity pocket-binding group (binding group) 
The affinity pocket binding moieties (Figure 84) used in the current study can 
be classified into two types. 
4.3.2.1 Commonly used polar functional group 
The first group include the functional groups that are commonly found in drug 
molecules and traditionally used to engage in either hydrogen bonding or 
ionic interactions with polar residues of the target protein, which involves 
hydroxyl (-OH), amino (-NH2), amido (-CONH2) and urea (-NH-CO-NH2) 
(Table 32). These groups consist of OH and NH groups that can donate 
hydrogen bonds or C=O that can accept them. The hydroxyl group has the 
ability to serve as both hydrogen bond donor and acceptor (Table 32). An 




charged aspartates (Asp787 and Asp911) lining the affinity pocket. An amide (-
CONH2) can donate and accept three hydrogen bonds (Table 32). Finally, the 
urea group (-NH-CO-NH2) could bind within the affinity pocket through a set 
of four hydrogen bonds, where the oxygen atom acts as a hydrogen bond 
acceptor and the -NH and -NH2 protons act as hydrogen bond donors (Table 
32)327. Additionally, a reference compound 160 bearing an ethyl group 
extending into the affinity pocket would be synthesized. Because the ethyl 
linker lacks the polar functional group, it cannot form hydrogen bond with the 
affinity pocket, thus ethyl analogue 160 would be expected to show much less 
PI3K δ activity than the other analogues (156-159). 
 
Table 32. Number of hydrogen bond donors and acceptors in the binding groups of 
compounds (156-160), and types of interactions that can make with variable residues of the 














1 1 hydrogen bond 








2 1 hydrogen bond 
159 
 
3 1 hydrogen bond 
160  0 0 





4.3.2.2 Affinity pocket binder from the previously published work 
Previous studies proved that there are certain functional groups that 
preferably bind to the affinity pocket and are able to increase the activity 
against PI3K δ. For instance, Patel et al155 used the nitrile group to project 
deep into the affinity pocket, where it forms a new hydrogen bond to Tyr813 
(Figure 86b). This additional hydrogen bond helps to explain the 245-fold 
increase in PI3K δ activity with the nitrile-containing compound 161 compared 
to the parent unsubstituted compound 151 (Table 33). Moreover, Patel et al155 
proved that the extension of the acetylene of 162 into the affinity pocket 
improved the PI3K δ affinity by 990-fold compared to its parent compound 
151 (Table 33). Although no explanation was given for the observed activity 
of compound 162, it was hypothesized that the hydrogen bond interaction 
between the relatively acidic proton of the terminal acetylene and the side 
chain of Asp787 or Asp911 lining the affinity pocket could be the reason behind 
the high activity (IC50 value of 0.1 nM) of the acetylene-containing compound 
162.  
a)                                                 b) 
              
Figure 86. a) The nitrile-containing compound 161, highlights the nitrile group (in pink) that 
projects from the hinge binding group (aminopyrimidine) into the affinity pocket. b) Crystal 
structure of murine PI3K δ (PDB code 5I4U) with compound 161 bound. Nitrile group forms 
a hydrogen bond with the side chain of Tyr813 in the affinity pocket. Blue dashed lines 





Table 33. Biological evaluation for PI3K δ for the nitrile 161 and acetylene 162 derivatives. 
The unsubstituted analogue 151 is used as a reference. 
compd R1 PI3K δ IC50 (nM) 
151 -H 99 
161  0.4 
162  0.1 
Consequently, the nitrile 163 and acetylene 164 containing analogues would 
be designed and synthesized (Table 34).  
 









Erra et al154 in his series of pyrrolotriazinone derivatives used the 
methanesulfonamide (-NH-SO2-CH3) group installed at position 3 of the 




towards the affinity pocket and was shown to have a dramatic effect on the 
PI3K δ inhibition (IC50 value of 0.3 nM) (Table 35), where the 
methanesulfonamide group acts as a hydrogen bond acceptor and forms a 
hydrogen bond with the side chain of Lys779 in the affinity pocket (Figure 87)154 
. It was thus recommended to test the effect of methanesulfonamide in this 
series of N-7-substituted purine derivatives. (Table 34).  
 
Table 35. Biological evaluation and isoform selectivity for PI3K δ for compound 167 reported 
by Erra et al154. 
 
Figure 87. Crystal structure of human PI3K δ (PDB code 6G6W) with compound 167 bound. 
Blue dashed line represents the proposed hydrogen bond between the methylslfonamide 
group and Lys779 in the affinity pocket. 
Novartis scientists reported the development of leniolisib (7) (Figure 88a), 
which is in a late-stage pipeline for treatment of APDS. They described the 
Isoform potencya,b IC50 (nM) Isoform selectivity 
PI3Kδ δ/α δ/β δ/Ɣ 




importance of the trifluoromethyl moiety extending towards the affinity pocket 
for modulating PI3K δ activity, where they found that the replacement of the 
trifluoromethyl interacting group of 7 with hydrogen 168 reduces the PI3K δ 
potency by a factor of 5 (Table 36). This indicates that the trifluoromethyl 
group interacts with the affinity pocket, by making a charge-enhanced 
hydrogen bond interaction with the side chain of Lys779 (Figure 88b). 
a)                                                                    b) 
  
Figure 88. a) The selective PI3K δ inhibitor leniolisib (7), highlights the trifluouromethyl group 
that extends towards the affinity pocket in PI3K δ. b) Crystal structure of murine PI3K δ (PDB 
code 5O83) with leniolisib (7) bound. Blue dashed line represents the proposed hydrogen 
bond between the trifluorometly group and Lys779 in the affinity pocket. 
 
Table 36. Biological evaluation and isoform selectivity for PI3K δ for leniolisib (7), highlights 
the trifluoromethyl group that forms a hydrogen bond interaction with the affinity pocket. The 
unsubstituted analogue 168 is used as a reference239.  
compd R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
168239 -H 132 50 68 >70 
7239 -CF3 27 29 63 >70 
4.3.3 Modification of Hinge-binding moiety 
As mentioned before, insertion of a functional group to the N-7-purine of 




which makes an important interaction with the backbone carbonyl of Glu826 in 
the hinge region (Figure 89a and 89b). It was thought that this loss can be 
compensated through the introduction of a new hydrogen bond donor (-NH2) 
into the 2-position of purine (Figure 89c), which can make a new hydrogen 
bond with the hinge region. Patel et al155 showed that the newly added amino 
group at the 2-position (equivalent to the position 2 of purine) of 2,4-
diaminopyrimidine of compound 169 (Figure 90a) can make a novel hydrogen 
bond with the carbonyl backbone of Val828 at the hinge region (Figure 90b), 
in addition to the two traditional hydrogen bonds that are made through N-3 
and 4-amino group (equivalent to N-3 and NH-9 of purine), thus, compound 
169 forms triple hydrogen bonds with the hinge region.  
a)                                                       b)                                                 c) 
 
Figure 89. A schematic representation of the hinge binding region depicts the potential 
number of hydrogen bonds connecting three different purine derivatives with Val828 and Glu826 
at the hinge region. a) Unsubstituted purine forms two hydrogen bonding interactions, b) the 
N-7-substituted purine derivative can only form one hydrogen bond, c) the introduction of 
amino group at 2-position of purine aimed to restore the double hydrogen bonds, which could 





a)                                                    b) 
                        
Figure 90. a) Compound 169, the pyrimidine ring is numbered, highlights the newly 
introduced amino group (in pink) at the 2-position, which forms a third hydrogen bond with 
the hinge region b) Crystal structure of murine PI3K δ (PDB code 5I4U) with compound 169 
bound. Blue dashed lines represent the triple hydrogen bonds formed between the 
diaminopyrimidine group with the amide back bone of Glu826 and Val828 at the hinge region. 
The 2-aminopurine ring can be regarded as a bioisosteric replacement for the 
2,4-diaminopyrimidine hinge binder of compound 169, due to their high 
degree of the structural similarity (Figure 91), Hence, a new series of N-7-
substituted purine-based compounds (Table 37) would be synthesized with 
an amino group installed at the 2-position of the purine ring to serve as a 
hydrogen bond donor and restore the dual hydrogen bonds with the hinge 
region. 
 
Figure 91. Comparison of the chemical structure between 2,4-diaminopyrimidine hinge 
binder of compound 169 and the proposed 2-amino-7-substituted purine hinge binder. It 
reveals striking structural similarity (highlighted in blue) between the two heterocyclic 
systems, which indicates that the 2-amino group of 2-amino purine may make the same 





Table 37. Structure of the proposed compounds beloging to 2-amino-N-7-substituted purine 
series 170 and 171.  
Compd R1 R2 





4.4.1 Chemistry Section 
The synthetic protocol was similar to that used in Chapter 3 for the synthesis 
of idelalisib (8), except for the addition of the extra substituent to the N-7 
position of purine. The synthetic plan involves first the formation of the two 
intermediates, the quinazolinone derivative 77 and N-7-substituted-6-
chloropurine purine. These two intermediates then can react together to form 
the proposed final products.  
Scheme 17. Synthesis of the amino intermediate 77 
 
aReagents and conditions: (a) HATU (2.5 equiv), DIPEA (3 equiv), DMF, rt, 24 h, yield 98%; 
(b) H2, 10%Pd/C (0.05 equiv), methanol, rt, 12 h, yield 100%; (c) IBCF (3.5 equiv), NMM (3.5 





The key intermediate 77 was synthesized according to the general synthetic 
route shown in Scheme 17. Treatment of the benzoic acid derivative 73 with 
aniline gave 74 in 98% yield which then underwent catalytic hydrogenation of 
the nitro group to give the corresponding aniline derivative 75 in 100% yield, 
followed by IBCF-promoted coupling with (S)-2-(Boc-amino)butyric acid to 
generate the desired diamide product 76. Finally, the reaction of 76 with 
HMDS in the presence of the 3 equivalents of iodine resulted in cyclisation to 
give the key amino intermediate 77 in moderate yield (56%). 
The last step involves the nucleophilic displacement of N-7-substituted-6-
chlorinepurine with 77, which was expected to be straightforward. However, 
synthesis of N-7-substituted-6-chloropurine intermediates was the most 
challenging step in the entire synthesis, this was due to the fact that N-9 of 6-
chloropurine 78 is known to be more reactive than N-7, as the steric hindrance 
exerted by the 6-chlorine atom disfavours the reaction at N-7 (Figure 92). 
Thus, the direct alkylation of 6-chloropurine 78 resulted in the formation of 
two regioisomers N-7 (desired) and N-9 (undesired) the latter always being 
the major regioisomer. 
 
Figure 92. General alkylation of 6-chloropurine 78, illustrates the steric effect exerted by the 
6-chlroine atom on the N-7 of purine, results in a significant decrease in the nucleophilic 
characteristics of N-7 in contrast to N-9 of purine. Thus, N-9 atom undergoes alkylation faster 




4.4.1.1 Synthesis of N-7-substituted purine derivatives  
4.4.1.1.1 Direct alkylation method  
Traditional alkylation methodology (Scheme 18) was applied for the 
incorporation of suitable functional groups at the N-7 atom of purine. This 
method was based on a direct nucleophilic substitution reaction, where the 6-
chloropurine was alkylated with a variety of alkylating reagents, K2CO3 was 
selected as a base to promote the reaction.  
Scheme 18. Synthesis of 6-chloropurine intermediates (172-176) 
 
aReagents and conditions: (a) K2CO3 (3 equiv), CH3CN, rt, 24 h, yields 7-16%; (b) 4 N HCl, 
dioxane, 2 h, yield 97%; (c) methanesulfonyl chloride (1.1 equiv), triethylamine (1.1 equiv), 
DCM, rt, 16 h, yield 44%. 
Scheme 19. Synthesis of final compounds (156-159, 165 and 177) 
 
aReagents and conditions: (e) DIPEA (10 equiv), tert-butanol, 100 °C, 72 h, yields 10- 30%; 
f) 4 N HCl, dioxane; rt, 2 h, yield 95%; g) Trimethylsilyl isocyanate (2 equiv), TEA (2 equiv), 
DCM, rt, 18 h, yield 68%. 
Following a synthetic procedure reported by Zhang et al 328, 6-chloropurine 
78 and 2-iodoethanol were reacted in a 1: 3 ratio in the presence 3 
equivalents of K2CO3 in water at RT for 16 h, to give a mixture of the N-7 172 
and N-9 178 regioisomers in a 1:1.3 ratio with 37% overall yield. The isolated 




in tert-butanol to give the alcohol product 156 (Scheme 19), this reaction 
required high temperature (100 °C) and prolonged reaction time (3 days) to 
obtain a low yield (18%), this can best be explained due to significant steric 
hindrance provided by N-7-hydroxylethyl group (Scheme 20), whereas in 
comparison, the reaction of the primary amine 77 with 7-unsubstituted 6-
chloropurine 78 to generate idelalisib (8) required a shorter reaction time and 
lower temperature to achieve optimum yield of 65% (Scheme 20). 
Scheme 20. The effect of the steric hindrance exerted by the N-7-substituent on the reactivity 
of 6-chloropurine derivative 172 towards nucleophilic aromatic substitution reaction 
 
aReagents and conditions: a) DIPEA (10 equiv), tert-butanol, 100 °C, 72 h, yield 18%. b) 
DIPEA (10 equiv), tert-butanol, 85°C, 16 h, yield 65%. 
The synthesis of amide 173, was carried out starting from 6-chloropurine 78 
which was alkylated with 2-bromoacetamide in the presence of K2CO3 in 
acetonitrile at RT for 3 days to afford 47% yield of a mixture of regioisomeric 
products N-7 173 and N-9 179 in a ratio of 1:7. The 7-isomer 173 was isolated 
from the mixture by flash chromatography in 7% yield (Scheme 18). 
Treatment of 173 with the primary amine 77 in tert-butanol at 100°C, gave the 
amide product 158 in 10% yield (Scheme 19), with 48% of starting amine 77 




for the product 158 was probably due to two reasons. First, the steric 
hindrance applied by N-7-substituent. Second, the lack of solubility of the 
amide intermediate 173 in tert-butanol. 
6-Chloropurine 78 was treated with 3 equiv of N-boc-2-bromoethyl amine and 
3 equiv. of K2CO3 in acetonitrile at RT for 18 h, to give the N-7 regioisomer 
174 in 10% isolated yield, following chromatography (Scheme 18), in addition 
to 60% of the undesired N-9 regioisomer 180. The obtained N-7-purine 
intermediated 174 was used for alkylation of the primary amine 77, using 
DIPEA in tert-butanol to give compound 177 in an overall yield 30% (Scheme 
19). After the deprotection step using 4 N HCl in dioxane, the final amine 
product 157 was isolated as its hydrochloride salt in 95% yield. Finally, 157 
was reacted with trimethylsilyl isocyanate at RT in DCM to yield the urea 
product 159 in 68% yield. 
4.4.1.1.2 Differentiation of N-7 and N-9-substituted purine derivatives 
using 1H and 13C NMR 
1D NMR spectroscopy is an attractive tool for distinguishing between N-7 and 
N-9 purine isomers329, due to the high sensitivity of 1H and 13C chemical shifts 
to the substituent position. Much efforts have been given to evaluate the effect 
of the substituent site in the purine ring on 1H and 13C chemical shifts329,330. 
Dracinsky et al329 and Kjellberg et al330 have studied the effect of the 
substituent site on the chemical shift of protons and carbons in a large range 
of purines, where they found that N-7 and N-9 regioisomers of the substituted 
purine precursor showed characteristic differences in their 1H and 13C NMR 
chemical shifts, that can be utilized to distinguish between the two 




and carbons between the regioisomeric N-7 and N-9 pairs of different purine 
series (Table 38)329,330. This study illustrates a general rule for 1H and 13C 
chemical shift changes. In the N-7-regioisomer, the C-8 signal appeared 
about 3-6 ppm down field and C-4 appeared 7-10 ppm lower field of their 
positions in N-9 regioisomer. On the contrary, the signal of C-5 appeared 
about 8-9 ppm up field and C-6 2-6 ppm up field in N-7-regioisomer than in 
N-9-regioisomer. While the C-2 signal was the least affected as it is distal to 
the alkylation site. The general trends for the difference in 1H and 13C 
chemical shifts of N-7 and N-9 regioisomers of different 6-substituted purines 
are summarized in Table 38329,330.  
Table 38. The difference of 1H and 13C Chemical shift between the regioisomeric N-7 and N-
9 pairs of substituted purines, which were reported by Dracinsky et al329 and Kjellberg et al330. 
Cells highlighted in blue represent more deshielded signals, cells highlighted in red represent 
more shielded signals. 
General rules presented in Table 38 can be applied to distinguish between N-
7 and N-9-regioisomers of 6-substituted purines synthesized in this study. 
The 1H and 13C chemical shifts of alcohol derivatives 172 and 178 were 
determined and assigned (Table 39). After straightforward comparison with 
Proton and 
carbon 





        
N-9-regioisomer 
H-8 down field not reported up field 
C-4 down field 7- 10 up field 
C-8 down field 3- 6 up field 
C-5 up field 8- 9 down field 
C-6 up field 2- 6 down field 




Table 38, it was found that the compound 172 is in accord with N-7 
substitution and compound 178 with N-9 substitution (the colours of the cells 
in Table 39 match those of Table 38). Moreover, the differences in the 
chemical shift values between the same carbons of 172 and 178 are in 
excellent agreement with those observed in Table 38. 
Table 39. Comparison of 1H and 13C NMR chemical shifts (δ, ppm) between pairs of 









H-8 8.74 0.09 8.65 
C-4 162.20 9.62 152.58 
C-8 151.80 3.35 148.45 
C-5 122.62 8.7 131.32 
C-6 142.51 6.76 149.27 
C-2 152.09 0.29 151.80 
Cells highlighted in blue represent more deshielded signals, cells highlighted in red represent 
more shielded signals. 
The differentiation of N-7 173 and N-9 179 regioisomeric pairs of the amide 
derivatives and N-7 174 and N-9 180 regioisomeric pairs of boc-protected 
amine derivatives, was achieved in the same way as mentioned for the 
alcohol regioisomeric derivatives 172 and 178. 
4.4.1.1.3 Challenges encountered in the direct alkylation method 
The major synthetic problem associated with the direct alkylation method is 
that it led to predominant formation of the unwanted N-9-regioisomer, as it is 
less sterically hindered than the N-7 regioisomer. Accordingly, a large amount 




of N-7 substituted purine intermediate for the next reaction step. Moreover, 
the two regioisomers of 6-chloropurine have the same molecular mass and 
similar polarity, making purification and characterization processes 
challenging and time-consuming. In order to avoid this problem, an alternative 
synthetic route should be pursued to avoid the formation of the undesired N-
9-regioisomer and achieve regioselective N-7-alkylation of 6-chloropurine.  
4.4.2 Regiospecific N-7 alkylation of 6-chloropurine derivatives  
Chen et al331 developed methodology for the regioselective formation of the 
key intermediates N-7 substituted purine. In this method, 6-chloropurine is 
treated with an alkylmagnesium reagent, instead of K2CO3, prior to the 
addition of the alkylating reagent, to give N-7 substituted purine as the only 
regioisomer. The exact mechanism for this reaction is still not fully 
understood331. However, it was hypothesized that this reaction follows similar 
mechanistic pathway as the previously reported regioselective N-alkylation of 
the more hindered nitrogen of benzimidazole 181, shown in Scheme 21332,333, 
where the less-hindered NH-9 is deprotonated by the Grignard reagent and 
then coordinates to the magnesium of MgCl gives the complex 186 (Scheme 
22), with the less-hindered N-9 of purine is now blocked, the N-7 of purine 
attacks the alkylating reagent to provide a quaternary imidazolium salt 187, 
finally it undergoes in situ deprotection of the protected N-9 to generate N-7-
substituted purine 188 as a single regioisomer. 
In order to test the applicability of this new method in the present study. 6-
chloropurine 32 was treated with isopropylmagnesium chloride, followed by 




Scheme 21. The mechanism proposed by Van Deg Berge et al332,333 for regioselective N-
alkylation of the more sterically hindered nitrogen (N-1) in 6-methylbenzimidazole 181. 
 
Scheme 22. The proposed mechanism for the regioselective N-alkylation of the more 
hindered N-7 of purine 
 
Scheme 23. Synthesis of compounds (160, 163, 164, 166, 170 and 171) 
 
aReagents and conditions: (a) i-PrMgCl (1.1 equiv), dry THF, 60 °C, 18 h, yields 31- 62%; b) 
DIPEA (10 equiv), tert-butanol, 100 °C, 72 h, yields 6- 41%. 
regioisomer in 37% yield. The identity of the regioisomer was confirmed by 
comparison its 1H and 13C chemical shifts along with literature data reported 
for 6-chloro-N-7-ethylpurine 189 and 6-chloro-N-9-ethylpurine 190 (Table 
40)334. The resulting spectra were in good agreement to literature values of 
N-7 regioisomer 189. This suggested that this reaction is completely 




the other hand, the undesired N-9-regioisomers was not detected by TLC, 
LCMS and NMR. 
                           
Table 40. Comparison the chemical shifts (ppm) of the carbon atoms in an unidentified 











C-11 16.7 17.25 15.20 
C-10 41.8 42.30 39.47 
C-5 121.8 122.34 131.21 
C-6 142.45 141.9 147.40 
C-8 150.5 150.97 149.27 
C-2 151.5 151.97 151.59 
C-4 161.6 162.12 152.02 
Encouraged by this excellent result, this regioselective alkylation method has 
been extended to synthesise a variety of N-7 substituted purine derivatives 
(Scheme 23). Alkylation of 6-chloropurine with bromoacetonitrile and 
propargyl bromide provided the desired nitrile 191 and propargyl 192 
derivatives in 44% and 31% yields, respectively (Scheme 23). In both cases, 
exclusively one regioisomer was detected via TLC, LC-MS and NMR. Best 
yield of N-7-substituted purine (62%) was obtained when using 2,2,2-
trifluoroethyl trifluoromethanesulfonate as an alkylating reagent to afford the 




In the preparation of the 2-aminopurine final compounds 170 and 171, 2-
amino-6-chloropurine 194 was chosen as a starting material, instead of 6-
chloropurine 78. Accordingly, 194 was treated with a 1.1 equivalent of 
isopropylmagnesium chloride, followed by addition of bromoacetonitrile and 
2,2,2-trifluoroethyl trifluoromethanesulfonate to give 195 and 196 in 14% and 
6% yields, respectively (Scheme 23). Low yields of the N-7 substituted 
purines obtained when 2-amino-6-chloropurine was used as a starting 
material in contrast to 6-chloropurine, this was attributed to two reasons. First, 
formation of significant quantity of the side product 197, resulting from 
nucleophilic displacement of 2-amino-6-chloropurine 194 with the isopropyl 
group from the Grignard reagent (Scheme 24). Second, N-7 selectivity was 
reduced, with a small amount of N-9 substituted regioisomer were detected 
in these cases, where N-7/N-9 selectivity was reduced from 25:1 to 5:1, when 
changing the starting material from 6-chloropurine to 2-amino-6-chloropurine. 
This result is consistent with data reported by Chen et al331 which 
demonstrated that the yield and regiochemistry were diminished upon the 
regioselective alkylation of 2-substituted-6-chloropurine compared to the 6-
chloropurine 78. 
Scheme 24. Proposed mechanism for the nucleophilic displacement of 6-chloro group in the 
2-amino-6-chloropurine 194 by the Grignard reagent and formation of the 6-isopropylpurine 
side product 197 
 
Nucleophilic attack of amine 77 on N-7-substituted purine 195 and 196 in the 
presence of DIPEA in tert-butanol yielded final compounds 170 and 171, 




and 171 were obtained in poor yield (9% and 6%, respectively) (Scheme 23), 
compared to their des-amino analogues 163 and 166 (37% and 23% 
respectively), which can be attributed to the low solubility of the starting 
purines 195 and 196 in the tert-butanol. 
4.4.3 Biology Section 
The target compounds were screened by GSK for their in vitro inhibitory 
activity against the four isoforms of class I PI3K (Table 41). In this SAR study, 
idelalisib (8) was used as a reference inhibitor and displayed an IC50 value of 
11 nM against PI3K δ. 
Disappointingly, all of the compounds in Table 41 showed poor or no 
inhibitory activities against the four isoforms of class I PI3K. Compared to the 
control compound (idelalisib 8), these compounds were much less potent 
inhibitors of PI3K δ, where most of them were at least 1000-fold less active 
than idelalisib 8 against PI3K δ. Taken together, this SAR study indicates that 
the substitution at the N-7 position of the purine ring produced a detrimental 
effect on the PI3K δ potency. It is noteworthy to mention that the compounds 
166 and 171 bearing trifluoroethyl group in the purine hinge binder showed 
better activity against PI3K δ (IC50 values of 2.80 and 2.22 μM) compared to 
the rest of the compounds in this series. The reason for the improvement in 
PI3K δ potency of the trifluoroethyl analogues is not clear. Moreover, the 
acetylene-containing compound 164 was also found to display PI3K δ 






Table 41. Biological evaluation and isoform selectivity for PI3K δ for compounds (8, 156-160, 
163-166, 170 and 171). 
aPotency against the different PI3K isoforms is given as IC50 values (n = 2). The standard 
errors were not provided by GlaxoSmithKline (GSK). bThe potency threshold for the PI3K δ 
assay is ~ IC50 1 nM due to substrate concentration.  
4.4.3.1 Reasons for the poor activity of the series of N-7-
substituetd purine derivatives  
There are two possible reasons for the poor PI3K activity of idelalisib 
derivatives bearing a new substituent in the N-7 position of the purine ring. 
 Isoform potencya,b IC50 (nM) 
Compd R1 R2 PI3Kδ PI3Kα PI3Kβ PI3KƔ 
8 -H -H 11 14000 2800 56 
156  -H >28000 >28000 >28000 >28000 
157  -H 11000 >28000 >28000 >28000 
158 
 
-H 22000 >28000 >28000 >28000 
159 
 
-H 22000 >28000 >28000 >28000 
160  -H >28000 >28000 >28000 >28000 
163  -H 14000 >28000 >28000 >28000 
164  -H 5500 >28000 >28000 17500 
165 
 
-H >28000 >28000 >28000 >28000 
166 
 
-H 2800 >28000 >28000 11000 
170  -NH2 10000 >28000 >28000 22000 
171 
 




4.4.3.1.1 Loss of hydrogen bond donor (NH-9) 
As previously discussed in Section 4.2, NH-9 of idelalisib (8) acts as a hinge 
binder by donating a hydrogen bond to the backbone oxygen atom of Glu826 
(Figure 83). However, the N-7-substituted purine derivatives of idelalisib lacks 
the hydrogen donor necessary to form the second hydrogen bond with the 
hinge. Thus, one could hypothesize that the absence of this hydrogen bond 
could explain the sudden loss of activity of this series of N-7 substituted purine 
derivatives. However, several studies have provided evidence that this 
hypothesis was unlikely to be true. For example, Novartis324 have reported a 
PI3K δ inhibitor 198 with IC50 value of 150 nM (Table 42). The purine ring of 
198 forms a bidentate hydrogen bond interaction with the hinge region 
between the hydrogen bond acceptor purine N-3 and the amide backbone of 
Val828 and the hydrogen bond donor NH-9 of the purine to carbonyl backbone 
of Glu826. Surprisingly, removing the hydrogen bond donor by replacing the 
NH-9 of purine with a sulphur atom 199, increased potency at PI3K δ by about 
20-folds (Table 42), which suggested that that the hydrogen bond made by 
NH-9 of the purine ring is not crucial for PI3K δ activity. 
Taken together, findings from Novartis335 study suggested that the absence 
of the hydrogen bond donor (NH-9) of the purine hinge-binding group has 
absolutely no effect on PI3K δ activity. Moreover, they uncovered that a single 
hydrogen bond acceptor (N-3) of the purine hinge binder is enough to achieve 
a satisfactory inhibition of PI3K δ. These examples rule out the lack of the 
hydrogen bond donor (NH-9) as a main factor in the significant loss of PI3K 
δ potency of this series of N-7-substituted purine derivatives and suggests 





Table 42. Biological evaluation for PI3K δ for compounds 198 and 199 described in WO 
2014/128612 A1 study324. 
compd -X- PI3K δ IC50 (nM) 
198324 -NH- 150 
199324 -S- 7 
4.4.3.1.2 Steric clash with the gatekeeper Ile825 side chain 
Unfavourable steric clash between the newly added bulky substituent at the 
N-7 position of purine and the isoleucine (Ile825) gatekeeper, provides a 
possible explanation for the observed loss in PI3K δ potency336. As mentioned 
in the previous chapter, the gatekeeper residue is present in all kinases320,337, 
which is situated at the entrance of the affinity pocket and plays a role in 
controlling the sensitivity of a wide range of kinase inhibitors323,336. Kinases 
that have small residues (Gly, Ala, Thr, Val or Cys) at this position, can be 
targeted by inhibitors from structurally diverse chemical classes. Whereas, 
kinases which have a bulky side chain (Ile, Met or Glu) at the gatekeeper 
position are widely resistant, because of steric hindrance142. PI3K δ has a 
bulky isoleucine gatekeeper which limits accessibility to the affinity pocket 
(Figure 93). It was hypothesized that the steric clash between the N-7 
substituent and the gatekeeper Ile825 displaces N-7 substituted purine 
derivatives from their optimal orientation (Figure 94), where these compounds 
are oriented in such way that the N-7 substituent escapes the steric clash with 




the purine ring and the hinge region338,339, this consequently results in a 
significant loss in PI3K δ potency (202- to 2500-fold). 
a)                                                                    b) 
.  
Figure 93.a) Schematic representation of idelalisib (8) binding interactions in the binding site 
of PI3K δ. The gatekeeper residue Ile825 (highlighted in red) limits the accessibility to the 
affinity pocket. b) Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) 
bound, highlights the gatekeeper Ile825 (represented by a space-filling model) that is located 
between the affinity pocket and the hinge region, where it restricts the access to the affinity 
pocket. 
a)                                                                                   b) 
  
Figure 94. a) Idelalisib-PI3Kδ interactions are depicted by a chemical structure, the 
gatekeeper residue (Ile825) (highlighted in green) controls the accessibility to the affinity 
pocket. The chemical structure depicts the purine ring that engages in crucial hydrogen 
bonds to the hinge region. Dashed red lines represent the proposed hydrogen bonds with 
the hinge region. b) Compound 156-PI3Kδ is depicted by a chemical structure, Ile825 
obstructs access to the affinity pocket and results in serious steric clash with the hydroxyethyl 
group at the N-7 position of the purine ring, therefore hinders crucial hydrogen bond 
interaction with the hinge region, leads to compound 156 being more than 2500-fold less 
potent than idelalisib (8). 
4.4.3.2 Docking study 
To verify the hypothesis discussed above and to rationalize the observed 
PI3K δ activities for all reported compounds, docking analysis were 




active site of the PI3K δ enzyme, compound 156 was used as an example. 
(Figure 95b) shows that compound 156 did not dock into the active site of 
PI3K δ like idelalisib (8) (Figure 95a). The introduction of the bulky substituent 
at N-7 position of the purine ring might make steric clashes with the 
gatekeeper Ile825 and could be a reason why these compounds were unable 
to bind into the active site. Therefore, no interaction was observed between 
the purine ring of compound 156 and the hinge region of PI3K δ (Figure 95b), 
the absence of this interaction is suggested to be responsible for the loss of 
activity of these series of compounds as compared to idelalisib (8).  
a)                                                                            b) 
    
Figure 95. a) Crystal structure of murine PI3K δ (PDB code 4XE0) with idelalisib (8) bound. 
b) compound 156 docked into the PI3K δ-model (generated from PDB 4XE0), it reveals that 
the purine ring of compound 156 fails to form hydrogen bond with the hinge region of PI3K δ 
active site as in idelalisib (8). The missing hinge region is marked by a blue circle.  
4.4.3.3 Clinical example of the gatekeeper influences inhibitor-
kinase interaction resulting in significant effect on 
inhibitory activity  
The two tyrosine kinase inhibitors (imatinib 200 and ponatinib 201) give a 
relevant example of the significant role played by the gatekeeper residue in 
influencing the biological activity of kinase inhibitors. Imatinib (200) (Figure 
96a) is a first generation ATP-competitive inhibitor of BCR-ABL, approved for 
the treatment of chronic myeloid leukaemia (CML) 340,341, imatinib (200) has 




wild type of BCR-ABL expressed in Ba/F3 transfected cells (Table 43), which 
has a threonine (Thr315) in the gatekeeper position (Table 43)342,343. 
However, it was found to be poorly active (IC50= 13200 nM) against the T315I 
mutant form of BCR-ABL, in which the Thr315 gatekeeper is replaced by a 
more bulky isoleucine (Table 43)342–344, this is due to the steric clash created 
between the side chain of isoleucine with a hydrogen atom of the exocyclic 
amino group of imatinib (200) (Figure 96c), precludes imatinib (200) from 
binding to the active site, results in a significant loss of activity345,346. 
Table 43. Biological activity of imatinib (200) and ponatinib (201) against the wild-type and 
T315I-mutated BCR-ABL expressed in Ba/F3 transfected cells, highlights chemical nature of 
the linkers connecting the hinge-binding group to the affinity pocket binder in both 
compounds343. 
Compd 



















To overcome imatinib-resistant BCR-ABL mutation, the third-generation 
BCR-ABL inhibitor ponatinib (201) (Figure 97a) has been developed, which 
demonstrated excellent inhibitory activity against BCR-ABLT315I (IC50 value of 
11 nM) with 1200-fold more activity than imatinib (200) (Table 43)342,343. Liu 
et al340 suggested that the plausible explanation for the high activity observed 
for ponatinib (201) is the ability of the acetylene linker to escape the steric 





a)                                            b) 
      
c) 
 
Figure 96. a) The first-generation BCR-ABL inhibitor imatinib (200), highlighted the exocyclic 
amine (in pink). b) Crystal structure of murine wild-type BCR-ABL (PDB code 1IEP) with 
imatinib (200) bound. c) Wild-type BCR-ABL has a small gatekeeper residue (Thr315), which 
does not cause a steric hindrance with the exocyclic amine of imatinib (200). c) The mutation 
of the gatekeeper Thr315 to the bulkier Isoleucine (Ile315) leads to steric clash with the 
exocylic amine of imatinib (200), which explains why imatinib (200) is 130-fold less potent 
against T315I-mutant BCR-ABL compared to the wild-type enzyme. T315I mutation was 
performed computationally.  
a)                                        b) 
        
Figure 97. a) The third-generation BCR-ABL inhibitor ponatinib (201), highlights the 
acetylene linkage between the pyrrolopyridazine hinge binder and the diarylamide side chain 
that occupies the affinity pocket. b) Crystal structure of murine T315I-mutant Bcr-AbL (PDB 
code 3IK3) with ponatinib (201) bound, ponatinib (201) avoids the steric clash with the 
gatekeeper Ile825 residue, due to a lesser sterically demanding acetylene linker, which 
explains why ponatinib (201) is only 10-fold less potent against T315I-mutant BCR-ABL 




4.4.3.4 The reason for the steric clash between the series of N-7-
substituted purine derivatives and the gatekeeper Ile825 
Based on the example of imatinib (200) and ponatinib (201), it seems likely 
that the poor PI3K δ potency of the compounds described in this chapter was 
due to the steric clash created between the gatekeeper Ile825 and the ethyl 
linker connecting the purine hinge binder to the terminal functional groups 
(Figure 98a). The ethyl linker adopted a three-dimensional tetrahedral 
geometry with high degree of flexibility (Figure 98b)347; thus it could not pass 
the narrow channel embraced by gatekeeper Ile825 to reach the affinity pocket, 
resulted in an undesirable steric clash. 
a)                                                              b) 
               
Figure 98. a) 2D-representation of the alcohol compound 156 binding interaction in the active 
site of PI3K δ. Highlights the proposed steric clash between the gatekeeper Ile825 with the 
tetrahedral ethyl linker b) 3D-representation of the alcohol compound 156 binding interaction 
in the active site of PI3K δ. The three-dimensional chemical structures of compound 156 and 
gatekeeper isoleucine were generated using Chem3D Ultra XML. It highlights the proposed 
steric clash between the tetrahedral ethyl linker and the gatekeeper Ile825, preventing the 
optimal fit of compound 156 into the PI3K δ binding site. The gatekeeper Ile825 is represented 
as a space-filling model to study steric hindrance. 
Extensive literature search relating to PI3K δ inhibitors strongly supports the 
above mentioned hypothesis144,145,154,155, where there have been no reports 
that tried to use alkyl group as a linker to connect the hinge-binding scaffold 




demonstrates that the linker used to connect between the hinge-binding 
moiety and the terminal functional group is exclusively linear acetylene or 
planar aryl group. For example, in a series of highly potent quinazolinone 
derivatives 152, 202 and 203 (Table 44), acetylene linker was used to place 
nitrogen heterocycles within the affinity pocket (Figure 99), which was 
reflected by a more than 200-fold increase in PI3K δ activity as compared to 
their parent compound 151 (Table 44). 
 
Table 44. Biological evaluation and isoform selectivity for PI3K δ for compounds (152, 202 
and 203 reported by Patel et al155), highlights the acetylene linker connecting the affinity 
pocket-binding groups (heteroaryl rings) to the aminopyrimidine hinge binder. The 
unsubstituted analogue 151 is used as a reference. 
compd R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
151155 -H 99 1600 120 320 
152155  0.3 1500 260 230 
202155 
 
0.5 620 240 100 
203155 
 






a)                                                b) 
        
Figure 99. a) Compound 152, highlights the acetylene linker connecting the affinity pocket-
binding group (pyrazole) to the aminopyrimidine hinge-binding core. b) Crystal structure of 
murine PI3K δ (PDB code 5I6U) with compound 152 bound, acetylene linker can pass the 
narrow channel embraced by gatekeeper Ile825 and reach the affinity pocket. Blue dashed 
lines represent the proposed hydrogen bonds that take place between the pyrazole ring with 
Asp787 and Lys779 in the affinity pocket.  
Furthermore, in the pyrazolopyrimidinineamine derivative 10 reported by 
Berndt et al149. The use of the rigid phenyl linker (Figure 100) directs the 
functional groups (hydroxyl) into the affinity pocket shows 186-fold 
improvement in PI3K δ potency compared with the parent compound 9 (Table 
45). 
 
Table 45. Biological evaluation and isoform selectivity for PI3K δ for compound 10, highlights 
the phenyl linker connecting the affinity pocket-binding groups (hydroxyl and fluorine) to the 
pyrazolopyrimidine hinge binder. The unsubstituted analogue 9 is used as a reference.  
compd R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
9149 -H 130 1538 123 469 
10149 
 






a)                                          b) 
    
Figure 100. a) Compound 10, highlights the phenyl linker connecting the affinity pocket-
binding groups (hydroxyl) to the pyrazolopyrimidinineamine hinge-binding core. b) Crystal 
structure of murine PI3K δ (PDB code 2WXG) with compound 10 bound. phenyl linker can 
pass the narrow channel embraced by gatekeeper Ile825 and reach the affinity pocket. Blue 
dashed lines represent the proposed hydrogen bonds that take place between the phenol 
group in compound 10 with Asp787 and Tyr813 in the affinity pocket. 
The previous findings clearly highlight the important role of the linker 
geometry for PI3K δ potency, as both the planar aryl and linear acetylene 
linkers have the ability to deliver the functional group into the affinity pocket 
bypass the gatekeeper Ile825. Therefore, it was proposed to use a suitable 
rigid planar linker, in order to prevent the steric collision with the gatekeeper 
Ile825 and access the affinity pocket. This will be discussed in more detail in 
Chapter 5. 
4.5 Conclusion  
This chapter has the same aim as the previous chapter, which was to attach 
a new functional group to the idelalisib (8) structure to gain access to the 
nearby unoccupied affinity pocket and achieve additional binding interactions, 
which may result in increased PI3K δ activity. As seen in Chapter 3, the 
incorporation of the polar functional groups into the exocyclic amine of 
idelalisib (8) resulted in a dramatic reduction in PI3K δ potency. It was 
hypothesized that changing the position of the functional group on idelalisib 




Thus, in this chapter, substituents containing polar functional groups was 
added at the N-7 position of the purine ring of idelalisib (8). For this purpose, 
a series of novel N-7-substituted purine derivatives of idelalisib have been 
designed, synthesized and evaluated for their PI3K δ activity with idelalisib 
(8) as a positive reference. Disappointingly, all compounds exhibited weak or 
no activity against PI3K δ with almost 200- to 2500-folds less active than 
idelalisib (8). Taken together, the results of Chapter 3 and 4 suggested that 
substitution of idelalisib (8) with a functional group at all possible positions 
resulted in a loss of activity (Figure 101), which could be attributed to the 
steric clash created between the gatekeeper Ile825 and the extra functional 
group, resulted in the loss of the most favourable geometry for hydrogen bond 
interaction between the purine ring and the hinge region. The cause of the 
steric clash may be attributable to high flexibility and/or tetrahedral geometry 
of the alkyl linker connecting the hinge-binding scaffold to the terminal 
functional group. Hence, replacement of alkyl linker by a more rigid aryl or 
acetylene linker could avoid any steric overlap with the gatekeeper Ile825 and 
ultimately improve the PI3K δ activity. 
 
Figure 101. The selective PI3K δ inhibitor idelalisib (8), highlights the influence of new 
substituent in different positions of idelalisib (8) on PI3K δ inhibitory activity. SAR studies 
discussed in Chapter 3, revealed that substitution of idelalisib (8) at the exocyclic amine 
results in loss of PI3K δ activity, whereas SAR studies discussed in Chapter 4, revealed that 





Chapter 5  Design, Synthesis, biological 
evaluation and docking studies of pyrimidine 
derivatives as highly potent and selective PI3K δ 
inhibitors (propeller-shaped inhibitor) 
5.1 Aim 
As seen in the previous two chapters, substitution of idelalisib (8) on the 
exocyclic amine or the N-7 position of the purine ring resulted in a dramatic 
loss of PI3K δ inhibitory activity. This could be reasoned by the steric clash 
that might occur between the gatekeeper Ile825 and the tetrahedral alkyl linker 
connecting the affinity pocket-binding group to the purine hinge binding 
moiety. This may explain why alkyl linkers have not been in PI3K δ inhibitors 
(Figure 102b). Accordingly, in this chapter, it was proposed to use a planar 
linker to avoid the steric contact with the gatekeeper Ile825. Furthermore, 
subtle structural modification of the idelalisib (8) structure would be made by 
replacement of the purine hinge binder with the structurally similar 
aminopyrimidine. 
a)                                                                       b) 
                          
Figure 102. a) The selective PI3K δ inhibitor idelalisib (8) and its binding interactions at PI3K 
δ, highlighting the unoccupied affinity pocket; b) Schematic diagram displaying the three 
types of linkers (alkyl, aryl and acetylene) connecting the hinge binder to the affinity pocket-
binding group in PI3K δ inhibitors, it shows that incorporation of an alkyl linker leads to a 
major loss of PI3K δ activity, whereas the introduction of aryl and acetylene linkers increased 
PI3K δ potency. 
Alkyl (loss of 
activity)













5.2 Types of the linker used in the previously reported PI3K δ 
inhibitors 
Previous studies on PI3K δ inhibitors revealed that the design of highly potent 
PI3K δ inhibitors relies on the introduction of a planar aryl or linear acetylene 
linker between the hinge-binding scaffold and the affinity pocket-binding 
group.  
5.2.1 Planar aryl linker 
An interesting study was published by Erra et al154 describing a series of 
pyrrolotriazinone compounds and their activity as PI3K δ inhibitors. Some of 
the compounds were reported to be highly potent with IC50 in the sub-
nanomolar range (Table 46). These active compounds consist of aromatic or 
heteroaromatic linkers connecting the affinity pocket-binding groups to the 
hinge-binding scaffold (pyrrolopyrimidine). For example, compound 204 
interacts with the affinity pocket via hydroxyl and methanesulfonamido 
groups, which are linked to the hinge binder through a phenyl spacer (Figure 
103). On the other hand, Compounds 205 and 206 consist of pyrazole and 
indole rings, respectively, which simultaneously act as a linker and affinity 
pocket binding moiety (Table 46).  
5.2.2 Linear acetylene linker 
Although the use of acetylene group in medicinal chemistry is not popular; it 
has been widely exploited as a linker in the development of PI3K δ inhibitors 
targeting the affinity pocket. Berndt et al173 reported the design of a novel 
quinazolinone 11 with acetylene utilized as a linker to connect the hinge 




(hydroxyl) (Figure 104). Compound 11 shows remarkable improvement (19-
fold) in PI3K δ potency compared with the parent compound 9 (Table 47). 
 
Table 46. Biological evaluation for PI3K δ for compounds (204-206 reported by Erra et al154), 
highlights the aryl/heteroaryl linkers and the functional groups that form hydrogen bond 
interactions with the affinity pocket.  









a)                                                          b) 
    
Figure 103. a) Compound 204, highlights the phenyl linker connecting the affinity pocket-
binding groups (hydroxyl and methanesulfonamido) to the pyrrolopyrimidine hinge binder. b) 
Crystal structure of human PI3K δ (PDB code 6G6W) with compound 204 bound. There is 
no apparent steric clash between the phenyl linker and the gatekeeper Ile825 (represented by 





Table 47. Biological evaluation for PI3K δ for the acetylene-containing compound 11, 
highlights the acetylene linker and the functional group (hydroxyl group) that forms hydrogen 





Functional group (R1) PI3K δ IC50 (nM) 




a)                                                        b) 
       
Figure 104. a) Compound 11, highlights the acetylene linker connecting the affinity pocket-
binding group (hydroxyl) to the pyrazolopyrimidine hinge-binding core. b) Crystal structure of 
murine PI3K δ (PDB code 2WXI) with compound 11 bound. There is no apparent steric clash 
between the acetylene linker and the gatekeeper Ile825 (represented by a space-filling model). 
Blue dashed lines represent the proposed hydrogen bonds. 
5.3 Reasons for selection of planar aryl and linear ethynyl 
linkers in PI3K δ inhibitors 
Although structurally the affinity pocket has a wide cavity, the entrance to the 
affinity pocket is narrow due to the presence of the gatekeeper Ile825. Using 
aryl rings and ethynyl linkers appears to prevent a steric contact with the 
gatekeeper Ile825. Aromatic rings adopt a planar geometry, whereas the 
ethynyl linker adopts a linear structure, thus they are able to traverse the 




affinity pocket leading to the increased PI3K δ activity (Figure 103b) (Figure 
104b). Whereas the tetrahedral shape of the alkyl linker is more likely to 
experience a steric clash with the gatekeeper Ile825, that prevents the 
functional group entering the affinity pocket, resulting in a dramatic loss in 
PI3K δ potency. The affinity pocket resembles the letter box in that it has a 
deep bottom but it is only accessible via a narrow entrance (Figure 105). 
According to this, the linkers of the PI3K δ inhibitors need to be planar similar 
to a letter in order pass the narrow channel embraced by gatekeeper Ile825 to 
reach into the affinity pocket.  
 
Figure 105. The affinity pocket resembles a letter box, where the access to the large cavity 
is highly restricted by the gatekeeper Ile825. As a result, the linker should have a planar 
geometry, just like a letter, to allow the inhibitor to enter the affinity pocket and make 
additional hydrogen bonds with the protein. 
5.4 Medicinal chemistry strategy  
In this medicinal chemistry effort, a new strategy was followed for a structural 
modification of the lead compound (idelalisib 8), which was achieved by: 1) 
the replacement of the purine hinge-binding scaffold with a 4-aminopyrimidine 
ring, 2) decoration of this ring at position 5 with a variety of substituents able 
to target the affinity pocket. 
Narrow entrance 
The linker needs to be 







5.4.1 Modification of the hinge-binding scaffold  
The previous chapter has shown that the addition of the new substituent 
(affinity pocket binder) at the N-7 position of the purine ring in idelalisib (8) 
resulted in a dramatic drop in PI3K δ activity compared to the parent 
compound (idelalisib 8), suggesting that the substitution of the purine hinge 
binder is not tolerated for PI3K δ inhibition. These disappointing results 
encouraged us to conduct structural optimisation of the hinge binding scaffold 
by replacing the purine ring with a 4-aminopyrimidine ring, which can be easily 
decorated with functional groups at the 5-position. This optimisation design 
strategy is based on the findings from Patel et al155 study (Table 48), which 
reported that 5-substituted aminopyrimidine series (151, 161 and 162) 
displayed greater than 250-fold increase in PI3K δ activity versus the 
unsubstituted compound 151, suggesting that the 4-aminopyrimidine scaffold 
orients the 5-substituent into the right position to make new binding 
interactions within the affinity pocket. For instance, the crystal structure of 
 
Table 48. Biological evaluation for PI3K δ for compounds (151, 161and 162 reported by Patel 
et al155), highlights the affinity-pocket binding groups (R1) projected from the 5-position of 4-
aminopyrimidine hinge-binding scaffold. The unsubstituted analogue 151 is used as a 
reference.  
compd R1 PI3K δ IC50 (nM) 
151155  99 
161155  0.4 





PI3K δ in complex with compound 161 (Figure 106b) reveals that the nitrile 
group projected from the 5-position of the 4-aminopyrimidine core into the 
affinity pocket, where it makes a hydrogen bond interaction with the phenolic 
side chain of Tyr813. Hence, in this chapter, a new series of PI3K δ inhibitors 
based on the 4-aminopyrimidine hinge binder was synthesized and evaluated 
for their PI3K δ inhibitory effect. 
a)                                                   b) 
              
Figure 106. a) The nitrile-containing compound 161, highlights the 4-aminopyrimidine 
carrying a nitrile group at position 5. b) Crystal structure of murine PI3K δ (PDB code 5I4U) 
with compound 161 bound, highlights the nitrile group that projects from the 5-position of the 
4-aminopyrimidine core into the affinity pocket, making a hydrogen bond with Tyr813. Blue 
dashed lines represent the proposed hydrogen bonds with the affinity pocket and hinge 
region. 
5.4.2 Linker  
As was previously mentioned, all of the reported PI3K δ inhibitors targeting 
the affinity pocket contained either a planar aryl or linear acetylene group as 
a linker to connect the hinge-binding scaffold with a terminal binding group 
(Table 49). A Study of the wide range of functional groups was conducted, 
with the aim of finding a novel planar linker for developing new potent PI3K δ 
inhibitors (Table 49). It was found that the amide group adopts a trigonal 
planar geometry, owing to the resonance between the lone pair on the amide 




to the C-N bond (Figure 107)348–350. Consequently, the atoms comprising the 
amide and also those directly connected to it are forced to lie in the same 
plane.  
Table 49. Examples of planar and linear functional groups, which can be used as linkers in 
the development of PI3K δ inhibitors. 
Planar or linear linker  Use in PI3K δ inhibitors 
Aryl group Widely used 
Acetylene group Widely used 
Amide group Reported only in one PI3K δ inhibitor  
 
Figure 107. Resonance structures of amide. The delocalisation of the nitrogen lone pair into 
the pi system of the carbonyl group, results in a partial double bond between the nitrogen 
atom and the carbonyl carbon of the amide with the nitrogen atom being sp2-hybridized. Thus, 
the entire amide group tends to be planar. 
Based on this idea, the present study reported the synthesis of a new class 
of PI3K δ inhibitors based on 4-aminopyrimidine scaffold with an amide linker 
to a terminal functional group that projects into the affinity pocket. To the best 
of authors’ knowledge, compound 208 is the only PI3K δ inhibitor reported to 
have an amide linker (Figure 108)154. The excellent PI3K δ activity displayed 
by compound 208 (IC50 value of 0.2 nM), indicates that the use of an amide 
group as a linker could represent a promising strategy in the development of 





Figure 108. Structure and biological activity of the only PI3K δ inhibitor 208 reported to have 
an amide linkage between the aminopyrimidine hinge binder and the phenol group that 
occupies the affinity pocket154. 
5.4.3 Types of functional groups 
In this project, a new approach is applied for designing compounds as potent 
PI3K δ inhibitors by exploring a variety of affinity pocket-binding groups 
(heteroaromatic, aromatic and aliphatic rings) some of them not commonly 
seen in the previously discovered PI3K δ inhibitors. The affinity pocket-
binding groups used in this SAR study can be classified on the basis of their 
chemical structure into two groups: 1) five-membered heteroaromatic rings, 
2) miscellaneous functional groups. 
5.4.3.1 Five-membered heteroaromatic ring 
Five-membered heterocycles were selected to explore the affinity pocket, 
because they successfully served as affinity pocket-binding groups for highly 
potent PI3K δ inhibitors in the past154,220. In addition, only a small number of 
PI3K δ inhibitors have been reported with five-membered heterocycles acting 
as affinity pocket binders. An interesting study published by Erra et al154 
showed that extension of the pyrazole ring toward the affinity pocket offered 
a PI3K δ inhibitor 205 with IC50 as low as 0.4 nM (Table 50). Whereas the 
change of a pyrazole for a N-methylpyrazole ring in the affinity pocket resulted 





Table 50. Biological evaluation for PI3K δ for compounds 205 and 209 having five-membered 
heterocycles as the affinity pocket-binding group154. 
compd 
Affinity pocket-
binding group (R1) 







Based on the findings of Erra et al154 study, In this research, three 
regioisomers of N-methylpyrazole derivatives (210-211) were synthesized 
with an aim to obtain high PI3K δ potency (Table 51). However, the synthesis 
of the pyrazole derivative 212 was planned but due to the challenges in the 
process of synthesis it was not made. 
In addition, molecular docking studies have been performed to identify the 
binding interactions of a plethora of five-membered heterocyclic derivatives 
in the active site of the PI3K δ enzyme. The docking study results revealed 
that, among all 25 compounds docked against PI3K δ, 5-methyl-1,3,4-
thiadiazole 214 and isoxazole 215 derivatives could form hydrogen bond 
interactions with the residues located within the affinity pocket. In both cases, 
the N-3 atom of the thiadiazol ring in 214 (Figure 109b) and the oxygen atom 
of the isoxazole ring in 215 acts as hydrogen bond acceptors to the primary 
amine of Lys779. Whereas the remaining 23 heterocyclic derivatives did not 




docking results, only compounds 214 and 215 were selected to test for their 
in vitro activity against PI3K δ (Table 51). 
 
Table 51. Structure of the proposed compounds (210-215) having five-membered 
















a)                                                     b) 
        
Figure 109. a) Compound 214, highlights the 5-methyl-1,3,4-thiadiazole ring (in pink) that 
extends into the affinity pocket. b) Compound 214 docked into the PI3K δ model (generated 
from PDB code 5I6U). In the affinity pocket, the thiadiazole ring forms a hydrogen bond to 
the amino group of Lys779 through the N-4 nitrogen atom. Blue dashed lines represent the 




5.4.3.2 Miscellaneous functional groups 
In addition to the heterocyclic derivatives, it was suggested to develop a new 
approach which consists of exploring the affinity pocket with different 
functional groups (Table 52), taking into account the size of the pocket as well 
as the chemical nature of the amino acids comprising it.  
5.4.3.2.1 Phenyl group 
One of the objectives of this chapter was to identify the amino acids and the 
type of interactions (hydrogen bond, cation-pi or pi-pi) involved in the binding 
between the affinity pocket of PI3K δ and the ligands used in this study. 
Phenyl derivative 216 (Table 52) lacking the heteroatoms has been 
synthesized to test whether the hydrogen bonding groups has any importance 
towards the activity of the heterocyclic derivatives (210-215) listed in Table 
51. As shown in Figure 110, the affinity pocket consists of 5 residues, one of 
these residues is Tyr813 which can form a pi-pi interaction with the phenyl 
group of 216. There is also Lys779, which may also interact with the phenyl 
group of 216 via a cation-pi interaction. Therefore, if the phenyl analogue 216 
exhibited a similar level of activity to the heterocyclic derivatives (210-215), 
then it is very likely that the inhibitors would form a pi-pi interaction with Tyr813 
or cation-pi interaction with Lys779. On the other hand, if the phenyl analogue 
216 was much less active than the heterocycles-containing compounds (210-
215), then this would suggest that the interactions between the heterocyclic 
derivatives (210-215) and the affinity pocket are mediated primarily through 





Table 52. Structure of the proposed compounds (216-220) having miscellaneous functional 











Figure 110. Crystal structure of murine PI3K δ (PDB code 4XE0) displays the 5 residues that 
line the affinity pocket. Tyr813 and Lys779 (highlighted in magenta) can make a pi-pi and cation-
pi interactions, respectively, with the phenyl group of compound 216. 
5.4.3.2.2 Saturated bioisosters of phenyl ring 
Additionally, cyclopropyl and cyclohexyl groups were employed as saturated 
bioisosters for the heterocycles and phenyl group. To the best of authors’ 
knowledge, this is the first study to target the affinity pocket using saturated 
groups, where the affinity pocket has always been filled by aryl or heteroaryl 




cyclohexyl in 218 as affinity pocket-binding groups can provide advantages 
in terms of intellectual property and physical properties (fraction of sp3 carbon 
atoms (Fsp3), solubility, lipophilicity and topological polar surface area). 
Our idea of introducing a cyclopropane group into the affinity pocket is based 
on the assumption that this group may interact favourably with Tyr813 in the 
affinity pocket through a pi-pi interaction. The cyclopropyl is considered to be 
isosteric to the phenyl ring, this is due to the fact that the cyclopropyl ring 
behaves like the double bonds of alkenes, with a greater p-character (partial 
aromatic character) than the normal aliphatic C-C bond351–354. The Coulson-
Moffitt model for cyclopropane suggests that C-C bond in cyclopropane has 
about 20% less orbital overlap than the corresponding C-C bond in ethane 
354,355, thus C-C bond in cyclopropane is neither a sigma nor pi bond, it is 
intermediate between them (Figure 111)356. This type of bond is named a bent 
bond or banana bond353,354. Furthermore, in terms of physiochemical 
properties, cyclopropyl analogue 217 has a smaller molecular weight and 
greater proportions of sp3 carbons (higher Fsp3) than the phenyl 216 and 
heterocyclic (210-215) analogues (Table 53). Therefore, the cyclopropyl-
containing compound 217 could provide improved physical characteristics, 
for example solubility357. 
a)                                                          b)                                             c) 
 
Figure 111. a) The sigma bond in ethane is formed by end-to-end overlap of atomic orbitals. 
b) The pi bond in ethene is formed by the lateral overlap of atomic orbitals. c) The Coulson-
Moffitt model suggests that the C-C bond in cyclopropane is intermediate between sigma 





Table 53. Comparison of the physical properties of methylpyrazole 211, phenyl 216 
cyclopropyl 217 analogues264,357–359, the cyclopropyl analogue exhibits improved physical 













range for oral 
bioavailability 
MW 513.54 509.55 473.51 <500 
Fsp3 0.11 0.107 0.24 >0.47 
tPSA 140.14 124.54 124.54 60-140 A° 
To identify the type of hydrophobic interactions that may be involved in the 
binding of phenyl analogue 216 to the affinity pocket, 218 was synthesized, 
which contained a cyclohexyl ring as an affinity pocket binding moiety. In 
contrast to the phenyl group, the cyclohexyl group has no possibility to form 
a pi-pi interaction, however, it can make a C-H/pi interaction with the side 
chain of Tyr813 lining the affinity pocket. Ninkovic et al360 and Gunaydin et al361 
pointed out that the C-H/pi interaction between cyclohexane and benzene ring 
is stronger than that between two benzene rings (Table 54), Ninkovic et al360 
attributed this to the ability of the cyclohexane ring to make 3 C-H/pi 
interactions, which work cooperatively (Figure 112). Moreover, it was 
reasoned that replacing the phenyl group with its saturated counterpart 
(cyclohexyl) leads to the increase of molecule saturation (Fsp3 value), that 
would inevitably result in improved physical properties. The comparison 




Table 54. Comparison of the nature and characteristics of the C-H/pi interaction with the pi-




















a)                                                                   b) 
      
Figure 112. a) Schematic representation of the cyclohexane-benzene interaction. b) 3D-
representation of the cyclohexane-benzene interaction, highlighting the formation of the 3 C-
H/pi interactions between the axial hydrogens of cyclohexane and pi cloud of benzene. 
5.4.3.2.3 Define the size limit of the affinity pocket  
The quinoline analogue 219 (Table 52) was synthesized to examine the effect 
of extending a bulky bicyclic ring into the affinity pocket, which would provide 
information regarding the size limitation of the affinity pocket. If the quinoline-
containing compound 219 displayed similar or higher activity than that of the 
other above-mentioned analogues (210-218), then this would indicate that the 
affinity pocket of PI3K δ is large enough to tolerate a wide variety of ring 





5.4.3.2.4 Investigate the role of the amide linker in ligand binding  
The amide linker has the simple role of connecting the aminopyrimidine 
hinge-binding scaffold to the terminal functional group. However, oxygen and 
hydrogen in the amide linker can participate in hydrogen bond interactions 
with the residues lining the affinity pocket. To explore this possibility, the 
primary amide derivative 220 was synthesised (Table 52), in which the 
functional group that interacts with the affinity pocket does not present. 
5.4.3.2.5 Reference compound  
The next step was to synthesize a reference compound in which the binding 
interactions with the affinity pocket are not possible, to compare its PI3K δ 
potency to those of the other analogues in this series, which will help 
determine the extent to which the potency is enhanced by making additional 
interactions with the affinity pocket. The original strategy was to synthesize 
the compound 221, which has no substitution on the 5-position of the 
aminopyrimidine hinge binder (Table 55). Unfortunately, compound 221 could  
 
Table 55. Structure of the proposed reference compounds 221 and 222, lacking the affinity 
pocket-binding group and amide linker at the 5-position of the 4-aminpyrimidine hinge binder. 
compd R1 






not be synthesized, this had been attributed to challenges associated with the 
last step in the synthesis of this compound (more details in the Chemistry 
Section 5.5.1.3). Consequently, aldehyde derivative 222 was synthesized to 
be used as an alternative reference (Table 55). Compound 222 is not likely 
to be involved in interactions with the residues lining the affinity pocket due to 
lack of affinity pocket-binding group and NH2 group of the amide linker.  
5.4.3.3 Investigate the role of the hydrogen bond donor at the 
hinge region  
Most δ-selective PI3K inhibitors traditionally make two hydrogen bonds to the 
hinge region via the hydrogen bond donor/acceptor pair of the hinge-binding 
scaffold. However, in one example reported by Novartis335, Compound 199 
does not make the typical hydrogen bond donor interaction with the PI3K δ 
hinge region, as it lacks the hydrogen bond donor in the hinge binding moiety 
(thiazolopyrimidine) (Table 56). However, 199 still display 12-times greater 
activity than the parent compound 198 containing hydrogen bond donor (NH-
9 of purine) (Table 56), which can be involved in hydrogen bonding with the 
 
Table 56. Biological evaluation for PI3K δ for compounds (198, 199 and 223)335. Compound 
198 which has no a hydrogen bond donor, shows 12-fold improvement in PI3K δ potency 
over the parent purine derivative 199. 
compound -X- PI3K δ IC50 (nM) 
198335 -NH- 150 
199335 -S- 7 




backbone carbonyl of Glu826 in the hinge region. Based on this example, it 
was hypothesized that the presence of hydrogen bond donor (4-NH2) at the 
hinge binding moiety is not necessary to achieve high PI3K δ inhibiting 
activity.  
Quite strikingly, masking the hydrogen bond donor of 198 with N-9 
methylation of purine resulted in compound 223 which showed 10-fold 
decrease in activity compared to the parent compound 198 (Table 56). The 
biological results of 199 and 223 are somewhat contradictory as both 
compounds lack the hydrogen bond donor, but there is a dramatic difference 
(205-fold) in the PI3K δ potency between them. These observations suggest 
that the complete removal of the amino group does not reduce the PI3K δ 
inhibitory activity. Whereas, substitution of this amino group leads to a 
significant decrease in the PI3K δ activity, suggesting a low tolerance for the 
substituent protruding toward the hinge region.  
To test this hypothesis in the current study, two compounds 224 and 225 were 
designed and docked into the active site of the PI3K δ enzyme (Figure 113 
and Figure 114). In both compounds, the amino group at the 4-position of the 
4-aminopyrimidine hinge binder has been removed. In compound 224 the 4-
amino group has been replaced by a chlorine atom (Figure 113a), whereas 
the 4-amino group of compound 225 has been replaced by a hydrogen atom 
(Figure 114a). The docking results revealed that the chlorine atom of 
compound 224 makes steric clashes with Val828, a residue lining the hinge 
region and thus moves the pyrimidine hinge binder away from the hinge 
region (Figure 113b). As a consequence, the N-3 atom (acceptor) of the 




of the hinge Val828. This lack of interaction is explained by 3.48 Å separation 
distance between N-3 atom of pyrimidine and the amide backbone of Val828 
(Figure 113b). This distance is not consistent with the range for hydrogen 
bond length (2.5- 3.2 Å)362,363. Thus, the chloride analogue 224 does not make 
any hydrogen contact with the hinge region. Based on this docking result, 
compound 224 is expected to have a little or no inhibitory activity against PI3K 
δ. 
a)                                                 b) 
        
Figure 113. a) The chlorine-containing compound 224. b) Compound 224 docked into the 
PI3K δ model (generated from PDB code 5I6U), steric clashes are represented by orange 
dashed lines and interatomic distance (in Å) is represented by a blue dashed line. It reveals 
that the steric clash created between the chlorine atom on pyrimidine and Val828 moves the 
pyrimidine ring away from the hinge region, thus, the N-3 atom of pyrimidine cannot form a 
hydrogen bond with the amide backbone of Val828, this lack of interaction is explained by 3.48 
Å separation between N-3 atom of pyrimidine and the backbone amide of Val828. As a 
consequence, compound 224 does not form any hydrogen bonds with the hinge region. 
On the other hand, the docking result of compound 225 showed that the 
hydrogen atom in the 4-position of the pyrimidine hinge binder does not give 
rise to a steric clash with Val828 (Figure 114b), because of its small size. 
Thereby, the pyrimidine ring of compound 225 comes close to the hinge 
region and makes a hydrogen bond with the amide backbone of Val828 




donor and acceptor is 2.82 Å, which falls within the optimal range for 
hydrogen bonds (2.5 to 3.2 Å)364. 
a)                                                 b) 
       
Figure 114. a) Compound 225, which is unsubstituted at position 4 of the pyrimidine hinge 
binder. b) Compound 225 docked into the PI3K δ model (generated from PDB code 5I6U), 
interatomic distance (in Å) is represented by a blue dashed line. It reveals that the distance 
between N-3 of pyrimidine and the amide backbone of Val828 is 2.82 A° which is within the 
optimum range of hydrogen bond formation (2.5 to 3.2 Å), suggesting that compound 225 
can form one hydrogen bond with the hinge region. 
Taken together, the findings of Novartis324 and the above mentioned docking 
studies suggest a hypothesis that the absence of a hydrogen bond donor in 
the hinge binding motif may result in a slight decrease to no change in PI3K 
δ inhibitory activity, whereas, the replacement of an amino group by atoms 
other than hydrogen or groups of atoms leads to a major loss in the PI3K δ 
activity that may be caused by the steric clash with Val828 at the hinge region. 
It was decided to test this hypothesis in the current study, by designing 
compounds 226 and 227 (Table 57) in which the hydrogen bond donor (4-
amino group) is removed and replaced with a hydrogen atom, then the IC50 
values of 226 and 227 are compared with those of the corresponding 4-





Table 57. Structure of the proposed compounds belonging to 4-desaminopyrimidine 







5.5.1 Chemistry Section 
The synthetic protocol is almost similar to what was used in Chapters 3 and 
4 for the synthesis of idelalisib derivatives. However, the structure of the 
inhibitors in this study is subtly different from those of idelalisib derivatives in 
that they utilize 4-aminopyrimidine hinge-binding motif instead of purine. 
The synthesis of the quinazolinone intermediate 77 (the upper part of the 
molecules) has been outlined previously in Chapter 3 and 4 (Scheme 3 and 
17). Therefore, this study focused on the synthesis of 4-aminopyrimidine 
derivatives (the lower part of the molecules) followed by the installation of 
these groups on the primary amine of quinazolinone intermediate 77. The 
synthetic route of each final product (210-222) was divided into three steps 
(Scheme 25): 1. amide coupling of pyrimidine carboxylic acid derivative 228 
with various aromatic and aliphatic amines (step a) 2. aromatic nucleophilic 




intermediate 77 (step d) 3. amination of 4-chloropyrimidine derivatives with 
ammonia (step e). 
Scheme 25. Synthesis of compounds (210-220) 
 
aReagents and conditions: (a) 2-bromo-1-ethyl pyridinium tetrafluoroborate (BEP) (1.1 equiv), 
DIPEA (3.2 equiv), DCM, rt, 24 h, yields 10-63%; (b) SOCl2, 80°C, 1 h, yields 90%; (c) 
NH4OH-dioxane (1:1, v/v), 50°C, 1h, yield 31%; (d) DIPEA (10 equiv), dioxane, 50°C, 30 min, 
yields 23-74%; (e) Cu2O (0.01 equiv), NH4OH-NMP (1:1, v/v), microwave, 50°C, 30 min, 
yields 9-57%. 
5.5.1.1 Amide coupling of pyrimidine carboxylic acid derivatives 
(step a) 
Our synthetic approach to the hinge-binding scaffold starting from 4,6-
dichloropyrimidine-5-carboxylic acid 228 (Scheme 25), which can react with 
several heteroaryl and alicyclic amines to provide the corresponding 
pyrimidine amides (230-238). A wide range of conventional amide coupling 
reagents (HATU, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 
benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate 




and ethylchloroformate) under different conditions were tested but generally 
no amide product was obtained (Table 58). The failure of this reaction is 
probably due to a combination of two factors. First, the carboxyl group in 4,6-
dichloropyrimidine-5-carboxylic 228 is highly sterically hindered as it is 
flanked by the two bulky chlorine atoms. Secondly, the heteroaryl amines are 
poor nucleophiles as the lone pair of electrons on the exocyclic nitrogen takes 
part in resonance stabilisation with the heterocyclic rings. 
Table 58. Screening of coupling reagents and bases for the synthesis of pyrimidine amide 
intermediates (230-238). 
 
Coupling reagent Baseb Convc(%) 
HATU DIPEA 0 
EDCI DIPEA 0 
PyBrop DIPEA 0 
PyBOP DIPEA 0 
Ethylchloroformate K2CO3 0 
bThe reactions were carried out in the presence of 3 equiv of base. 
cConversion was based on LC-MS analysis. 
These disappointing results stimulated us to search for more efficient coupling 
reagents. Li et al365,366 have reported the utilisation of a novel coupling 
reagent called 2-bromo-1-ethyl pyridinium tetrafluoroborate (BEP) 249 
(Figure 115) which was found to be the most efficient reagent for the 
preparation of a series of sterically hindered amino acids. Consequently, in 
this study, BEP was used as a reagent for the coupling of different heteroaryl 
amines with 4,6-dichloropyrimidine-5-carboxylic acid 228 in CH2Cl2 at RT, the 
corresponding N-heteroaryl amides derivatives (230-234) were obtained in 




carboxylic acid 228 was reacted with aniline, cyclopropylamine and 
cyclohexylamine to afford the corresponding amides 235, 236 and 237, 
respectively in modest yields (25-28%). 
 
Figure 115. The powerful coupling reagent 2-bromo-1-ethyl pyridinium tetrafluoroborate 249 
(BEP) used in the synthesis of N-heteroaryl amides 230-238365,366. 
Finally, the primary amide intermediate 239 was prepared via two successive 
reactions from the commercially available 4,6-dichloropyrimidine-5-carboxylic 
acid 228 (Scheme 25). First, compound 228 was refluxed in thionyl chloride 
to generate the corresponding acid chloride 229. This compound 229 thus 
obtained was treated with ammonium hydroxide (28% ammonia in water) in 
dioxane at 0 °C to cleanly afford the corresponding primary amide 239 (63% 
over two steps). It is noteworthy that the reaction temperature should be kept 
below 0 °C, to avoid the formation of the side product that results from 
aromatic nucleophilic substitution (SNAr) at the easily displaceable chlorine 
atoms in 4,6-dichloropyrimidine-5-carbonyl chloride 229.  
It should also be noted that in the amide coupling reaction of 4,6-
dichloropyrimidine-5-carboxylic acid 228 with different amines (step a), the 
use of protic solvent, in particular methanol, has to be avoided due to the high 
reactivity of dichloropyrimidine starting material 228 towards SNAr 
displacement, whereas one of the chlorine atoms can be easily replaced by 






Scheme 26. Hydrogen bond-catalysed nucleophilic substitution of a chlorine atom by a 
methoxy group typically happens when methanol is used as a reaction solvent or eluent in 
column chromatography 
 
5.5.1.2 nucleophilic substitution of the chlorine atom in 4,6-
dichloropyrimidine (230-239) (step d) 
The next step is the nucleophilic displacement of 4-chlorine of 4,6-
dichloropyrimidine derivatives (230-239) with the primary amine intermediate 
77 to provide the late-stage intermediates (240-248) (Scheme 25). The 
reaction was carried out in dioxane using DIPEA as a base at 50 °C to afford 
the monochloropyrimidine derivatives (240-248) in moderate to good yields 
(23-72%). In most cases, the reaction was finished in less than one hour, with 
both reactants completely consumed. Two reasons can be suggested for this 
high reactivity. First, the two chlorine atoms attached to the pyrimidine ring 
have a negative inductive effect, thus they reduce the electron density in the 
ring and makes it more susceptible to nucleophilic attack. Consequently, one 
of the two of the chlorine atoms was quickly displaced by the primary amine 
77. Second, the pyrimidine ring is more reactive towards nucleophilic 
substitution reaction than the other six-membered nitrogen heterocycles. 
John et al367 and Katritzky et al304 reported that halogen substituents in the 4-
position of the pyrimidine ring are more easily displaced than those in the 
pyrazine, pyridazine and pyridine (Figure 116).  
 
Figure 116. Comparison of the relative reactivity of the halopyrimidine to nucleophilic 




5.5.1.3 Amination of the late-stage 4-chloropyrimidine 
intermediates with ammonia (step e) 
The last step is the amination of the monochloropyrimidine intermediates 
(240-248) using ammonia to generate the final screening compounds (210-
220) (Scheme 25). The monochloropyrimidine-containing intermediates (240-
248) proved unreactive under the same conditions used for amination of 
dichloropyrimidine derivatives (230-239) in the previous step (Figure 117), 
due to the introduction of the electron-donating primary amine 77 into the 
pyrimidine ring in step d, which increases the electron density of the 
pyrimidine ring and makes it more resistant to nucleophilic attack than the 
4,6-dichloropyrimidine-containing compounds (Figure 117). 
 
Figure 117. Explain the difference in reactivity towards amino nucleophiles between 
dichloropyrimidine derivative (in step d) and monochloropyrimidine derivative (in step e) 
under the same reaction conditions. 
The failure of the monochloropyrimidine derivatives to undergo traditional 
nucleophilic aromatic substitution reaction prompted us to investigate the 
transition-metal mediated nucleophilic aromatic substitutions as an 




derivatives (240-248). Elmkaddem et al368 and Xu et al369 have reported the 
copper-catalysed amination of electron-rich aryl halides using ammonium 
hydroxide as the ammonia source in NMP. As a starting point, the reaction 
parameters such as types of copper catalysts, reaction temperature and time 
were screened. Compounds 241, 242 and 243 were allowed to react with 5 
mol% of cupper (II) oxide in a 50:50 NH3.H2O:NMP mixture at 80°C for 3 h 
under microwave condition, to give the corresponding aminopyrimidine 
products 211, 212 and 214, respectively, in moderate yields (20-37%) (Table 
59). However, in all the cases, a significant amount of unknown side product 
was detected and isolated. By combination of LC-MS and 1H NMR, the side 
product has been identified as the lactam analogues (250-252) (Table 59), 
resulting from the nucleophilic displacement of chlorine with hydroxyl derived 
from aqueous ammonium hydroxide.  
Although the desired products were obtained, the reaction conditions must be 
optimized to suppress the formation of the lactam side product, which 
possess similar polarity to the desired products and thereby making the 
purification process very challenging and time-consuming. 
The optimized reaction conditions involved the use of copper (I) oxide as a 
catalyst instead of copper (II) oxide. Xu et al369 reported that copper (I) oxide 
was found to be the most effective catalyst for the amination of aryl halides 
with ammonia. Accordingly, the reaction of several chloropyrimidine 
derivatives (240, 244- 249) with ammonium hydroxide was carried out in the 





Table 59. Reaction conditions and yields of the aryl amine products (210-212, 214-220) and 
the lactam side products (250-259) produced via Scheme 25. 
Copper 
catalyst 









3 h 80°C 211 (31%) 250 (14%) 
CuO 
 
3 h 80°C 212 (20%) 251 (26%) 
CuO 
 
3 h 60°C 214 (37%) 252 (14%) 
Cu2O 
 
3 h 50°C 210 (39%) 253 (8%) 
Cu2O 
 
3 h 50°C 215 (12%) 254 (7%) 
Cu2O 
 
30 min 40°C 216 (57%) 255 (6%) 
Cu2O  3 h 40°C 217 (23%) 256 (0%) 
Cu2O 
 
10 h 60°C 218 (5%) 257 (0%) 
Cu2O 
 
1 h 40°C 219 (38%) 258 (12%) 
Cu2O  1 h 40°C 220 (9%) 259 (0%) 
aAll reactions were carried out under microwave irradiation in NH3.H2O: NMP (1: 1). 
bThe cyclohexyl analogue 218 required a significantly longer reaction time to achieve 5% 
yield due to the lack of solubility of the starting monochloropyrimidine intermediate 247. 
cIsolated yield. 
and 40°C). Overall, the results presented in Table 59 show that the reaction 
catalysed by Copper (I) oxide occurred with much greater selectivity for 
formation of primary arylamine products (210, 215-220) versus lactam side 
products (253-259) than did reactions catalysed by copper (II) oxide. 
Moreover, it is also clear that the amount of the lactam side product 




is worth noting that the cyclohexyl-containing compound 218 was obtained in 
poor yield (5%), most likely due to the poor solubility of the substrate 247 in 
the reaction solvent (NH3.H2O: NMP, 1:1), factors such as high lipophilicity of 
247 (cLogP= 5.42) may be related to this poor solubility.  
5.5.2 Synthesis of aldehyde analogue 220 (reference)  
The synthesis of aldehyde-containing compound 220 to be used as a 
reference, started from 4,6-dichloropyrimidine-5-carboxaldehyde 260 
(Scheme 27). In the first step, nucleophilic attack of primary amine 77 on 
aldehyde 260 in the presence of DIPEA gave intermediate 261 in good yield 
(64%). Subsequent amination of 261 with Cu2O in NH4OH: NMP (1: 1, v/v) at 
40°C providing the corresponding arylamine 222 in 18% yield. 
Scheme 27. Synthesis of the aldehyde-containing analogue 222 and the two des-aminated 
analogues (226 and 227) 
 
aReagents and conditions: (a) DIPEA (10 equiv), dioxane, 50°C, 30 min, yield 64%; (b) Cu2O 
(0.01 equiv), NH4OH-NMP (1:1, v/v), microwave, 40°C, 60 min, yield 18%; (c) Zn powder (3 
equiv), acetic acid (10 equiv), THF, 70°C, 3 h, yield of 226 is 54%, yield of 227 is 33%. 
5.5.3 Synthesis of des-aminated analogues 226 and 227 
The final task was to synthesize the final compounds 226 and 227, which lack 




the late-stage 4-chloropyrimidine intermediates 240 and 241 were employed 
as substrates which would undergo a hydrodechlorination reaction. Catalytic 
hydrogenation is frequently selected as a method for the replacement of 
chlorine with hydrogen. However, treatment of 240 and 241 with hydrogen 
gas in the presence of a palladium catalyst failed to afford the final products 
226 and 227, probably because the pyrimidine rings of 240 and 241 are 
electron-rich systems due to the presence of the electron-donating alkylamino 
substituent, which made the rings resistant to the Pd-catalysed 
hydrodechlorination (see Section 5.5.1.3 and Figure 117).  
Therefore, an alternative synthetic route is required. Xingyong et al370 
reported a new method for replacing chlorine atoms of chlorinated 
heterocyclic compounds with hydrogens. In this method, the chlorinated 
heterocyclic compounds were treated with zinc catalyst and acetic acid in 
refluxing THF for 3 h to yield the corresponding dechlorinated products 
(Scheme 27). Under the same reaction conditions, the chloropyrimidine 
derivatives 240 and 241 were converted to the corresponding dechlorinated 
analogues 226 and 227 in isolated yields of 54% and 33%, respectively. It is 
believed that the role of the acetic acid was simply to provide a source of 
hydrogen (Scheme 28). 
Scheme 28. Acetic acid reacts with zinc to produce zinc acetate and hydrogen gas necessary 
for hydrodehalogentation reaction 
Zn + 2CH3COOH                      (CH3COO)2Zn  +  H2  
5.5.4 Biology Section 
Herein, the biological activity of the series of 4-aminopyrimidines (211-220) 
was measured against PI3K δ enzyme. Furthermore, the chloropyrimidine 




for their inhibitory activity against PI3K δ. The chloropyrimidine intermediates 
(230-239) were screened to assess the effect of replacing the hydrogen bond 
donor (amino group) with a bulky non-hydrogen bonding atom (chlorine) on 
PI3K δ activity. On the other hand, although the lactam derivatives (250-259) 
have emerged as side products during synthesis of the desired 
aminopyrimidine products, they still possess a hydrogen bond donor (lactam 
N-H) and acceptor (lactam carbonyl group) pair at the hinge binding group, 
which enable them to make a bi-dentate contact to the hinge region. Thus, 
these compounds have been evaluated for inhibitory activities against PI3K 
δ.  
Key elements of this experimental design including primary screening of all 
compounds against PI3K δ at 1 μM and 500 nM final compound 
concentrations, then the full IC50 of the active compounds would be 
determined to confirm their inhibitory activity. In each assay, the FDA-
approved idelalisib (8) was included for direct comparison. 
5.5.4.1 Single-concentration screening assay 
5.5.4.1.1 Initial screening (1 μM final concentration) 
For this experiment, a set of 8 compounds were tested, including 3 
aminopyrimidine derivatives (211, 212 and 214), 3 chloropyrimidine 
derivatives (241, 242 and 243) and 3 lactam side products (250, 251 and 252) 
in addition to idelalisib (8), which represent compounds that were prepared 
when this assay was performed. All compounds were tested at a single 
concentration (1 μM) for their inhibitory activity against PI3K δ (Table 60). 
Furthermore, the PI3K δ selectivity of these compounds was assessed by 





Table 60. % inhibition of PI3K δ activity at 1 μM and 500 nM of compounds (8, 210-212, 214-
220, 222, 226, 227, 241- 243 and 250- 252). 
Compd R1 R2 
Inhibition of PI3K δa 
% Inhibition 
at 1 μM 
% Inhibition 
at 500 nM 
Idelalisib (8) - - 76.2 79.9 
210 
 
-NH2 n/a 77.3 
211 
 
-NH2 56.0 1 
212 
 
-NH2 66.8 53.0 
214 
 
-NH2 58.5 54.7 
215 
 
-NH2 n/a 75.1 
216  -NH2 n/a 69.5 
217  -NH2 n/a 64 
218 
 
-NH2 n/a 87.7 
219 
 
-NH2 n/a 78.1 
220 -NH2 -NH2 n/a 69.4 
222 -H -NH2 n/a 81.9 
226 
 
-H n/a 11.7 
227 
 
-H n/a 4.0 
241 
 
-Cl 14.1 n/a 
242 
 
-Cl 5.73 n/a 
243 
 
-Cl 24.4 n/a 
250 
 
-OH 12.2 n/a 
251 
 




Compd R1 R2 
Inhibition of PI3K δa 
% Inhibition 
at 1 μM 
% Inhibition 
at 500 nM 
252 
 
-OH 20.9 n/a 
aPI3K δ % inhibition was determined at 1μM and 500 nM compound concentration. n/a means 
that the compound was not tested in this assay.  
Chapter 2) was selected as a reference compound in this selectivity study, 
since it is a potent inhibitor of PI3K α (IC50 value of 44 nM) (see Section 2.1 
in Chapter 2).  
Encouragingly, all three aminopyrimidine derivatives (211, 212 and 213) 
showed significant inhibitory activity against PI3K δ (66.9%, 56.0% and 
58.5%, respectively), nearly equipotent to the positive control of idelalisib (8) 
(76.2%) (Table 60). On the other hand, the PI3K δ selectivity of the 
aminopyrimidine derivatives (211, 212 and 213) over PI3K α was also 
investigated. Interestingly, the two pyrazole regioisomers 211 and 212 
showed weak activity against PI3K α (34.5%, 33.3%, respectively) at 1 μM 
concentration, whilst the thiadiazole analogue 213 provided no inhibition 
(0%). In contrast, the reference compound (pictilisib 4) at 1 μM led to 81.9% 
inhibition of PI3K α activity. These results suggest that the three 
aminopyrimidine derivates exhibit a high degree of PI3K δ selectivity. 
In contrast to aminopyrimidines (211, 212 and 213), their chloropyrimidine 
analogues 241, 242 and 243 displayed weak inhibitory activities (5.7%, 14.1% 
and 24.4%, respectively) against PI3K δ (Table 60). This analysis revealed 
that substitution of the hydrogen bond donor (amino group) with a bulky atom 
(chlorine) resulted in a large drop in PI3K δ potency. These findings clearly 
support the hypothesis (see Section 0) that replacement of an amino group 




clash with the hinge residues, resulted in significant loss of the PI3K δ 
inhibitory activity. Docking study of compound 243 was performed to further 
strengthen this hypothesis (see Figure 113b), it showed that the pyrimidine 
ring of compound 243 did not form any hydrogen bond with Val828 and Glu826 
in the hinge region, which could be reasoned by the steric clash that might 
occur between the chlorine atom and the backbone amide of Val828. 
Furthermore, the three lactam side products (250, 251 and 252) exhibited < 
30% inhibitory activity (250:12.2%, 251: 28.1%, and 252: 20.9%, respectively) 
(Table 60). Such findings were surprising, given the fact that the hinge binding 
group of these compounds does contain the hydrogen bonding 
donor/acceptor pair, typical for kinase inhibitors. It was proposed that the 
lactam side products failed to hydrogen bond with the hinge region of PI3K δ, 
This fact was attributed to the inversion of the positions of the hydrogen-bond 
donor/acceptor in contrast to their aminopyrimidine analogues (Figure 118a), 
whereas the hydrogen bond donor and acceptor of the lactam side products 
(250, 251 and 252) are oriented in the opposite direction to the hydrogen bond 
donor residue (Val828) and acceptor residue (Glu826) in the hinge region 
(Figure 118b). Furthermore, the lactam carbonyl oxygen of (250, 251 and 
252) is oriented towards the backbone carbonyl of Glu826, which might result 
in the repulsive electrostatic interaction (Figure 118b). 
Based on the preliminary results described above, the aminopyrimidine-
containing derivatives were the only compounds which showed greater than 
50% inhibition against PI3K δ at 1 μM, coupled with a good target selectivity, 
thus they were selected for further more detailed screening (500 nM) to 





Figure 118. a) Schematic representation of the ligand binding interactions in the hinge region 
of PI3K δ. The hydrogen bond donors and acceptors are highlighted in yellow and green, 
respectively. a) the aminopyrimidine group forms two hydrogen bonds to the hinge backbone. 
b) In the pyrimidone ring of lactam side products the positions of hydrogen-bond donor and 
acceptor are inverted, thus lactam side products do not form hydrogen bonds with the hinge 
region. Moreover, electronic repulsion may occur between the lactam oxygen and the 
backbone carbonyl oxygen of Glu826. 
5.5.4.1.2 Initial screening (500 nM final concentrations) 
In the second preliminary screening, all the aminopyrimidine analogues (210- 
212 and 214- 220) and the 2 des-aminated analogues (226 and 227) were 
tested for their inhibitory activity against PI3K δ at a single-concentration (500 
nM) (Table 60). 
Quite strikingly, the cyclohexyl analogue 218 showed the most inhibitory 
activity in this series (87.7%), which was slightly higher than that of idelalisib 
(8) (79.9%). Although it is too early to discuss the activity of this compound, 
to the best of the authors’ knowledge, this is the first preliminary study to 
suggest that extension of saturated group (cyclohexyl) into the affinity pocket 
resulting in high PI3K δ potency, this is due to the fact that the affinity pocket 
has been traditionally occupied by aryl or heteroaryl groups. 
Furthermore, pyrazole (210: 77.3%), isoxazole (215: 75.1%) phenyl (216: 
69.5%) aldehyde (222: 81.9%), quinoline (219: 78.1%) and amide 




idelalisib (8) (79.9%). In addition, the three compounds, 212 (53.0%), 214 
(54.7%) and 217 (64.0%) were found to be slightly less potent than idelalisib 
(8) (79.9%) (Table 60).  
On the other hand, replacement of 1-methylpyrazol-4yl group of 210 with 1-
methylpyrazol-3-yl resulted in the regioisomeric analogue 211 (Figure 119). 
Quite surprisingly, an interesting difference in the PI3K δ inhibitory activity 
was observed between the two regioisomeric pyrazoles (210: 77.3%, 211: 
1%) (Table 60). This result indicates that variation in the position of the 
pyridine-type nitrogen atom (green circle in Figure 119) in the pyrazole ring 
affects the PI3K δ activity. It was hypothesized that the unexpected very poor 
activity (1%) of 1,4-pyrazole regioisomer 211 is attributed to the electrostatic 
repulsion that might occur between the pyridine-type nitrogen atom of 
pyrazole ring and the nearby residues in the affinity pocket. This hypothesis 
was suggested based on a relevant example reported by Patel et al155. In 
their research for novel and selective PI3K δ inhibitors, Patel et al155 
synthesized the quinazolinone derivatives 203 and 262 bearing pyrazine and 
pyridazine rings, respectively, that extend into the affinity pocket (Figure 120). 
These two regioisomeric compounds were compared on the basis of their 
PI3K δ activity. It was found that the pyrazine analogue 203 is 600-fold more 
potent than the corresponding pyridazine counterpart 262 (Figure 120). The 
author hypothesized that the electrostatic repulsion between the pyridazine 
nitrogen atom (green circle in Figure 120) and the nearby residues that line 





Figure 119. A comparison of the inhibitory activity between 1,4- and 1,3-pyrazole 
regioisomers (210 and 211, respectively) against PI3K δ at a single concentration (500 nM). 
Only 1,4-isomer 210 has PI3K δ inhibitory activity while 1,3-isomer 211 is inactive. 
 
Figure 120. A comparison of the PI3K δ potency between the two regioisomers (203 and 262 
reported by Patel et al155). The pyrazine analogue 203 is 600-fold more potent than the 
corresponding pyridazine counterpart 262. 
Unexpectedly, compounds 226 and 227 which do not possess a hydrogen 
bond donor (amino group) at the hinge-binding motif show very weak 
inhibitory activity at 500 nM (11.7 and 4%, respectively) (Table 60). Such 
findings are not consistent with the previously mentioned hypothesis (see 
Section 0) that the presence of hydrogen bond donor (4-NH2) at the hinge 
binding moiety is preferred but it is not essential for PI3K δ inhibition and could 
be replaced with a hydrogen atom, since the inhibitors are still able to form a 
single hydrogen bond with the hinge region through the N-3 position of the 
pyrimidine ring. Taken together, these results demonstrated that the double 
hydrogen bonds made by the 4-NH2 and N-3 of 4-aminopyrimidine hinge 
binder can both contribute to the PI3K δ potency of this series, indicating that 




To sum up, among the 12 tested compounds, most of compounds displayed 
considerable PI3K δ inhibitory activity. Especially the cyclohexyl-containing 
analogue 218 gave the highest level of PI3K δ inhibition with 87.7%. 
5.5.4.2 IC50 determination 
The eight most active compounds (210, 212, 214-220 and 222) identified from 
single-point screening (500 nM), would be tested further in a dose-response 
assay to determine their IC50 values. However, the inhibitor screening assay 
which is carried out by researchers at Monash University was delayed due to 
COVID-19. Thus, the IC50 data for the reported compounds were not included 





Chapter 6 General conclusion and 
recommendations for future work 
6.1 General conclusion 
This research project focused on PI3K δ enzyme, which is predominately 
expressed in leukocytes where it plays an important physiological role in the 
activation, proliferation and survival of immune cells (B- and T-cells). 
However, dysregulation of PI3K δ pathway leads to the development of 
different types of haematological malignancies such as CLL, FL and SLL. 
Furthermore, aberrations in PI3K δ pathway have been implicated in the 
aetiology of several autoimmune diseases such as rheumatoid arthritis and 
systemic lupus erythematosus. Hence, inhibition of PI3K δ provides a 
promising therapeutic opportunity to treat different types of blood cancer and 
autoimmune diseases. Accordingly, the aim of this research was to discover 
and develop novel orally active small molecule inhibitors of PI3K δ, it is 
important for these inhibitors not only to display potent PI3K δ inhibition, but 
also to exhibit high selectivity toward PI3K δ in order to prevent off-target 
adverse events resulting from non-selective inhibition of PI3K α, β and Ɣ. 
Currently, there is only one FDA-approved selective PI3K δ inhibitor named 
idelalisib (8), which is used for the treatment of three types of haematological 
malignancies including CLL, relapsed FL and relapsed SLL. However, 
idelalisib (8) tends to cause serious side effects which encompass: diarrhoea, 
serious hepatotoxicity, colitis, serious pneumonitis and neutropenia, which 
frequently lead to idelalisib (8) dose reduction and treatment discontinuation, 
indicating a high need for novel, equieffective and less toxic selective PI3K δ 




This thesis reports the design and synthesis of 92 novel compounds belong 
to the two classes of selective PI3K δ inhibitors: 1) flat-shaped inhibitors, 2) 
propeller-shaped inhibitors. These two classes of inhibitors differ in their 
binding modes in the binding site of PI3K δ. All the compounds reported in 
this study were biologically evaluated for their inhibitory activity against PI3K 
δ. Furthermore, the selectivity of these compounds was tested for inhibition 
of PI3K δ versus other class I PI3K isoforms (PI3K α, β and Ɣ). 
Chapter 2 focused on flat-shaped PI3K δ inhibitors, in which the non-selective 
PI3K inhibitor pictilisib (4) provided a new starting point for a lead optimisation 
programme, which resulted in the synthesis of 41 novel thienopyrimidine 
derivatives with potent activity against PI3K δ (IC50 values ranging from1.1 to 
44 nM). In addition, upon comparison with the lead compound pictilisib (4), all 
derivatives elicited far superior selectivity profile for PI3K δ over the other 
class I PI3K isoforms. Two regions of PI3K δ binding site were responsible 
for conferring high PI3K δ potency and selectivity of the reported inhibitors. 
First, tryptophan shelf which defines the region of space located between 
δTrp760 and δThr750 (Figure 121), this region is exclusively present in PI3K δ, 
but absent in PI3K α, β and Ɣ. In this project, the tryptophan shelf was 
targeted using aliphatic heterocycles, which were able to make C-H/pi 
interactions with Trp760. Secondly, the non-conserved residues that surround 
the affinity pocket were exploited to aid PI3K δ selectivity. These residues 
made hydrogen bond networks with the conserved residues lining the affinity 
pocket. This new hydrogen bond network was only accommodated in PI3K δ, 
but was not accommodated in the remaining isoforms. The SAR research for 




series indole> indazole≈ phenol, whereas the PI3K potency improved in 
series phenol> indole≈ indazole.  
 
Figure 121. Crystal structure of murine PI3K δ (PDB code 2WXP) with pictilisib (4) bound. 
Highlights the shallow dimple, termed the tryptophan shelf, which is exclusively found in the 
PI3K δ isoform and not in the other three isoforms160. The side chain (4-methanesulfonyl-
piperazine-ylmethyl group) of pictilisib (4) points towards the solvent channel, where it does 
not play a significant role in the binding182. Thus, in Chapter 2, structural modifications on 
pictilisib (4) were conducted to develop inhibitors capable of accessing the tryptophan shelf. 
These modifications resulted in an improved PI3K δ potency and selectivity.  
Among this series of 41 PI3K δ inhibitors, the best selective compound was 
48, which bears a 4-fluoropiperidine substituent extending towards the 
tryptophan shelf and an indole ring occupying the affinity pocket. Additionally, 
in silico screening for the inhibitors in this chapter was performed to determine 
the drug-like physiochemical properties, it was found that compound 48 had 
more optimal physiochemical and ADME properties for oral drugs, than the 
other analogues and the lead compound pictilisib (4). Taking together, indole 
48 is a promising potential drug for the treatment of different types of blood 
cancers (such as leukaemia and lymphoma) and autoimmune diseases (such 
as rheumatoid arthritis and asthma).  
Chapter 3, 4 and 5 focused on propeller-shaped PI3K δ inhibitors, which bind 
to PI3K δ in a mode different from that of flat-shaped inhibitors. In this study, 
the only FDA-approved selective PI3K δ inhibitor idelalisib (8) was used as a 




potency. In this study, idelalisib (8) was first synthesised and tested in 
enzymatic assay and found to inhibit the PI3K δ activity with IC50 of 11 nM, 
meaning there was substantial room for improvement of potency to 1 nM or 
even sub-nanomolar range. The crystal structure (PDB code 4XE0) revealed 
that idelalisib (8) bound to PI3K δ at three interaction points (specificity 
pocket, hinge region and hydrophobic region II), leaving the fourth region 
(affinity pocket) unexploited. Thus, a structure-based inhibitor design program 
was conducted, focused on increasing the size of idelalisib (8) by adding a 
new substituent to access the unoccupied affinity pocket. This strategy is 
known as drug extension, which may result in a significant improvement in 
the PI3K δ binding affinity. 
Hence, in Chapter 3, structure-based drug design was conducted by 
introducing hydrogen bond donor or/and acceptor substituent into the 
exocyclic amine of the lead compound idelalisib (8) (Figure 122). After 
overcoming major synthetic challenges, a series of new exocyclic N-
substituted idelalisib derivatives were finally obtained. Unfortunately, all 
compounds were inactive or far less active than idelalisib (8) (Figure 122). 
According to the results of Chapter 3, it was proposed to use an alternative 
attachment site to connect the new substituent to idelalisib (8). Based on the 
examples of PI3K δ inhibitors reported in the literature, it was suggested that 
substitution at the N-7 site of purine provided the best conventional extension 
strategy to position the binding group into the unoccupied affinity pocket 
(Figure 122), this was because the N-7 atom of the purine was oriented 





Figure 122. The selective PI3K δ inhibitor idelalisib (8), highlighting the positions of idelalisib 
(8) for the extension of the binding group into the unoccupied affinity pocket. SAR studies 
discussed in Chapter 3, reveal that substitution of idelalisib (8) on the exocyclic amine (in 
green) results in loss of PI3K δ activity. On the other hand, SAR studies discussed in Chapter 
4, reveal that the addition of the extra substituent to the N-7 position of purine (in cyan) 
produces a detrimental effect on the PI3K δ potency. 
chapter, series of novel N-7 substituted purines were synthesized and tested 
for their PI3K δ potency and selectivity. Disappointingly, all compounds 
exhibited weak or no activity against PI3K δ with almost 200-2500-fold less 
active than idelalisib (8). It was reasoned that the steric clash between the 
newly added substituent, and the isoleucine (Ile825) gatekeeper (Figure 123) 
could account for the substantial loss of PI3K δ potency observed across all 
compounds of Chapter 3 and 4. The cause of the steric clash may be 
attributable to high flexibility and/or tetrahedral geometry of the alkyl linker 
connecting the hinge-binding scaffold to the terminal functional group (Figure 
123). 
In light of the findings in Chapter 3 and 4, it was decided to use a planar or 
linear linker, to connect between the affinity pocket-binding group and the 
purine hinge binding moiety (Figure 134), in order to avoid the steric contact 




            
Figure 123. Crystal structure of murine PI3K δ (PDB code 4XE0) shows that the gatekeeper 
residue Ile825 (represented by a space-filling model) located at the entrance to the affinity 
pocket, where it limits accessibility to this pocket. Thus, steric clash is highly likely to occur 
between the gatekeeper Ile825 and compounds covered in Chapter 3 and 4, due to the 
tetrahedral geometry of the alkyl linkers, connecting the hinge-binding scaffold to the affinity 
pocket binder. 
 
Figure 134. The use of linkers with planar or linear geometry allows the inhibitor to enter into 
the affinity pocket, as these linkers are able to traverse the gatekeeper Ile825 residue and 
prevent the steric clash. 
targeting the affinity pocket contained either a planar aryl or linear acetylene 
group as a linker. Thus, a planar amide group was selected as a novel spacer 
to develop patentable PI3K δ inhibitors (Figure 135). Furthermore, the 
disappointing results obtained from Chapter 3 and 4 encouraged us to 
conduct structural optimisation of the hinge binding scaffold by replacing the 
Tetrahedral alkyl 
linker could not 




Ile825 to reach 
the affinity 
pocket. 
Planar and linear linkers can pass the 
narrow channel embraced by 
gatekeeper Ile825 and reach the 




purine ring with a 4-aminopyrimidine ring (Figure 135), which can be easily 
decorated at position 5 with a linker attached to affinity pocket-binding groups 
(Figure 135). 
 
Figure 135. Structural modifications of idelalisib (8) were performed in Chapter 5, resulted in 
the development of new amide containing 4-aminopyrimidine derivatives with potent 
inhibitory activity against PI3K δ in the primary screening assay (1 μM and 500 nM single 
concentration compound screening). 
In Chapter 5, three series of pyrimidine derivatives were synthesized and 
tested for the in vitro inhibition of PI3K δ at a concentration of 1 μM and 500 
nM. The three series include 1) 13 compounds belong to 4-chloropyrimidine 
derivatives, 2) 7 compounds belong to 4-pyrimidinone derivatives, 3) 13 
compounds belong to 4-aminopyrimidine derivatives. The former two series 
did not display any activity versus PI3K δ at concentration as high as 1 μM. 
These findings clearly indicate that the presence of a hydrogen bond donor (-
NH2) at position 4 of the pyrimidine ring is required for the inhibition of PI3K 
δ. While the third series of 4-aminopyrimidine derivatives showed significant 
inhibitory activity against PI3K δ at a single concentration of 1 μM and 500 
nM. Interestingly, 7 compounds from this series exhibited equal or even 
superior potency to idelalisib (8) towards PI3K δ. For example, cyclohexyl 
derivative 218, which was the most potent inhibitor in this series of 4-
aminopyrimidines, showed higher PI3K δ inhibitory activity (87.7%) than 




suggested that the use of an amide group as a linker represent a promising 
and novel strategy in the development of new, highly potent PI3K δ inhibitors, 
with the potential to treat different types of blood cancers and autoimmune 
diseases. The second screening step aimed to determine the IC50 of 13 
compounds, belonging to this series of amide bearing 4-aminopyrimidines, 
that exhibited significant inhibition toward PI3K δ at 1 μM and 500 nM. 
6.2 Recommendations for future work  
Although many of 92 compounds tested in this thesis potently inhibited PI3K 
δ, recommendations for future research have been made to develop more 
potent and selective PI3K δ inhibitors with improved physiochemical profile. 
Furthermore, this future study also suggested that PI3K δ could serve as a 
promising therapeutic target for treatment of COVID-19-associated acute 
respiratory distress syndrome (ARDS).  
6.2.1 Flat-shaped PI3K δ inhibitors (Chapter 2) 
Future studies will be aimed at the design and synthesis of more novel flat-
shaped PI3K δ inhibitors, focusing on modifications of substituents that 
extend toward tryptophan shelf and affinity pocket to improve PI3K δ activity 
and selectivity.  
6.2.1.1 Tryptophan shelf 
As previously mentioned (see Section 2.5.3 of Chapter 2), it was believed that 
the introduction of fluorine atom into the piperidine ring enhanced the PI3K δ 
activity and selectivity (Table 62) potentially by attracting the electron density 
away from the piperidine ring and made the piperidine hydrogens more acidic 




in the most selective PI3K δ inhibitor 48 among the thienopyrimidine series 
(see Figure 49 (Plot of PI3K δ activity as a function of PI3K δ isoform 
selectivity (vs PI3K α) in Chapter 2). 
 
Table 62. Biological evaluation and isoform selectivity for PI3K δ for compounds pictilisib (4), 
idelalisib (8) and fluoropiperidine derivatives 48 and 49. 
Marvin, C et al371 have measured and tabulated the inductive substituents 
constant for many hundreds of substituent groups, which have higher and 
lower inductive substituent constants than fluorine atom. Monofluorinated 
analogue 48 with its excellent activity and selectivity profile will be used as a 
basis of comparison to measure any increase or decrease in the inhibitory 
activity that may be brought about by replacement of fluorine with another 
atom or group. The objective of this future research is to design and 
synthesize some novel piperidine analogues, which have electron 
withdrawing substituents that are stronger or weaker than fluorine on their 





Compd R1 PI3Kδ δ/α δ/β δ/Ɣ 
Pictilisib (4) - 11 4 20 20 
Idelalisib (8) - 11 14000 56 56 
48 
 
4.4 506 636 161 
49 
 





Table 63. Inductive substituent constants for many substituent groups, it also highlighted the 
biological activity of 4-fluoropiperidine 48 and 4-unsubstitutedpiperidine 37 derivatives. 
Compd X- Inductive Substituent 
Constant 
PI3K δ potency 
IC50 (nM) 
37 H- 0.00 11 
263 CH3- -0.05  
264 MeO- 0.25  
265 CF3- 0.42  
266 Cl- 0.47  
48 F- 0.52 4.4 
267 CN- 0.58  
268 NH3+ 0.60  
269 MeNH2+- 0.60  
270 MeSO2- 0.61  
271 SCN- 0.61  
272 Me2NH+- 0.70  
273 Me3N+- 0.93  
274 NO2- 0.76  
electron-withdrawing groups stronger than fluorine will provide higher PI3K δ 
activity and selectivity than compound 48 (Table 63), while those having 
electron-withdrawing groups weaker than fluorine will provide less PI3K δ 
activity and selectivity than compound 48 (Table 63). This study may provide 
the rationalization for the difference in PI3K δ activity of analogues having 
different substitution on the piperidine ring. 
The second approach is to replace the piperidine ring with the six-membered 










are in general more acidic than the hydrogens on saturated sp3-carbon 
atoms, thus unsaturated heterocycles, such as pyridine and pyrazine could 
make stronger C-H/pi interactions than their saturated counterparts piperidine 
and piperazine. Targeting the tryptophan shelf with an aryl group (phenyl) 
was not a novel idea and had been done before in this project (compounds 
34 and 35 in Chapter 2) as well as by Terstiege et al220 group (compound 67 
in Chapter 2)220, where the phenyl derivatives showed weaker activity in 
contrast to the saturated heterocycles such as piperidine and morpholine, 
however, in this study the tryptophan shelf will be targeted with aromatic 
heterocycles, which are generally more electron deficient compared to phenyl 
ring (Figure 136)372,373, and thus they have more acidic protons and able to 
make stronger C-H/pi interactions with Trp760 in contrast to the benzene ring. 
To the best of authors’ knowledge, unsaturated heterocycles have not 
previously been used to explore the tryptophan shelf.  
 
Figure 136. The local and total pi-deficiency of the four six-membered unsaturated 
heterocycles showed that they are more electron deficient than benzene373,374. The pi-
deficiency values of benzene were taken from a study of ‘Anion-π interactions: from concept 
to application’ conducted by Xiaonan Kan et al374, while the pi-deficiency values of the four 
six-membered unsaturated heterocycles were taken from a book ‘The Chemistry of 
Heterocycles’ written by Vishnu Ji Ram et al375.  
6.2.1.2 Affinity pocket  
6.2.1.2.1 Investigate the role of the hydrogen bond donor (hydrogen 
at C-2 on indole) in PI3K δ selectivity. 
As pointed out in Chapter 2 (see Section 2.5.1 on pages 63 to 66), Sutherlin 
et al160 hypothesized that the high PI3K δ selectivity of indole analogues was 




hydrogen bond network with Tyr813 and His909 that could be only 
accommodated in PI3K δ (see Figure 34 in Chapter 2). Although Sutherlin’s 
hypothesis was accepted by many researchers144, there is an element of 
doubt about its validity. The basis of this doubt is on the evidence presented 
in the Safina et al161study, which was published two months before Sutherlin 
et al paper160, as one of the findings to emerge from Safina et al161study was 
that the 2-methylindole derivative 63, which did not have a proton (hydrogen 
bond donor) at position 2 of the indole ring, showed similar PI3K δ selectivity 
profile to its 2-unsubstituted indole analogue 62 (Table 64), indicating that the 
absence of the hydrogen bond donor (C-2 proton) did not have impact on the 
selectivity for PI3K δ over the remaining isoforms, which was not consistent 
with Sutherlin et al160 theory. 
 
Table 64. Biological evaluation and isoform selectivity for PI3K δ for compounds 62 and 63 
reported by Safina et al161. 
compd X PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/ Ɣ 
62161 H 1.8 129 104 1444 
63161 CH3 1.1 122 101 715 
Therefore, it was decided to further test Sutherlin et al160 hypothesis in the 
best selective compound 48 reported in the thienopyrimidine series by 
removing the hydrogen bond donor, this can be achieved by the substitution 
of acidic hydrogen at C-2 position of the indole ring with another atom or group 




option due to its small Van der Waals radius which is slightly higher than that 
of hydrogen (1.47 and 1.20 A°, respectively)376,377, The use of small Van der 
Waal atoms is to eliminate the possibility of steric clash with the binding site 
that could arise when bulkier atoms or groups are used, if the 2-flouorindole 
analogue 275 was more potent or equipotent to the 2-non-substituted indole 
derivative 48 (Table 65), then the Sutherlin et al172 theory about the high PI3K 
δ selectivity of indole analogues was not true. 
The synthesis of 2-fluoroindole derivatives is not widely known, this has been 
attributed to challenges associated with the synthesis of such compounds, 
however, Ichikawa et al378 developed a new two-step method to synthesize 
2-fluoroindole-4-boronic acid pinacol ester 278 From o-tosylamino-β,β-
difluorostyrene derivative 276 (Scheme 29), which can be utilised to 
synthesize the 2-fluoroindole-containing compound 275 (Scheme 30). 
 
Table 65. Biological evaluation and isoform selectivity for PI3K δ for compound 48 and 
suggested compound 275, which is aimed to be synthesised in the future. 
compound R1 PI3K δ IC50 (nM) 
Isoform selectivity 
δ/α δ/β δ/γ 
48 
 
4.4 506 636 161 
275 
 






Scheme 29. Synthesis of 2-Fluoroindole -4-boronic acid pinacol ester 278 reported by 
Ichikawa et al378 
 
aReagents and conditions: (a) sodium hydride, DMF, 70°C, 23 h, yields 73%; (b) KOH, THF, 
ethanol, rt, 2h, yields 53%.  
Scheme 30. Synthesis of the proposed 2-fluoroindole based compound 275 
 
aReagents and conditions: (a) Na2CO3, EtOH, bis(triphenylphosphine) palladium (II) chloride, 
microwave 125 °C, 3 h. 
6.2.1.2.2 Investigate the correlation between the hydrogen bond 
donor (phenolic proton) acidity and PI3K δ potency  
The next step in the future work will be on the phenol derivative 49, which 
was emerged to be the most active compound in the whole series, with 10 
times more active than the clinically approved idelalisib (8) (Table 62). It has 
already been mentioned that the high PI3K δ activity of the phenol derivatives 
in contrast to their indole and indazole counterparts might be due to the 
formation of stronger hydrogen bond with Lys779 and Asp787 in the affinity 
pocket (Figure 137b), because phenol is a stronger hydrogen bond donor. 
Further research will attempt to modify the strength of hydrogen bond to 
improve the PI3K δ activity by introducing an electron-withdrawing group into 
the para-position to the OH group (Table 66). The ortho substitution will be 
avoided to prevent the formation of intramolecular hydrogen bond which will 





a)                                                b) 
   
Figure 137. a) Compound 49, highlights the phenol group that bound to the affinity pocket. 
b) Compound 49 docked into (K802T) PI3K Ɣ (generated from PDB code 4EZJ). Dashed 
pink lines represent the proposed charge-enhanced hydrogen bonds. 
 
Table 66. Biological evaluation and isoform selectivity for PI3K δ for compound 49 and 
suggested compounds (280- 284), which are aimed to be synthesised in the future.  
compd R1 








δ/α δ/β δ/γ 
49 
 
1.1 16 505 32 9.89 
280 
 
? ? ? ? 7.15 
281 
 
? ? ? ? 7.97 
282 
 
? ? ? ? 7.83 
283 
 
? ? ? ? 7.81 
284 
 




PI3K δ activity379. The strength of the hydrogen bond depends on the value 
of pKa, therefore as the acidity of the phenol increases the hydrogen bond 
donating ability also increases. Accordingly, the aim of this study is to 
synthesize numerous phenol derivatives with a powerful electron-withdrawing 
group in para-position to a hydroxy group. (Table 66). 
6.2.2 Propeller-shaped PI3K δ inhibitors (Chapter 5)  
6.2.2.1 Escape from flatland 
To the best of authors’ knowledge, the chemical structures of the vast majority 
of the reported PI3K δ inhibitors contain 4 to 5 aromatic rings144,154,155,173, thus 
they are more planar and contain less fraction of sp3 carbons in contrast to 
other drugs380. Ritchie et al381 mentioned that most of the compounds that 
contain more than 3 aromatic rings exhibit poor aqueous solubility, resulting 
in deterioration in compound developability and increased risk of attrition in 
drug development382,383. By contrast, increase in the Fsp3 content by 
replacement of aromatic rings with aliphatic rings leads to an increase in the 
aqueous solubility and reduction in lipophilicity, which positively affects the 
developability of drug candidates357,381,384. Furthermore, Lovering et al357 and 
Hetal et al385 reported that compounds with enriched sp3 carbon content tend 
to possess out-of-plane substituents, which can lead to additional PI3K δ-
ligand interactions357,386.  
Consequently, the future study will be focused on the development of PI3K δ 
inhibitors with desirable drug properties, by limiting the number of aromatic 
rings and increasing the Fsp3 content, this approach is known as escape from 
flatland. The suggested compounds comprise a hinge binding scaffold (4-




cyclopropyl linker (Figure 138). The utilisation of the saturated cyclopropyl as 
a linker represents an alternative approach to the widely used aryl and 
acetylene groups (see Section 5.2.1 and 5.2.2 in Chapter 5). The 
cyclopropane group is unique among alicycles for having a planar geometry, 
like aryl groups387, which enables it to avoid the steric clash with the 
gatekeeper Ile825 and allows the functional group to access the affinity pocket. 
As far as is known, this is the first study employing a saturated group as a 
linker in the design of PI3K δ inhibitors, therefore, it can provide an advantage 
in term of novel intellectual property. Furthermore, compared with the phenyl 
linker, which is widely applied for the design of PI3K δ inhibitors, the 
introduction of cyclopropyl linker leads to the superior physiochemical 
properties such as a smaller molecular weight, higher Fsp3 carbons, greater 
aqueous solubility and lower lipophilicity (Figure 138). 
 
Figure 138. Replacement of the phenyl linker with a bioisosteric cyclopropyl group can 





In addition to cyclopropane group, there are other saturated rings have 
emerged as bioisosters for phenyl rings due to their rigidity, planarity and size, 
suggesting that they might be utilized as a spacer between the hinge binder 
and affinity pocket-binding moiety. These groups include cubane, 
bicyclopentane and bicyclooctane (Figure 139)388, which might have a 
beneficial impact on the future design of patent-free PI3K δ inhibitors with 
high 3-dimensionality. 
 
Figure 139. Bioisosteric replacement of benzene ring with three saturated bioisosters 
(cubane, bicyclo[1,1,1]pentane, bicyclo[2,2,2}octane) to create patent-free molecules with 
improved physical properties (solubility and permeability)388. 
Moreover, the phenyl group, that extends into the hydrophobic region II will 
also undergo structural modifications by bioisosteric replacement with a 
saturated group. The objective of this modification is to further improve the 
physicochemical properties of the new series of PI3K δ inhibitors. Somoza et 
al180 reported that the phenyl moiety of idelalisib (8), that inserts deep into the 
hydrophobic region II, only engaged in hydrophobic interactions with the side 




phenyl ring with a cyclopropyl would maintain potency at PI3K δ, since the 
latter group, like the former, is also capable of making hydrophobic 
interactions. This is supported by evidence from Novartis study335, which 
showed that compound 286 with a cyclopropyl group oriented towards the 
hydrophobic region II displayed equipotent activity against PI3K δ, compared 
with its phenyl counterpart 285 (Table 67)324. Based on this, the cyclopropyl 
group is adopted as a hydrophobic region II-binding motif for the design of 
future inhibitors, which ultimately leads to the development of a novel series 
of dicyclopropyl-containing PI3K δ inhibitors (Table 68). 
 
Table 67. SAR exploration of the hydrophobic region II (reported by Novartis)324. 







The introduction of a cyclopropyl group to replace the phenyl substituent 
affords compounds with physicochemical properties (molecular weight, tPSA 
and HBD/ HBA) within a range expected to be optimum for oral bioavailability 
(Table 69). Furthermore, the Fsp3 values for this series of dicyclopropyl 
derivatives are 0.64, which is consistent with optimal Fsp3 values (0.47-0.75) 
for the most FDA-approved small molecules (Table 69)357. Lovering et al357 
reported that compounds having Fsp3 greater than 0.47 have often favourable 




additional protein-ligand interactions not accessible to a planar aromatic 
ring357,385. 
 
Table 68. Structure of the proposed dicyclopropyl-containing compounds (287- 291), the first 
cyclopropyl group acts as a linker to connect the aminopyrimidine hinge-binding core with a 
terminal binding group (R1), whereas the second cyclopropyl group acts as a hydrophobic-








Table 69. Physicochemical properties of dicyclopropyl-containing compound 287. It displays 
that compound 287 has the appropriate physicochemical properties required for optimal oral 
bioavailability264,357–359. 
Physical properties Compound 287 Optimal range for oral 
bioavailability 
Molecular weight 409.47 <500 
Fsp3 0.642 0.47-0.75 
H.B. D 3 <5 
H.B. A 6 <10 
tPSA 121.46 60-140 A° 
clog P 1.05 2-3 




Hence, the main objective of future study is to design and synthesize a novel 
series of dicyclopropyl derivatives as potential PI3K δ inhibitors (287- 291) 
(Table 68). Herein, a synthetic method has been reported for the preparation 
of these compounds (Scheme 31). The first key step of the synthesis is based 
on the borylation of mono substituted cyclopropanes (292- 296) with 
pinacolborane in the presence of an iridium catalyst389. Next, the obtained 
boronate ester (297- 301) is subjected to the Suzuki coupling with 4,6-
dichloro-5-bromopyrimidine 302 to generate the respective coupling products 
(303- 307), followed by a subsequent substitution with the primary amine 
intermediate 77 to afford the monochloropyrimidine derivatives (308- 312). 
Finally, the second chloride of compounds (308- 312) was substituted by an 
amino group using ammonium hydroxide in NMP to generate the final 
screening diaminopyrimidines (287- 291). 
Scheme 31. Proposed synthesis of dicyclopropyl derivatives (287- 291) 
 
aReagents and conditions: (a) (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (0.03 equiv), 
2,9-dimethyl-1,10-phenanthroline (0.06 equiv), THF, 90°C, 18 h; (b) Na2CO3 (3 equiv), 
bis(triphenylphosphine) palladium (II) chloride (0.1 equiv), EtOH, microwave 125 °C, 3 h; (c) 
DIPEA (10 equiv), dioxane, 50°C, 30 min; (d) Cu2O (0.01 equiv), NH4OH-NMP (1:1, v/v), 




6.2.3 A novel potential role of PI3K δ inhibitors in the treatment 
of COVID-19 induced acute respiratory distress 
syndrome (ARDS) 
ARDS is a life-threatening condition, characterized by acute sever hypoxemia 
due to massive alveolar damage, allows fluid from the surrounding small 
blood vessels to accumulate in alveoli and limiting oxygen intake, makes it 
difficult for lung to provide enough oxygen to the body’s vital organs390. ARDS 
is the leading source of morbidity in hospitalised COVID-19 patients391,392, 
where ARDS causes COVID-19 patients to lose their ability to breathe on 
their own and may require assistance via mechanical ventilation to help the 
circulation of oxygen393. Thus, unified ARDS treatment can play an important 
role in reducing the mortality of COVID-19. It is now widely accepted that 
ARDS is caused by neutrophils infiltration into the lung, where neutrophils are 
activated and release of inflammatory mediators resulting in direct alveolar 
and endothelial injury394,395. neutrophils are recruited to the lung in response 
to pro-inflammatory mediators (TNF-α, IL-6, IL-8 and IL-10) secreted by 
alveolar macrophages394,395. It has been reported that Bruton tyrosine kinase 
(BTK) is a key signalling enzyme controlling the secretion of TNF-α, IL-6, IL-
8 and IL-10 from alveolar macrophages (Figure 140)394,396. Thus, 
pharmacological inhibition of BTK activity would be an effective strategy to 
treat ARDS. Recently, AstraZeneca has initiated a clinical trial of BTK inhibitor 
(acalabrutinib, 313) (Figure 141) in severely ill COVID-19 patients with acute 
respiratory distress syndrome (ARDS)397. Early data suggest that 
acalabrutinib (313) was able to reduce inflammation and improve survival 





Figure 140. The role of BTK in the pathogenesis of COVID-19-associated acute respiratory 
distress syndrome (ARDS). Alveolar macrophages recognise the viral particle or cellular 
debris containing viral single-stranded RNA (ssRNA) and clear them by phagocytosis. In 
alveolar macrophages, Toll-like receptors (TLRS) directly recognize and bind to the viral 
single-stranded RNA, resulting in the activation of BTK signalling pathway. BTK then 
activates the transcription factor NF-kB and thereby initiates NF-kB translocation to the 
nucleus, leading to the transcription and secretion of pro-inflammatory cytokines, which are 
responsible for the rapid recruitment of neutrophils and monocytes/macrophages to the lung 
at a later stage of sever COVID-19 infection397.  
 
Figure 141. The BTK inhibitor acalabrutinib (313), which is currently undergoing phase II 
clinical trials for the treatment of coronavirus-induced acute respiratory distress 
syndrome398,399. 
Songbo Xie et al400 and Hawkins et al401 reported that PI3K δ pathway also 
triggers the production of proinflammatory cytokines/chemokines (TNF-α, IL-
6 and IL-10) by alveolar macrophages (Figure 142). Suggesting that PI3K δ 
signalling, like BTK, may play a key role in the pathogenesis of ARDS. 
Accordingly, the objective of the future study is to evaluate the therapeutic 
effect of PI3K δ inhibitor on release of pro-inflammatory mediators from 




a new therapeutic agent for COVID19-associated ARDS. Furthermore, the 
synergetic inhibition effect of PI3K δ inhibitor and BTK inhibitor (acalabrutinib, 
313) will also be investigated. If the benefit of PI3K δ inhibitors was confirmed 
in the previous two above-mentioned studies, then the aim of the next project 
will be to develop novel dual PI3K δ/BTK inhibitors for the treatment of 
COVID-19-induced ARDS. 
 
Figure 142. In alveolar macrophages, PI3K δ signalling and BTK signalling share the same 
transcription factor (NF-KB), which initiates and regulates the expression of proinflammatory 
cytokines that trigger ARDS induced by COVID-19 virus. Thus, it was hypothesized that 
development of dual inhibitors targeting both PI3K δ and BTK can be a promising 
evolutionary strategy for the treatment of life-threatening acute respiratory syndrome caused 




Chapter 7  Experimental 
7.1 Molecular Docking 
All the ligand-protein docking studies were performed using Schrodinger suite 2017 
(LLC, New York, NY, USA). The following Maestro 11.7 version packages were 
used: Protein Preparation Wizard, Grid Generation, LigPrep and Glide ligand 
docking. 
7.1.1 Preparation of protein  
The X-ray crystal structure of murine PI3K δ in complex with idelalisib (8) (PDB code 
4XE0) and compound 66 (PDB code 5IS5) and the crystal structure of human 
K802T-mutant PI3K Ɣ in complex with compound 60 (PDB code 4EZJ) and 
compound 61 (PDB code 4EZK) were used as a protein template. All the selected 
crystal structures were obtained from the PDB, accessible at www.rcsb.org. The 3-
D structure of PI3K δ was prepared using the protein preparation wizard 
(Schrödinger Suite, version 10.7.15), where the non-protein portion, including 
ligands and water molecules were eliminated and hydrogen atoms were added to 
the protein structures. In the final step of protein preparation, proteins structure was 
minimized using OPLS_2005 force field.  
7.1.2 Receptor grid generation 
Afterwards, receptor grids were generated by defining the active site with a 3D cubic 
box using “Receptor Grid Generation” panel in the Grid-based Ligand Docking With 
Energetics (Glide) application. The receptor grid box was created around the binding 
site residues which include (Thr750, Met752, Pro758, Trp760, Ile777, Lys779, Leu784, Asp787, 
Leu791, Tyr815, Glu826, Val827, Val828, Leu829, His830, Ser831, Asp832, Thr833, Leu834, Ala835 
, Asn836 and Asp911). Each grid is set with inner and outer box sizes of 10 and 30 Å, 
respectively. 
7.1.3 Ligand preparation 
All studied inhibitors were sketched using Chemdraw Professional 16 (Version 
16.0.1.4, PerkinElmer informatic) in SDF file. The LigPrep 2.5 module (Small-
molecule drug Discovery Suite 2017-4, Schrödinger, LLC, New York, NY, USA) was 
used for the final preparation of ligands into their lowest energy 3D conformation. 




7.1.4 Ligand virtual screening 
All compounds were docked into the active site of the PI3K δ protein using the 
standard-precision mode of Glide docking (Small-Molecule Drug Discovery Suit 
2017-4 Schrödinger, LLC, New York, NY, USA). The number of positions per ligand 
was set to three, after energy minimisation. The best docked structures were chosen 
based on consistency of binding mode with retention of critical interactions. 
7.2 Analysis of drug-likeness 
The physiochemical properties of the studied compounds such as molecular weight, 
lipophilicity (clog P) and topological polar surface area (tPSA) were calculated using 
Osiris Data Warrior 5.0.0. software. 
7.3 Chemistry 
7.3.1 Materials and instrumentation 
Reagents and solvents which were used in the experiments were purchased from 
commercial supplier such as Fluorochem, Sigma-Aldrich, Tokyo Chemical Industry 
UK and Fisher Scientific. Column chromatography was performed with analytical-
grade solvents using silica gel 60 Å, 230-400 mesh particle size (Sigma-Aldrich). 
Reactions were monitored by thin-layer chromatography (TLC). TLC was performed 
on Fischer Scientific silica gel plates and visualized by ultraviolet lamp with 254 nM 
wavelength. 
NMR spectra were recorded on a Bruker advance II series (9.4T). 1H NMR spectra 
were recorded at 400 MHz and 13C NMR spectra at 100 MHz. Chemical shifts δ are 
given in [ppm] relative to TMS and all coupling constants J are given in [Hz]. The 
spectra are referenced to the signal of the deuterated solvent: CDCl3 (δH= 7.26, δc= 
77.16 ppm), DMSO (δH= 2.50, δc= 39.50 ppm) and MeOD4 (δH= 3.31, δc= 49.00 
ppm). The following abbreviations were used to explain the multiplicititeis: s, singlet; 
doublet; t, triplet; q, quartet and m, mutiplet. Furthermore, 2D-NMR experiment 
(HMPC) was used to distinguish between the regioisomers. The spectra NMR data 
were analyzed and processed with Mnova 14.1.2 software from Mestrela Research 
S. L.  
LCMS spectra were performed on a Shimadzu UFLCXR system coupled to an 




(channel 1). LC-MS was carried out using a Phenomenex Gemini-NX C18 110A (50 
mm Ꭓ 2 mm Ꭓ 3 μm) at a flow rate 0.5 ml/min over a 5 min period. 
All microwave reactions were performed in a Bioteg Intiator Microwave. Sonication 
were carried out in a Fisher Scientic FS30H Ultrasonic Cleaning Bath. 
7.3.2 Experimental for Chapter 2  
Ethyl N-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-
methylglycinate (18, 55% yield). 
 
A solution of 2-chloro-4-morpholinothieno [3,2-d]pyrimidine-6-carbaldehyde 17 
(10.60 mmol, 1 equiv), sarcosine ethyl ester (10.60 mmol, 1 equiv) and triethylamine 
(21.2 mmol, 2 equiv) in methanol (30 mL) was stirred for 30 min at RT, followed by 
the addition of acetic acid (4.8 mL) and the solution was stirred for other 30 min, 
followed by the addition of picoline borane (21.1 mmol, 2 equiv). The mixture was 
stirred for 16 h at RT. The solvent was removed and the residue was partitioned 
between ethyl acetate (100 mL) and saturated sodium hydrogen carbonate (100 
mL). The aqueous phase was washed twice with ethyl acetate, then the combined 
organic phases were dried over (MgSO4), filtered and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
eluting with 3% methanol (containing 0.7N ammonia) in DCM to afford tertiary amine 
18 (35.62%) as a white solid. 1H NMR (400 MHz, DMSO) δ 7.29 (d, J = 1.1 Hz, 1H, 
H-7), 4.12 (q, J = 7.1 Hz, 2H, H-13), 4.07 (d, J = 1.1 Hz, 2H, H-9), 3.89 (dd, J = 5.8, 
4.0 Hz, 4H, H-1), 3.76 (dd, J = 5.7, 3.9 Hz, 4H, H-2), 3.46 (s, H-11), 2.37 (s, 3H, H-
10), 1.22 (t, J = 7.1 Hz, 3H, H-14). 13C NMR (101 MHz, DMSO-d6) δ 170.79 (C-12), 
163.17 (C-5), 158.44 (C-4), 156.31 (C-3), 154.37 (C-8), 121.92 (C-7), 112.78 (C-6), 
66.39 (C-1), 60.50 (C-13), 57.57 (C-11), 55.42 (C-9), 46.47 (C-2), 41.85 (C-10), 
14.73 (C-14). LCMS m/z calc. for C16H21ClN4O3S [M+H]+: 385.1, found 384.8 with tR 
2.48 min. 
General procedure for Suzuki reaction. A mixture of chlorinated pyrimidine 8 (2.6 
mmol, 1 equiv), aryl boronic acid (3.9 mmol, 1.5 equiv), aqueous 2 M Na2CO3 (7.8 
mmol, 3 equiv) and bis(triphenylphosphine) palladium chloride (0.26 mmol, 0.1 
equiv) in THF (8 mL) was irradiated under microwave radiation for 3 h at 125 C°. 




gel), eluting with 0-10% methanol (containing 0.7 N ammonia) in DCM to give the 
products (19 and 21) as solids. 
Ethyl-N-((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-
methylglycinate (40, 29% yield). 
 
1H NMR (400 MHz, DMSO) δ 11.23 (s, NH), 8.13 (dd, J = 7.5, 1.0 Hz, 1H, H-20), 
7.53 (dd, J = 8.0, 0.9 Hz, 1H), 7.47 – 7.43 (m, 2H), 7.43 (s, 1H, H-7), 7.20 (t, J = 7.8 
Hz, 1H, H-15), 4.13 (q, J = 7.1 Hz, 2H, H-13), 4.11 – 4.08 (m, 2H, H-9), 4.03 – 3.96 
(m, 4H, H-1), 3.83 (dd, J = 5.7, 3.9 Hz, 4H, H-2), 3.47 (s, 2H, H-11), 2.41 (s, 3H, H-
10), 1.23 (t, J = 7.1 Hz, 3H, H-14). 13C NMR (101 MHz, DMSO) δ 170.72 (C-12), 
162.84 (C-4), 161.70 (C-5), 157.97 (C-3), 151.79 (C-8), 137.47 (C-14), 130.20, 
126.80, 126.38, 123.34, 120.90, 120.86, 113.77 (C-6), 112.02 (C-18), 103.84 (C-15), 
66.53 (C-1), 60.38 (C-13), 57.44 (C-11), 55.48 (C-9), 46.54 (C-2), 41.77 (C-10), 
14.60 (d, J = 7.0 Hz, C-14). LCMS m/z calc. for C24H27N5O3S [M+H]+: 466.2, found 
465.8 with tR 2.48 min (98%). 
EthylN-methyl-N-((4-morpholino-2-phenylthieno[3,2-d]pyrimidin-6-
yl)methyl)glycinate (41, 68% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, OH), 7.89 – 7.68 (m, 2H, H-19/20), 7.38 (s, 
1H, H-10), 7.28 (t, J = 8.0 Hz, 1H, H-16), 7.04 – 6.61 (m, 1H, H-18), 4.11 (q, J = 7.1 
Hz, 2H, H-13), 3.99 (dd, J = 9.1, 4.4 Hz, 4H, H-1), 3.81 (t, J = 4.7 Hz, 4H, H-2), 3.47 
(s, 2H, H-9), 3.35 (s, 2H, H-11), 2.32 (s, 3H, H-10), 1.20 (t, J = 7.1 Hz, 3H, H-14).13C 
NMR (101 MHz, DMSO-d6) δ 170.74 (C-12), 162.83 (C-4), 161.68 (C-5), 157.95 (C-
3), 151.76 (C-8), 137.45 (C-14), 130.17, 126.78, 126.36, 123.31, 120.94, 120.82, 
113.75 (C-6), 112.05 (C-18), 103.82 (C-15, 66.46 (C-1), 60, 42 (C-13), 59.21 (C-11), 
55.91 (C-9), 46.35 (C-2), 42.15 (C-10), 14.53 (C-14). LCMS m/z calc. for 
C22H26N4O4S [M+H]+: 443.2, found 443.1 with tR 2.02 min (99%). 
General process for ester hydrolysis. To a solution of the ester (40 and 41) (2.34 
mmol, 1 equiv) in methanol (30 mL), was added KOH (12.38 mmol, 5 equiv). The 
reaction was then allowed to stir at 50°C for 20 h. The reaction mixture was 




organic layers were combined, dried over anhydrous MgSO4, and concentrated 
under reduced pressure to give the carboxylic acids (19 and 21). 
N-((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-
methylglycine (19, 95% yield). 
 
1H NMR (400 MHz, DMSO) δ 11.56 (s, NH), 8.10 (d, J = 7.4 Hz, 1H, H-20), 7.77 (s, 
OH), 7.62 (d, J = 7.9 Hz, 1H), 7.50 (t, J = 2.8 Hz, 1H, H-19), 7.30 (s, 1H, H-7), 7.24 
(t, J = 7.8 Hz, 1H, H-15), 4.47 (s, 2H, H-9), 4.08 (t, J = 4.5 Hz, 4H, H-1), 3.85 (t, J = 
4.7 Hz, 4H, H-2), 3.77 (s, 2H, H-11), 2.65 (s, 3H, H-10). 13C NMR (101 MHz, DMSO) 
δ 170.43 (C-12), 162.56 (C-4), 161.51 (C-5), 157.60 (C-3), 137.43 (C-17), 127.14 , 
126.70, 121.27, 120.90 (C-7), 112.74 (C-18), 103.15 (C-15), 66.39 (C-1), 56.28 (C-
11), 54.29 (C-9), 46.81 (C-2), 41.38 (C-10). LCMS m/z calc. for C22H23N5O3S [M+H]+: 
438.2, found 438.0 with tR 2.08 min (99%). 
N-((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-
methylglycine (21, 82% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 7.88 – 7.79 (m, 2H, H-14/18), 7.33 (s, 1H, H-7), 
7.25 (t, J = 7.8 Hz, 1H, H-17), 6.85 (ddd, J = 7.9, 2.6, 1.1 Hz, 1H, H-16), 4.10 – 3.90 
(m, 6H, H-1/H-9), 3.87 – 3.69 (m, 4H, H-2), 2.35 (s, 3H, H-10). 13C NMR (101 MHz, 
DMSO-d6) δ 162.77 (C-12), 159.44 (C-5), 157.82 (C-3), 157.79, 139.96, 129.65 (C-
17), 118.95 (C-7), 117.46 (C-16), 114.95 (C-14), 112.57 (C-6), 66.47 (C-1), 55.52 
(C-11), 49.06 (C-9), 46.31 (C-2), 42.02 (C-10). LCMS m/z calc. for C20H22N4O4S 
[M+H]+: 415.1, found 415.0 with tR 2.01 min (95%). 
General procedure for amide coupling. To a solution of carboxylic acid (19 and 
21) (0.24 mmol, 1 equiv) in DMF (1 mL) was added amine (0.28 mmol, 1.2 equiv), 
HATU (0.26 mmol, 1.1 equiv) and DIPEA (0.72 mmol, 3 equiv) and the mixture was 
stirred at RT overnight. The reaction mixture was diluted with ethyl acetate (20 ml) 
and saturated aqueous NaHCO3 (20 mL). The water phase was extracted with ethyl 
acetate (3*20 mL). The combined organic phases were washed with saturated 
aqueous sodium chloride (20 mL), dried over MgSO4, filtered and the crude product 
was purified by column chromatography on silica gel (DCM/methanol: 10:1) to yield 





yl)methyl)(methyl)amino)-N-propylacetamide (24, 31.0% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.49 (s, NH), 7.88 – 7.81 (m, 2H, H-19/H-23), 7.77 (t, 
J = 6.0 Hz, 1H, H-22), 7.42 (s, 1H, H-7), 7.27 (t, J = 8.2 Hz, OH), 6.88 – 6.82 (m, 1H, 
H-21), 3.99 (s, 2H, H-9), 3.97 (d, J = 4.8 Hz, 4H, H-1), 3.80 (dd, J = 5.7, 3.9 Hz, 4H, 
H-2), 3.10 (s, 2H, H-11), 3.09 – 3.05 (m, 2H, H-15), 2.33 (s, 3H, H-10), 1.44 (q, J = 
7.2 Hz, 2H, H-16), 0.85 (t, J = 7.4 Hz, 3H, H-17). 13C NMR (101 MHz, DMSO) δ 
169.49 (C-12), 162.77 (C-4), 159.54, 157.85 (C-3), 154.28, 151.21, 139.91, 129.72 
(C-22), 123.55, 119.03, 117.50 (C-21), 114.92 (C-19), 112.54 (C-5), 66.45 (C-1), 
60.14 (C-11), 56.22 (C-9), 46.32 (C-2), 42.76 (C-10), 22.93 (C-16), 11.85 (C-17). 
LCMS m/z calc. for C23H29N5O3S [M+H]+: 456.2, found 456.1 with tR 2.21 min (98%). 
2-(((5-(3-hydroxyphenyl)-7-morpholinobenzo[b]thiophen-2-
yl)methyl)(methyl)amino)-N-(2-methoxyethyl)acetamide (27, 59.5% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.49 (s, OH), 7.98 – 7.79 (m, 3H, H-19/H-23), 7.42 (s, 
1H, H-7), 7.27 (t, J = 7.9 Hz, 1H), 6.91 – 6.81 (m, 1H, H-7), 4.05 – 3.95 (m, 6H, H-
1/H-9), 3.81 (t, J = 4.9 Hz, 4H, H-2), 3.39 – 3.28 (m, 4H, H-15/16), 3.25 (s, 3H, H-
17), 3.13 (s, 2H, H-11), 2.33 (s, 3H, H-10). 13C NMR (101 MHz, DMSO-d6) δ 169.68 
(C-12), 162.75 (C-4), 159.54, 157.86 (C-3), 139.91, 129.72 (C-22), 119.02 (C-7), 
117.50 (C-21), 114.92 (C-18), 112.58 (C-6), 71.04 (C-16), 66.47 (C-1), 60.13 (C-11), 
58.35 (C-17), 56.17 (C-9), 46.32 (C-2), 42.68 (C-10), 38.43 (C-15). LCMS m/z calc. 
for C23H29N5O4S [M+H]+: 472.2, found 472.2 with tR 2.10 min (94%). 
Ethyl-N-((5-(3-hydroxyphenyl)-7-morpholinobenzo[b]thiophen-2-yl)methyl)-N-
methylglycylglycinate (30, 25.5% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.50 (s, OH), 8.25 (s, 1H, NH), 7.85 (d, J = 7.3 Hz, 2H, 




22), 4.04 (s, 2H, H-15), 4.00 (t, J = 4.7 Hz, 4H, H-1), 3.93 (d, J = 6.0 Hz, 2H, H-9), 
3.82 (t, J = 4.8 Hz, 4H, H-2), 3.66 (s, 3H, H-17), 3.18 (d, J = 12.7 Hz, 2H, H-11), 2.38 
(s, 3H, H-10), 1.26 (q, J = 6.1 Hz, 3H, H-18). 13C NMR (101 MHz, DMSO-d6) δ 
170.74 (C-16), 162.59 (C-12), 159.42 (C-5), 157.75 (C-3), 139.78, 129.62 (C-23), 
121.10, 118.92 (C-7), 117.40 (C-22), 114.82 (C-20), 112.52 (C-6), 66.37 (C-1), 56.02 
(C-11), 53.97 (C-9), 52.09 (C-17), 46.21 (C-2), 42.57 (C-10), 42.21 (C-15), 14.6 (C-
18). LCMS m/z calc. for C24H29N5O5S [M+H]+: 500.2, found 499.9 with tR 2.15 min 
(97%). 
EthylN-((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)-N-methylglycylalaninate (33, 70% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.50 (s, OH), 8.17 (d, J = 7.3 Hz, 1H, H-25), 7.86 (d, J 
= 1.8 Hz, 1H, H-21), 7.42 (s, 1H, H-7), 7.28 (t, J = 7.8 Hz, 1H, H-24), 6.95 – 6.60 (m, 
1H, H-23), 4.42 – 4.28 (m, 1H, H-15), 4.11 (qp, J = 7.2, 3.6 Hz, 2H, H-18), 4.03 (s, 
2H, H-9), 3.99 (t, J = 5.0 Hz, 4H, H-1), 3.81 (t, J = 4.8 Hz, 4H, H-2), 3.62 (dtd, J = 
13.2, 6.6, 3.8 Hz, 1H), 3.24 – 3.11 (m, 2H, H-11), 2.37 (s, 3H, H-10), 1.26 (t, J = 6.0 
Hz, 3H, H-16), 1.19 (t, J = 7.1 Hz, 3H, H-19). 13C NMR (101 MHz, DMSO-d6) δ 
169.63 (C-17), 162.76 (C-12), 159.54 (C-5), 157.85 (C-3), 139.91, 129.71 (C-24), 
123.52, 119.03 (C-7), 117.49 (C-23), 114.93 (C-21), 112.57 (C-6), 66.48 (C-1), 61.05 
(C-18), 59.64 (C-11), 56.02 (C-9), 46.32 (C-2), 42.55 (C-10), 17.59 (C-16), 14.49 (C-
19). LCMS m/z calc. for C25H31N5O5S [M+H]+: 514.2, found 514.0 with tR 2.27 min 
(90%). 
2-(((5-(3-hydroxyphenyl)-7-morpholinobenzo[b]thiophen-2-
yl)methyl)(methyl)amino)-1-(piperidin-1-yl)ethan-1-one (39, 75.8% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.50 (s, 1H), 7.85 (d, J = 8.2 Hz, 2H, H-17/H-21), 7.38 
(s, 1H, H-7), 7.28 (t, J = 7.8 Hz, 1H, H-20), 6.96 – 6.78 (m, 1H, H-19), 4.01 (s, 2H, 
H-9), 3.98 (t, J = 4.7 Hz, 4H, H-1), 3.81 (t, J = 4.8 Hz, 4H, H-2), 3.45 (d, J = 4.7 Hz, 
2H, H-11), 3.44 – 3.34 (m, 4H, H-13), 2.32 (s, 3H, H-10), 1.64 – 1.49 (m, 4H, H-14), 
1.45 (s, 2H, H-15). 13C NMR (101 MHz, DMSO) δ 167.67 (C-12), 162.75 (C-4), 




19), 114.92 (C-17), 112.64 (C-6), 66.46 (C-1), 59.17 (C-11), 55.92 (C-9), 46.35 (C-
2), 42.12 (C-10), 25.89 (C-14), 24.51 (C-15). LCMS m/z calc. for C25H31N5O3S 
[M+H]+: 482.2, found 482.0 with tR 2.13 min (95%). 
2-(((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)(methyl)amino)-1-morpholinoethan-1-one (42, 69% yield). 
 
1H NMR (400 MHz, DMSO) δ 11.23 (t, J = 2.3 Hz, NH), 8.13 (dd, J = 7.5, 1.0 Hz, 1H, 
H-22), 7.53 (dt, J = 8.0, 1.0 Hz, 1H, H-20), 7.48 – 7.40 (m, 3H, H-7/H-18/H-20), 7.21 
(t, J = 7.8 Hz, 1H, H-17), 4.03 (s, 2H, H-9), 4.00 (dd, J = 5.7, 3.9 Hz, 4H, H-1), 3.84 
(dd, J = 5.8, 3.8 Hz, 4H, H-2), 3.62 (d, J = 4.5 Hz, 4H, H-14), 3.57 (ddq, J = 8.8, 5.3, 
3.3, 2.8 Hz, 4H, H-13), 3.45 (s, 2H, H-11), 2.34 (s, 3H, H-10). 13C NMR (101 MHz, 
DMSO) δ 168.35 (C-12), 162.83 (C-4), 161.71 (C-5), 157.95 (C-3), 137.48 (C-19), 
130.16, 126.60 (d, J = 39.7 Hz), 123.58, 120.90, 120.88 (C-7), 113.79 (C-20), 112.02 
(C-6), 103.83 (C-17), 66.69 (C-14), 66.52 (C-1), 58.93 (C-11), 55.90 (C-9), 46.56 (C-
2), 45.95 (C-13), 42.11 (C-10). LCMS m/z calc. for C26H30N6O3S [M+H]+: 507.2, 
found 507.3 with tR 2.06 min (99%). 
2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)(methyl)amino)-1-morpholinoethan-1-one (43, 45%yield). 
 
1H NMR (400 MHz, DMSO) δ 9.49 (s, OH), 7.90 – 7.80 (m, 2H, H-16/H-20), 7.38 (d, 
J = 1.0 Hz, 1H, H-7), 7.31 – 7.24 (m, 1H, H-19), 6.88 – 6.84 (m, 1H, H-18), 4.00 (s, 
2H, H-9), 3.98 (dd, J = 5.8, 3.9 Hz, 4H, H-1), 3.88 – 3.78 (m, 4H, H-2), 3.67 – 3.44 
(m, 8H, H-13/H-14), 3.43 (s, 2H, H-11), 2.32 (s, 3H, H-10). 13C NMR (101 MHz, 
DMSO) δ 168.40 (C-12), 162.77 (C-4), 159.51 (C-5), 157.85 (C-3), 151.86, 139.92, 
131.95 (d, J = 9.9 Hz), 129.72, 129.23 (d, J = 11.7 Hz), 123.24, 119.02 (C-7), 117.48 
(C-18), 114.91 (C-16), 112.58 (C-6), 66.68 (C-14), 66.47 (C-1), 58.94 (C-11), 55.87 
(C-9), 46.35 (C-2), 45.94 (C-13), 42.10 (C-10). LCMS m/z calc. for C24H29N5O4S 
[M+H]+: 484.2, found 483.9 with tR 2.12 min (95%). 
2-(((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-






1H NMR (400 MHz, DMSO) δ 11.23 (t, J = 2.4 Hz, NH), 8.13 (d, J = 7.5 Hz, 1H, H-
23), 7.53 (d, J = 8.0 Hz, 1H, H-22), 7.46 – 7.43 (m, 2H, H-19/H-21), 7.43 (s, 1H, H-
7), 7.20 (t, J = 7.7 Hz, 1H, H-18), 4.00 (d, J = 4.2 Hz, 6H, H-1/H-9), 3.84 (t, J = 4.8 
Hz, 4H, H-2), 3.55 (t, J = 5.0 Hz, 2H, H-13), 3.48 (dd, J = 9.2, 4.2 Hz, 2H, H-13), 3.41 
(s, 2H, H-11), 2.40 (d, J = 34.9 Hz, 4H, H-14), 2.32 (s, 3H, H-10), 2.22 (s, 3H, H-15). 
13C NMR (101 MHz, DMSO) δ 168.18 (C-12), 162.88 (C-4), 161.72 (C-5), 157.96 (C-
3), 151.57, 137.48 (C-20), 130.18, 126.80, 126.40, 123.42, 120.89 (d, J = 3.0 Hz, C-
7), 113.79 (C-21), 111.98 (C-6), 103.84 (C-18), 66.52 (C-1), 59.30 (C-11), 55.97 (C-
9), 55.37 (C-14), 46.56 (C-2), 46.05 (C-13), 45.19 (C-15), 42.14 (C-10). LCMS m/z 





1H NMR (400 MHz, DMSO) δ 9.51 (s, OH), 7.93 – 7.73 (m, 2H, H-17/H-21), 7.37 (s, 
1H, H-7), 7.28 (t, J = 8.0 Hz, 1H, H-20), 6.98 – 6.79 (m, 1H, H-19), 3.98 (d, J = 6.1 
Hz, 6H, H-1/H-9), 3.82 (t, J = 4.7 Hz, 4H, H-2), 3.52 (d, J = 28.3 Hz, 4H, H-13), 3.41 
(s, 2H, H-11), 2.41 (d, J = 34.9 Hz, 4H, H-14), 2.31 (s, 3H, H-10), 2.27 (s, 3H, H-15). 
13C NMR (101 MHz, DMSO) δ 168.20 (C-12), 162.79 (C-4), 159.51 (C-5), 157.85, 
151.94, 139.92, 129.72, 123.18, 119.02 (C-7), 117.49 (C-19), 114.91 (C-17), 112.56 
(C-6), 66.47 (C-1), 59.23 (C-11), 55.91 (C-9), 55.16 (C-14), 54.66, 46.35 (C-2), 45.77 
(C-13), 44.95 (C-15), 42.12 (C-10). LCMS m/z calc. for C25H32N6O3S [M+H]+: 497.2, 
found 497.1 with tR 1.86 min (99%). 
2-(((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-






1H NMR (400 MHz, DMSO) δ 11.24 (s, NH), 8.13 (d, J = 7.5 Hz, 1H, H-24), 7.53 (d, 
J = 8.0 Hz, 1H, H-23), 7.45 (d, J = 3.0 Hz, 2H, H-20/H-22), 7.33 (s, 1H, H-7), 7.21 (t, 
J = 7.8 Hz, 1H, H-19), 4.04 (s, 2H, H-9), 4.00 (d, J = 3.7 Hz, 4H, H-1), 3.89 (t, J = 
4.7 Hz, 3H, H-14), 3.84 (t, J = 4.8 Hz, 4H, H-2), 3.76 (t, J = 4.7 Hz, 4H, H-13), 3.45 
(s, 2H, H-11), 2.35 (s, 3H, H-10), 2.04 (s, 3H, H-16). 13C NMR (101 MHz, DMSO) δ 
169.05 (C-15), 168.35 (C-12), 162.82 (C-4), 161.72 (C-5), 157.95 (C-3), 154.25, 
137.48 (C-21), 130.14, 126.80, 126.41, 120.89 (C-7), 113.80 (C-22), 112.01 (C-6), 
103.83 (C-19), 66.52 (C-1), 66.43 (C-14), 59.18 (C-11), 55.38 (C-9), 54.08, 46.56 
(C-2), 46.35 (C-13), 42.11 (C-10), 21.72 (C-16). LCMS m/z calc. for C28H33N7O3S 
[M+H]+: 548.2, found 548.3 with tR 2.02 min (95%). 
1-(4-acetylpiperazin-1-yl)-2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-
d]pyrimidin-6-yl)methyl)(methyl)amino)ethan-1-one (47, 68% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.96 (s, OH), 7.75 (m, 2H, H-7/H-21), 7.41 – 7.31 (m, 
2H, H-7/H-21), 6.84 (d, J = 8.8 Hz, 1H, H-20), 4.14 – 4.00 (m, 2H, H-9), 3.97 – 3.85 
(m, 4H, H-1), 3.85 – 3.76 (m, 8H, H-2/H-14), 3.70 (dt, J = 9.0, 4.4 Hz, 4H, H-13), 
3.53 (s, 3H, H-11), 2.33 (s, 3H, H-10),1.87 (s, 3H, H-16). 13C NMR (101 MHz, DMSO) 
δ 169.13 (C-15), 168.60 (C-12), 162.77 (C-4), 159.42 (C-5), 157.32 (C-3), 156.34, 
139.84, 132.62, 132.11, 131.90, 129.83 (C-21), 129.28, 129.17, 122.96, 119.02 (C-
7), 116.20 (C-20), 114.91 (C-18), 112.59 (C-6), 66.92 (C-1), 66.84 (C-14), 60.01 (C-
11), 55.31 (C-9), 46.50 (C-2), 46.24 (C-13), 42.45 (C-10), 21.74 (C-16). LCMS m/z 
calc. for C26H32N6O4S [M+H]+: 525.2, found 525.2 with tR 2.04 min (93%). 
2-(((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)(methyl)amino)-1-(4-fluoropiperidin-1-yl)ethan-1-one (48, 66% yield). 
 
1H NMR (400 MHz, DMSO) δ 11.23 (t, J = 2.4 Hz, NH), 8.13 (dd, J = 7.5, 1.0 Hz, 
1H, H-23), 7.53 (dt, J = 8.0, 1.0 Hz, 1H, H-22), 7.48 – 7.40 (m, 3H, H-7/H-19/H-21), 
7.21 (t, J = 7.8 Hz, 1H, H-18), 4.90 (ddt, J = 48.4, 7.1, 3.6 Hz, 1H, H-15), 4.01 (s, 2H, 
H-9), 4.01 – 3.98 (m, 4H, H-1), 3.89 – 3.76 (m, 4H, H-2), 3.71 – 3.45 (m, 4H, H-13), 
3.44 (s, 2H, H-11), 2.33 (s, 3H, H-10), 2.05 – 1.64 (m, 2H, H-14). 13C NMR (101 
MHz, DMSO) δ 168.17 (C-12), 162.86 (C-4), 161.72 (C-5), 157.95 (C-3), 137.48 (C-




(C-6), 103.84 (C-18), 88.81 (d, J = 169.4 Hz, C-15), 66.51 (C-1), 59.32 (C-11), 56.00, 
55.38 (C-9), 46.56 (C-2), 42.15 (C-10), 41.77 (C-13), 31.17 (C-14). LCMS m/z calc. 
for C27H31FN6O2S [M+H]+: 523.2, found 523.1 with tR 2.22 min (97%). 
1-(4-fluoropiperidin-1-yl)-2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-
d]pyrimidin-6-yl)methyl)(methyl)amino)ethan-1-one (49, 44% yield). 
 
1H NMR (400 MHz, DMSO) δ 9.50 (s, OH), 7.85 (dd, J = 7.0, 1.5 Hz, 2H, H-17/21), 
7.38 (d, J = 1.1 Hz, 1H, H-7), 7.28 (t, J = 7.9 Hz, 1H, H-20), 7.04 – 6.67 (m, 1H, H-
19), 4.99 – 4.78 (m, 1H, H-15), 4.00 (s, 3H, H-9), 3.98 (d, J = 4.7 Hz, 4H, H-1), 3.81 
(t, J = 4.7 Hz, 4H, H-2), 3.46 (s, 4H, H-13), 3.43 (s, 2H, H-11), 2.31 (s, 3H, H-10), 
2.07 – 1.54 (m, 4H, H-14). 13C NMR (101 MHz, DMSO) δ 168.18 (C-12), 162.79 (C-
4), 159.52 (C-5), 157.85 (C-3), 151.82, 139.92, 129.72 (C-20), 123.25, 119.02 (C-
7), 117.49 (C-19), 114.91 (C-17), 112.57 (C-6), 88.81 (d, J = 169.4 Hz, C-15), 66.46 
(C-1), 59.28 (C-12), 55.96 (C-9), 46.35 (C-2), 42.14 (C-10), 41.74 (C-13), 38.01 (C-






1H NMR (400 MHz, DMSO) δ 11.23 (t, J = 2.3 Hz, NH), 8.13 (dd, J = 7.5, 1.0 Hz, 1H, 
H-23), 7.53 (dt, J = 8.1, 1.0 Hz, 1H, H-22), 7.47 – 7.43 (m, 3H, H-7/H-19/H-21), 7.21 
(t, J = 7.7 Hz, 1H, H-18), 4.02 (s, 2H, H-9), 4.01 – 3.97 (m, 4H, H-1), 3.83 (dd, J = 
5.7, 3.9 Hz, 4H, H-2), 3.61 (dd, J = 15.4, 9.4 Hz, 4H, H-13), 3.47 (s, 2H, H-11), 2.33 
(s, 3H, H-10), 2.09 (q, J = 13.1 Hz, 4H, H-14). 13C NMR (101 MHz, DMSO) δ 168.45 
(C-12), 165.05, 162.82 (d, J = 10.3 Hz, C-4), 161.74 (C-5), 157.95 (C-3), 151.27, 
137.48 (C-20), 130.17 (C-19), 126.80, 126.39, 125.62, 123.59, 123.22, 120.89 (d, J 
= 2.2 Hz), 113.79 (C-21), 111.99 (C-6), 103.84 (C-18), 66.51 (C-1), 59.28 (C-11), 
55.98 (C-9), 46.56 (C-2), 42.16 (C-10), 38.71 (C-13), 31.24 (C-14). LCMS m/z calc. 
for C27H30F2N6O2S [M+H]+: 541.2, found 541.1 with tR 2.20 min (95%). 
1-(4,4-difluoropiperidin-1-yl)-2-(((2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-





1H NMR (400 MHz, DMSO) δ 9.50 (s, OH), 7.89 – 7.81 (m, 2H, H-17/H-21), 7.38 (s, 
1H, H-7), 7.28 (t, J = 8.0 Hz, 1H, H-20), 6.94 – 6.80 (m, 1H, H-19), 4.00 (s, 2H, H-
9), 4.00 – 3.97 (m, 4H, H-1), 3.81 (t, J = 4.7 Hz, 4H, H-2), 3.61 (dd, J = 17.1, 5.9 Hz, 
4H, H-13), 3.47 (s, 2H, H-11), 2.32 (s, 3H, H-10), 2.01 (d, J = 52.1 Hz, 4H, H-14). 
13C NMR (101 MHz, DMSO) δ 168.43 (C-12), 162.78 (C-4), 159.53 (C-5), 157.85 (C-
3), 151.68, 139.91, 129.72 (C-20), 123.34, 119.02 (C-7), 117.49 (C-19), 114.91 (C-
17), 112.57 (C-6), 66.46 (C-1), 59.21 (C-11), 55.91 (C-9), 46.35 (C-2), 42.15 (C-10), 
38.65 (C-14). LCMS m/z calc. for C25H29F2N5O3S [M+H]+: 518.2, found 517.9 with tR 
2.21 min (99%). 
tert-butyl 4-(N-((2-(1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)-N-methylglycyl)piperazine-1-carboxylate (52, 56% yield). 
 
1H NMR (400 MHz, DMSO) δ 11.23 (d, J = 2.4 Hz, NH), 8.13 (d, J = 7.4 Hz, 1H, H-
25), 7.53 (d, J = 8.0 Hz, 1H, H-24), 7.44 (t, J = 2.4 Hz, 2H, H-21/H-23), 7.43 (s, 1H, 
H-7), 7.20 (t, J = 7.8 Hz, 1H, H-20), 4.00 (d, J = 5.7 Hz, 6H, H-1/H-9), 3.83 (t, J = 4.7 
Hz, 4H, H-2), 3.54 (t, J = 5.2 Hz, 4H, H-13), 3.43 (s, 2H, H-11), 3.32 (t, J = 5.2 Hz, 
4H, H-14), 2.32 (s, 3H, H-10), 1.43 (s, 9H, H-17). 13C NMR (101 MHz, DMSO) δ 
168.42 (C-15), 162.89 (C-4), 161.73 (C-5), 157.94 (C-3), 154.33, 151.46, 137.48 (C-
22), 130.18 (C-21), 126.80, 126.39, 123.45, 120.88 (d, J = 2.0 Hz, C-7), 113.78 (C-
23), 111.97 (C-6), 103.84 (C-20), 78.64 (C-16), 66.53 (C-1), 59.33 (C-11), 55.99 (C-
9), 47.94 (C-14), 46.57(C-2), 44.95 (C-13), 42.13 (C-10), 28.51 (C-17). LCMS m/z 




1H NMR (400 MHz, DMSO) δ 9.49 (s, OH), 7.95 – 7.79 (m, 2H, H-19/23), 7.38 (d, J 




2H, H-9), 3.99 – 3.95 (m, 4H, H-1), 3.81 (dd, J = 5.7, 3.9 Hz, 4H, H-2), 3.52 (d, J = 
5.8 Hz, 4H, H-13), 3.44 (d, J = 10.3 Hz, 4H, H-14), 2.31 (s, 3H, H-10), 1.43 (s, 9H, 
H-17). 13C NMR (101 MHz, DMSO) δ 168.41 (C-15), 162.81 (C-4), 159.52 (C-5), 
157.85 (C-3), 154.32, 151.87, 139.92, 129.72 (C-22), 123.20, 119.02 (C-7), 117.49 
(C-21), 114.91 (C-19), 112.55 (C-6), 79.64 (C-16), 66.49 (C-1), 59.28 (C-11), 55.94 
(C-9), 46.36 (C-2), 45.15 (C-14), 42.12 (C-10), 41.37 (C-13), 28.51 (C-17). LCMS 




1H NMR (400 MHz, DMSO) δ 11.23 (s, 1H), 8.13 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 8.0 
Hz, 1H), 7.44 (p, J = 3.0 Hz, 2H), 7.42 (s, 1H), 7.21 (t, J = 7.7 Hz, 1H), 4.44 – 4.17 
(m, 1H, H-13), 4.02 (s, 2H, H-11), 4.00 (d, J = 4.4 Hz, 4H, H-1), 3.84 (t, J = 4.7 Hz, 
4H, H-2), 3.65 (d, J = 13.8 Hz, 2H, H-17), 3.32 – 3.05 (m, 2H, H-18), 2.33 (s, 3H, H-
10), 1.67 – 1.55 (m, 6H, H-14/H-15/H-16), 1.34 (s, 9H, H-21). 13C NMR (101 MHz, 
DMSO) δ 168.60 (C-12), 162.89 (C-4), 161.73 (C-5), 157.93 (C-3), 137.48 (C-26), 
126.78, 126.44, 120.86, 113.89 (C-27), 103.74 (C-24), 66.55 (C-1), 59.28 (C-11), 
55.98 (C-9), 49.03 (C-13), 46.58 (C-2), 42.35, (C-18) 42.06 (C-10), 38.31, 28.25 (C-
14), 27.56 (C-21), 22.73 (C-15), 22.65 (C-16). LCMS m/z calc. for C33H43N7O4S 
[M+H]+: 634.3, found 634.2 with tR 2.31 min (97%). 
tert-butyl ((1-(N-((2-(3-Hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)-N-methylglycyl)piperidin-2-yl)methyl)carbamate (55, 97%yield). 
 
1H NMR (400 MHz, DMSO) δ 9.50 (s, OH), 7.89 – 7.81 (m, 2H, H-23/H-27), 7.36 (s, 
1H, H-7), 7.27 (t, J = 8.1 Hz, 1H, H-26), 6.92 – 6.82 (m, 1H, H-25), 4.36 – 4.12 (m, 
1H, H-13), 3.99 (s, 2H, H-9), 3.98 (d, J = 5.0 Hz, 4H, H-1), 3.81 (t, J = 4.8 Hz, 4H, H-
2), 3.28 – 2.95 (m, 4H, H-17/H-18), 2.31 (d, J = 1.8 Hz, 3H, H-10), 1.79 – 1.48 (m, 
6H, H-14/H-15/H-16), 1.40 (s, 9H, H-21). 13C NMR (101 MHz, DMSO) δ 168.60 (C-
12), 162.77 (C-4), 159.50 (C-5), 157.85 (C-3), 156.24, 139.94, 132.52, 132.00, 
131.90, 129.71 (C-26), 129.28, 129.17, 122.96, 119.02 (C-7), 117.47 (C-25), 114.91 




46.37 (C-2), 41.88 (C-10), 38.72 (C-17), 36.25 (C-16), 31.24 (C-21), 28.68 (C-16), 
28.63 (C-15). LCMS m/z calc. for C31H42N6O5S [M+H]+: 611.3, found 611.2 with tR 
2.35 min (90%). 
General procedure for boc-deprotection. To the above amides (52- 55) (0.16 
mmol, 1 equiv) was added 4 N HCl in 1, 4-Dioxane (2 mL) and the reaction mixture 
was stirred at RT for 1 h. The excess hydrogen chloride solution was evaporated to 
yield the hydrochloride salt of the amines (56-59) as oils. 
2-(((2-(1H-Indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)(methyl)amino)-1-(piperazin-1-yl)ethan-1-one (56, 98 % yield). 
 
1H NMR (400 MHz, DMSO) δ 11.37 (s, NH), 9.87 (s, 1H, NH), 8.12 (d, J = 7.4 Hz, 
1H, H-22), 7.59 – 7.50 (m, 1H, H-21), 7.45 (t, J = 2.8 Hz, 2H, H-18/H-20), 7.44 – 7.38 
(m, 1H, H-7), 7.38 – 7.28 (m, 3H), 7.20 (t, J = 7.7 Hz, 1H, H-17), 4.17 (s, 2H, H-9), 
4.01 (t, J = 4.7 Hz, 4H, H-1), 3.85 (t, J = 4.8 Hz, 4H, H-2), 3.74 (d, J = 5.1 Hz, 4H, H-
13), 3.38 (s, 2H, H-11), 3.17 (s, 2H, H-), 3.14 (d, J = 5.8 Hz, 2H, H-14), 3.06 (d, J = 
5.4 Hz, 2H, H-14), 2.35 (s, 3H, H-10). 13C NMR (101 MHz, DMSO) δ 168.85 (C-12), 
164.97 (C-4), 157.13 (C-3), 137.36 (C-19), 126.63, 121.01 (C-7), 116.33, 113.90 (C-
20), 112.07 (C-6), 102.38 (C-17), 66.25 (C-1), 56.20 (C-2), 50.59 (C-13), 47.35 (C-
14), 46.91 (C-2), 41.94 (C-10). LCMS m/z calc. for C26H31N7O2S [M+H]+: 506.2, 
found 506.5 with tR 1.85 min (99%). 
2-(((2-(3-Hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-
yl)methyl)(methyl)amino)-1-(piperazin-1-yl)ethan-1-one (57, 99% yield) . 
 
1H NMR (400 MHz, DMSO) δ 9.77 (s, OH), 7.92 (dd, J = 7.9, 1.4 Hz, 1H, H-20), 7.87 
(t, J = 2.1 Hz, 1H, H-16), 7.68 – 7.53 (m, 1H, H-19), 7.03 (dd, J = 8.0, 2.5 Hz, 1H, H-
18), 4.42 (s, 2H, H-9), 4.12 (t, J = 4.6 Hz, 4H, H-1), 3.86 (t, J = 4.9 Hz, 4H, H-2), 3.74 
– 3.62 (m, 4H, H-13), 3.35 (s, 2H, H-11), 3.24 – 3.03 (m, 4H, H-14). 13C NMR (101 
MHz, DMSO) δ 168.40 (C-18)158.20 (C-5), 157.21 (C-3), 131.89, 130.20, 129.24 (d, 
J = 11.7 Hz, C-19), 119.52 (C-7), 115.53 (C-18), 114.49 (C-16), 66.32 (C-1), 59.35 
(C-11), 55.88 (C-9), 46.92 (C-2), 42.64 (C-14), 41.88 (C-10). LCMS m/z calc. for 








1H NMR (400 MHz, DMSO) δ 11.70 (s, NH), 8.27 (s, NH2), 8.19 (d, J = 4.7 Hz, 1H, 
H-26), 8.07 (t, J = 7.7 Hz, 1H, H-25), 7.73 (dd, J = 8.1, 2.6 Hz, 1H, H-24), 7.60 (d, J 
= 2.8 Hz, 1H, H-22), 7.30 (td, J = 7.8, 2.5 Hz, 1H, H-7), 7.13 (s, 1H, H-21), 4.51 (t, J 
= 18.2 Hz, 2H, H-9), 4.25 – 4.16 (m, 4H, H-1), 3.90 (t, J = 4.7 Hz, 4H, H-2), 3.62 (d, 
J = 30.9 Hz, 2H, H-17), 3.44 (d, J = 3.0 Hz, 2H, H-11), 2.94 (s, 2H, H-18), 2.34 (s, 
3H, H-10), 1.65 (dd, J = 45.9, 32.7 Hz, 6H, H-14/H-15/H-16). 13C NMR (101 MHz, 
DMSO) δ 168.43 (C-12), 162.77 (C-4), 157.10 (C-3)137.36 (C-23), 126.63, 121.92, 
121.01 (C-7), 113.90 (C-24), 102.39 (C-21), 66.25 (C-1), 59.43 (C-11), 56.03 (C-9), 
46.91 (C-2), 34.48, 25.51 (C-14), 22.40 (C-16), 18.88 (C-15). LCMS m/z calc. for 





1H NMR (400 MHz, DMSO) δ 8.56 (s, OH), 8.00 – 7.84 (m, 2H, H-20/H-24), 7.72 – 
7.49 (m, 1H, H-23), 7.48 – 7.21 (m, 1H, H-7), 7.09 – 7.00 (m, 1H, H-22), 4.48 (s, 2H, 
H-9), 4.13 (d, J = 4.7 Hz, 4H, H-1), 3.86 (t, J = 4.8 Hz, 6H, H-2/H-17), 3.49 (d, J = 
16.0 Hz, 0H), 3.40 (s, 1H, H-11), 3.30 (s, 0H), 2.91 (d, J = 9.2 Hz, 2H, H-17 ), 2.70 
(s, 2H, H-18), 1.94 – 1.20 (m, 6H, H-14/H-15/H-16). 13C NMR (101 MHz, DMSO) δ 
168.17 (C-12), 158.22 (C-5), 157.22 (C-3), 131.95 (d, J = 9.2 Hz), 130.21, 129.30 
(C-28), 119.55 (C-7), 115.59 (C-22), 114.55 (C-20) 66.31 (C-1), 60.57 (C-11), 53.90 
(C-9), 46.95 (C-2), 43.93 (C-18), 41.81 (C-10), 40.94 (C-17), 34.52, 26.04 (C-14), 
21.71 (d, J = 7.0 Hz, C-16), 18.87 (C-15). LCMS m/z calc. for C26H34N6O3S [M+H]+: 
511.2, found 511.2 with tR 1.94 min (96%). 
7.3.3 Experimental for Chapter 3  





To a solution of 2-fluoro-6-nitrobenzoic acid 73 (5.40 mmol, 1 equiv) in DMF (10 mL) 
was added aniline (6.48 mmol, 1.2 equiv), HATU (5.94 mmol, 1.1 equiv) and DIPEA 
(16.20 mmol, 3 equiv). The reaction mixture was stirred at RT for 18 h, at which time 
it was diluted with ethyl acetate (50 mL) and washed with saturated sodium 
bicarbonate (2* 40 mL), water (40 mL) and brine (40 mL). The organic layer was 
then dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (DCM/methanol: 10:1) to yield 
amide 74 (98%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 10.83 (s, NH), 
8.12 (dt, J = 8.1, 1.0 Hz, 1H, H-3), 7.92 – 7.76 (m, 1H, H-4), 7.70 – 7.60 (m, 1H, H-
5), 7.39 (dd, J = 8.5, 7.4 Hz, 2H, H-9), 7.24 – 7.09 (m, 2H, H-10), 7.07 – 6.91 (m, 
1H, H-11). 13C NMR (101 MHz, DMSO-d6) δ 160.16 (C-7), 159.42 (C-6), 146.73 (d, 
J = 5.2 Hz) (C-2), 138.92 (C-8), 132.37 (d, J = 9.0 Hz) (C-4), 129.46 (C-10), 124.69 
(C-11), 121.13 (C-5), 121.10 (C-13), 119.93 (C-3), 114.31 (C-1). LCMS m/z calc. for 
C13H9FN2O3 [M+H]+: 261.1, found 261.2 with tR 2.66 min. 
2-amino-6-fluoro-N-phenylbenzamide (75, 100% yield). 
 
To a solution of nitro compound 74 (3.84 mmol, 1 equivalent) in methanol (15 mL) 
was added 10% Pd/C (0.096 mmol, 0.025 equiv) and the reaction was stirred under 
hydrogen atmosphere for 16 h. The crude product was filtered through Celite and 
filtrate was concentrated in vacuum to give amine 75 (100%) as a brown solid. 1H 
NMR (400 MHz, DMSO-d6) δ 10.28 (s, NH), 7.73 (d, J = 7.9 Hz, 2H, H-9), 7.34 (t, J 
= 7.7 Hz, 2H, H-10), 7.12 (dt, J = 19.7, 7.6 Hz, 2H, H-4/11), 6.57 (d, J = 8.3 Hz, 1H, 
H-5), 6.40 (t, J = 9.2 Hz, 1H, H-3), 5.77 (s, NH2). 13C NMR (101 MHz, DMSO) δ 
163.50 (C-7), 160.66 (d, J = 243.1 Hz, C-6), 149.78 (d, J = 6.2 Hz, C-2), 139.44 (C-
8), 131.81 (d, J = 11.1 Hz, C-4), 129.13 (C-10), 124.14 (C-11), 120.26 (C-9), 111.86 
(d, J = 2.3 Hz, C-3), 109.07 (d, J = 19.2 Hz, C-1), 102.40 (d, J = 22.7 Hz, C-5). LCMS 
m/z calc. for C13H11FN2O [M+H]+: 231.1, found 231.2 with tR 2.70 min. 
General procedure for amide coupling. To a solution of α-N-Boc-amino acid 
(13.02 mmole, 3 equiv) in dry THF (15 mL) at -15 °C was slowly added N-
methylmorpholine (15.19 mmol, 3.5 equiv) dropwise followed by 
isobutylchloroformate (15.19 mmole, 3.5 equiv). The reaction mixture was stirred at 
-10 °C under N2 for 2 h. Compound 75 (4.34 mmol,1 equiv) was then added to the 




°C at which time it was concentrated under reduced pressure. The residue was 
dissolved in ethyl acetate (50 mL) and the organic phase was washed with water (3 
* 40 mL) and brine (1* 40 mL). The organic layer was then dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
column chromatography (10-15% ethyl acetate in petroleum ether) to yield the 
diamides (76 and 108) as solids. 
tert-butyl (1-((3-fluoro-2-(phenylcarbamoyl)phenyl)amino)-1-oxobutan-2-
yl)carbamate (76, 61% yield). 
 
1H NMR (400 MHz, DMSO) δ 10.62 (s, NH-13), 10.03 (s, NH-8), 8.03 (d, J = 8.3 Hz, 
1H, H-4), 7.76 (d, J = 8.0 Hz, 2H, H-10), 7.52 (q, J = 7.8 Hz, 1H, H-5), 7.35 (q, J = 
7.5 Hz, 3H, H-11, NH-18), 7.13 (q, J = 9.2, 8.1 Hz, 2H, H-5/H-12), 3.93 (dt, J = 8.4, 
4.3 Hz, 1H, H-15), 1.92 – 1.72 (m, 1H, H-16), 1.59 (dq, J = 14.7, 7.6 Hz, 1H, H-16), 
1.32 (s, 9H, H-21), 0.91 – 0.86 (m, 3H, H-17). 13C NMR (101 MHz, DMSO) δ 171.96 
(C-14), 161.90 (C-7), 160.76 (C-6), 158.32 (C-6), 156.17 (C-19), 139.07, 138.21, 
132.24 (d, J = 9.9 Hz, C-4), 129.10 (C-11), 124.53 (C-12), 120.45 (C-9), 118.01 (C-
3), 116.17 (d, J = 18.6 Hz, C-5), 111.57 (d, J = 22.4 Hz, C-1), 78.80 (C-20), 57.48 
(C-15), 28.47 (C-21), 24.85 (C-16), 11.00 (C-17). LCMS m/z calc. for C22H26FN3O4 
[M+H]+: 416.2, found 416.4 with tR 2.91 min. 
tert-butyl (2-((3-fluoro-2-(phenylcarbamoyl)phenyl)amino)-2-
oxoethyl)carbamate (108, 20% yield). 
 
1H NMR (400 MHz, DMSO) δ 10.62 (s, 1H, NH-13), 10.03 (s, 1H, NH-8), 8.03 (d, J 
= 8.3 Hz, 1H, H-3), 7.76 (d, J = 8.0 Hz, 2H, H-10), 7.52 (q, J = 7.8 Hz, 1H, H-4), 7.35 
(q, J = 7.5 Hz, 3H, H-11), 7.13 (q, J = 9.2, 8.1 Hz, 2H, H-5/H-12), 3.93 (dt, J = 8.4, 
4.3 Hz, 1H, NH-16), 3.36 (s, H-15), 2.51 (t, J = 2.1 Hz, 1H, H-15), 1.32 (s, 9H, H-19). 
13C NMR (101 MHz, DMSO) δ 171.96 (14), 161.90 (C-7), 160.76 (C-6), 158.32 (C-
6), 156.17 (C-17), 139.07, 138.21, 132.24 (d, J = 9.9 Hz, C-4), 129.10 (C-11), 124.53 




Hz, C-1), 78.80 (C-18), 57.48 (C-15), 28.47 (C-19). LCMS m/z calc. for C20H22FN3O4 
[M+H]+: 388.2, found 388.3 with tR 2.87 min. 
General procedure for the synthesis of quinazolinone derivatives. To a 
suspension of the diamide (76 and 108) (4.44 mmol, 1 equiv) and iodine (12.43 
mmol, 2.8 equiv) in DCM (60 mL) at RT was slowly added HMDS (35.52 mmol, 8 
equiv) over 1 h. The reaction mixture was stirred at RT for 18 h. The reaction was 
quenched with 5% sodium thiosulfate solution (30 mL), diluted with DCM (50 mL) 
and stirred for a further 50 min at 25 °C. The organic layer was separated and 
washed with 5% sodium thiosulfate solution (2 * 40 mL), water (1 * 40 mL) and brine 
(1 * 40 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and 
evaporated. The residue was purified by silica gel chromatography eluting with 2% 





1H NMR (400 MHz, Chloroform-d) δ 7.69 (td, J = 8.2, 5.4 Hz, 1H), 7.55 (dddd, J = 
13.4, 11.8, 6.5, 3.3 Hz, 4H), 7.28 (ddd, J = 7.5, 4.1, 2.0 Hz, 2H), 7.16 – 7.04 (m, 1H), 
3.43 (dd, J = 7.5, 5.2 Hz, 1H, H-13), 1.87 – 1.70 (m, 2H, H-14), 0.81 (t, J = 7.4 Hz, 
3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 162.78 (C-7), 161.23 (C-6), 160.13, 
159.42 (d, J = 4.4 Hz), 149.50, 136.20, 134.81 (d, J = 10.5 Hz, C-4), 130.03, 129.73, 
129.43, 129.00, 128.27, 123.16 (d, J = 4.3 Hz, C-3), 113.25 (d, J = 20.7 Hz, C-5), 
54.30 (C-13), 30.25 (C-14), 10.53 (C-15). LCMS m/z calc. for C17H16FN3O [M+H]+: 
298.1, found 298.3 with tR 1.96 min (99%). 
2-(aminomethyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (109, 20 %yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.73 (td, J = 8.2, 5.4 Hz, 1H), 7.64 – 7.50 (m, 
4H), 7.32 – 7.22 (m, 2H), 7.15 (ddd, J = 10.5, 8.1, 1.0 Hz, 1H, H-5), 5.30 (s, 2H, H-
13), 3.49 (s, NH2). 13C NMR (101 MHz, CDCl3) δ 162.78 (C-7), 160.14 (C-6), 159.16 
(d, J = 4.4 Hz), 157.51, 149.19, 135.46, 134.90 (C-4), 130.06, 129.65, 128.23, 
123.10 (d, J = 4.2 Hz, C-3), 113.52 (d, J = 20.8 Hz, C-5), 110.66 (d, J = 5.9 Hz, C-
1)), 45.03 (C-13). LCMS m/z calc. for C15H12FN3O [M+H]+: 270.1, found 270.2 with 




General procedure for nucleophilic substitution of alkyl halides. Alkyl halide 
derivative was added to a solution of primary amine 77 (0.39 mmol, 1 equiv) in 
acetonitrile (20 mL) followed by K2CO3 (2.34 mmol, 6 equiv). The reaction mixture 
was stirred at reflux for 24 h. Upon cooling to RT, insoluble solid was filtered off. The 
solvent was then removed under reduced pressure and the resulting residue was 
purified by flash chromatography (1.5% methanol in DCM) to yield the products (79-
87) as white solids. 
(S)-5-fluoro-2-(1-((2-hydroxyethyl)amino)propyl)-3-phenylquinazolin-4(3H)-
one (79, 30% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.71 (td, J = 8.2, 5.3 Hz, 1H), 7.62 – 7.49 (m, 
4H), 7.28 (t, J = 4.5 Hz, 1H), 7.23 – 7.18 (m, 1H), 7.13 (dd, J = 10.5, 8.1 Hz, 1H, H-
5), 3.53 (t, J = 5.2 Hz, 2H, H-17), 3.21 (dd, J = 7.9, 4.6 Hz, 1H, H-13), 2.80 (dt, J = 
12.2, 4.9 Hz, 1H, H-16), 2.53 (dt, J = 11.7, 5.3 Hz, 1H, H-16), 1.71 (dqd, J = 14.6, 
7.3, 4.5 Hz, 1H, H-14), 1.54 (dp, J = 14.6, 7.4 Hz, 1H, H-14), 0.83 (t, J = 7.3 Hz, 3H, 
H-15). 13C NMR (101 MHz, Chloroform-d) δ 162.83 (C-7), 160.74 (C-6), 160.17 (C-
6), 159.36 (d, J = 4.3 Hz), 149.38 (C-12), 135.99, 134.94 (d, J = 10.5 Hz, C-4), 
130.08, 129.86, 129.59, 128.95, 128.27, 123.09 (d, J = 4.3 Hz, C-3), 113.37 (d, J = 
20.8 Hz, C-5), 60.95 (C-13), 60.53 (C-17), 49.37 (C-16), 28.84 (C-14), 10.80 (C-15). 
LCMS m/z calc. for C19H20FN3O2 [M+H]+: 341.2, found 342.3 with tR 1.87 min (99%). 
(S)-5-fluoro-2-(1-((3-hydroxypropyl)amino)propyl)-3-phenylquinazolin-4(3H)-
one (80, 51% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.86 – 7.64 (m, 1H), 7.58 (m, 4H), 7.28 (td, J = 
4.2, 2.1 Hz, 2H), 7.21 (dt, J = 8.4, 1.7 Hz, 1H), 7.18 – 7.03 (m, 1H, H-5), 3.86 – 3.65 
(m, 2H, H-18), 3.27 (dd, J = 8.0, 4.5 Hz, 1H, H-13), 2.95 (ddd, J = 10.8, 6.2, 4.0 Hz, 
2H, H-16), 2.52 (ddd, J = 11.8, 7.8, 4.2 Hz, 2H, H-17), 1.74 – 1.59 (m, 2H, H-14), 
0.82 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 162.83 (C-7), 
160.29 (C-6), 149.37 (C-12), 135.92, 134.96 (d, J = 10.4 Hz, C-4), 130.11, 129.93, 
129.66, 128.94, 128.28, 123.10 (d, J = 4.3 Hz, C-3), 113.40 (d, J = 20.6 Hz, C-5), 
64.26 (C-18), 60.75 (C-13), 48.24 (C-16), 30.69 (C-14), 28.85 (C-17), 10.74 (C-15). 





(81, 34% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.72 (q, J = 7.4 Hz, 1H), 7.56 (dq, J = 13.2, 7.6 
Hz, 4H), 7.35 – 7.21 (m, 1H), 7.22 – 7.07 (m, 2H), 3.58 (tt, J = 14.4, 11.2, 4.9 Hz, 
2H, H-19), 3.24 (t, J = 6.1 Hz, 1H, H-13), 2.75 (dd, J = 11.5, 5.9 Hz, 2H, H-16), 2.42 
– 2.16 (m, 2H, H-18), 1.72 (tt, J = 13.5, 7.3 Hz, 2H, H-14), 1.49 – 1.23 (m, 2H, H-
17), 0.83 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 162.83 (C-
7), 160.18 (C-6), 159.31 (d, J = 4.3 Hz), 149.39 (C-12), 135.87, 134.93 (d, J = 10.4 
Hz, C-4), 130.09, 129.90, 129.65, 128.96, 128.32, 123.14 (d, J = 4.3 Hz, C-3), 113.38 
(d, J = 20.7 Hz, C-5), 62.58 (C-19), 60.51 (C-13), 48.00 (C-16), 32.27 (C-18), 28.84 
(C-17), 28.67 (C-14), 10.58 (C-15). LCMS m/z calc. for C21H24FN3O2 [M+H]+: 370.2, 
found 370.3 with tR 1.95 min (98%).  
(S)-2-(1-(ethylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (82, 26% 
yield).  
 
1H NMR (400 MHz, CDCl3) δ 7.71 (td, J = 8.2, 5.4 Hz, 1H), 7.64 – 7.50 (m, 4H), 7.28 
(d, J = 1.6 Hz, 1H), 7.27 – 7.19 (m, 1H), 7.12 (ddd, J = 10.4, 8.2, 1.1 Hz, 1H, H-5), 
3.23 (dd, J = 7.1, 5.4 Hz, 1H, H-13), 2.58 (dq, J = 10.9, 7.1 Hz, 1H, H-16), 2.41 (dq, 
J = 10.9, 7.1 Hz, 1H, H-16), 1.70 (dqd, J = 14.8, 7.4, 5.4 Hz, 1H, H-14), 1.57 (dp, J 
= 14.4, 7.3 Hz, 1H, H-14), 1.05 (t, J = 7.1 Hz, 3H, H-17), 0.83 (t, J = 7.4 Hz, 3H, H-
15). 13C NMR (101 MHz, CDCl3) δ 162.85 (C-7), 161.20 (C-6), 160.20, 159.51 (d, J 
= 4.5 Hz), 149.66, 136.22, 134.78 (d, J = 10.4 Hz, C-4), 129.84 (d, J = 17.1 Hz), 
129.44, 129.01, 128.52, 123.20 (d, J = 4.2 Hz, C-3), 113.14 (d, J = 20.7 Hz, C-5), 
110.65 (C-1), 60.49 (C-13), 42.28 (C-16), 28.68 (C-14), 15.46 (C-17), 10.65 (C-15). 







1H NMR (400 MHz, Chloroform-d) δ 7.71 (td, J = 8.2, 5.4 Hz, 1H), 7.57 (dddd, J = 
11.8, 10.1, 5.5, 3.2 Hz, 4H), 7.38 – 7.19 (m, 2H), 7.12 (ddd, J = 10.4, 8.1, 1.0 Hz, 
1H, H-5), 3.21 (dd, J = 7.3, 5.3 Hz, 1H, H-13), 2.47 (ddd, J = 10.9, 7.8, 6.7 Hz, 1H, 
H-16), 2.35 (ddd, J = 10.9, 7.9, 5.9 Hz, 1H, H-16), 1.70 (ddd, J = 13.2, 7.3, 5.4 Hz, 
1H, H-14), 1.56 (dt, J = 14.1, 7.2 Hz, 1H, H-14), 1.49 – 1.34 (m, 2H, H-17), 0.90 (t, J 
= 7.4 Hz, 3H, H-18), 0.82 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-
d) δ 162.83 (C-7), 161.16 (C-6), 160.19, 159.50 (d, J = 4.3 Hz), 149.64 (C-12), 
136.19, 134.77 (d, J = 10.4 Hz, C-4), 129.90, 129.73, 129.42, 128.99, 128.49, 123.18 
(d, J = 4.3 Hz, C-3), 113.12 (d, J = 20.7 Hz, C-5), 60.69 (C-13), 50.02 (C-16), 28.65 
(C-14), 23.38 (C-17), 11.74 (C-18), 10.69 (C-15). LCMS m/z calc. for C20H22FN3O 




1H NMR (400 MHz, Chloroform-d) δ 7.70 (td, J = 8.2, 5.4 Hz, 1H), 7.59 – 7.38 (m, 
5H), 7.21 – 7.07 (m, 2H), 3.41 (dd, J = 9.6, 4.5 Hz, 1H, H-13), 2.54 (ddd, J = 13.2, 
9.2, 6.1 Hz, 2H, H-16), 2.25 (ddd, J = 13.1, 9.3, 5.4 Hz, 2H, H-16), 2.15 (ddt, J = 
14.2, 9.6, 7.1 Hz, 1H, H-14), 1.65 (dtt, J = 14.7, 7.5, 3.5 Hz, 1H, H-14), 1.22- 0.90 
(m, 4H, H-17), 0.83 (t, J = 7.3 Hz, 3H, H-15), 0.68 (t, J = 7.3 Hz, 6H, H-18). 13C NMR 
(101 MHz, Chloroform-d) δ 161.18 (C-6), 149.66 (C-12), 136.21, 134.84, 134.74, 
129.91, 129.74, 129.44, 129.00, 128.50, 123.22, 123.17 (C-3), 113.24 (C-5), 113.03, 
60.69 (C-13), 50.03 (C-16), 28.65 (C-14), 23.39 (C-17), 11.73 (C-18), 10.69 (C-15). 
LCMS m/z calc. for C23H28FN3O [M+H]+: 382.2, found 382.3 with tR 2.22 min (99%).  
(S)-2-(1-(butylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (86, 34 % 
yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.71 (td, J = 8.2, 5.4 Hz, 1H), 7.61 – 7.48 (m, 
4H), 7.30 – 7.22 (m, 2H), 7.12 (ddd, J = 10.5, 8.2, 1.1 Hz, 1H, H-5), 3.21 (dd, J = 7.2, 
5.3 Hz, 1H, H-13), 2.51 (dt, J = 11.1, 6.9 Hz, 1H, H-16), 2.37 (dt, J = 11.0, 6.6 Hz, 
1H, H-16), 1.76 – 1.64 (m, 1H, H-14), 1.56 (dp, J = 14.5, 7.3 Hz, 1H, H-14), 1.45 – 
1.25 (m, 4H, H-17/18), 0.89 (t, J = 7.1 Hz, 3H, H-15), 0.82 (t, J = 7.4 Hz, 3H, H-19). 




J = 4.4 Hz), 149.66 (C-12), 136.21, 134.76 (d, J = 10.5 Hz, C-4), 129.88, 129.72, 
129.41, 128.99, 128.50, 123.17 (d, J = 4.3 Hz, C-3), 113.11 (d, J = 20.7 Hz, C-5), 
60.73 (C-13), 47.76 (C-16), 32.37 (C-17), 28.67 (C-14), 20.32 (C-18), 13.92 (C-19), 
10.70 (C-15). LCMS m/z calc. for C21H24FN3O [M+H]+: 354.2, found 354.3 with tR 
2.12 min (99%).  
(S)-2-(1-(dibutylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (87, side 
product). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J = 5.4 Hz, 1H), 7.58 – 7.41 (m, 5H), 
7.18 – 7.08 (m, 2H, H-5), 3.43 (dd, J = 9.9, 4.2 Hz, 1H, H-13), 2.57 (ddd, J = 14.2, 
8.6, 5.6 Hz, 2H, H-16), 2.18 (m, 2H, H-16), 1.78 – 1.55 (m, 1H, H-14), 1.48 – 1.21 
(m, 1H, H-14), 1.20 – 0.90 (m, 8H, H-16/17), 0.84 (t, J = 7.3 Hz, 3H, H-15), 0.77 (t, 
J = 6.9 Hz, 6H, H-19). 13C NMR (101 MHz, Chloroform-d) δ 162.75 (C-7), 161.14 (C-
6), 156.95, 149.19 (C-12), 136.56, 134.46 (d, J = 10.3 Hz, C-4), 130.62, 129.19 (d, 
J = 1.9 Hz), 128.86, 128.13, 123.55 (d, J = 4.3 Hz, C-3), 113.19 (d, J = 20.7 Hz, C-
5), 63.95 (C-13), 50.51 (C-16), 30.97 (C-17), 20.45 (C-14), 18.55 (C-18), 13.96 (C-
19), 11.37 (C-15). LCMS m/z calc. for C25H32FN3O [M+H]+: 410.3, found 410.4 with 
tR 2.38 min (99%).  
(S)-2-(1-((2-(benzyloxy)ethyl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-
one (142, 47% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 7.70 (td, J = 8.2, 5.4 Hz, 1H), 7.64 – 7.44 (m, 
5H), 7.41 – 7.29 (m, 5H), 7.22 (dt, J = 6.7, 2.3 Hz, 1H), 7.13 (ddd, J = 10.4, 8.2, 1.0 
Hz, 1H, H-3), 4.50 (d, J = 2.1 Hz, 2H, H-18), 4.08 – 3.69 (m, 1H, H-17), 3.55 (dt, J = 
9.7, 4.9 Hz, 1H, H-17), 3.35 (s, NH), 2.82 (ddt, J = 11.9, 8.6, 4.5 Hz, 1H, H-16), 2.65 
(d, J = 11.3 Hz, 1H, H-16), 1.77 (dt, J = 13.6, 6.7 Hz, 1H, H-14), 1.62 (dq, J = 14.1, 
7.1 Hz, 1H, H-14), 0.84 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-d) 
δ 162.81 (C-7), 160.16 (C-6), 138.17, 135.95, 134.85 (d, J = 10.4 Hz, C-4), 129.96, 
129.74, 129.03, 128.48, 128.37, 127.66, 123.28 (d, J = 4.3 Hz, C-3), 123.23, 113.44 




(C-15). LCMS m/z calc. for C26H26FN3O2 [M+H]+: 432.2, found 432.1 with tR 2.29 min 
(90%).  
methyl (S)-2-((2-(benzyloxy)ethyl)amino)butanoate (100, 28% yield). 
 
To a magnetically stirred solution of methyl (S)-2-aminobutanoate (8.53 mmol, 1 
equiv) in CH3CN (10 mL) was added ((2-bromoethoxy)methyl)benzene 99 (10.23 
mmol, 1.2 equiv) and K2CO3 (51.18 mmol, 6 equiv). The reaction mixture was stirred 
at reflux for 18 h. The solvent was then removed under reduced pressure and the 
resulting residue was purified by flash chromatography (ethyl acetate/ petroleum 
ether, 1:1) to give secondary amine 100 as a yellowish green oil.1H NMR (400 MHz, 
Chloroform-d) δ 7.37 (s, 2H), 7.35 (s, 2H), 7.34 – 7.26 (m, 1H, H-12), 4.55 (d, J = 
2.4 Hz, 2H, H-8), 3.73 (s, 3H, H-1), 3.64 – 3.51 (m, 2H, H-7), 3.26 (t, J = 6.5 Hz, 1H, 
H-3), 2.87 (ddd, J = 11.7, 6.7, 4.7 Hz, 1H, H-6), 2.70 (ddd, J = 12.2, 5.4, 4.5 Hz, 1H, 
H-6), 1.90 (s, NH), 1.71 (dtd, J = 13.7, 7.4, 1.5 Hz, 2H, H-4), 0.95 (t, J = 7.4 Hz, 3H, 
H-5). 13C NMR (101 MHz, Chloroform-d) δ 175.57 (C-2), 138.33 (C-9), 128.38 (C-
11), 127.69 (C-10), 127.60 (C-12), 73.00 (C-8), 69.77 (C-1), 62.88 (C-7), 51.62 (C-
3), 47.57 (C-6), 26.48 (C-4), 10.11 (C-5). LCMS m/z calc. for C14H21NO3 [M+H]+: 
252.2, found 252.2 with tR 1.94 min.  
methyl (S)-2-((9-(4-methoxybenzyl)-9H-purin-6-yl)amino)butanoate (101, 34% 
yield). 
 
n-butanol (2 mL) was added to methyl (S)-2-aminobutanoate (1.822 mmol, 2.5 
equiv), and the resulting solution was transferred to a microwave vial containing 6-
chloro-9-(4-methoxybenzyl)-9H-purine 110 (0.728 mmol, 1 equiv). DIPEA (5.832 
mmol, 8 equiv) was added and the reaction mixture was heated to 120ºC for 4 h in 
the microwave. Upon cooling to RT, the reaction mixture was concentrated to 
dryness under reduced pressure. The crude residue was purified by flash 
chromatography (ethyl acetate/ petrol ether, 1:1) to give arylamine 101 (34% yield) 
as a yellowish green oil. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H, H-2), 7.73 (s, 1H, 




2H, H-6), 4.96 (s, 1H, H-13), 4.18 (t, J = 6.6 Hz, 3H, H-16), 3.81 (s, 3H, H-11), 2.18 
– 2.02 (m, 1H, H-14), 1.93 (dp, J = 14.5, 7.3 Hz, 1H, H-14), 0.93 (t, J = 6.6 Hz, 3H, 
H-15). 13C NMR (101 MHz, CDCl3) δ 173.18 (C-12), 159.62 (C-10), 154.15, 153.04 
(C-2), 139.86 (C-5), 129.34 (C-8), 127.61, 114.38 (C-9), 60.38 (C-13), 55.30 (C-11), 
52.26 (C-16), 46.73 (C-6), 25.78 (C-14), 9.82 (C-15). LCMS m/z calc. for C18H21N5O3 
[M+H]+: 356.2, found 356.3 with tR 2.65 min.  
General procedure for the N-9-alkylation of 6-chloropurine. A stirred suspension 
of potassium carbonate (19.41 mmol, 3 equiv) in DMF (10 mL) was treated with 6-
chloro-9H-purine 78 (6.47 mmol, 1 equiv) under N2 atmosphere at RT for 1 h. p-
methoxybenzyl bromide (5.55 mmol, 0.85 equiv) was added to the reaction mixture, 
and the resulting solution was stirred at RT for 12 h. The solvent was then removed 
via rotary evaporation and the residue dissolved in ethyl acetate (100 mL) and 
washed with water (2* 100 mL) and brine (1* 100 mL), the organic layer was dried 
over MgSO4, filtered and evaporated. The crude product was purified by silica gel 
chromatography (30- 40% ethyl acetate in petroleum ether) to yield N-9-alkylated-6-
chloropurine 110 with N-7-regioisomer 110b as white solids. 
6-chloro-9-(4-methoxybenzyl)-9H-purine (110, 52% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 8.82 (s, 1H, H-2), 8.80 (s, 1H, H-5), 7.45 – 7.21 (m, 
2H, H-8), 6.96 – 6.83 (m, 2H, H-9), 5.45 (s, 2H, H-6), 3.71 (s, 3H, H-11). 13C NMR 
(101 MHz, DMSO-d6) δ 159.50 (C-10), 152.04 (C-1), 149.60 (C-3), 147.67 (C-5), 
131.32 (C-4), 129.84 (C-8), 128.35 (C-7), 114.54 (C-9), 55.53 (C-11), 47.07 (C-6). 
LCMS m/z calc. for C13H11ClN4O [M+H]+: 275.1, found 275.1 with tR 2.55 min.  
6-chloro-7-(4-methoxybenzyl)-7H-purine (110b, 28%). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.88 (s, 1H, H-2), 8.21 (s, 1H, H-5), 7.17 (d, J = 
8.7 Hz, 2H, H-8), 6.92 (d, J = 8.7 Hz, 2H, H-9), 5.63 (s, 2H, H-6), 3.82 (s, 3H, H-11). 
13C NMR (101 MHz, Chloroform-d) δ 162.09 (C-10), 160.03, 152.52 (C-2), 148.93 
(C-5), 143.17, 128.89 (C-8), 126.25, 114.75 (C-9), 55.38 (C-11), 50.43 (C-6). LCMS 
m/z calc. for C13H11ClN4O [M+H]+: 275.1, found 275.1 with tR 2.49 min.  





1-propanethiol (25 mmol, 4 equiv) was added to a solution of 6-chloropurine 78 (6.46 
mmol, 1 equiv) and DBU (12.92 mmol, 2 equiv) in DMF (10 mL). The reaction mixture 
was stirred for 18 h at RT at which time it was concentrated under reduced pressure. 
The residue was rediluted in ethyl acetate, and the organic phase was washed with 
water (3* 50 mL) and brine (1* 50 mL). The organic layer was then dried over 
Na2SO4, filtered and concentrated. The resulting residue was purified by flash 
chromatography on silica gel eluting with 2.5% MeOH containing 0.7N ammonia in 
DCM to give thioether 97 (168 mg, 13%) as a white solid. 1H NMR (400 MHz, 
Chloroform-d) δ 13.55 (s, NH), 8.79 (s, 1H, H-2), 8.31 (s, 1H, H-5), 3.41 (t, J = 7.2 
Hz, 2H, H-6), 1.85 (q, J = 7.3 Hz, 2H, H-7), 1.10 (t, J = 7.3 Hz, 3H, H-8). 13C NMR 
(101 MHz, Chloroform-d) δ 165.44 (C-1), 151.42 (C-2), 141.21 (C-5), 129.72 (C-4), 
30.82 (C-6), 22.87 (C-7), 13.46 (C-8). LCMS m/z calc. for C8H10N4S [M+H]+: 195.1, 
found 195.2 with tR 2.31 min.  
6-(propylsulfonyl)-9H-purine (98, 36% yield). 
 
To a solution of thioether 97 (2.573 mmol, 1 equiv) in DCM (10 mL) was added oxone 
(24.45 mmol, 9.5 equiv). The solution was stirred for 18 h at RT. The solvent was 
removed in vacuum and the crude residue was dissolved in ethyl acetate (30 mL). 
The insoluble solid was filtered off, then the filtrate was concentrated in vacuum to 
yield sulfone 98 (36% yield) as a yellowish green solid. 1H NMR (400 MHz, DMSO-
d6) δ 9.15 (s, 1H, H-2), 8.90 (s, 1H, H-5), 3.50– 3.33 (t, 2H, H-6), 1.71 (hept, J = 7.6 
Hz, 2H, H-7), 0.97 (t, J = 7.4 Hz, 3H, H-8). 13C NMR (101 MHz, DMSO-d6) δ 165.44 
(C-1), 155.73 (C-3), 151.74 (C-2), 143.89 (C-5), 134.13 (C-4), 60.00 (C-6), 16.02 (C-
7), 13.13 (C-8). LCMS m/z calc. for C8H10N4O2S [M+H]+: 227.1, found 227.3 with tR 
1.90 min.  
6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (122, 90% yield). 
 
To a magnetically stirred suspension of 6-chloro-9H-purine 78 (6.512 mmol, 1 equiv) 




was added 3,4-dihydro-2H-pyran (19.536 mmol, 3 equiv). The reaction mixture was 
stirred at 90°C and the solid slowly dissolved over 1 h. The cloudy yellow solution 
was filtered and concentrated in vacuo. The pale-yellow residue was purified via 
column chromatography (1:1 ethyl acetate: hexane) to afford 6-chloro-9-(tetrahydro-
2H-pyran-2yl)-9H-purine 122 (90% yield) as a colorless oil which slowly crystalized. 
1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H, H-2), 8.81 (s, 1H, H-5), 5.79 (dd, J = 10.8, 
2.3 Hz, 1H, H-6), 4.03 (ddt, J = 11.6, 4.2, 2.4 Hz, 1H, H-10), 3.85 – 3.61 (m, 1H, H-
10), 2.34 (tdd, J = 13.4, 10.8, 4.4 Hz, 2H, H-7), 2.01 (ddq, J = 18.3, 13.1, 3.3 Hz, 2H, 
H-8), 1.61 (td, J = 9.9, 9.1, 4.6 Hz, 2H, H-9). 13C NMR (101 MHz, DMSO) δ 152.27 
(C-2), 151.77 (C-1), 149.76 (C-3), 146.03 (C-5), 131.42 (C-4), 82.15 (C-6), 68.23 (C-
10), 30.14 (C-7), 24.90 (C-9), 22.67 (C-8). LCMS m/z calc. for C10H11ClN4O [M+H]+: 
239.1, found 238.7 with tR 2.33 min.  
General procedure for nucleophilic aromatic substitution of 6-chloropurine. 
tert-butanol (5 mL) was added to the starting amine (77 and 109) (1.68 mmol, 1 
equiv) and the resulting solution was transferred to a microwave tube containing 6-
chloropurine derivative (78, 110 and 122) (2.184 mmol, 1.3 equiv). DIPEA (16.80 
mmol, 10 equiv) was added and the reaction mixture was heated to 130 °C for 16 h 
in the microwave. The solvent was then removed under reduced pressure and the 
resulting residue was diluted with DCM (50 mL) and washed with water (1 * 50 mL) 
and brine (1 * 50 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered and evaporated under reduced pressure. The resulting residue was purified 
by flash chromatography (silica gel), eluting with 5% methanol (containing 0.7 N 
ammonia) in DCM to give arylamines (8, 128, 106, 111 and 123) as white solids. 
(S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 
(8, 75% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.56 (s, 1H, N-21), 8.16 (s, 1H, H-18), 7.79 (td, J 
= 8.2, 5.3 Hz, 2H), 7.66 – 7.41 (m, 6H), 7.27 (dd, J = 10.9, 8.1 Hz, 1H, H-3), 4.69 (s, 
1H, N-16), 2.04 – 1.73 (m, 2H, H-14), 0.76 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 
MHz, DMSO-d6) δ 162.32 (C-7), 159.70 (C-6), 158.91, 152.39, 149.55, 136.52, 
135.77 (d, J = 10.5 Hz, C-4), 131.35 – 126.05 (m), 123.53 (C-3), 113.58 (d, J = 20.3 
Hz, C-5), 110.79 (d, J = 5.6 Hz, C-1), 55.38 (C-13), 26.28 (C-14), 11.37 (C-15). 





phenylquinazolin-4(3H)-one (128, 65 % yield). 
 
1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H, H-17), 7.85 – 7.44 (m, 7H), 7.40 – 7.31 
(m, 1H), 7.28 (s, 1H, H-20), 7.26 (d, J = 8.6 Hz, 2H), 7.16 – 7.09 (m, 1H), 6.89 (d, J 
= 8.6 Hz, 2H, H-24), 5.30 (s, 2H, H-21), 3.81 (s, 3H, H-26), 2.05 – 1.89 (m, 1H, H-
14), 1.80 (dp, J = 14.9, 7.5 Hz, 1H, H-14), 0.87 (t, J = 7.4 Hz, 3H, H-15). 13C NMR 
(101 MHz, CDCl3) δ 171.14 (C-22), 159.51 (d, J = 35.1 Hz), 135.66, 134.75 (C-4), 
129.94, 129.60, 129.46 (d, J = 9.4 Hz), 128.94, 114.42, 113.39 (C-5), 60.40 (C-26), 
55.32 (C-13), 46.82 (C-21), 27.80 (C-14), 10.15 (C-15). LCMS m/z calc. for 




1H NMR (400 MHz, DMSO-d6) δ 13.01 (s, 1H, NH-18), 8.15 (s, 1H, H-16), 7.91 – 
7.75 (m, 1H, H-19), 7.70 – 7.44 (m, 7H), 7.31 (dd, J = 11.0, 8.2 Hz, 1H, H-5), 4.27 
(s, 2H, H-13).  13C NMR (101 MHz, DMSO) δ 162.33 (C-7), 159.71 (C-6), 158.67, 
152.59 (C-16), 149.30 (C-19), 136.22, 135.94 (d, J = 10.8 Hz, C-4), 130.17, 129.86, 
129.17, 123.51 (C-3), 113.76 (d, J = 20.4 Hz, C-5), 110.74 (C-1), 55.37 (C-13). 
LCMS m/z calc. for C20H14FN7O [M+H]+: 388.1, found 388.1 with tR 2.27 min (99%). 
5-fluoro-2-(((9-(4-methoxybenzyl)-9H-purin-6-yl)amino)methyl)-3-





1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H, H-16), 7.76 (s, 1H, H-19), 7.71 (dd, J = 
8.2, 5.3 Hz, 1H), 7.61 (dd, J = 6.2, 4.5 Hz, 4H), 7.44 – 7.32 (m, 2H), 7.31 – 7.21 (m, 
2H, H-22), 7.16 (dd, J = 10.3, 8.4 Hz, 1H, H-5), 6.95 – 6.84 (m, 2H, H-23), 5.30 (s, 
2H, H-20), 4.47 (s, 2H, H-13), 3.80 (s, 3H, H-25). 13C NMR (101 MHz, CDCl3) δ 
162.78 (C-7), 160.13 (C-6), 159.64, 158.99 (d, J = 4.5 Hz), 153.88, 153.34, 153.03 
(C-16), 148.65 (C-19), 139.95, 135.10 (d, J = 10.6 Hz, C-4), 130.34, 130.01, 129.34, 
128.29, 127.59, 123.30 (d, J = 4.2 Hz, C-3), 119.97, 114.40, 113.89 (d, J = 20.8 Hz, 
C-5), 110.81 (d, J = 6.0 Hz, C-1), 55.32 (C-25), 46.76 (C-30), 29.71 (C-13). LCMS 
m/z calc. for C28H22FN7O2 [M+H]+: 508.2, found 508.2 with tR 2.77 min (98%). 
5-fluoro-3-phenyl-2-((1S)-1-((9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-
yl)amino)propyl)quinazolin-4(3H)-one (123, 60% yield).  
 
1H NMR (400 MHz, CDCl3) δ 8.29 (s, 1H, H-17), 8.02 (s, 1H, H-20), 7.75 – 7.43 (m, 
6H), 7.40 – 7.32 (m, 1H), 7.26 (d, J = 7.7 Hz, 1H), 7.18 – 7.02 (m, 1H, H-3), 5.71 
(dd, J = 10.2, 2.5 Hz, 1H, H-21), 4.22 – 4.13 (m, 1H, H-26), 3.84 – 3.72 (m, 1H, H-
26), 2.22 – 1.91 (m, 3H, H-14/H-22), 1.78 (qdd, J = 11.1, 6.8, 3.3 Hz, 3H, H-14/H-
24), 1.70 – 1.58 (m, 1H, H-24), 0.87 (dq, J = 8.4, 3.5, 2.8 Hz, 3H, H-15). 13C NMR 
(101 MHz, CDCl3) δ 162.78 (C-7), 160.12, 159.35, 158.19, 154.03, 152.88 (C-17), 
149.22 (C-2), 137.84, 135.71, 134.80 (d, J = 10.4 Hz, C-4), 129.98, 129.62, 129.51 
(d, J = 1.7 Hz), 128.94 (d, J = 4.8 Hz), 123.40 (d, J = 4.2 Hz, C-2), 113.46 (d, J = 
20.6 Hz, C-5), 110.82 (d, J = 5.9 Hz, C-1), 81.79 (C-21), 68.82 (C-26), 31.95 (d, J = 
1.5 Hz, C-22), 24.92 (C-24), 23.94 (C-14), 22.86 (C-23), 10.16 (C-15). LCMS m/z 
calc. for C27H26FN7O2 [M+H]+: 500.2, found 499.9 with tR 2.86 min. 
General procedure for nucleophilic substitution of allyl, benzyl and phenyl 




resulting solution was transformed to a microwave vial containing allyl, benzyl or 
phenyl halide (0.202 mmol, 1.5 equiv). DIPEA (0.804 mmol, 6 equiv) was added and 
the reaction mixture was heated to 130 °C for 2 h in the microwave. The solvent was 
evaporated and the crude residue was purified by column chromatography, eluting 
with 2-3% methanol in DCM to yield the tertiary amines (116-121, 146 and 147) as 
oils. 
(S)-5-fluoro-2-(1-((4-nitrobenzyl)(9H-purin-6-yl)amino)propyl)-3-
phenylquinazolin-4(3H)-one (116, 40% yield). 
 
1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 2.0 Hz, 1H, H-18), 8.20 (dt, J = 8.2, 1.5 Hz, 
1H, H-25), 8.10 (s, 1H, H-21), 8.05 (s, 1H, H-21), 7.81 (d, J = 7.8 Hz, 1H), 7.70 (dt, 
J = 8.3, 4.2 Hz, 1H), 7.64 – 7.46 (m, 5H), 7.43 – 7.32 (m, 2H), 7.17 – 7.07 (m, 1H, 
H-5), 5.71 – 5.57 (m, 2H, H-23), 5.17 (dd, J = 8.4, 4.3 Hz, 1H, H-13), 1.97 (ddd, J = 
14.3, 7.4, 4.5 Hz, 1H, H-14), 1.83 (dp, J = 14.8, 7.4 Hz, 1H, H-14), 0.84 (t, J = 7.4 
Hz, 3H, H-15). 13C NMR (101 MHz, CDCl3) δ 162.68 (C-7), 160.03 (C-6), 159.20, 
157.07, 154.32, 152.47 (C-18), 149.86, 148.95, 148.50, 141.46, 136.38, 135.66, 
135.06 (d, J = 10.3 Hz, C-4), 134.36, 130.30, 129.87, 129.76, 129.67, 129.06, 
128.65, 123.88, 123.52 (C-3), 122.96, 113.75 (d, J = 20.6 Hz, C-5), 110.73 (d, J = 
5.8 Hz, C-1), 53.24 (C-13), 52.49 (C-23), 27.80 (C-14), 10.19 (C-15). LCMS m/z calc. 
for C29H23FN8O3 [M+H]+: 551.2, found 551.1 with tR 2.34 min (90%). 
(S)-5-fluoro-2-(1-((9-(3-nitrobenzyl)-9H-purin-6-yl)amino)propyl)-3-
phenylquinazolin-4(3H)-one (117, 7% yield). 
 
1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H, H-17), 8.21 (s, 1H, H-23), 8.18 (s, 1H, H-
20), 7.85 (s, 1H), 7.76 – 7.43 (m, 8H), 7.36 (d, J = 7.5 Hz, 1H), 7.12 (t, J = 9.3 Hz, 
1H, H-5), 5.48 (s, 2H, H-21), 5.23 (s, NH), 2.12 – 1.92 (m, 1H, H-14), 1.87 – 1.59 (m, 
1H, H-14), 0.88 (t, J = 7.5 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 153.32 




128.92, 123.43 (C-3), 122.53,113.52 (d, J = 20.6 Hz, C-5), 52.47 (C-13), 46.34 (C-
21), 29.72 (C-14), 10.14 (C-15). ). LCMS m/z calc. for C29H23FN8O3 [M+H]+: 551.2, 
found 551.3 with tR 2.87 min (95%). 
(S)-2-(1-((9-benzyl-9H-purin-6-yl)(3-nitrobenzyl)amino)propyl)-5-fluoro-3-
phenylquinazolin-4(3H)-one (118, side product). 
 
1H NMR (400 MHz, CDCl3) δ 8.31 – 8.18 (m, 2H), 8.16 – 8.01 (m, 2H), 7.84 – 7.71 
(m, 1H), 7.66 (td, J = 8.2, 5.3 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.55 – 7.43 (m, 2H), 
7.37 (t, J = 8.2 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.19 – 7.12 (m, 1H), 7.08 (dd, J = 10.3, 
8.3 Hz, 1H, H-5), 5.84 (s, 2H, H-28), 5.25 (s, 2H, H-23), 2.04 (dt, J = 13.5, 6.9 Hz, 
1H, H-14), 1.80 (dt, J = 14.5, 7.5 Hz, 1H, H-14), 0.78 (s, 3H, H-15). 13C NMR (101 
MHz, CDCl3) δ 162.70 (C-7), 160.05 (C-6), 148.54, 148.37, 136.51, 134.53 (C-4), 
130.15, 129.73, 129.47, 128.81, 128.52, 123.60, 123.43 (d, J = 4.3 Hz, C-3), 123.19, 
122.76, 112.93 (d, J = 24.5 Hz, C-5), 110.74 (d, J = 5.7 Hz, C-1), 53.44 (C-23), 49.39 
(C-28), 27.33 (C-14), 10.91 (C-15). LCMS m/z calc. for C36H28FN9O5 [M+H]+: 686.2, 
found 686.3 with tR 2.44 min (99%). 
(S)-2-(1-(allyl(9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-
one (119, 53% yield ). 
 
1H NMR (400 MHz, CDCl3) δ 10.39 (s, NH), 8.15 (s, 2H, H-18/H-21), 7.75 – 7.43 (m, 
6H), 7.36 (dd, J = 7.6, 2.1 Hz, 1H), 7.17 – 7.04 (m, 1H, H-3), 6.10 (ddt, J = 16.5, 
10.0, 6.1 Hz, 1H, H-24), 5.55 – 5.35 (m, 2H, H-23), 5.03 (d, J = 6.0 Hz, 2H, H-25), 
2.12 – 1.94 (m, 1H, H-14), 1.60 (t, J = 7.5 Hz, 1H, H-14), 0.93 (t, J = 7.3 Hz, 3H, H-
15). 13C NMR (101 MHz, CDCl3) δ 162.63 (C-7), 159.30 (C-6), 156.43, 151.87 (C-
18), 149.06 (C-21), 135.78, 135.05 (C-4), 134.95 (C-24), 129.86, 129.83, 129.78, 
129.66, 129.09, 128.72, 123.91 (C-3), 121.78 (C-25), 113.68 (d, J = 20.6 Hz, C-5), 
110.72 (C-1), 54.96 (C-13), 53.45 (C-23), 27.08 (C-14), 10.83 (C-15). LCMS m/z 
calc. for C25H22FN7O [M+H]+: 456.2, found 456.1 with tR 2.21 min (93%). 
(S)-2-(1-((9-allyl-9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-





1H NMR (400 MHz, Chloroform-d) δ 8.21 (s, 1H, H-17), 7.71 (s, 1H, H-20), 7.62 – 
7.56 (m, 1H), 7.55 – 7.35 (m, 4H), 7.31 – 7.21 (m, 1H), 7.03 (ddd, J = 10.4, 8.1, 1.1 
Hz, 1H, H-5), 5.96 (ddt, J = 17.0, 10.2, 5.7 Hz, 1H, H-22), 5.28 – 5.18 (m, 2H, H-23), 
4.72 (dt, J = 5.7, 1.6 Hz, 2H, H-21), 1.87 (dtd, J = 14.8, 7.3, 4.7 Hz, 1H, H-14), 1.71 
(dp, J = 14.8, 7.3 Hz, 1H, H-14), 0.79 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
Chloroform-d) δ 162.63 (C-7), 158.29 (C-6), 154.04, 152.92 (C-17), 149.22 (C-20), 
139.88, 135.69, 134.87 (C-4), 134.76, 131.91 (C-22), 129.99, 129.64, 129.52, 
128.96, 123.37, 123.33 (C-3), 118.92 (C-23), 113.48 (d, J = 20.7 Hz, C-5), 45.72 (C-
21), 29.71 (C-14), 10.14 (C-15). LCMS m/z calc. for C25H22FN7O [M+H]+: 456.2, 
found 456.1 with tR 2.76 min (99%). 
(S)-5-fluoro-3-phenyl-2-(1-(vinyl(9-vinyl-9H-purin-6-
yl)amino)propyl)quinazolin-4(3H)-one (121, side product). 
 
1H NMR (400 MHz, DMSO-d6) δ 9.14 (s, 1H, H-18), 8.88 (d, J = 49.1 Hz, 3H), 8.27 
(d, J = 8.3 Hz, 2H), 8.08 (s, 1H, H-21), 7.80 (dd, J = 27.8, 7.6 Hz, 2H), 7.56 (s, 2H), 
7.49 – 7.01 (m, 6H), 6.13 (ddt, J = 16.5, 10.0, 6.1 Hz, 1H, H-23), 5.93 (ddt, J = 17.0, 
10.2, 5.7 Hz, 1H, H-23/H-26), 5.28 – 5.18 (m, 4H, H-24/H-27), 4.75 (dt, J = 5.7, 1.6 
Hz, 2H, H-25), 2.12 – 1.92 (m, 1H, H-14), 1.87 – 1.59 (m, 1H, H-14),, 0.81 (m, 3H, 
H-15). 13C NMR (101 MHz, DMSO) δ 162.78 (C-7), 160.12 (C-6), 159.35, 158.19, 
154.03, 152.88 (C-17), 149.19 (C-2), 137.84, 135.71, 134.76 (d, J = 10.4 Hz, C-4), 
129.98, 129.62, 129.51 (d, J = 1.7 Hz), 128.94 (d, J = 4.8 Hz), 123.40 (d, J = 4.2 Hz, 
C-2), 113.42 (d, J = 20.6 Hz, C-5), 110.62 (d, J = 5.9 Hz, C-1)39.38 (C-14),66.80 (C-
13) 48.93 (C-22), 44.57 (C-25), 23.74 (C-14), 12.80 (C-15). LCMS m/z calc. for 
C28H26FN7O [M+H]+: 496.2, found 496.2 with tR 2.26 min (99%). 
(S)-5-fluoro-2-(1-((4-nitrobenzyl)(9H-purin-6-yl)amino)propyl)-3-





1H NMR (400 MHz, Chloroform-d) δ 8.66 – 8.56 (m, 2H, H-25), 8.54 (s, 1H, H-18), 
8.17 (s, 1H, H-21), 7.94 – 7.79 (m, 2H), 7.75 – 7.56 (m, 4H), 7.50 – 7.40 (m, 1H), 
7.33 (dt, J = 6.8, 2.3 Hz, 1H), 7.16 – 7.09 (m, 1H, H-3), 7.05 (d, J = 8.2 Hz, 1H), 5.54 
(d, J = 8.1 Hz, 1H, H-13), 1.85 (dt, J = 7.4, 3.7 Hz, 1H, H-14), 1.54 (dt, J = 14.5, 7.3 
Hz, 1H, H-14), 0.72 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 
162.88 (C-7), 160.78 (C-6), 160.22, 158.87 (d, J = 4.3 Hz), 157.97, 153.94 (C-18), 
149.27, 148.44, 147.81, 144.29 (C-21), 140.63, 135.26 (d, J = 1.8 Hz, C-4), 130.23, 
129.97, 129.66, 129.06, 128.42, 126.05 (C-25), 125.94 (C-24), 122.40 (d, J = 4.2 
Hz, C-3), 113.91 (d, J = 20.7 Hz, C-5), 110.83 (C-1), 52.52 (C-13), 27.02 (C-14), 
9.55 (C-15). LCMS m/z calc. for C28H21FN8O3- [M+H]+: 537.2, found 537.1 with tR 
2.78 min (95%). 
(S)-5-fluoro-2-(1-((9-(4-nitrophenyl)-9H-purin-6-yl)amino)propyl)-3-
phenylquinazolin-4(3H)-one (147, 57% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.45 (dd, J = 9.1, 2.6 Hz, 2H), 8.37 (s, 1H, H-
17), 8.21 (s, 1H, H-20), 8.06 (d, J = 9.0 Hz, 2H), 7.78 – 7.46 (m, 5H), 7.42 – 7.31 (m, 
1H), 7.13 (dd, J = 10.4, 8.2 Hz, 1H), 6.75 (s, 1H), 5.24 (s, NH), 2.00 (ddt, J = 14.7, 
12.0, 7.4 Hz, 1H, H-14), 1.83 (dp, J = 15.0, 7.5 Hz, 1H, H-14), 0.90 (t, J = 7.3 Hz, 
3H, H-15). 13C NMR (101 MHz, Chloroform-d) δ 162.78 (C-24), 162.55 (C-7), 160.12 
(C-6), 159.25 (d, J = 4.5 Hz), 154.38, 153.89 (C-17), 149.06, 146.47 (C-20), 140.17, 
137.99, 135.60 (C-4), 134.88, 130.03, 129.63, 128.82, 125.45, 123.11 (d, J = 36.6 
Hz, C-23), 113.64 (d, J = 20.8 Hz, C-5), 110.85 (C-1), 52.48 (C-13), 27.73 (C-14), 
10.15 (C-15). LCMS m/z calc. for C28H21FN8O3- [M+H]+: 537.2, found 537.1 with tR 
2.96 min (98%). 
General procedure for nucleophilic substitution of α-haloesters, α-haloamide 
and α-halonitrile. Alkylating agent (0.500 mmol, 2.5 equiv) was added dropwise to 




K2CO3 (0.80 mmol, 4 equiv) in DMF (1 mL). The reaction mixture was stirred for 18 
h at 60°C under nitrogen atmosphere, the solvent was removed and the residue was 
purified by flash column chromatography (30-40% ethyl acetate in petroleum ether) 
to yield the tertiary amines (129, 126 and 124). Carboxylic acid 130 produced as a 
side product during the synthesis of ester 129. 
tert-butyl (S)-N-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)-
N-(9-(4-methoxybenzyl)-9H-purin-6-yl)glycinate (129, 27% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.18 (s, 1H, H-17), 7.68 (td, J = 8.1, 5.0 Hz, 1H), 
7.61 (d, J = 4.7 Hz, 3H), 7.52 – 7.38 (m, 1H), 7.19 (d, J = 8.3 Hz, 2H), 7.08 (dd, J = 
10.2, 8.1 Hz, 1H), 7.00 – 6.90 (m, 2H, H-23), 6.87 – 6.76 (m, 2H, H-24), 6.70 (t, J = 
7.5 Hz, 1H), 5.20 (d, J = 14.9 Hz, 1H, H-27), 5.04 (d, J = 5.5 Hz, 1H, H-27), 4.91 – 
4.70 (m, 1H, H-13), 4.64 (d, J = 16.3 Hz, 1H, H-27), 4.29 (d, J = 16.3 Hz, 1H, H-27), 
3.85 (s, 3H, H-26), 1.86 (dt, J = 13.8, 7.3 Hz, 1H, H-14), 1.55 (dd, J = 7.9, 3.6 Hz, 
1H, H-14), 1.26 (s, 9H, H-31), 0.88 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
Chloroform-d) δ 168.65 (C-28), 163.24 (C-7), 161.95 (C-6), 159.10 (C-22), 155.78, 
151.61 (C-17), 142.15 (C-30), 137.25 (C-8), 135.17 (d, J = 10.4 Hz, C-4), 129.38, 
129.28, 114.34 (C-24), 113.71 (d, J = 20.8 Hz, C-5), 110.25 (C-1), 80.78 (C-30), 
66.42 (C-13), 55.40 (C-26), 46.52 (C-27), 27.72 (C-31), 23.83 (C-4), 10.28 (C-15). 
LCMS m/z calc. for C36H36FN7O4 [M+H]+: 650.3, found 650.1 with tR 2.53 min. 
(S)-N-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)-N-(9-(4-
methoxybenzyl)-9H-purin-6-yl)glycine (130, side product, 26% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.79 (s, H-17), 8.25 (s, 1H, H-20), 7.76 – 7.43 




(d, J= 7.0 Hz, 1H, H-27) 5.22 (s, 2H, H-21), 4.75 – 4.60 (m, 1H, H-27), 4.48 (q, J = 
16.1 Hz, 1H, H-27), 3.77 (s, 3H, H-26), 2.34 – 1.77 (m, 1H, H-14), 1.85 – 1.56 (m, 
1H, H-14), 0.87 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, CDCl3) δ 171.18 (C-
28), 165.64, 162.82 (C-7), 160.36 (C-6), 160.16, 156.93, 150.48 (C-17), 148.24, 
148.23, 143.54 (C-20), 135.39, 135.29 (C-4), 135.18, 130.14, 129.96, 129.78, 
129.20, 128.38, 124.69, 123.02 (C-3) 114.15 (d, J = 20.8 Hz, C-5), 110.85 (C-1), 
110.69, 55.31 (C-13), 53.38 (C-26), 51.41 (C-27), 49.21 (C-21), 26.50 (C-14), 9.62 
(C-15). LCMS m/z calc. for C32H28FN7O4 [M+H]+: 594.2, found 594.0 with tR 2.60 min. 
2-(((S)-1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)(9-
(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)amino)acetonitrile (126, 7% yield). 
 
1H NMR (400 MHz, MeOD) δ 8.30 (s, 1H, H-17), 7.99 (s, 1H, H-20), 7.80 (td, J = 8.2, 
5.4 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.63 – 7.48 (m, 5H), 7.25 (ddd, J = 11.0, 8.2, 1.0 
Hz, 1H, H-3), 5.48 (d, J = 5.0 Hz, 1H, H-21), 5.40 (d, J = 5.0 Hz, 1H, H-26), 4.27 – 
4.18 (m, 1H, H-25), 3.88 – 3.76 (m, 1H, H-25), 2.37 (tdd, J = 13.4, 10.8, 4.4 Hz, 2H, 
H-22), 2.25 – 1.94 (m, 3H, H-14/H-23),1.80 (m, 2H, H-14/H-24), 1.67– 1.55 (m, 1H, 
H-24), 0.90 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 163.17 (C-
7),160.74, 159,31, 157.27, 153.09, 152.25 (C-17), 149.28, 148.32, 143.78 (C-20), 
135.88, 135.63 (d, J = 10.7 Hz, C-4), 129.46, 129.36, 128.92 (d, J = 15.6 Hz), 123.52 
(d, J = 4.4 Hz, C-3), 119.93, 113.40 (d, J = 20.8 Hz, C-5), 110.87 (d, J = 5.9 Hz, C-
1), 53.76 (C-13), 36.78 (C-26), 30.20 (C-22), 26.51 (C-14), 24.87 (C-24), 22.70 (23), 
9.38 (C-15). LCMS m/z calc. for C29H27FN8O2 [M+H]+: 539.2, found 538.9 with tR 2.25 
min. 
2-(((S)-1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)(9-
(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)amino)acetamide (124, 8 % yield). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.20 (s, 1H, H-17), 8.01 (s, 1H, H-20), 7.73 – 




5.79 (dd, J = 10.2, 2.5 Hz, 1H, H-21), 4.18 – 4.10 (m, 1H, H-25), 4.20 – 4.06 (m, 1H, 
H-25), 3.82 – 3.70 (m, 3H, H-22/H-26), 2.15 – 1.84 (m, 3H, H-22/H-23), 2.04 – 1.73 
(qdd, J = 11.1, 6.8, 3.3 Hz, 3H, H-14/H-24), 1.63 – 1.51 (m, 1H, H-24), 0.89 (t, J = 
7.3 Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 167.87 (C-22), 162.53 (C-
7),160.74, 159,31, 157.27, 153.09, 152.25 (C-17), 149.28, 146.19 (C-20), 143.78, 
135.68 (C-8), 135.47 (d, J = 10.7 Hz, C-4), 129.46, 129.36, 128.92 (d, J = 15.6 Hz), 
122.39 (d, J = 4.4 Hz, C-3), 119.93, 113.71 (d, J = 20.8 Hz, C-5), 110.87 (d, J = 5.9 
Hz, C-1), 81.92 (C-21), 68.20 (C-25), 55.60 (C-13), 41.06 (C-26), 36.78 (C-26), 30.15 
(C-22), 25.64 (C-14), 24.87 (C-24), 22.67 (23), 10.05 (C-15). LCMS m/z calc. for 
C24H21FN8O2 [M+H]+: 473.2, found 472.8 with tR 2.49 min 
5-fluoro-2-((1S)-1-((2-hydroxyethyl)(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-
yl)amino)propyl)-3-phenylquinazolin-4(3H)-one (141, 18% yield). 
 
To a cooled (0°C) solution of compound 123 (0.20 mmol, 1 equiv) in THF (2 mL) 
under N2 was added isopropylmagnesium chloride (2M/THF, 0.22 mmol, 1.1 equiv). 
The mixture was allowed to stir at 0°C under nitrogen atmosphere for 30 min. 2-
iodoethanol (0.40 mmol, 2 equiv) was then added to the reaction mixture. After 
stirring for 16 h at 70°C, the solution was evaporated until dryness. The resultant 
solid was purified by flash column chromatography (100% ethyl acetate) to yield 
alcohol 141 as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.27 (s, 1H, H-17), 
8.01 (s, 1H, H-20),, 7.73 – 7.41 (m, 6H), 7.43– 7.31 (m, 1H), 7.22 (d, J = 7.7 Hz, 1H), 
7.16– 7.00 (m, 1H, H-3), 5.72 dd, J = 10.2, 2.5 Hz, 1H, H-21), 4.66 – 4.34 (m, 2H, 
H-27), 4.22 – 4.14 (m, 1H, H-25), 4.20 – 4.06 (m, 1H, H-25), 3.82 – 3.70 (m, 3H, H-
22/H-26), 2.20 – 1.89 (m, 3H, H-22/H-23), 1.75 (qdd, J = 11.1, 6.8, 3.3 Hz, 3H, H-
14/H-24), 1.69 – 1.57 (m, 1H, H-24), 0.90 (dq, J = 8.4, 3.5, 2.8 Hz, 3H, H-15). 13C 
NMR (101 MHz, CDCl3) δ 162.81 (C-7), 160.15, 159.38, 158.21, 154.06, 152.91 (C-
17), 149.25 (C-2), 137.87, 135.74, 134.84 (d, J = 10.4 Hz, C-4), 129.99, 129.66, 
129.54 (d, J = 1.7 Hz), 128.96 (d, J = 4.8 Hz), 123.43 (d, J = 4.2 Hz, C-2), 113.49 (d, 
J = 20.6 Hz, C-5), 110.86 (d, J = 5.9 Hz, C-1), 82.14 (C-21), 68.25 (C-25), 61.58 (C-
26), 54.34 (C-25) 30.14 (d, J = 1.5 Hz, C-22), 25.51 (C-14),24.92 (C-24), 22.67 (C-
23), 9.38 (C-15). LCMS m/z calc. for C29H30FN7O3 [M+H]+: 544.2, found 543.9 with 




General method for THP-deprotection. Hydrochloric acid (1 M, 1 mL) was added 
dropwise to a solution of THP-protected amines (126, 124, and 141) (0.092 mmol, 1 
equiv) in a mixture of ethanol (3 mL) and water (3 mL). The reaction mixture was 
stirred for 5 h at RT at which time it was concentrated under reduced pressure. The 
residue was then dissolved in ethyl acetate (30 mL), and the organic phase was 
washed with water (2* 20 mL) and brine (2* 20 mL). The organic solution was dried 
over anhydrous Na2SO4, filtered and the filtrate was concentrated under pressure to 
yield the unprotected amines (127, 125 and 72). 
(S)-2-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)(9H-purin-
6-yl)amino)acetonitrile (127, 16% yield). 
 
1H NMR (400 MHz, MeOD) δ 8.37 (s, 1H, H-17), 7.99 (s, 1H, H-20), 7.80 (td, J = 8.2, 
5.4 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.59 – 7.44 (m, 5H), 7.22 (ddd, J = 11.0, 8.2, 1.0 
Hz, 1H, H-3), 5.45 (d, J = 5.0 Hz, 1H, H-21), 5.11 (dd, J = 8.9, 4.3 Hz, 1H, H-21), 
2.41 – 1.97 (m, 2H, H-14), 0.92 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) 
δ 162.77 (C-7),160.12, 159,33, 157.26, 153.08, 152.00 (C-17), 149.28, 148.18, 
143.72 (C-20), 135.88, 135.23 (d, J = 10.7 Hz, C-4), 129.46, 129.36, 128.92 (d, J = 
15.6 Hz), 123.18 (d, J = 4.4 Hz, C-3), 119.95, 113.29 (d, J = 20.8 Hz, C-5), 110.80 
(d, J = 5.9 Hz, C-1), 54.03 (C-13), 36.44 (C-21), 26.51 (C-14), 9.38 (C-15). LCMS 
m/z calc. for C24H19FN8O [M+H]+: 455.2, found 454.9 with tR 2.15 min (90%). 
(S)-2-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)(9H-purin-
6-yl)amino)acetamide (125, 12% yield). 
 
1H NMR (400 MHz, MeOD) δ 8.64 (s, 1H, H-17), 8.46 (s, 1H, H-20), 7.82 (td, J = 8.2, 
5.3 Hz, 1H), 7.75 – 7.43 (m, 6H), 7.30 – 7.19 (m, 1H, H-3), 5.26 (s, NH2), 5.23 – 5.05 
(m, 1H, H-13), 3.93 (s, 2H, H-21), 2.06 – 1.93 (m, 2H, H-14), 0.93 (t, J = 7.4 Hz, 3H, 
H-15). 13C NMR (101 MHz, MeOD) δ 167.89 (C-22), 162.56 (C-7), 152.04 (C-17), 
149.22 (C-2), 148.66, 143.50 (C-20), 135.73, 135.40 (C-4), 129.69 (d, J = 12.4 Hz), 




(C-21), 26.58 (C-14), 9.50 (C-15). LCMS m/z calc. for C24H21FN8O2 [M+H]+: 473.2, 
found 472.8 with tR 2.06 min (95%). 
(S)-5-fluoro-2-(1-((2-hydroxyethyl)(9H-purin-6-yl)amino)propyl)-3-
phenylquinazolin-4(3H)-one (72, 90% yield). 
 
1H NMR (400 MHz, MeOD) δ 8.16 (d, J = 1.0 Hz, 1H, H-17), 7.70 – 7.58 (m, 2H), 
7.54 (ddd, J = 7.7, 6.0, 3.3 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.44 – 7.35 (m, 2H), 7.08 
(ddd, J = 11.0, 8.2, 1.0 Hz, 1H, H-3), 4.68 – 4.36 (m, 2H, H-22), 3.93 (t, J = 4.6 Hz, 
1H, H-21), 3.41 (qdd, J = 9.7, 5.7, 3.7 Hz, 1H, H-21), 1.93 (dtt, J = 15.0, 7.5, 3.4 Hz, 
1H, H-14), 1.76 (ddq, J = 14.5, 9.0, 7.2 Hz, 1H, H-14), 0.79 (t, J = 7.4 Hz, 3H, H-15). 
13C NMR (101 MHz, MeOD) δ 162.65 (C-7), 159.16, 158.03, 153.95, 151.61 (C-17), 
149.01 (C-2), 135.55 (d, J = 94.4 Hz, C-4), 129.41, 129.28 (d, J = 7.4 Hz), 129.06, 
128.79, 122.99 (C-3), 113.09 (C-1),110.79 ((d, J = 5.9 Hz, C-1), 61.55 (C-22), 54.30 
(C-13), 49.47 (C-21), 26.27 (C-14), 9.77 (C-15). LCMS m/z calc. for C24H22FN7O2 
[M+H]+: 460.2, found 459.7 with tR 2.31 min (96%). 
(S)-5-fluoro-2-(1-((2-hydroxyethyl)(9-(4-methoxybenzyl)-9H-purin-6-
yl)amino)propyl)-3-phenylquinazolin-4(3H)-one (112, 31% yield).  
 
LiBH4 (1M/THF; 0.169 mmol, 2 equiv) was added to a solution of ester 129 (0.0847 
mmol, 1 equiv) in dry THF (3 mL) at 0 °C. After 2 h, the reaction mixture was 
quenched with methanol (3 mL) and the solution was evaporated to dryness under 
reduced pressure. The resulting residue purified via flash column chromatography 
(100% ethyl acetate) to afford alcohol 112 as a white solid. 1H NMR (400 MHz, 
Chloroform-d) δ 7.69 (s, 1H, H-17), 7.68 – 7.60 (m, 2H), 7.43 – 7.36 (m, 2H), 7.34 
(s, 1H), 7.26 – 7.04 (m, 5H), 6.95 – 6.89 (m, 2H, H-24), 5.19 – 5.05 (m, 2H, H-21), 
4.58 – 4.44 (m, 1H, H-27), 4.08 – 3.96 (m, 2H, H-27), 3.97 – 3.88 (m, 1H, H-28), 
3.83 (s, 3H, H-26), 3.74 (m, H-28), 2.13 – 1.96 (m, 1H, H-14), 1.85 – 1.68 (m, 1H, H-




6), 149.66, 148.63, 147.65 (C-17), 143.99, 136.23 (d, J = 12.1 Hz, C-4), 134.48, 
129.27, 129.03, 128.62, 128.36 127.65, 123.51 (C-3), 121.94, 114.38 (C-24), 113.00 
(d, J = 20.9 Hz, C-5), 63.66 (C-13), 59.31 (C-28), 55.36 (C-26), 53.31 (C-27), 46.65 
(C-21), 28.44 (C-14), 10.36 (C-15). LCMS m/z calc. for C32H30FN7O3 [M+H]+: 580.2, 
found 580.0 with tR 2.33 min. 
General method for PMB-deprotection. To a solution of protected amines (129 
and 130) (0.0675 mmol, 1 equiv) in CH3CN/H2O (1/1, 2 mL), was added CAN (0.337 
mmol, 5 equiv). The reaction mixture was stirred at RT for 18 h, at which time it was 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (100% ethyl acetate) to yield the free amines (131 and 145). 
tert-butyl (S)-N-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)-
N-(9H-purin-6-yl)glycinate (131, 31%). 
 
1H NMR (400 MHz, CDCl3) δ 7.67 (tdd, J = 7.7, 5.3, 1.7 Hz, 1H), 7.60 (s, 1H, H-20), 
7.45 (s, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.28 (s, 1H), 7.26 – 7.14 (m, 2H), 7.11 – 7.03 
(m, 1H), 7.02 – 6.88 (m, 1H, H-3), 5.49 (ddd, J = 9.3, 6.7, 2.8 Hz, 1H, H-13), 4.59 
(dd, J = 28.6, 16.3 Hz, 1H, H-21), 4.34 (dd, J = 32.6, 16.3 Hz, 1H, H-21), 2.23 – 2.09 
(m, 1H, H-14), 2.04 – 1.96 (m, 1H, H-14), 1.23 (s, 9H, H-24), 0.92 – 0.86 (m, 3H, H-
15). 13C NMR (101 MHz, CDCl3) δ 167.29 (C-22), 162.71 (C-7), 160.05 (d, J = 4.6 
Hz, C-6), 159.72, 150.16 (C-17), 148.00, 146.26 (C-20), 136.41 (d, J = 23.1 Hz), 
134.23 (d, J = 9.9 Hz, C-4), 133.43, 129.55, 129.01 (d, J = 3.4 Hz), 128.36, 128.11, 
123.53 (d, J = 4.2 Hz, C-3), 122.24, 112.77 (d, J = 20.6 Hz, C-5), 110.95 (C-1), 81.51 
(C-23), 68.72 (C-13), 50.11 (C-21), 40.88 (C-24), 24.88 (C-14), 10.21(C-15). LCMS 
m/z calc. for C28H28FN7O3 [M+H]+: 530.2, found 530.1 with tR 2.31 min. 
(S)-N-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)-N-(9H-
purin-6-yl)glycine (145, 50%). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.27 (s, 1H, H-17), 7.99 – 7.74 (s, 1H, H-20), 
7.66 (dt, J = 8.2, 4.0 Hz, 1H), 7.61 – 7.45 (m, 3H), 7.24 (dd, J = 10.9, 8.1 Hz, 1H, H-




Hz, 1H, H-14), 0.90 – 0.84 (m, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 171.58 (C-
22), 162.43 (C-7), 161.95 (C-6), 151.54 C-17), 141.96 (C-20), 129.24, 128.08, 
127.30, 119.99, 119.82, 111.09, 56.40 (C-13), 52.58 (C-21), 26.43 (C-14), 9.00 (C-
15). LCMS m/z calc. for C24H20FN7O3 [M+H]+: 474.2, found 474.1 with tR 2.80 min, 
(96%). 
7.3.4 Experimental for Chapter 4  
General procedure for the N-7-alkylation of 6-chloropurine. To a stirred solution 
of 6-chloropurine 78 (19.04 mmol, 1 equiv) in acetonitrile (15 mL) was added K2CO3 
(58.20 mmol, 3 equiv). The reaction mixture was allowed to stir at RT for 30 min. 
Alkylating agent (38.08 mmol, 2 equiv) was then added and the resulting mixture 
was stirred for 18 h. The solvent was removed and the residue was purified by 
column chromatography (2% methanol in ethyl acetate) to yield the N-7-substituted-
6-chloropurines (172, 173 and 174) as well as the N-9-regioisomers (178, 179 and 
180) as white solids. 
2-(6-chloro-7H-purin-7-yl)ethan-1-ol (172, 16% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.80 (s, 1H, H-2), 8.74 (s, 1H, H-5), 4.87 (d, J = 50.2 
Hz, OH), 4.54 (t, J = 5.3 Hz, 2H, H-6), 3.79 (t, J = 5.3 Hz, 2H, H-7). 13C NMR (101 
MHz, DMSO) δ 162.20 (C-3), 152.09 (C-2), 151.83 (C-5), 142.51 (C-1), 122.62 (C-
4), 60.56 (C-7), 49.62 (C-6). LCMS m/z calc. for C7H7ClN4O [M+H]+: 199.0, found 
198.9 with tR 1.04 min. 
2-(6-chloro-9H-purin-9-yl)ethan-1-ol (178, 21 % yield). 
 
1H NMR (400 MHz, DMSO) δ 8.78 (s, 1H, H-2), 8.65 (s, 1H, H-5), 5.01 (t, J = 5.5 Hz, 
OH), 4.35 (t, J = 5.4 Hz, 2H, H-6), 3.80 (q, J = 5.2 Hz, 2H, H-7). 13C NMR (101 MHz, 
DMSO) δ 152.58 (C-4), 151.81 (C-2), 149.27 (C-1), 148.45 (C-5), 131.32 (C-4), 
59.34 (C-7), 47.08 (C-6). LCMS m/z calc. for C7H7ClN4O [M+H]+: 199.0, found 198.9 
with tR 1.07 min. 





1H NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H, H-2), 8.75 (s, 1H, H-5), 7.83 (s, 1H, 
NH), 7.45 (s, 1H, NH), 5.17 (s, 2H, H-6). 13C NMR (101 MHz, DMSO-d6) δ 168.69 
(C-7), 161.95 (C-3), 152.25 (C-2), 152.02 (C-5), 142.83 (C-1), 123.21 (C-4), 49.08 
(C-6). LCMS m/z calc. for C7H6ClN5O [M+H]+: 212.0, found 211.9 with tR 0.65 min. 
2-(6-chloro-9H-purin-9-yl)acetamide (179, 42% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H, H-5), 8.64 (s, 1H, H-2), 7.83 (s, 1H, 
NH), 7.43 (s, 1H, NH), 4.99 (s, 2H, H-6). 13C NMR (101 MHz, DMSO-d6) δ 168.00 
(C-7), 152.70 (C-1), 152.02 (C-2), 149.32 (C-3), 148.91 (C-5), 130.99 (C-4), 45.98 
(C-6). LCMS m/z calc. for C7H6ClN5O [M+H]+: 212.0, found 211.9 with tR 0.65 min. 
tert-butyl (2-(6-chloro-7H-purin-7-yl)ethyl)carbamate (174, 10% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.68 (s, 1H), 8.11 (s, 1H), 5.88 (t, J = 6.1 Hz, 
NH), 4.63 (t, J = 5.4 Hz, 2H), 3.64 (q, J = 5.9 Hz, 2H), 1.41 (s, 9H). 13C NMR (101 
MHz, Chloroform-d) δ 161.55 (C-3), 156.14 (C-8), 152.05 (C-2), 149.62 (C-5), 
142.91 (C-1), 122.17 (C-4), 80.01 (C-8), 46.97 (C-6), 41.42 (C-7), 28.31 (C-10). 
LCMS m/z calc. for C12H16ClN5O2 [M+H]+: 298.1, found 298.0 with tR 2.33 min. 
tert-butyl (2-(6-chloro-9H-purin-9-yl)ethyl)carbamate (180, 60% yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 8.72 (s, 1H, H-2), 8.09 (s, 1H, H-5), 5.14 (d, J = 
6.3 Hz, NH), 4.47 (t, J = 5.7 Hz, 2H, H-6), 3.61 (q, J = 5.9 Hz, 2H, H-7), 1.39 (s, 9H, 
H-10). 13C NMR (101 MHz, Chloroform-d) δ 155.88 (C-8), 151.91 (C-5), 151.84 (C-
3), 150.92 (C-1), 145.66 (C-2), 131.55 (C-4), 80.14 (C-9), 44.19 (C-6), 40.11 (C-7), 
28.24 (C-10). LCMS m/z calc. for C12H16ClN5O2 [M+H]+: 298.1, found 298.0 with tR 
2.40 min. 
General method for regiospecific N-7alkylation of 6-chloropurine. To a solution 
of 6-chloro-9H-purine (6.46 mmol, 1 equiv) in dry THF (10 mL) was added 
isopropylmagnesium chloride (2M/THF, 7.10 mmol, 1.1 equiv) and the reaction was 
stirred at RT under N2 for 30 minutes. The alkylating reagent (19.38 mmol, 3 equiv) 




it was concentrated under reduced pressure. The resulting residue was purified by 
silica gel chromatography, eluting with 5% methanol in DCM to yield exclusively the 
N-7-alkylated-6-chloropurines (189, 191, 192, 193, 195 and 196) as white solids. 
6-chloro-7-ethyl-7H-purine (189, 37% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.84 (s, 1H, H-2), 8.79 (s, 1H, H-5), 4.51 (q, J = 7.2 
Hz, 2H, H-6), 1.48 (t, J = 7.2 Hz, 3H, H-7).13C NMR (101 MHz, DMSO-d6) δ 162.12 
(C-3), 151.97 (C-2), 150.97 (C-5), 142.45 (C-1), 122.34 (C-4), 42.30 (C-6), 17.25 (C-
7). LCMS m/z calc. for C7H7ClN4 [M+H]+: 183.0, found 182.7 with tR 1.88 min. 
2-(6-chloro-7H-purin-7-yl)acetonitrile (191, 44% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.89 (s, 1H, H-2), 8.87 (s, 1H, H-5), H-2, 5.78 (s, 2H, 
H-6). 13C NMR (101 MHz, DMSO) δ 161.99 (C-3), 152.95 (C-2), 151.31 (C-3), 142.78 
(C-1), 122.37 (C-4), 116.26 (C-7), 35.43 (C-6). LCMS m/z calc. for C7H4ClN5 [M+H]+: 
194.0, found 193.9 with tR 1.03 min. 
2-(2-amino-6-chloro-7H-purin-7-yl)acetonitrile (195, 14% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.44 (s, 1H, H-5), 6.82 (s, NH2), 5.59 (s, 2H, H-6). 13C 
NMR (101 MHz, DMSO) δ 164.65 (C-3), 160.95 (C-1), 149.98 (C-5), 142.77 (C-2), 
116.48 (C-4), 114.83 (C-7), 35.13 (C-6). LCMS m/z calc. for C7H5ClN6 [M+H]+: 209.0, 
found 208.9 with tR 0.75 min. 
6-chloro-7-(prop-2-yn-1-yl)-7H-purine (192, 31% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.89 (s, 1H, H-2), 8.84 (s, 1H, H-5), 5.40 (d, J = 2.5 
Hz, 2H, H-6), 3.66 (t, J = 2.5 Hz, 1H, H-8). 13C NMR (101 MHz, DMSO) δ 162.08 (C-
3), 152.54 (C-2), 150.83 (C-5), 142.93 (C-1), 122.30 (C-4), 78.41 (C-7), 78.25 (C-8), 
36.97 (C-6). LCMS m/z calc. for C8H5ClN4 [M+H]+: 193.0, found 192.9 with tR 2.03 
min. 





1H NMR (400 MHz, DMSO) δ 8.94 (s, 1H, H-2), 8.90 (s, 1H, H-5), 5.54 (q, J = 8.8 
Hz, 3H, H-6). 13C NMR (101 MHz, DMSO) δ 161.93 (C-3), 152.84 (C-2), 152.01 (C-
5), 142.88 (C-1), 124.98 (C-7), 122.58 (C-4), 46.79 (q, J = 34.4 Hz, C-6). LCMS m/z 
calc. for C7H4ClF3N4 [M+H]+: 237.0, found 236.7 with tR 2.23 min. 
6-chloro-7-(2,2,2-trifluoroethyl)-7H-purin-2-amine (196, 6% yield). 
 
1H NMR (400 MHz, DMSO) δ 8.49 (s, 1H, H-5), 6.81 (s, NH2), 3.34 (s, 2H, H-6). 13C 
NMR (101 MHz, DMSO) δ 164.52 (C-3), 160.77 (C-1), 150.72 (C-5), 142.88 (C-2), 
123.74 (d, J = 279.8 Hz, C-7), 115.13 (C-4), 46.55 (d, J = 34.1 Hz, C-6). LCMS m/z 
calc. for C7H5ClF3N5 [M+H]+: 252.0, found 251.2 with tR 1.73 min. 
N-(2-(6-chloro-7H-purin-7-yl)ethyl)methanesulfonamide (176, 62 % yield). 
 
To a 0°C solution of amine 175 (1.01 mmol, 1 equiv) and triethylamine (1.113 mmol, 
1.1 equiv) in DCM (3 mL) was added methanesulfonyl chloride (1.11 mmol, 1.1 
equiv). The reaction mixture was stirred at ambient temperature for 16 h. The solvent 
was then removed under reduced pressure and the resulting residue was purified by 
flash chromatography (silica gel), eluting with 5% methanol (containing 0.7 N 
ammonia) in DCM to yield sulfonamide 176 (23% yield) as a white solid. 1H NMR 
(400 MHz, D2O) δ 8.72 (s, 1H, H-2), 8.60 (s, 1H, H-5), 3.83 – 3.69 (m, 2H, H-6), 3.43 
– 3.35 (m, 2H, H-7), 2.89 (s, 3H, H-8). 13C NMR (101 MHz, D2O) δ 151.84 (C-2), 
151.61 (C-5), 143.93 (C-1), 58.43 (C-6), 41.03 (C-8), 39.15 (C-7). LCMS m/z calc. 
for C8H10ClN5O2S [M+H]+: 276.0, found 275.9 with tR 0.82 min. 
General procedure for nucleophilic aromatic substitution of N-7-substituted-6-
chloropurine derivatives. To a stirred solution of primary amine 77 (0.33 mmol, 1 
equiv) in tert-butanol (3 mL) was added N-7-substituted-6-chloropurines (172-174, 
176, 189, 191-193, 195 and 196) (0.43 mmol, 1.3 equiv) and DIPEA (3.3 mmol, 10 
equiv). The reaction mixture was stirred at 110°C for 48 h at which time the solution 
was evaporated in vacuo to dryness. The resulting residue was purified by flash 
chromatography (silica gel), eluting with 5% methanol (containing 0.7 N ammonia) 
in ethylacetate to afford the arylamines (156, 157-160, 163-166, 170, 171 and 177) 
as white solids. 
(S)-5-fluoro-2-(1-((7-(2-hydroxyethyl)-7H-purin-6-yl)amino)propyl)-3-





1H NMR (400 MHz, MeOD) δ 8.27 (s, 1H, H-17), 8.25 (s, 1H, H-20), 7.74 (dt, J = 
13.4, 3.8 Hz, 2H, H-3), 7.65 (dt, J = 7.9, 4.5 Hz, 1H), 7.62 – 7.56 (m, 2H), 7.56 – 7.43 
(m, 2H), 7.18 (dd, J = 10.9, 8.2 Hz, 1H, H-3), 4.69 (dt, J = 15.4, 4.3 Hz, 1H, H-21), 
4.64 – 4.50 (m, 1H, H-21), 4.04 (t, J = 4.6 Hz, 2H, H-22), 2.03 (dtd, J = 20.0, 12.6, 
10.0, 5.9 Hz, 1H, H-14), 1.88 (dq, J = 14.7, 7.3 Hz, 1H, H-14), 0.91 (t, J = 7.3 Hz, 
3H, H-15). 13C NMR (101 MHz, MeOD) δ 162.51 (C-7), 159.88, 159.85, 159.20 (C-
18), 158.11, 151.70 (C-17), 151.16 (C-16), 149.40 (C-2), 145.90 (C-20), 136.04 (C-
8), 135.11 (d, J = 10.5 Hz, C-4), 122.97 (d, J = 4.1 Hz, C-3), 113.08 (C-5), 112.87 
(C-19), 110.18 (d, J = 6.0 Hz, C-1), 61.55 (C-22), 54.28 (C-13), 49.45 (C-21), 26.27 
(C-14), 9.77 (C-15). LCMS m/z calc. for C24H22FN7O2 [M+H]+: 460.2, found 459.9 
with tR 2.32 min (95%). 
(S)-2-(6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl) 
amino)-7H-purin-7-yl)acetamide (158, 10% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.28 (s, 1H, H-17), 8.22 (s, 1H, H-20), 7.79 (dt, 
J = 8.4, 4.2 Hz, 1H), 7.66 (qd, J = 8.2, 7.3, 2.5 Hz, 2H), 7.62 – 7.46 (m, 4H), 7.21 
(dd, J = 10.9, 8.2 Hz, 1H, H-3), 5.32-5.14(m, 2H, H-21), 2.06 (dtd, J = 14.9, 7.4, 4.5 
Hz, 1H, H-14), 1.87 (dp, J = 14.8, 7.2 Hz, 1H, H-14), 0.90 (t, J = 7.4 Hz, 3H, H-15). 
13C NMR (101 MHz, Methanol-d4) δ 170.21 (C-22), 162.53 (C-7), 159.90 (C-18), 
159.77 (d, J= 4.3, C-6) 158.96 (C-12), 151.99 (C-17), 149.21 (C-2), 135.92 (C-20), 
135.19 (d, J = 10.3 Hz, C-4), 129.33 (C-10), 129.01 (C-9), 128.79 (C-11), 122.82 (d, 
J = 4.3 Hz, C-3), 113.20 (C-5), 112.99 (C-1), 110.22 (C-19), 54.13 (C-13), 49.03 (C-
21), 26.23 (C-14), 9.52 (C-15). LCMS m/z calc. for C24H21FN8O2 [M+H]+: 473.2, found 
472.9 with tR 2.28 min (96%). 
(S)-2-(1-((7-ethyl-7H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-





1H NMR (400 MHz, MeOD) δ 8.31 (s, 1H, H-17), 8.28 (s, 1H, H-20), 7.77 (td, J = 8.2, 
5.4 Hz, 1H), 7.72 – 7.56 (m, 4H), 7.56 – 7.50 (m, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.18 
(ddd, J = 10.9, 8.2, 1.0 Hz, 1H, H-3), 5.05 (dd, J = 9.2, 3.7 Hz, 1H, H-13), 4.65 (ddt, 
J = 21.8, 14.6, 7.3 Hz, 2H, H-21), 2.05 (ddp, J = 15.0, 7.5, 3.8 Hz, 1H, H-14), 1.93 
(ddt, J = 14.3, 9.2, 7.3 Hz, 1H, H-14), 1.63 (t, J = 7.2 Hz, 3H, H-22), 0.89 (t, J = 7.3 
Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 162.55 (C-7), 159.88, 159.85, 159.42 
(C-18), 158.11, 151.78 (C-17), 151.08 (C-16), 150.03 (C-2), 145.87 (C-20), 136.30 
(C-8), 135.17 (d, J = 10.5 Hz, C-4), 122.46 (d, J = 4.1 Hz, C-3), 113.10 (C-5), 112.89 
(C-19), 110.20 (d, J = 6.0 Hz, C-1), 54.30 (C-13), 41.97 (C-21), 26.22 (C-14), 16.08 
(C-22), 9.77 (C-15). LCMS m/z calc. for C24H22FN7O [M+H]+: 444.2, found 443.9 with 
tR 2.51 min (96%). 
(S)-2-(6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-7H-purin-7-yl)acetonitrile (163, 37% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.33 (s, 2H, H-17/20), 7.77 – 7.67 (m, 2H), 7.63 
(ddt, J = 8.7, 7.6, 3.0 Hz, 1H), 7.57 – 7.49 (m, 3H), 7.47 (d, J = 8.2 Hz, 1H), 7.14 
(ddd, J = 10.8, 8.2, 1.0 Hz, 1H, H-3), 5.99 – 5.76 (m, NH), 3.89 (pd, J = 6.3, 4.9 Hz, 
1H, H-21), 3.53 (qd, J = 7.0, 2.0 Hz, 1H, H-21), 2.19 – 1.88 (m, 2H, H-14), 0.92 (t, J 
= 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 162.46 (C-7), 159.83 (C-
18), 159.73 (d, J = 4.2 Hz, C-6), 159.10 (d, J = 13.4 Hz, C-12), 152.59 (C-17), 150.24 
(C-16), 149.16 (C-2), 145.95 (d, J = 2.4 Hz, C-20), 135.86 (C-8), 135.16 (d, J = 10.6 
Hz, C-4), 129.35 (d, J = 4.7 Hz, C-10), 129.08 (C-9), 128.78 (C-11), 122.74 (d, J = 
4.2 Hz, C-8), 114.69 (d, J = 1.5 Hz, CN), 113.09 (d, J = 20.9 Hz, C-5)), 111.48 (C-
19), 110.21 (d, J = 6.1 Hz, C-5), 20.01 (C-21), 54.57 (C-13), 25.95 (C-14), 9.98 (C-
15). LCMS m/z calc. for C24H19FN8O [M+H]+: 455.2, found 454.8 with tR 2.55 min 
(99%). 
(S)-5-fluoro-3-phenyl-2-(1-((7-(prop-2-yn-1-yl)-7H-purin-6-





1H NMR (400 MHz, MeOD) δ 8.31 (s, 2H, H-17/20), 7.77 (td, J = 8.2, 5.4 Hz, 1H), 
7.71 – 7.61 (m, 1H), 7.61 – 7.57 (m, 2H), 7.54 – 7.44 (m, 1H), 7.18 (ddd, J = 10.9, 
8.2, 1.1 Hz, 1H, H-3), 5.48 (qd, J = 18.3, 2.6 Hz, 2H, H-21), 5.00 (dd, J = 8.9, 3.9 Hz, 
1H, H-13), 3.63 – 3.39 (m, 1H, H-23), 2.07 (dtd, J = 15.0, 7.5, 4.0 Hz, 1H, H-14), 
1.91 (ddt, J = 14.3, 8.9, 7.2 Hz, 1H, H-14), 0.92 (t, J = 7.4 Hz, 3H, H-15). 13C NMR 
(101 MHz, MeOD) δ 162.53 (C-7), 159.90, 159.68 (d, J = 4.3 Hz, C-18), 158.89, 
152.32, 150.27, 149.13 (C-2), 145.21 (C-20), 135.87 (C-8), 135.26 (d, J = 10.6 Hz, 
C-4), 129.70 – 129.20 (m), 128.92 (d, J = 7.7 Hz), 122.78 (d, J = 4.2 Hz, C-3), 113.16 
(d, J = 20.9 Hz, C-5), 111.73, 110.22 (d, J = 6.1 Hz, C-1), 77.19 (C-23), 77.05 (C-
22), 54.14 (C-13), 36.34 (C-21), 26.23 (C-14), 9.61 (C-15). LCMS m/z calc. for 
C25H20FN7O [M+H]+: 454.2, found 453.9 with tR 2.57 min (99%). 
(S)-N-(2-(6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-7H-purin-7-yl)ethyl)methanesulfonamide (165, 3% yield).  
 
1H NMR (400 MHz, MeOD) δ 8.33 (s, 1H, H-17), 8.27 (s, 1H, H-20), 7.82 – 7.70 (m, 
2H), 7.63 (dd, J = 12.1, 6.0 Hz, 3H), 7.51 (d, J = 8.2 Hz, 2H), 7.30 – 7.14 (m, 1H, H-
3), 5.00 (dd, J = 8.9, 4.4 Hz, 1H, H-13), 4.78 – 4.41 (m, 2H, H-21), 3.85 – 3.41 (m, 
2H, H-22), 2.89 (s, 3H, H-23), 2.01 (dd, J = 15.4, 8.2 Hz, 2H, H-14), 0.89 (t, J = 7.4 
Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 162.53 (C-7), 159.90 (C-18), 159.11 
(d, J = 32.4 Hz), 152.31, 150.12 (C-16), 149.13 (C-2), 147.51 (C-20), 135.87 (C-8), 
135.25(d, J = 10.6 Hz, C-4), 129.40 (d, J = 3.9 Hz), 129.26, 129.03, 128.78, 122.78 
(d, J = 4.2 Hz, C-3), 113.11 (d, J = 20.9 Hz, C-5), 111.75, 110.26 (d, J = 6.1 Hz, C-
1), 58.11 (C-21), 54.58 (C-13), 38.54 (C-22), 25.86 (C-14), 23.39 (C-23), 10.08 (C-
15). LCMS m/z calc. for C25H25FN8O3S [M+H]+: 537.2, found 536.9 with tR 2.40 min 
(90%). 
(S)-5-fluoro-3-phenyl-2-(1-((7-(2,2,2-trifluoroethyl)-7H-purin-6-





1H NMR (400 MHz, MeOD) δ 8.38 (s, 1H, H-17), 8.35 (s, 1H, H-20), 7.77 (td, J = 8.2, 
5.4 Hz, 1H), 7.73 – 7.55 (m, 3H), 7.51 (dd, J = 7.5, 2.0 Hz, 1H), 7.45 (d, J = 8.3 Hz, 
1H), 7.19 (dd, J = 10.9, 8.2 Hz, 1H, H-19), 5.68 (dq, J = 16.7, 8.4 Hz, 1H, H-21), 5.45 
(dq, J = 17.1, 8.7 Hz, 1H, H-21), 4.99 (dd, J = 9.6, 3.7 Hz, 1H, H-13), 2.40 – 1.80 (m, 
1H, H14), 0.86 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 162.56 (C-
7), 159.93, 159.70 (C-18), 159.11 (d, J = 32.4 Hz), 152.31, 150.12 (C-16), 149.22 
(C-2), 147.09 (C-20), 135.87 (C-8), 135.22 (d, J = 10.6 Hz, C-4), 129.40 (d, J = 3.9 
Hz), 129.26, 129.03, 128.78, 122.61 (d, J = 4.2 Hz, C-3), 113.11 (d, J = 20.9 Hz, C-
5), 111.75, 110.26 (C-1), 66.00 (C-21), 54.54 (C-13), 25.88 (C-14), 9.76 (C-16). 
LCMS m/z calc. for C24H19F4N7O [M+H]+: 498.2, found 497.8 with tR 2.70 min (90%). 
(S)-2-(2-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-7H-purin-7-yl)acetonitrile (170, 9% yield). 
 
1H NMR (400 MHz, MeOD) δ 8.04 (s, 1H, H-20), 7.80 (td, J = 8.3, 5.5 Hz, 1H), 7.69 
– 7.55 (m, 4H), 7.55 – 7.47 (m, 1H), 7.22 (ddd, J = 10.9, 8.2, 1.0 Hz, 1H, H-3), 5.85 
– 5.55 (m, 1H, H-21), 5.06 (dd, J = 8.9, 4.1 Hz, 1H, H-21), 2.14 – 2.02 (m, 1H, H-
14), 1.98 – 1.78 (m, 1H, H-14), 0.89 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
MeOD) δ 162.56 (C-7), 160.05, 159.93, 159.85, 158.48, 150.75 (C-16), 149.17, 
144.75 (C-20), 135.78 (C-8), 135.21 (d, J = 10.6 Hz, C-4), 129.38 (d, J = 3.7 Hz), 
129.31, 128.94 (d, J = 3.2 Hz), 122.93 (C-3), 114.73, 113.31, 113.10 (C-5), 110.26 
(C-1), 105.64 , 53.59 (C-13), 26.04 (C-14), 19.68 (C-21), 9.67 (C-15). LCMS m/z 
calc. for C24H20FN9O [M+H]+: 470.2, found 469.9 with tR 2.19 min (96%). 
(S)-2-(1-((2-amino-7-(2,2,2-trifluoroethyl)-7H-purin-6-yl)amino)propyl)-5-fluoro-





1H NMR (400 MHz, MeOD) δ 8.08 (s, 1H, H-20), 7.81 (td, J = 8.3, 5.4 Hz, 1H), 7.66 
(ddd, J = 7.7, 6.1, 2.2 Hz, 1H), 7.59 (t, J = 2.6 Hz, 3H), 7.51 (dd, J = 8.6, 6.1 Hz, 2H), 
7.23 (dd, J = 10.9, 8.2 Hz, 2H), 5.47 (dt, J = 16.6, 8.3 Hz, 1H, H-21), 5.37 (dq, J = 
17.1, 8.7 Hz, 1H, H-21), 5.08 (dd, J = 9.1, 3.9 Hz, 1H, H-13), 2.09 – 1.98 (m, 1H, H-
14), 1.86 (ddd, J = 14.0, 8.9, 7.0 Hz, 1H, H-14), 0.83 (t, J = 7.3 Hz, 3H, H-15). 13C 
NMR (101 MHz, MeOD) δ 162.53 (C-7), 159.90, 159.68 (C-18), 150.54 (C-16), 
149.15 (C-2), 147.09 (C-20), 135.79 (C-8), 135.21 (d, J = 10.6 Hz, C-4), (129.41 (d, 
J = 5.3 Hz), 129.29, 128.91 (d, J = 10.8 Hz), 122.67 (C-3), 113.16 (d, J = 20.9 Hz, 
C-5), 111.73, 110.26 (C-1), 53.40 (C-13), 26.09 (C-14), 9.44 (C-15). LCMS m/z calc. 
for C24H20F4N8O [M+H]+: 513.2, found 512.8 with tR 2.31 min (96%). 
tert-butyl (S)-(2-(6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-7H-purin-7-yl)ethyl)carbamate (177, 30% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.31 (s, 1H, H-17), 8.20 (s, 1H, H-20), 7.78 – 7.71 
(m, 3H), 7.58 (ddd, J = 34.9, 15.9, 7.9 Hz, 4H), 7.44 (d, J = 8.2 Hz, 1H), 7.17 (t, J = 
9.3 Hz, 1H), 5.05 (d, J = 9.5 Hz, NH), 4.61 (t, J = 7.4 Hz, 2H, H-21), 3.76 – 3.44 (m, 
2H, H-22), 2.18 (dt, J = 21.3, 10.3 Hz, 1H, H-14), 1.74 (s, 1H, H-14), 1.33 (s, 9H, H-
25), 0.91 (t, J = 7.7 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 162.52 (C-7), 
159.89 (C-18), 159.53 (C-6), 158.59 (C-16), 157.27 (C-12), 151.81 (C-17), 150.35 
(C-, 149.35 (C-2), 145.63 (C-20), 135.96 (C-8), 135.13 (d, J = 10.7 Hz, C-4), 129.31 
(C-10), 129.09 (C-9), 128.75 (C-11), 122.87 (C- 8), 112.99 (d, J = 20.4 Hz, C-5), 
111.75, 110.22 (d, J = 6.0 Hz, C-1), 79.23 (C-24), 54.89 (C-13), 45.49 (C-21), 41.16 
(C-22), 27.19 (C-25), 25.51 (C-14), 10.42 (C-15). LCMS m/z calc. for C29H31FN8O3 
[M+H]+: 559.3, found 558.8 with tR 2.64 min. 
General method for N-Boc deprotection. To the Boc-protected amines (174 and 
177) (0.143 mmol, 1 equiv) was added 4 N HCl in 1,4-dioxane (3 mL) and the solution 
was stirred at ambient temperature for 2 h. The solvent was removed in vacuo and 
the resulting yellow solid was triturated with diethyl ether to yield the hydrochloride 
salt of the amines (175 and 157).  





1H NMR (500 MHz, Chloroform-d) δ 8.68 (s, 1H, H-2), 8.11 (s, 1H, H-5), 4.42 (t, J = 
3.4 Hz, 2H, H-6), 3.10 (tt, J = 6.3, 3.3 Hz, 2H, H-7). 13C NMR (101 MHz, Chloroform-
d) δ 161.23 (C-3), 156.22 (C-2), 149.53 (C-5), 142.75 (C-1), 122.66 (C-4), 46.69 (C-
6), 41.72 (C-7). LCMS m/z calc. for C7H8ClN5 [M+H]+: 198.1, found 197.9 with tR 1.40 
min. 
(S)-2-(1-((7-(2-aminoethyl)-7H-purin-6-yl)amino)propyl)-5-fluoro-3-
phenylquinazolin-4(3H)-one (157, 100 % yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.74 (s, 1H, H-17), 8.65 (s, 1H, H-20), 7.85 (td, 
J = 8.2, 5.4 Hz, 1H), 7.75 – 7.55 (m, 6H), 7.26 (dd, J = 10.8, 8.2 Hz, 1H, H-3), 5.24 
(dddd, J = 27.8, 15.6, 8.3, 4.2 Hz, 2H, H-21), 3.68 (tq, J = 13.4, 8.0, 6.7 Hz, 2H, H-
22), 2.32 – 2.02 (m, 2H, H-14), 0.89 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, 
Methanol-d4) δ 162.53 (C-7), 159.90 (C-18), 159.18 (d, J = 4.4 Hz, C-6), 158.05 (C-
12), 152.02 (C-16), 149.85 (C-2), 148.49 (C-17), 146.19 (C-20), 135.68 (d, J = 10.6 
Hz, C-4), 135.47 (C-8), 129.72 (d, J = 3.9 Hz, C-10), 129.52 (C-9), 128.92 (d, J = 8.8 
Hz, C-11), 122.39 (C-3), 113.71 (d, J = 20.7 Hz, C-5), 112.07 (C-19), 110.31 (C-10), 
55.60 (C-13), 44.77 (C-21), 39.78 (C-22), 25.64 (C-14), 10.05 (C-15). LCMS m/z 
calc. for C24H23FN8O [M+H]+: 459.2, found 459.0 with tR 2.06 min (95%). 
(S)-1-(2-(6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-7H-purin-7-yl)ethyl)urea (159, 68% yield). 
 
To a stirred solution of amine hydrochloride salt 157 (0.079 mmol, 1 equiv) and 
triethylamine (0.238 mmol, 3 equiv) in DCM (2 mL) was added trimethylsilyl 
isocyanate (0.086 mmol, 2 equiv). The reaction mixture was stirred for 18 h at RT 
under a nitrogen atmosphere. The solvent was then removed under reduced 
pressure and the resulting residue was purified by flash chromatography (silica gel), 
eluting with 7.5% methanol (containing 0.7 N ammonia) in DCM to afford urea 159 
(68% yield) as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 8.34 (s, 1H, H-17), 
8.26 (s, 1H, H-20), 7.96 – 7.31 (m, 6H), 7.17 (s, 1H, H-3), 5.41 (s, 1H, H-25), 4.69 




(s, 3H, H-15). 13C NMR (101 MHz, MeOD) δ 162.50 (C-6), 160.70 (C-24), 159.87 (C-
18), 159.41, 151.32 (C-17), 150.66 (C-16), 149.33 (C-2), 145.97 (C-20), 135.94, 
135.21 (d, J = 10.9 Hz, C-4), 129.41 (d, J = 8.3 Hz), 129.25, 128.95 (d, J = 3.9 Hz), 
122.87, 113.01 (d, J = 20.9 Hz, C-5), 111.81, 110.19 (C-1), 55.07 (C-13), 46.36 (C-
21), 40.86 (C-22), 25.58 (C-14), 10.33 (C-15). LCMS m/z calc. for C25H24FN9O2 
[M+H]+: 502.2, found 501.9 with tR 2.31 min (97%). 
7.3.5 Experimental for Chapter 5  
General procedure for amide coupling. To a cooled (0°C) solution of 4,6-
dichloropyrimidine-5-carboxylic acid 228 (5.18 mmol, 1 equiv) and BEP (5.70 mmol, 
1.1 equiv) in DCM (15 mL) was added DIPEA (18.13 mmol, 3.5 equiv). The resulting 
mixture was stirred at RT for 1 h. Amine (5.18 mmol, 1 equiv) was then added. After 
stirring for 18 h at RT, the solvent was evaporated under reduced pressure. The 
resulting residue was purified using silica gel chromatography (DCM/ ethyl acetate: 
70: 30) to yield the amides (230-238). 
4,6-dichloro-N-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxamide (230, 21% 
yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.92 (s, 1H, H-2), 8.05 (s, 1H, H-8), 7.59 (s, 1H, 
H-6), 3.93 (s, 3H, H-7). 13C NMR (101 MHz, Methanol-d4) δ 163.20 (C-4), 158.60 (C-
2), 158.15 (C-1), 138.05 (C-5), 130.09 (C-8), 129.87 (C-3), 122.48 (C-6), 37.91 (C-
7). LCMS m/z calc. for C9H7Cl2N5O [M+H]+: 272.0, found 272.1 with tR 2.15 min. 
4,6-dichloro-N-(1-methyl-1H-pyrazol-3-yl)pyrimidine-5-carboxamide (231, 33% 
yield). 
 
1H NMR (400 MHz, Chloroform-d) δ 9.23 (s, NH), 8.85 (s, 1H, H-2), 7.33 (d, J = 2.3 
Hz, 1H, H-7), 6.82 (d, J = 2.4 Hz, 1H, H-6), 3.74 (s, 3H, H-8). 13C NMR (101 MHz, 
Chloroform-d) δ 159.13 (C-4), 158.32 (C-1), 158.16 (C-2), 145.78 (C-5), 131.41 (C-
7), 129.77 (C-3), 98.21 (C-6), 38.74 (C-8). LCMS m/z calc. for C9H7Cl2N5O [M+H]+: 
272.0, found 271.8 with tR 2.22 min. 






1H NMR (400 MHz, Chloroform-d) δ 8.86 (s, 1H, H-2), 7.45 (d, J = 2.0 Hz, 1H, H-7), 
6.35 (d, J = 2.0 Hz, 1H, H-6), 3.84 (s, 3H, H-8). 13C NMR (101 MHz, Chloroform-d) 
δ 159.91 (C-4), 158.86 (C-2), 158.49 (C-1), 138.60 (C-7), 133.45 (C-5), 129.30 (C-
3), 101.28 (C-6), 36.13 (C-8). LCMS m/z calc. for C9H7Cl2N5O [M+H]+: 272.0, found 
271.8 with tR 2.21 min. 
4,6-dichloro-N-(5-methylthiazol-2-yl)pyrimidine-5-carboxamide (233, 10% 
yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.98 (s, 1H, H-2), 2.76 (s, 3H, H-7). 13C NMR 
(101 MHz, Methanol-d4) δ 162.15 (C-4), 158.75 (C-2), 158.44 (C-1), 147.30 (C-5), 
145.70 (C-6), 128.77 (d, J = 26.3 Hz, C-3), 13.67 (C-7). LCMS m/z calc. for 
C8H5Cl2N5OS [M+H]+: 290.0, found 289.8 with tR 2.41 min. 
4,6-dichloro-N-(isoxazol-3-yl)pyrimidine-5-carboxamide (234, 11% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.94 (s, 1H, H-2), 8.67 (d, J = 1.8 Hz, 1H, H-7), 
7.09 (d, J = 1.7 Hz, 1H, H-6). 13C NMR (101 MHz, Methanol-d4) δ 162.96 (C-4), 
160.03 (C-1), 158.37 (C-2), 158.28 (C-7), 156.76 (C-5), 104.04 (C-6). LCMS m/z 
calc. for C8H4Cl2N4O2 [M+H]+: 259.0, found 261.9 with tR 2.67 min. 
4,6-dichloro-N-phenylpyrimidine-5-carboxamide (235, 25% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.92 (s, 1H, H-2), 7.73 – 7.61 (m, 2H, H-6), 7.41 
(dd, J = 8.6, 7.4 Hz, 2H, H-7), 7.27 – 7.18 (m, 1H, H-8). 13C NMR (101 MHz, 
Methanol-d4) δ 160.13 (C-4), 158.40 (C-1), 158.01 (C-2), 137.58 (C-5), 130.25 (C-
3), 128.76 (C-7), 124.97 (C-8), 119.88 (C-6). LCMS m/z calc. for C11H7Cl2N3O 
[M+H]+: 268.0, found 269.1 with tR 2.60 min. 





1H NMR (400 MHz, Methanol-d4) δ 8.87 (s, 1H, H-2), 2.91 (tt, J = 7.4, 3.9 Hz, 1H, H-
5), 0.94 – 0.80 (m, 2H, H-6), 0.75 – 0.55 (m, 2H, H-6). 13C NMR (101 MHz, Methanol-
d4) δ 163.66 (C-4), 158.36 (C-1), 157.91 (C-2), 129.99 (C-3), 22.27 (C-5), 4.96 (C-
6). LCMS m/z calc. for C8H7Cl2N3O [M+H]+: 232.0, found 233.9 with tR 1.44 min. 
4,6-dichloro-N-cyclohexylpyrimidine-5-carboxamide (237, 28% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.86 (s, 1H, H-2), 3.89 (tt, J = 10.2, 3.9 Hz, 1H, 
H-5), 2.24 – 1.94 (m, 2H, H-6), 1.82 (dp, J = 10.9, 3.6, 3.0 Hz, 2H, H-6), 1.68 (dq, J 
= 12.1, 3.8 Hz, 1H, H-8), 1.53 – 1.09 (m, 4H, H-7). 13C NMR (101 MHz, Methanol-
d4) δ 161.36 (C-4), 158.31 (C-2), 157.73 (C-1), 130.28 (C-3), 48.96 (C-5), 31.81 (C-
6), 25.19 (C-8), 24.43 (C-7). LCMS m/z calc. for C11H13Cl2N3O [M+H]+: 274.0, found 
274.2 with tR 2.68 min. 
4,6-dichloro-N-(quinolin-4-yl)pyrimidine-5-carboxamide (238, 31% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.98 (s, 1H, H-2), 8.89 (d, J = 5.1 Hz, 1H, H-7), 
8.29 (d, J = 5.1 Hz, 1H), 8.24 (dd, J = 8.5, 1.2 Hz, 1H), 8.10 (dd, J = 8.6, 1.1 Hz, 1H), 
7.84 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 7.68 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 6.63 – 6.34 
(m, 1H, H-6). 13C NMR (101 MHz, Methanol-d4) δ 163.20 (C-4), 161.26, 158.30 (C-
2), 150.25 (C-2), 148.29, 141.26, 140.62, 130.05 (d, J = 5.4 Hz), 128.44, 126.90, 
121.31, 121.16, 119.32, 113.06, 107.47 (C-6). LCMS m/z calc. for C14H8Cl2N4O 
[M+H]+: 319.0, found 321.2 with tR 2.08 min. 
4,6-dichloropyrimidine-5-carboxamide (239, 63% yield). 
 
A solution of 4,6-dichloropyrimidine-5-carboxylic acid 228 (5.18 mmol, 1 equiv) in 
thionyl chloride (5 mL) was refluxed for 1 h. After cooling at ambient temperature, 
the solvent was removed under reduced pressure. THF (5 mL) and 25% aqueous 
ammonia (5 mL) were then added to the residue, and the mixture was stirred at 0°C 




residue was purified using silica gel chromatography (DCM/ ethyl acetate: 70: 30) to 
yield primary amide 239. 1H NMR (400 MHz, Methanol-d4) δ 8.87 (s, 1H, H-2). 13C 
NMR (101 MHz, Methanol-d4) δ 164.51 (C-4), 158.01 (C-1), 157.69 (C-2), 130.36 
(C-3). LCMS m/z calc. for C5H3Cl2N3O [M+H]+: 192.0, found 193.9 with tR 0.62 min. 
General procedure for nucleophilic aromatic substitution of 4, 6-
dichloropyrimidine derivatives. To a solution of the above amides (230-239 and 
260) in dioxane (3 mL) was added primary amine 77 (0.672 mmol, 1 equiv) and 
DIPEA (6.72 mmol, 10 equiv). The reaction mixture was stirred for 1 h at 50°C at 
which time it was concentrated under reduced pressure. The crude product was 
purified by flash chromatography (DCM/ ethyl acetate: 40: 60) to afford compounds 





1H NMR (400 MHz, Methanol-d4) δ 8.24 (s, 1H, H-17), 8.09 (s, 1H, H-24), 7.79 (td, 
J = 8.2, 5.4 Hz, 1H), 7.73 – 7.51 (m, 6H), 7.50 – 7.42 (m, 2H), 7.21 (ddd, J = 10.9, 
8.2, 1.0 Hz, 1H), 4.91 (dd, J = 8.8, 4.2 Hz, NH), 3.93 (s, 3H, H-23), 1.98 (ddt, J = 
15.0, 7.5, 3.7 Hz, 1H, H-14), 1.78 (ddt, J = 14.4, 8.7, 7.2 Hz, 1H, H-14), 0.82 (t, J = 
7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 171.56 (C-16), 162.50, 
160.93, 157.37 (C-17), 154.94, 149.12, 140.62, 138.02, 135.77, 135.17 (d, J = 10.5 
Hz, C-4), 130.18, 129.48, 129.33, 128.90 (d, J = 11.9 Hz), 123.03, 122.50, 120.94, 
119.32, 113.22 (d, J = 20.9 Hz, C-3), 111.86, 110.28 (d, J = 6.1 Hz, C-5), 107.47, 
53.95 (C-13), 37.82 (C-23), 26.09 (C-14), 9.31 (C-15). LCMS m/z calc. for 








1H NMR (400 MHz, Methanol-d4) δ 8.25 (s, 1H, H-17), 7.79 (td, J = 8.2, 5.5 Hz, 1H), 
7.69 – 7.53 (m, 5H), 7.48 (dd, J = 8.5, 5.7 Hz, 2H), 7.26 – 7.17 (m, 1H), 6.70 (d, J = 
2.3 Hz, 1H, H-22), 4.92 (dd, J = 8.8, 4.2 Hz, NH), 2.06 – 1.91 (m, 1H, H-14), 1.79 
(ddt, J = 16.0, 14.4, 7.3 Hz, 1H, H-14), 0.82 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 
MHz, Methanol-d4) δ 162.49, 161.78, 159.91, 157.69, 157.34 (C-17), 154.96, 
149.12, 146.05, 135.76, 135.13 (d, J = 10.4 Hz, C-4), 131.24, 129.49, 129.32 (d, J = 
2.5 Hz), 128.96, 128.86, 123.09 (d, J = 4.2 Hz), 113.20 (d, J = 20.4 Hz, C-3), 112.14, 
110.28 (d, J = 6.1 Hz, C-5), 97.60 (C-22), 53.95 (C-13), 37.51 (C-24), 26.09 (C-14), 
9.30 (C-15). LCMS m/z calc. for C26H22ClFN8O2 [M+H]+: 533.2, found 532.8 with tR 





1H NMR (400 MHz, Methanol-d4) δ 8.29 (s, 1H, H-17), 7.79 (td, J = 8.2, 5.4 Hz, 1H), 
7.66 – 7.55 (m, 4H), 7.51 – 7.45 (m, 3H), 7.21 (ddd, J = 10.9, 8.2, 1.0 Hz, 1H), 6.52 
(d, J = 2.1 Hz, 1H, H-22), 4.93 (dd, J = 8.8, 4.1 Hz, NH), 3.85 (s, 3H, H-24), 2.01 – 
1.91 (m, 1H, H-14), 1.86 – 1.71 (m, 1H, H-14), 0.83 (t, J = 7.4 Hz, 4H, H-15). 13C 
NMR (101 MHz, Methanol-d4) δ 171.57 (C-16), 162.63 (C-20), 162.51 (C-16), 
159.92, 159.62 (d, J = 4.2 Hz), 157.79, 157.66 (C-17), 155.37, 149.07, 137.96, 
135.75, 135.26 (d, J = 10.7 Hz, C-4), 129.52, 129.36 (d, J = 5.1 Hz), 128.91 (d, J = 
5.8 Hz), 122.92 (d, J = 4.3 Hz), 113.27 (d, J = 20.8 Hz, C-3), 111.24, 110.25 (d, J = 
6.1 Hz, C-5), 99.65 (C-22), 53.96 (C-13), 34.87 (C-24), 26.10 (C14), 9.29 (C-15). 







(243, 29% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.27 (s, 1H, H-17), 7.77 (td, J = 8.2, 5.4 Hz, 1H), 
7.62 (ddd, J = 7.8, 5.0, 3.2 Hz, 1H), 7.56 (dq, J= 3.4, 1.8, 1.3 Hz, 3H) 7.51 – 7.44 
(m, 2H), 7.25 – 7.14 (m, 1H), 5.11 – 4.99 (m, NH), 2.73 (s, 3H, H-23), 2.02 – 1.94 
(m, 1H, H-14), 1.82 (ddt, J = 17.0, 15.1, 7.8 Hz, 1H, H-14), 0.82 (t, J = 7.3 Hz, 3H, 
H-15). 13C NMR (101 MHz, Methanol-d4) δ 171.57 (C-16), 162.47 (C-20), 161.63, 
159.83, 159.68 (d, J = 2.3 Hz), 159.39 (C-17), 157.86, 157.65, 157.15, 155.64, 
149.13, 135.75, 135.17 (d, J = 10.6 Hz, C-4), 129.41, 129.28 (d, J = 5.7 Hz), 129.12, 
128.78, 123.07, 113.22 (d, J = 21.0 Hz, C-3), 110.67, 110.23 (d, J = 6.2 Hz, C-5), 
54.34 (C-13), 25.78 (C-14), 13.62 (C-23), 9.58 (C-15). LCMS m/z calc. for 
C25H20ClFN8O2S [M+H]+: 551.1, found 550.8 with tR 2.82 min (96%). 
(S)-4-chloro-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-N-(isoxazol-3-yl)pyrimidine-5-carboxamide (244, 37% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.62 (d, J = 1.8 Hz, 1H), 8.25 (s, 1H, H-17), 7.75 
(td, J = 8.2, 5.4 Hz, 1H), 7.61 (ddd, J = 7.6, 4.5, 3.3 Hz, 1H), 7.55 (dd, J = 4.6, 1.8 
Hz, 3H), 7.50 – 7.40 (m, 2H), 7.17 (ddd, J = 10.9, 8.2, 1.0 Hz, 1H), 7.11 (d, J = 1.8 
Hz, 1H, H-22), 4.90 (dd, J = 8.9, 4.2 Hz, NH), 3.78 – 3.44 (m, 1H, H-13), 1.97 (qd, J 
= 7.2, 4.3 Hz, 1H, H-14), 1.80 (ddt, J = 16.1, 14.4, 7.4 Hz, 1H, H-14), 0.82 (t, J = 7.3 
Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 162.45 (d, J = 3.3 Hz), 159.80, 
159.72, 159.63 (d, J = 4.3 Hz), 159.56 (C-23), 157.68, 157.61 (C-17), 157.22, 
155.17, 149.10, 135.75, 135.14 (d, J = 10.6 Hz, C-4), 129.45, 129.29 (d, J = 2.7 Hz), 
129.08, 128.83, 123.05 (d, J = 4.1 Hz), 113.21 (d, J = 20.8 Hz, C-3), 111.67, 110.22 
(d, J = 6.0 Hz, C-5), 99.09 (C-99), 54.16 (C-13), 25.93 (C-14), 9.51 (C-15). LCMS 





yl)propyl)amino)-N-phenylpyrimidine-5-carboxamide (245, 47% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.26 (s, 1H, H-17), 7.73 (t, J = 6.3 Hz, 3H), 7.66 
– 7.49 (m, 4H), 7.47 (dd, J = 7.7, 2.0 Hz, 1H), 7.43 – 7.35 (m, 3H), 7.19 (q, J = 10.8, 
9.0 Hz, 2H), 4.91 (dd, J = 8.7, 4.1 Hz, 1H, NH), 1.98 (dqd, J = 14.8, 8.8, 7.5, 3.5 Hz, 
1H, H-14), 1.83 – 1.69 (m, 1H, H-14), 0.81 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 
MHz, Methanol-d4) δ 162.42 (C-20), 159.82, 159.62, 157.77, 157.32 (C-17), 154.92, 
149.05, 138.01, 135.74, 135.16 (d, J = 10.6 Hz, C-4), 129.52, 129.33 (d, J = 4.8 Hz), 
128.91 (d, J = 5.5 Hz), 128.60 (C-23), 124.65, 122.99 (d, J = 4.2 Hz), 120.01 (C-22), 
113.21 (d, J = 20.9 Hz, C-3), 112.70, 110.21 (d, J = 6.0 Hz, C-5), 53.92 (C-13), 26.11 
(C-14), 9.30 (C-15). LCMS m/z calc. for C28H22ClFN6O2 [M+H]+: 529.2, found 529.1 
with tR 3.36 min (98%). 
(S)-4-chloro-N-cyclopropyl-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-
dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carboxamide (246, 51% 
yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.19 (s, 1H, H-17), 7.75 (td, J = 8.2, 5.4 Hz, 1H), 
7.63 – 7.42 (m, 6H), 7.13 (ddd, J = 10.9, 8.2, 1.0 Hz, 1H), 4.92 (dd, J = 8.5, 4.2 Hz, 
1H), 2.97 (dt, J = 7.3, 3.5 Hz, 1H, H-21), 1.97 (dtt, J = 14.8, 7.4, 3.6 Hz, 1H, H-14), 
1.81 – 1.59 (m, 1H, H-14), 0.85 (dd, J = 7.3, 2.0 Hz, 2H, H-22), 0.81 (t, J = 7.4 Hz, 
3H, H-15), 0.68 (td, J = 3.6, 1.8 Hz, 2H, H-22). 13C NMR (101 MHz, Methanol-d4) δ 
165.69 (C-20), 162.39, 159.81, 159.46 (d, J = 4.2 Hz), 157.69, 157.27 (C-17), 
154.83, 149.03, 135.75, 135.21 (d, J = 10.7 Hz, C-4), 129.57, 129.37 (d, J = 2.0 Hz), 
128.98 (d, J = 3.8 Hz), 123.02 (d, J = 4.2 Hz), 113.28 (d, J = 20.7 Hz, C-3), 111.88, 
110.20 (d, J = 6.0 Hz, C-5), 53.64 (C-13), 26.31 (C-14), 22.56 (C-21), 9.30 (C-15), 
5.19 (C-22). LCMS m/z calc. for C25H22ClFN6O2 [M+H]+: 493.2, found 493.1 with tR 





dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carboxamide (247, 72% 
yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.21 (s, 1H, H-17), 7.82 (td, J = 8.2, 5.4 Hz, 1H), 
7.70 – 7.45 (m, 6H), 7.22 (ddd, J = 10.8, 8.3, 1.0 Hz, 1H), 4.93 (dd, J = 8.5, 4.2 Hz, 
NH), 3.95 (m, 1 H, H-21), 2.09 – 1.92 (m, 4H, H-22), 1.79 – 1.71 (m, 2H, H-24), 1.59 
– 1.34 (m, 4H, H-14/23), 0.81 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-
d4) δ 163.26, 162.51, 159.88, 159.70, 159.57, 157.71, 157.11 (C-17), 154.58, 
149.08, 135.74, 135.23 (d, J = 10.6 Hz, C-4), 129.57, 129.37 (d, J = 7.7 Hz), 128.88 
(d, J = 8.4 Hz), 123.00 (d, J = 4.2 Hz), 113.27 (d, J = 20.9 Hz, C-3), 112.50, 110.21 
(d, J = 6.1 Hz, C-5), 53.48 (C-13), 49.09 (C-21), 31.96 (d, J = 5.0 Hz, C-22), 26.32 
(C-14), 24.63 (C-24), 23.02 (C-23), 9.05 (C-15). LCMS m/z calc. for C28H28ClFN6O2 
[M+H]+: 535.2, found 536.3 with tR 3.08 min (94%). 
(S)-4-chloro-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-N-(quinolin-4-yl)pyrimidine-5-carboxamide (248, 69% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.82 (s, 1H, H-17), 8.33 (d, J = 34.3 Hz, 3H), 
8.14 – 7.96 (m, 1H), 7.91 – 7.25 (m, 8H), 7.10 (s, 1H), 6.44 (d, J = 59.5 Hz, 1H, H-
22), 1.87 (d, J = 66.2 Hz, 2H, H-14), 0.80 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 
MHz, Methanol-d4) δ 163.69 (C-20), 159.80, 157.87, 157.60 (C-17), 155.29, 150.21 
(C-23), 148.98, 148.22, 141.69, 140.55, 137.99, 135.74, 135.07 (d, J = 10.5 Hz, C-
4), 129.80, 129.49, 129.32 (d, J = 1.8 Hz), 129.05, 128.89, 128.39, 126.53, 122.88, 
121.54, 121.18, 119.32, 113.16 (d, J = 21.0 Hz, C-3), 112.64, 112.27, 110.17 (d, J = 
5.7 Hz, C-5), 107.42 (C-22), 54.23 C-13), 26.03 (C-14), 9.61 (C-15). LCMS m/z calc. 
for C31H23ClFN7O2 [M+H]+: 580.2, found 579.4 with tR 2.71 min (99%). 
(S)-4-chloro-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-





1H NMR (400 MHz, Methanol-d4) δ 8.20 (s, 1H, H-17), 7.75 (td, J = 8.2, 5.4 Hz, 1H), 
7.65 – 7.44 (m, 5H), 7.15 (ddd, J = 10.8, 8.2, 1.1 Hz, 1H), 4.90 (dd, J = 8.7, 4.2 Hz, 
NH), 1.98 (dqd, J = 14.8, 7.4, 4.2 Hz, 1H, H-14), 1.77 (ddd, J = 14.0, 8.5, 7.1 Hz, 1H, 
H-14), 0.82 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 166.78 (C-
20), 162.41, 159.99, 159.78, 159.58 (d, J = 4.2 Hz), 157.80, 157.18 (C-17), 154.71, 
149.09, 135.78, 135.17 (d, J = 10.5 Hz, C-4), 129.54, 129.34 (d, J = 1.9 Hz), 128.93 
(d, J = 4.1 Hz), 123.01 (d, J = 4.2 Hz), 113.23 (d, J = 20.8 Hz, C-3), 111.37, 110.20 
(d, J = 6.0 Hz, C-5), 53.86 (C-13), 26.26 (C-14), 9.32 (C-15). LCMS m/z calc. for 
C22H18ClFN6O2 [M+H]+: 453.1, found 453.1 with tR 2.65 min (96%). 
(S)-4-chloro-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)pyrimidine-5-carbaldehyde (261, 64% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 10.47 – 10.15 (m, 1H, H-20), 8.30 (d, J = 3.2 Hz, 
1H, H-17), 7.74 (q, J = 7.0 Hz, 1H), 7.67 – 7.55 (m, 3H), 7.51 (d, J = 9.4 Hz, 3H), 
7.15 (d, J = 10.5 Hz, 1H), 5.06 (dd, J = 8.4, 4.3 Hz, NH), 1.56 – 1.41 (m, 1H, H-14), 
1.40 – 1.29 (m, 1H, H-14), 0.81 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
Methanol-d4) δ 191.00 (C-20), 164.65, 162.46, 160.22 (C-17), 157.10, 149.01, 
135.55 (d, J = 42.5 Hz, C-4), 129.68, 129.45 (d, J = 7.7 Hz), 129.01, 128.72, 123.09, 
113.36 (d, J = 20.7 Hz, C-3), 110.25 (d, J = 6.1 Hz, C-5), 108.09, 53.43 (C-13), 26.66 
(C-14), 8.96 (C-15). LCMS m/z calc. for C22H17ClFN5O2 [M+H]+: 438.1, found 438.3 
with tR 3.01 min (96%). 
General procedure for the Cu-catalyzed amination of monochloro pyrimidine 
derivatives. To a solution of the monochloropyrimidine derivatives (240- 249 and 
261) (0.187 mmol, 1 equiv) in N-methylpyrrolidinone (0.4 mL) was added Cu2O 
(0.0187 mmol, 0.1 equiv) and ammonium hydroxide solution (29% NH3, 0.4 mL). 
The reaction mixture was placed in a microwave oven and heated to 40°C for 30 
minutes. The solvent was evaporated and the crude residue was purified using silica 




220 and 222). Lactam side products (250- 255 and 258) were formed as side 





1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, NH), 7.97 (s, 1H, H-17), 7.88 (s, 1H, H-
24), 7.80 (td, J = 8.1, 5.4 Hz, 1H), 7.65 – 7.51 (m, 6H), 7.47 (s, 1H, H-22), 7.39 (d, J 
= 8.2 Hz, 1H), 7.28 (dd, J = 11.0, 8.1 Hz, 1H), 6.64 (s, NH2), 4.61 (ddd, J = 16.5, 
7.1, 4.4 Hz, NH), 3.83 (s, 3H, H-23), 1.93 – 1.79 (m, 1H, H-14), 1.60 (dt, J = 14.6, 
7.5 Hz, 1H, H-14), 0.72 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, DMSO-d6) δ 
163.90, 162.32, 161.07, 159.99, 159.85, 158.80, 158.00, 149.44, 136.52, 135.90, 
130.85, 129.87, 129.69, 129.58,123.44, 122.08 (d, J = 39.9 Hz), 113.45, 110.73, 
91.74, 53.72 (C-13), 39.10 (C-23), 26.83 (C-14), 10.82 (C-15). LCMS m/z calc. for 
C26H24FN9O2 [M+H]+: 514.2, found 514.4 with tR 2.50 min (95%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-N-(1-methyl-1H-pyrazol-3-yl)pyrimidine-5-carboxamide (211, 
31 % yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.93 (s, 1H, H-17), 7.75 (td, J = 8.2, 5.4 Hz, 1H), 
7.67 – 7.58 (m, 4H), 7.55 (s, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.49 – 7.44 (m, 1H), 7.18 
(ddd, J = 10.9, 8.2, 1.0 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H, H-22), 1.92 (ddq, J = 15.0, 
7.6, 3.8 Hz, 1H, H-14), 1.72 (ddd, J = 14.3, 8.8, 7.2 Hz, 1H, H-14), 0.82 (t, J = 7.4 
Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 165.09, 162.47, 161.24, 160.27, 
159.84, 159.68 (d, J = 4.2 Hz), 159.49, 157.68 (C-17), 149.18, 146.50, 135.86, 
135.08 (d, J = 10.5 Hz, C-4), 131.14, 129.54, 129.26 (d, J = 15.7 Hz), 128.85 (d, J = 




C-5), 97.91, 54.20 (C-13), 37.48 (C-24), 26.38 (C-14), 9.44 (C-15). LCMS m/z calc. 





1H NMR (400 MHz, Methanol-d4) δ 7.98 (d, J = 16.9 Hz, 1H, H-23), 7.68 – 7.52 (m, 
5H), 7.50 – 7.35 (m, 3H), 7.21 (dd, J = 10.8, 8.2 Hz, 1H), 6.46 (d, J = 1.8 Hz, 1H, H-
22), 3.82 (s, 3H, H-24), 2.05 – 1.90 (m, 1H, H-14), 1.74 (dt, J = 14.6, 7.5 Hz, 1H, H-
14), 0.84 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 135.89, 
129.51, 129.21, 128.82, 53.85 (C-13), 26.56 (C-14), 9.32 (C-15). LCMS m/z calc. for 
C26H24FN9O2 [M+H]+: 514.2, found 513.8 with tR 2.45 min (94%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-N-(5-methyl-1,3,4-thiadiazol-2-yl)pyrimidine-5-carboxamide 
(214, 37 % yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.84 (s, 1H, H-17), 7.78 (td, J = 8.3, 5.4 Hz, 1H), 
7.60 (td, J = 13.4, 11.6, 5.2 Hz, 5H), 7.50 – 7.41 (m, 1H), 7.20 (dd, J = 10.9, 8.2 Hz, 
1H), 4.83 (dd, J = 9.0, 4.2 Hz, NH), 2.59 (s, 3H, H-23), 2.03 (ddd, J = 14.3, 7.4, 4.3 
Hz, 1H, H-14), 1.88 (ddd, J = 14.1, 8.9, 7.2 Hz, 1H, H-14), 0.89 (t, J = 7.3 Hz, 3H, H-
15). 13C NMR (101 MHz, Methanol-d4) δ 161.93 (C-20), 159.89, 159.50, 157.10, 
149.43, 136.06, 135.16 (d, J = 10.3 Hz, C-4), 129.36, 129.19 (d, J = 5.2 Hz), 129.06, 
128.67, 122.84 (d, J = 4.2 Hz), 112.97 (d, J = 20.7 Hz, C-3), 110.15 (d, J = 6.2 Hz, 
C-5), 89.99 (C-19), 54.38 (C-13), 26.57 (C-14), 14.46 (C-23), 9.79 (C-15). LCMS m/z 
calc. for C25H22FN9O2S [M+H]+: 532.2, found 531.8 with tR 2.40 min (99%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-





1H NMR (400 MHz, Methanol-d4) δ 7.85 – 7.75 (m, 1H), 7.73 (s, 1H, H-17), 7.60 (d, 
J = 10.6 Hz, 1H), 7.56 (d, J = 2.9 Hz, 5H), 7.43 (d, J = 7.8 Hz, 1H), 7.21 (dd, J = 
11.0, 8.0 Hz, 2H), 6.85 (s, NH2), 2.04 (dt, J = 13.6, 6.8 Hz, 1H, H-14), 1.87 (dt, J = 
13.9, 7.5 Hz, 1H, H-14), 0.91 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-
d4) δ 167.92, 161.22, 160.41, 157.59, 149.24, 135.89, 135.26, 132.18, 130.99, 
129.50, 129.30, 129.19, 128.83, 128.45, 122.76, 113.17, 53.86 (C-13), 26.52 (C-14), 
10.01 (C-15). LCMS m/z calc. for C25H21FN8O3 [M+H]+: 501.2, found 500.1 with tR 
1.85 min (92%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)-N-phenylpyrimidine-5-carboxamide (216, 57% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.68 (d, J = 7.9 Hz, 3H), 7.61 (q, J = 9.4, 8.2 Hz, 
4H), 7.46 (d, J = 7.3 Hz, 1H), 7.34 (q, J = 8.8, 8.2 Hz, 3H), 7.15 (q, J = 7.5 Hz, 2H), 
4.85 (d, J = 3.7 Hz, 1H), 1.92 (ddq, J = 12.0, 8.4, 4.7, 4.2 Hz, 1H, H-14), 1.71 (dq, J 
= 14.7, 7.4 Hz, 1H, H-14), 0.82 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, 
Methanol-d4) δ 162.47 (C-20), 159.97, 159.84, 159.62 (d, J = 4.2 Hz), 159.38, 
149.06 (C-17), 138.36, 135.87, 135.14 (d, J = 10.4 Hz, C-4), 129.55, 129.35, 129.20, 
128.95, 128.81, 128.47 (C-23), 124.04 (C-24), 122.70 (d, J = 3.9 Hz), 120.29 (C-22), 
113.05 (d, J = 20.7 Hz, C-3), 110.12 (d, J = 5.7 Hz, C-5), 53.96 (C-13), 26.50 (C-14), 
9.35 (C-15). LCMS m/z calc. for C28H24FN7O2 [M+H]+: 510.2, found 510.1 with tR 2.83 
min (99%). 
(S)-4-amino-N-cyclopropyl-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-






1H NMR (400 MHz, Methanol-d4) δ 7.90 (s, 1H, H-17), 7.81 (td, J = 8.2, 5.4 Hz, 1H), 
7.68 – 7.52 (m, 6H), 7.45 (dt, J = 7.4, 1.7 Hz, 1H), 7.25 – 7.16 (m, 1H), 4.82 (dd, J = 
8.5, 4.1 Hz, 1H), 2.89 (tt, J = 7.4, 3.9 Hz, 1H, H-21), 1.93 (dqd, J = 14.8, 7.5, 4.2 Hz, 
1H, H-14), 1.82 – 1.56 (m, 1H, H-14), 0.89 – 0.74 (m, 5H, H-15/22), 0.72 – 0.65 (m, 
2H, H-22). 13C NMR (101 MHz, Methanol-d4) δ 176.26, 169.28, 162.52, 160.78, 
159.85, 159.64 (d, J = 4.3 Hz), 159.30, 157.37, 149.20 (C-17), 135.90, 135.23 (d, J 
= 10.6 Hz, C-4), 129.51, 129.27 (d, J = 12.0 Hz), 128.85 (d, J = 2.2 Hz), 122.72 (d, 
J = 4.1 Hz), 113.09 (d, J = 20.7 Hz, C-3), 110.15 (d, J = 6.1 Hz, C-5), 53.63 (C-13), 
26.59 (C-14), 22.35 (C-21), 9.22 (C-15), 5.31 (d, J = 11.1 Hz, C-22). LCMS m/z calc. 
for C25H24FN7O2 [M+H]+: 474.2, found 474.1 with tR 2.34 min (96%). 
(S)-4-amino-N-cyclohexyl-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-
dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carboxamide (218, 18% 
yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.82 (d, J = 5.8 Hz, 1H, H-17), 7.61 (s, 4H), 7.53 
(d, J = 8.1 Hz, 1H), 7.46 (d, J = 7.5 Hz, 1H), 7.22 (dd, J = 10.7, 8.1 Hz, 1H), 3.88 (s, 
1H, H-21), 1.82 (d, J = 12.4 Hz, 2H, H-14/22), 1.70 (d, J = 9.6 Hz, 2H, H-14/22), 1.58 
– 1.08 (m, 3H, H-23/24), 0.84 (t, J = 7.2 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-
d4) δ 135.94, 135.20 (d, J = 10.4 Hz, C-4), 129.52, 129.34, 129.21, 128.87, 122.73, 
113.05 (d, J = 20.7 Hz, C-3), 110.20 (d, J = 6.0 Hz, C-5), 53.73 (C-13), 48.95 (C-21), 
32.36 (C-22), 26.66 (C-14), 25.28 (C-24), 24.85 (C-23), 9.24 (C-15). LCMS m/z calc. 
for C28H30FN7O2 [M+H]+: 516.2, found 516.6 with tR 2.60 min (97%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-





1H NMR (400 MHz, Methanol-d4) δ 8.48 – 8.34 (m, 1H), 8.30 (s, 1H, H-17), 7.93 (d, 
J = 8.7 Hz, 2H), 7.73 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 7.68 – 7.51 (m, 4H), 7.51 – 7.35 
(m, 3H), 7.23 (d, J = 8.2 Hz, 1H), 7.16 – 7.06 (m, 1H), 2.03 – 1.92 (m, 1H, H-14), 
1.88 – 1.66 (m, 1H, H-14), 0.81 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
Methanol-d4) δ 162.41 (C-20), 159.12 (C-17), 157.88 (d, J = 20.1 Hz), 149.17 (C-
23), 148.95, 135.93, 135.68, 135.02 (d, J = 10.4 Hz, C-4), 129.47, 129.28, 129.21, 
128.92, 128.82, 126.08 (d, J = 25.7 Hz), 122.68 (d, J = 4.1 Hz), 112.95 (d, J = 20.9 
Hz, C-3), 110.08 (d, J = 6.0 Hz, C-5), 54.06 (C-13), 26.54 (C-14), 9.52 (C-15). LCMS 
m/z calc. for C31H25FN8O2 [M+H]+: 561.2, found 562.5 with tR 2.31 min (95%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-
yl)propyl)amino)pyrimidine-5-carboxamide (220, 9% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.87 – 7.72 (m, 2H), 7.71 – 7.50 (m, 7H), 7.47 (t, 
J = 10.7 Hz, 1H), 7.22 (dd, J = 10.9, 8.0 Hz, 2H), 2.03 – 1.85 (m, 1H, H-14), 1.72 (dt, 
J = 14.5, 7.7 Hz, 1H, H-14), 0.83 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, 
DMSO-d6) δ 162.32 (C-20), 160.26, 159.73 (d, J = 6.1 Hz), 158.80, 149.43 (C-17), 
136.50, 136.40, 135.84 (d, J = 10.8 Hz, C-4), 129.91, 129.70, 129.62 (d, J = 3.8 Hz), 
129.46, 123.47, 113.60 (d, J = 20.6 Hz, C-3), 110.75, 53.55 (C-13), 26.92 (C-14), 
10.72 (C-15). LCMS m/z calc. for C22H20FN7O2 [M+H]+: 434.2, found 434.4 with tR 
2.22 min (99%). 
(S)-4-amino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-





1H NMR (400 MHz, Methanol-d4) δ 10.18 (s, 1H, H-20), 7.92 – 7.71 (m, 1H), 7.71 – 
7.49 (m, 6H), 7.46 (d, J = 7.3 Hz, 1H), 7.21 (t, J = 9.0 Hz, 1H), 4.97 – 4.91 (m, NH), 
1.80 (dt, J = 14.8, 7.4 Hz, 1H, H-14), 1.40 – 1.20 (m, 1H, H-14), 0.84 (t, J = 7.2 Hz, 
3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 158.30, 149.31 (C-17), 135.90, 
135.25 (d, J = 10.7 Hz, C-4), 129.49, 129.29 (d, J = 5.2 Hz), 128.87 (d, J = 9.7 Hz), 
123.02, 113.12 (d, J = 20.1 Hz, C-3), 110.21 (d, J = 6.1 Hz, C-5), 53.59 (C-13), 26.50 
(C-14), 9.32 (C-15). LCMS m/z calc. for C22H19FN6O2 [M+H]+: 419.2, found 419.3 





1H NMR (400 MHz, Methanol-d4) δ 12.29 (s, NH), 10.84 (d, J = 7.4 Hz, NH), 7.89 (s, 
1H, H-17), 7.80 (td, J = 8.2, 5.4 Hz, 1H), 7.67 – 7.61 (m, 2H), 7.60 – 7.56 (m, 2H), 
7.55 – 7.50 (m, 1H), 7.47 (dd, J = 7.6, 1.9 Hz, 3H), 7.26 – 7.17 (m, 1H), 6.65 (d, J = 
2.3 Hz, 1H, H-22), 4.95 (dq, J = 7.5, 3.9, 3.4 Hz, NH), 2.02 (dd, J = 7.3, 4.3 Hz, 1H, 
H-14), 1.84 (ddd, J = 14.2, 8.6, 7.1 Hz, 1H, H-14), 0.91 – 0.86 (m, 3H, H-15). 13C 
NMR (101 MHz, Methanol-d4) δ 165.83, 163.28, 162.64, 162.47, 159.84, 159.78, 
158.00, 149.82 (C-17), 149.38, 146.70, 135.98, 135.20 (d, J = 10.6 Hz, C-4), 131.21, 
129.49, 129.32 (d, J = 2.8 Hz), 128.84 (d, J = 8.8 Hz), 123.22 (d, J = 4.3 Hz), 113.13 
(d, J = 20.7 Hz, C-3), 110.16 (d, J = 6.1 Hz, C-5) , 97.25 (C-22), 54.22 (C-13), 37.25 
(C-24), 26.89 (C-14), 9.36 (C-15). LCMS m/z calc. for C26H23FN8O3 [M+H]+: 515.2, 





1H NMR (400 MHz, Methanol-d4) δ 10.72 (d, J = 7.4 Hz, NH), 7.94 (s, 1H, H-17), 




(d, J = 2.0 Hz, 1H), 7.22 (dd, J = 10.9, 8.2 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H, H-22), 
4.97 (dq, J = 7.5, 3.9, 3.4 Hz, NH), 3.81 (s, 3H, H-24), 2.04 (ddq, J = 14.0, 10.8, 7.1, 
6.6 Hz, 1H, H-14), 1.83 (dp, J = 15.2, 7.5 Hz, 1H, H-14), 0.88 (t, J = 7.3 Hz, 3H, H-
15). 13C NMR (101 MHz, Methanol-d4) δ 163.10, 150.16, 149.33, 137.90, 135.96, 
135.28 (d, J = 10.7 Hz, C-4), 129.53, 129.35, 128.84, 123.17, 113.28(d, J = 20.8 Hz, 
C-3), 97.00 (C-19), 89.54 (C-22), 54.20 (C-13), 34.03 (C-24), 26.91 (C-14), 9.26 (C-




(252, 14% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.97 (s, 1H, H-17), 7.87 – 7.71 (m, 2H), 7.70 – 
7.57 (m, 5H), 7.56 – 7.38 (m, 4H), 7.27 – 7.16 (m, 2H ), 5.00 (dd, J = 8.6, 4.2 Hz, 
NH), 2.71 (s, 3H, H-23), 2.05 (ddd, J = 14.4, 7.4, 4.1 Hz, 1H, H-14), 1.89 – 1.76 (m, 
1H, H-14), 0.88 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 163.10, 
150.16, 149.33, 137.90, 135.96, , 135.28 (d, J = 10.3 Hz, C-4) 129.53, 129.35, 
128.84, 123.17, 113.28 (d, J = 20.7 Hz, C-3), 97.00, 89.54, 54.20 (C-13), 26.91 (C-
14), 17.15 (C-23), 9.26 (C-15). LCMS m/z calc. for C25H21FN8O3S [M+H]+: 533.1, 





1H NMR (400 MHz, Methanol-d4) δ 10.85 (d, J = 7.3 Hz, NH), 7.99 (s, 1H, H-17), 
7.89 (s, 1H, H-24), 7.81 (td, J = 8.2, 5.4 Hz, 1H), 7.66 – 7.56 (m, 5H), 7.50 (ddt, J = 
17.5, 7.7, 1.8 Hz, 2H), 7.27 – 7.12 (m, 1H), 4.94 (dd, J = 8.7, 4.3 Hz, NH), 2.04 (dqd, 
J = 14.7, 7.4, 4.3 Hz, 1H, H-14), 1.91 – 1.76 (m, 1H, H-14), 0.89 (t, J = 7.4 Hz, 3H, 




162.48, 159.85, 159.74, 158.04, 149.64, 149.39, 135.99, 135.20 (d, J = 10.6 Hz, C-
4), 130.43, 129.48, 129.32 (d, J = 3.6 Hz), 128.84 (d, J = 8.6 Hz), 123.21 (d, J = 4.3 
Hz), 122.35, 121.09, 113.14 (d, J = 20.9 Hz, C-3), 110.21 (d, J = 6.1 Hz, C-5), 89.75 
(C-19), 54.20 (C-13), 37.69 (C-23), 26.87 (C-14), 9.35 (C-15). LCMS m/z calc. for 
C26H23FN8O3 [M+H]+: 515.2, found 515.1 with tR 2.80 min (96%). 
(S)-4-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)-N-
(isoxazol-3-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide (254, 7% yield, 
NMR purity 97%). 
 
1H NMR (400 MHz, Methanol-d4) δ 10.71 (d, J = 7.4 Hz, NH), 8.55 (d, J = 1.7 Hz, 
1H, H-23), 7.93 (s, 1H, H-17), 7.81 (td, J = 8.3, 5.4 Hz, 1H), 7.70 – 7.56 (m, 5H), 
7.55 – 7.43 (m, 2H), 7.23 (dd, J = 10.9, 8.2 Hz, 1H), 7.10 (d, J = 1.7 Hz, 1H, H-22), 
4.98 (dq, J = 7.3, 4.1 Hz, NH), 2.12 – 1.97 (m, 1H, H-14), 1.95 – 1.75 (m, 1H, H-14), 
0.88 (t, J = 7.4 Hz, 3H, H-15). LCMS m/z calc. for C25H20FN7O4 [M+H]+: 502.2, found 
502.1 with tR 3.04 min (97%). 
(S)-4-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)-6-
oxo-N-phenyl-1,6-dihydropyrimidine-5-carboxamide (255, 6% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 7.89 (s, 1H, H-17), 7.80 (td, J = 8.0, 5.2 Hz, 1H), 
7.62 (p, J = 8.3, 7.6 Hz, 6H), 7.53 (d, J = 7.1 Hz, 1H), 7.47 (dd, J = 7.3, 1.9 Hz, 1H), 
7.34 (t, J = 7.6 Hz, 2H), 7.21 (dd, J = 10.8, 8.1 Hz, 1H), 7.10 (t, J = 7.2 Hz, 1H), 4.94 
(dd, J = 8.7, 4.1 Hz, NH), 2.03 (ddq, J = 12.0, 8.4, 4.7, 4.2 Hz, 1H, H-14), 1.84 (dp, 
J = 14.4, 7.1 Hz, 1H, H-14), 0.89 (t, J = 7.3 Hz, 3H, H-15). 13C NMR (101 MHz, 
Methanol-d4) δ 166.57 (C-18), 163.29, 162.78, 162.47, 158.07, 149.39, 138.29, 
136.00, 135.20 (d, J = 10.4 Hz), 129.50, 129.32 (d, J = 2.2 Hz), 128.85 (d, J = 7.3 
Hz), 128.52 (C-23), 123.53 (C-24), 123.21, 120.16 (C-22), 113.12 (d, J = 21.0 Hz), 
110.12 (d, J = 5.7 Hz, C-5), 54.28 (C-13), 26.89 (C-14), 9.36 (C-15). LCMS m/z calc. 





oxo-N-(quinolin-4-yl)-1,6-dihydropyrimidine-5-carboxamide (258, 12% yield). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.60 (s, NH), 10.80 (d, J = 7.5 Hz, NH), 8.54 (s, 
1H), 8.21 (d, J = 8.3 Hz, 1H, H-23), 8.15 (s, 1H, H-17), 8.05 (s, NH), 7.93 – 7.76 (m, 
2H), 7.74 – 7.64 (m, 1H), 7.59 (td, J = 8.6, 7.1, 3.8 Hz, 6H), 7.43 – 7.29 (m, 1H), 2.08 
– 1.83 (m, 1H, H-14), 1.73 (dt, J = 14.6, 7.5 Hz, 1H, H-14), 0.80 (t, J = 7.3 Hz, 3H, 
H-15). 13C NMR (101 MHz, DMSO-d6) δ 167.54 (C-18), 163.50 (C-20), 163.26, 
162.31, 161.66, 159.69, 158.74 (d, J = 4.2 Hz), 158.09 (C-17), 151.67, 149.33, 
140.16, 139.09, 136.45, 135.95 (d, J = 10.7 Hz, C-4), 130.09, 129.83 (d, J = 4.8 Hz), 
129.67, 129.55, 127.07, 123.80, 120.94, 120.02, 113.87 (d, J = 20.3 Hz, C-3), 110.85 
(d, J = 5.6 Hz, C-5), 105.75 (C-22), 54.02 (C-13), 27.31 (C-14), 10.45 (C-15). LCMS 
m/z calc. for C31H24FN7O3 [M+H]+: 562.2, found 563.1 with tR 2.37 min (90%). 
General procedure for Zn-catalyzed hydrodechlorination of 
monochloropyrimidine derivatives. To a solution of the monochloropyrimidine 
derivatives (240 and 241) (0.170 mmol, 1 equiv) in THF (1 mL) was added zinc dust 
(1.70 mmol, 10 equiv) and acetic acid (1.70 mmol, 10 equiv). The reaction mixture 
was stirred at reflux for 3 h at which time it was concentrated under reduced 
pressure. The crude residue was purified by flash chromatography (DCM/ methanol 
(containing 0.7 N ammonia: 99/1) to afford the dechlorinated products (226 and 227) 
as a white solid. 
(S)-4-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)-N-
(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxamide (226, 54% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.68 (s, 1H, H-17), 8.45 (s, 1H, H-18), 8.07 (s, 
1H, H-24), 7.79 (td, J = 8.2, 5.4 Hz, 1H), 7.72 – 7.53 (m, 6H), 7.48 (dd, J = 7.7, 1.9 
Hz, 1H), 7.20 (ddd, J = 10.9, 8.2, 1.0 Hz, 1H), 4.94 (dd, J = 8.6, 4.3 Hz, NH), 3.77 – 




H-14), 0.88 (t, J = 7.4 Hz, 3H, H-15) 13C NMR (101 MHz, Methanol-d4) δ 163.57, 
162.49, 160.00, 159.71 (d, J = 4.2 Hz), 158.87 (C-18), 158.10, 153.15 (C-17), 
149.27, 135.95, 135.19 (d, J = 10.6 Hz, C-4), 130.49, 129.51, 129.33 (d, J = 2.2 Hz), 
128.86 (d, J = 9.5 Hz), 123.04 (d, J = 4.2 Hz), 122.63, 121.21, 113.16 (d, J = 20.8 
Hz, C-3), 110.21 (d, J = 6.1 Hz, C-5), 108.80 (C-22), 53.34 (C-13), 37.77 (C-23), 
26.54 (C-14), 9.31 (C-15). LCMS m/z calc. for C26H23FN8O2 [M+H]+: 499.2, found 
499.1 with tR 2.70 min (99%). 
(S)-4-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)amino)-N-
(1-methyl-1H-pyrazol-3-yl)pyrimidine-5-carboxamide (227, 33% yield). 
 
1H NMR (400 MHz, Methanol-d4) δ 8.71 (s, 1H, H-17), 8.45 (s, 1H, H-18), 7.78 (td, 
J = 8.2, 5.4 Hz, 1H), 7.67 – 7.54 (m, 5H), 7.52 (d, J = 2.3 Hz, 1H), 7.48 (dd, J = 7.7, 
1.9 Hz, 1H), 7.20 (ddd, J = 11.0, 8.2, 1.0 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H, H-22), 
4.95 (dd, J = 8.6, 4.3 Hz, NH), 2.10 – 2.02 (m, 1H, H-14), 1.90 – 1.73 (m, 1H, H-14), 
0.87 (t, J = 7.4 Hz, 3H, H-15). 13C NMR (101 MHz, Methanol-d4) δ 164.57, 162.48 
(C-20), 160.04, 160.00 – 159.58 (m), 159.00 (C-17), 158.03, 153.72 (C-18), 149.26, 
146.26, 135.94, 135.18 (d, J = 10.4 Hz, C-4), 131.10, 129.53, 129.33 (d, J = 2.8 Hz), 
128.86 (d, J = 7.5 Hz), 123.06 (d, J = 4.2 Hz), 113.15 (d, J = 20.8 Hz, C-3), 110.22 
(d, J = 6.0 Hz, C-5), 108.81, 98.03 (C-22), 53.31 (C-13), 37.50 (C-24), 26.54 (C-14), 
9.29 (C-15). LCMS m/z calc. for C26H23FN8O2 [M+H]+: 499.2, found 499.1 with tR 2.74 
min (97%). 
7.4 Pharmacology 
A total of 92 compounds were screened in this thesis and of these, a total 70 
compounds were screened by GSK using a homogenous time-resolved 
fluorescence (HTRF) assay. The remaining 22 compounds were tested by our group 
(1μM final assay concentration) and Monash university (500 nM final assay 
concentration and IC50 determination) using ADP-Glo kinase assay. This chapter will 
discuss the two above-mentioned assays, with ADP-Glo kinase assay described in 




7.4.1  ADP-Glo assay 
7.4.1.1 Principle  
As it was mentioned in Chapter 1, PI3Ks catalyses the transfer of phosphate group 
from ATP to the 3 position hydroxyl group of the inositol ring of PI(4,5)P2 to generate 
PI(3,4,5)P3 which plays a central role in the regulation of various physiological 
process including cell growth, proliferation and motility (Figure 1 in Chapter 1)403–405. 
The principle of ADP-Glo assay relies on the formation of adenosine diphosphate 
(ADP) by transferring a phosphate group from adenosine triphosphate (ATP) to 
PI(4,5)P2 (Figure 143), which is mediated by PI3K. Then, the ADP-Glo reagent is 
added to stop the kinase reaction and deplete the residual ATP, leaving only ADP. 
Finally, the kinase detection reagent is added to convert ADP to ATP (Figure 143), 
which is in a coupled reaction with luciferase/luciferin, is converted into light (Scheme 
32), where the amount of light generated is directly proportional to the ADP produced 
and the activity of kinase406,407. 
 
Figure 143. Principle of ADP-Glo assay. The assay is composed of 2 steps: after the kinase 
or ATPase reaction. In the first step, the ADP-Glo reagent that terminates the kinase reaction 
and depletes the remaining ATP is added. Then, kinase detection reagent is added to convert 





Scheme 32. Mechanism of bioluminescence in ADP-Glo kinase assay. Luciferase catalyses 
the oxidation of luciferin to electronically excited oxyluciferin in the presence of ATP and 
oxygen. The excited oxyluciferin then releases energy in the form of light, as it returns to the 
ground state 
 
7.4.1.2 Comparison of ADP-Glo to other lipid kinase assays 
ADP-Glo assay offers many advantages compared to other 3 kinase assays: 
radiometric antibody-based ADP detection assay, HTRF assay and antibody-based 
ADP detection assay407,408. 
Robust: it remains unaffected by small variations in method parameters and 
environmental factors406–408. 
Highly sensitive: very low amount of enzymes are needed406,409. 
Cost effective and safe: antibodies or radioactive nucleotides are not required; 
thus, it can be performed by person with no radiation training or license in any 
research lab and with no concern about the quality of the antibodies410.  
Universal: it is applicable for all classes of kinases411. 
Flexible: the assay can be conducted over a wide range of ATP concentration (up 
to 1 mM), thus AD-Glo assay can distinguish between ATP competitive and non-
competitive inhibitors of PI3Ks406,407. 
7.4.1.3 Single-concentration screening 
Using the ADP-Glo luminescent assay, the compounds in Chapter 5 were tested for 
inhibition of PI3K δ at 1 μM and 500 nM final compound concentrations. Screening 
at 1 μM single-concentration was carried out by our group, whereas the assay at 500 
nM was performed by the Monash university. 
7.4.1.3.1 Primary screening (1 μM) 
14 Compounds (4, 8, 72, 125 and 127 in Chapter 3) and (211, 212, 214, 241-243 
and 250-252 in Chapter 5) were initially tested at a single concentration (1 μM) for 
their PI3K δ inhibitory activity and idelalisib (8) was used as the positive control. In 




PI(4,5)P2 (in water and lipid dilution buffer) and enzyme (in PI3K reaction buffer) 
were pre-incubated for 10 minutes, to allow inhibitor binding to kinase. The kinase 
reaction was initiated by addition of ATP, following incubation of 40 min, the reaction 
was stopped by adding (12.5 μL) of ADP-Glo reagent and the plate was incubated 
for 40 min followed by addition of (25 μL) of kinase detection reagent to convert ADP 
to ATP and the newly synthesised ATP was converted into light using 
luciferase/luciferin. After an incubation time of 40 min, luminescence was recorded 
using a plate-reading luminometer. 
7.4.1.3.2 Primary screening (500 nM) 
18 compounds (8, 72 and 127 in Chapter 3) and (210-212, 214-220, 222, 226 227, 
240 and 241 in Chapter 5) were tested in a second screen at a single concentration 
of 500 nM for their inhibitory activity against PI3K δ, these compounds were 
screened by Monash university using ADP-Glo kinase lipid assay. The experiment 
was carried out in the same manner as described above at 1 μM single concentration 
(see Section 7.4.1.3.1). 
7.4.2 Homogenous Time Resolved Fluorescence assay (HTRF) 
Potencies for PI3K isoforms (α, β, γ and δ) of 70 compounds in this thesis were 
measured using a HTRF assay. In contrast to the radioactive assay, the HTRF assay 
does not require radioisotopes and it can accommodate high ATP concentration, 
which allows the assay to be carried out under conditions mimicking the 
physiological environment412–414. In addition to that, HTRF assay is easy-to-use with 
an excellent level of reproducibility414,415. The principle of HTRF assay is based on 
the unique property of certain pleckstrin homology (PH) domains to interact 
specifically with PI(3,4,5)P3415, where it is believed that the PH domains in modular 
signalling proteins are the primary intracellular targets of PI(3,4 and 5)P3. In the 
HTRF assay, a stable complex is formed between the GST-tagged PH domain and 
biotinylated short chain PI(3,4,5)P3 (Figure 144)413. The GST-tagged PH domain and 
biotinylated PI(3,4,5)P3 recruit fluorophores (Europium-labelled anti-GST 
monoclonal antibody and Streptavidin-Allophycocyanin, respectively) generating a 
time-resolved fluorescence resonance energy transfer (TR-FRET). Excitation, at 330 
nM, of Europium in the complex leads to a transfer of energy to the Streptavidin-
Allophycocyanin, which emits at 665 nM (Figure 144)416. Non-biotinylated PI(3,4,5)P3 
formed by PI3K activity was detected by displacement of biotinylated PI(3,4,5)P3 
from the signal-generating complex, resulting in a loss of energy transfer and sever 





Figure 144. PI3 kinase HTRF Assay principle. The assay is composed of three steps: In the 
first step, inhibitor is incubated in assay buffer containing PI3-kinase, PI(4,5)P2 substrate and 
ATP at RT for 30 minutes. In the second step, the reaction is terminated by the addition of a 
stop solution containing biotinylated PI(3,4,5)P3 and ethylenediaminetetraacetic acid (EDTA). 
The last step involves the addition of detection buffer, containing GST-tagged GRP1 
pleckstrin homology (PH) domain, Europium-labelled anti-glutathione S-transferase (GST) 
antibody and streptavidine-allophycocyanin (APC). After incubation at RT for 14 h, the plate 
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